Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis,	B-D018805
deathCardiovascular	B-D003643
system	O
-	O
TachycardiaDigestive	B-D013610
system	O
-	O
Gastric	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesisHemic	B-D006396
and	O
lymphatic	B-D008208
system	I-D008208
-	O
LymphadenopathyNervous	B-D000072281
system	O
-	O
Anxiety,	B-D001007
dream	O
abnormalities,	O
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis,	B-D008581
tremors,	B-D014202
vertigoRespiratory	B-D014717
system	O
-	O
Respiratory	O
depression,	B-D003863
pneumoniaUrogenital	B-D011014
system	O
-	O
Oliguria/polyuria,	B-D009846
proteinuria	B-D011507
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(See	O
WARNINGS	O
and	O
PRECAUTIONS)	O

IBU	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(See	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinaladverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforationof	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
eventscan	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms.Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinalevents	O

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
withIbuprofen	O
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
thepercentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaintsranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
toaspirin	O
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidenceof	B-D015994
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
eitherthe	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
anincidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listedin	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000patients	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
ofat	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
werereported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience.These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
twoof	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
wherethe	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
inColumn	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
has	O
notbeen	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
thanat	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
withrheumatoid	O
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
stillwithin	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

table	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O
	O

Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
a	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
etodolac	B-D017308
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal),	O
vomiting	B-D014839
	O

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritis,	O
rashes,	O
tinnitus	B-D014012
	O

Adverse-reaction	O
information	O
for	O
etodolac	B-D017308
was	O
derived	O
from	O
2,629	O
arthritic	B-D001154
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
in	O
double-blind	O
and	O
open-label	O
clinical	B-D016430
trials	I-D016430
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies	O

In	O
clinical	B-D016430
trials,	I-D016430
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient	O

The	O
discontinuation	O
rate	O
in	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

New	O
patient	O
complaints	O
(with	O
an	O
incidence	B-D015994
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system	O

The	O
incidences	B-D015994
were	O
determined	O
from	O
clinical	B-D016430
trials	I-D016430
involving	O
465	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	B-D017308
b.i.d	O

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever	B-D005334
	O

Digestive	B-D004064
system	I-D004064
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	B-D015746
pain*,	I-D015746
diarrhea*,	B-D003967
flatulence*,	B-D005414
nausea*,	B-D009325
constipation,	B-D003248
gastritis,	B-D005756
melena,	B-D008551
vomiting	B-D014839
	O

Nervous	B-D009420
system	I-D009420
-	O
Asthenia/malaise*,	B-D001247
dizziness*,	B-D004244
depression,	B-D003863
nervousness	O

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus,	B-D011537
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus	B-D014012
	O

Urogenital	B-D014566
system	I-D014566
-	O
Dysuria,	B-D053159
urinary	O
frequency	O

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	B-D016430
trials,	I-D016430
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock)	B-D012769
	O

Cardiovascular	B-D002319
system	I-D002319
-	O
Hypertension,	B-D006973
congestive	O
heart	B-D006333
failure,	I-D006333
flushing,	B-D005483
palpitations,	O
syncope,	B-D013575
vasculitis	B-D014657
(including	O
necrotizing	O
and	O
allergic)	O

Digestive	B-D004064
system	I-D004064
-	O
Thirst,	B-D013894
dry	O
mouth,	B-D009055
ulcerative	B-D014456
stomatitis,	B-D013280
anorexia,	B-D000855
eructation,	B-D004884
elevated	O
liver	B-D008099
enzymes,	B-D004798
cholestatic	O
hepatitis,	B-D006505
hepatitis,	B-D006505
cholestatic	O
jaundice,	B-D007565
duodenitis,	B-D004382
jaundice,	B-D007565
hepatic	O
failure,	O
liver	B-D008099
necrosis,	B-D009336
peptic	B-D010437
ulcer	I-D010437
with	O
or	O
without	O
bleeding	O
and/or	O
perforation	O
,	O
intestinal	O
ulceration,	B-D014456
pancreatitis	B-D010195
	O

Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
Ecchymosis,	B-D004438
anemia,	B-D000740
thrombocytopenia,	B-D013921
bleeding	B-D001760
time	I-D001760
increased,	O
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000740
leukopenia,	B-D007970
neutropenia,	B-D009503
pancytopenia	B-D010198
	O

Metabolic	O
and	O
nutritional	O
-	O
Edema,	B-D004487
serum	B-D044967
creatinine	B-D003404
increase,	O
hyperglycemia	B-D006943
in	O
previously	O
controlled	O
diabetic	O
patients	B-D010361
	O

Nervous	B-D009420
system	I-D009420
-	O
Insomnia,	O
somnolence	O

Respiratory	B-D012137
system	I-D012137
-	O
Asthma,	B-D001249
pulmonary	O
infiltration	O
with	O
eosinophilia	B-D004802
	O

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema,	B-D000799
sweating,	B-D013546
urticaria,	B-D014581
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	B-D014657
with	O
purpura,	B-D011693
Stevens-Johnson	B-D013262
Syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis,	O
hyperpigmentation	B-D017495
,	O
erythema	B-D004892
multiforme	I-D004892
	O

Special	O
senses	O
-	O
Photophobia,	B-D020795
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
system	I-D014566
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	B-D051437
insufficiency,	I-D051437
renal	O
papillary	O
necrosis	B-D009336
	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	B-D017308
is	O
uncertain	O

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	B-D010820
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache	B-D006261
	O

Cardiovascular	B-D002319
system	I-D002319
-	O
Arrhythmias,	O
myocardial	B-D009203
infarction,	I-D009203
cerebrovascular	B-C079279
accident	O

Digestive	B-D004064
system	I-D004064
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis	B-D003092
	O

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
system	I-D009420
-	O
Paresthesia,	B-D010292
confusion	B-D003221
	O

Respiratory	B-D012137
system	I-D012137
-	O
Bronchitis,	B-D001991
dyspnea,	B-D004417
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis	B-D012852
	O

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia,	B-D000505
maculopapular	O
rash,	O
photosensitivity,	O
skin	B-D012867
peeling	O

Special	O
senses	O
-	O
Conjunctivitis,	B-D003231
deafness,	B-D003638
taste	B-D013649
perversion	O

Urogenital	B-D014566
system	I-D014566
-	O
Cystitis,	B-D003556
hematuria,	B-D006417
leukorrhea,	B-D007973
renal	O
calculus,	O
interstitial	O
nephritis,	B-D009393
uterine	O
bleeding	O
irregularities	O

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis,	B-D018805
death	B-D003643
Cardiovascular	B-D002319
system	I-D002319
-	O
Tachycardia	B-D013610
Digestive	B-D004064
system	I-D004064
-	O
Gastric	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis	B-D006396
Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
Lymphadenopathy	B-D000072281
Nervous	B-D009420
system	I-D009420
-	O
Anxiety,	B-D001007
dream	O
abnormalities,	O
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis,	B-D008581
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
system	I-D012137
-	O
Respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Urogenital	B-D014566
system	I-D014566
-	O
Oliguria/polyuria,	B-D009846
proteinuria	B-D011507
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(	O
5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(	O
4	O
,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(	O
5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
,	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
(GI)	O
events	O

[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(	O
5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(	O
5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[	O
]	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
]	O

minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
]	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

Two	O
large,	O
controlled	O
clinical	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-	O
cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
celecoxib	B-D000068579
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
celecoxib	B-D000068579
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants;	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
]	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
celecoxib	B-D000068579
capsules,	B-D002214
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules	B-D002214
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

The	O
rates	O
of	O
hypertension	B-D006973
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib	B-D000068579
capsules,	B-D002214
ibuprofen	B-D007052
and	O
diclofenac-treated	B-D004008
patients	B-D010361
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	B-D000078682
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
celecoxib	B-D000068579
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
]	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
celecoxib	B-D000068579
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

In	O
the	O
CLASS	O
study	O
[	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

In	O
the	O
CLASS	O
study	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
failure,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoadosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
celecoxib	B-D000068579
and	O
in	O
patients	B-D010361
with	O
aspirin	B-D001241
sensitive	O
asthma	B-D001249
	O

Celecoxib	B-D000068579
capsules	B-D002214
are	O
sulfonamides	B-D013449
and	O
both	O
NSAIDs	O
and	O
sulfonamides	B-D013449
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	B-D019369
or	O
less	O
severe	O
asthmatic	B-D001249
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
]	O

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

When	O
celecoxib	B-D000068579
capsules	B-D002214
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	B-D012867
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib	B-D000068579
capsules,	B-D002214
including	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	B-D056150
generalized	I-D056150
exanthematous	I-D056150
pustulosis	I-D056150
(AGEP)	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
celecoxib	B-D000068579
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	B-D000068579
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	B-D000068579
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.3	O
,	O
5.6)	O
]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
capsules	B-D002214
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
with	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	B-D010361
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	B-D010361
and	O
their	O
caregivers	B-D017028
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(	O
6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Of	O
the	O
celecoxib-treated	B-D000068579
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	B-D000068579
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
celecoxib	B-D000068579
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>	O
2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CXB	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CXB	O
=	O
celecoxib	B-D000068579
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	B-D000068579
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	B-D000068579
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General:	O
Hypersensitivity,	B-D006967
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	B-D010361
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis	B-D013924
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
General:	O
Sepsis,	B-D018805
sudden	O
death	B-D003643
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	B-D008196
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia,	B-D001259
suicide	B-D013405
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)	O
]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
celecoxib	B-D000068579
was	O
maintained	O
with	O
or	O
without	O
aspirin	B-D001241
use	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	B-D000068579
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
twice	O
daily	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥	O
5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Celecoxib	B-D000068579
3	O
mg/kg	O
Celecoxib	B-D000068579
6	O
mg/kg	O
Naproxen	B-D009288
7.5	O
mg/kg	O
Preferred	O
Term	O
N=77	O
N=82	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O

vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*	O
Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	B-D000068579
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	B-D000068579
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[	O
see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(	O
14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	B-D000068579
pre-marketing	O
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
Placebo	O
N=	O
2285	O
N=	O
1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
celecoxib,	B-D000068579
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post	O
approval	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
General:	O
Anaphylactoid	O
reaction,	O
angioedema	B-D000799
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	B-D009336
hepatitis,	B-D006505
jaundice,	B-D007565
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	B-D008196
Agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
Renal:	O
Interstitial	O
nephritis	B-D009393
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(	O
5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(	O
4	O
,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(	O
5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
,	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
(GI)	O
events	O

[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(	O
5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(	O
5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[	O
]	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
]	O

minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
]	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

Two	O
large,	O
controlled	O
clinical	O
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-	O
cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
celecoxib	B-D000068579
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
celecoxib	B-D000068579
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants;	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
]	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
celecoxib	B-D000068579
capsules,	B-D002214
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules	B-D002214
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

The	O
rates	O
of	O
hypertension	B-D006973
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib	B-D000068579
capsules,	B-D002214
ibuprofen	B-D007052
and	O
diclofenac-treated	B-D004008
patients	B-D010361
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	B-D000078682
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
celecoxib	B-D000068579
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
]	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
celecoxib	B-D000068579
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

In	O
the	O
CLASS	O
study	O
[	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

In	O
the	O
CLASS	O
study	O
[	O
see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
failure,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoadosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
celecoxib	B-D000068579
and	O
in	O
patients	B-D010361
with	O
aspirin	B-D001241
sensitive	O
asthma	B-D001249
	O

Celecoxib	B-D000068579
capsules	B-D002214
are	O
sulfonamides	B-D013449
and	O
both	O
NSAIDs	O
and	O
sulfonamides	B-D013449
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	B-D019369
or	O
less	O
severe	O
asthmatic	B-D001249
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
]	O

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

When	O
celecoxib	B-D000068579
capsules	B-D002214
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	B-D012867
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib	B-D000068579
capsules,	B-D002214
including	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	B-D056150
generalized	I-D056150
exanthematous	I-D056150
pustulosis	I-D056150
(AGEP)	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
celecoxib	B-D000068579
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	B-D000068579
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	B-D000068579
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.3	O
,	O
5.6)	O
]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
capsules	B-D002214
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
with	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	B-D010361
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	B-D010361
and	O
their	O
caregivers	B-D017028
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(	O
6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Of	O
the	O
celecoxib-treated	B-D000068579
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	B-D000068579
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
celecoxib	B-D000068579
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>	O
2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CXB	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CXB	O
=	O
celecoxib	B-D000068579
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	B-D000068579
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	B-D000068579
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General:	O
Hypersensitivity,	B-D006967
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	B-D010361
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis	B-D013924
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
General:	O
Sepsis,	B-D018805
sudden	O
death	B-D003643
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	B-D008196
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia,	B-D001259
suicide	B-D013405
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)	O
]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
celecoxib	B-D000068579
was	O
maintained	O
with	O
or	O
without	O
aspirin	B-D001241
use	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	B-D000068579
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
twice	O
daily	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥	O
5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Celecoxib	B-D000068579
3	O
mg/kg	O
Celecoxib	B-D000068579
6	O
mg/kg	O
Naproxen	B-D009288
7.5	O
mg/kg	O
Preferred	O
Term	O
N=77	O
N=82	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O

vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*	O
Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	B-D000068579
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	B-D000068579
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[	O
see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(	O
14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	B-D000068579
pre-marketing	O
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
Placebo	O
N=	O
2285	O
N=	O
1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
celecoxib,	B-D000068579
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post	O
approval	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
General:	O
Anaphylactoid	O
reaction,	O
angioedema	B-D000799
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	B-D009336
hepatitis,	B-D006505
jaundice,	B-D007565
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	B-D008196
Agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
Renal:	O
Interstitial	O
nephritis	B-D009393
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	B-D012306
FULL	O
PRESCRIBING	O
INFORMATION	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(	O
5.1)	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(	O
4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(	O
5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O

(	O
5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
	O

(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O

(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
	O

(	O
5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
gestation	O

(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
	O

(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	B-D004008
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)]	O

5.3	O
Hepatotoxicity	O
In	O
clinical	B-D016430
trials,	I-D016430
of	O
oral	O
diclofenac-containing	B-D004008
products,	O
meaningful	O
elevations	O
(i.e	O

more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
with	O
oral	O
diclofenac	B-D004008
sodium	B-D012964
for	O
2	O
to	O
6	O
months,	O
patients	B-D010361
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
tests	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

In	O
a	O
European	B-D005060
retrospective	O
population-based,	B-D011153
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	B-D004008
associated	O
drug-induced	O
liver	B-D008099
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	B-D004008
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	B-D016017
ratio	I-D016017
of	O
liver	B-D008099
injury	O

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	B-D016424
number	O
of	O
10	O
cases	O
of	O
liver	B-D008099
injury	O
associated	O
with	O
diclofenac,	B-D004008
the	O
adjusted	O
odds	B-D016017
ratio	I-D016017
increased	O
further	O
with	O
female	B-D005260
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days	O

Physicians	B-D010820
should	O
measure	O
transaminases	B-D000637
at	O
baseline	O
and	O
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
transaminases	B-D000637
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
be	O
discontinued	O
immediately	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver	B-D008099
related	O
event	O
in	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	B-D000082
antibiotics,	O
anti-epileptics)	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel,	O
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edem	O
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
diclofenac	B-D004008
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)]	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE-inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)]	O
	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
diclofenac	B-D004008
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.8)]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
Contraindications	B-D000075202
(	O
4)]	O

When	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(	O
4)]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel,	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(	O
8.1)]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel,	O
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2,	O
5.3,	O
5.6)]	O

5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	B-D000818
indicated	O
topical	O
diclofenac	B-D004008
treatment	O
resulted	O
in	O
an	O
earlier	B-D004423
onset	O
of	O
ultraviolet	O
light	B-D008027
induced	O
skin	B-D012867
tumors	O

The	O
potential	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
on	O
skin	B-D012867
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	B-D006801
are	O
not	O
known	O

5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
with	O
eyes	B-D005123
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided	O

Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	B-D005123
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	B-D005123
with	O
water	B-D014867
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour	O

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	B-D006470
more	O
frequent	O
abnormal	O
creatinine,	B-D003404
urea	B-D014508
and	O
hemoglobin	O

Do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	B-D012306
	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
and	O
greater	O
than	O
placebo)	O
are	O
application	O
site	O
reactions,	O
including	O
dermatitis	B-D003872
	O

(	O
6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
AvKARE,	O
Inc	O

at	O
1-855-361-3993;	O
email	O
drugsafety@avkare.com;	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

During	O
clinical	O
development,	O
913	O
patients	B-D010361
were	O
exposed	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	B-D010003
of	O
the	O
superficial	O
joints	B-D007596
of	O
the	O
extremities	B-D005121
	O

Of	O
these,	O
513	O
patients	B-D010361
received	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
for	O
osteoarthritis	B-D010003
of	O
the	O
knee	B-D007717
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	B-D010003
of	O
the	O
hand	B-D006225
	O

Additionally,	O
583	O
patients	B-D010361
were	O
exposed	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	B-D012449
trial	O
in	O
osteoarthritis	B-D010003
of	O
the	O
knee	B-D007717
	O

Of	O
these,	O
355	O
patients	B-D010361
were	O
treated	O
for	O
osteoarthritis	B-D010003
of	O
1	O
knee	B-D007717
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	B-D010003
of	O
both	O
knees	B-D007717
	O

Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	B-D012449
trial	O

Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions	O

These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
1%	O
of	O
treated	O
patients	B-D010361
with	O
a	O
greater	O
frequency	O
in	O
the	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%)	O

Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported	O

Application	O
site	O
dermatitis	B-D003872
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients	B-D010361
	O

Adverse	O
Reaction	O
†	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
N=913	O
Placebo	O
(vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	B-D003872
32	O
(4)	O
6	O
(˂1)	O
Application	O
site	O
pruritus	B-D011537
7	O
(˂1)	O
1	O
(˂1)	O
Application	O
site	O
erythema	B-D004890
6	O
(˂1)	O
3	O
(˂1)	O
Application	O
site	O
paresthesia	B-D010292
5	O
(˂1)	O
3	O
(˂1)	O
Application	O
site	O
dryness	O
4	O
(˂1)	O
3	O
(˂1)	O
Application	O
site	O
vesicles	O
3	O
(˂1)	O
0	O
Application	O
site	O
irritation	O
2	O
(˂1)	O
0	O
Application	O
site	O
papules	O
1	O
(˂1)	O
0	O
†Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1	O
In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel,	O
and	O
3%	O
for	O
patients	B-D010361
in	O
the	O
placebo	O
group	O

Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	B-D003872
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation	O

Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
safety	B-D012449
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies	O

In	O
this	O
study,	O
where	O
patients	B-D010361
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	B-D003872
was	O
observed	O
in	O
11%	O
of	O
patients	B-D010361
	O

Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients	B-D010361
	O

The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	B-D003872
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients	B-D010361
	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS]	O

Diclofenac	B-D004008
Sodium	B-D012964
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	B-D000075202
(4)	O
and	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	B-D004008
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
CONTRAINDICATIONS	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
diclofenac	B-D004008
sodium	B-D012964
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	B-D004008
sodium	B-D012964
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
DRUG	B-D004347
INTERACTIONS	I-D004347
(7)]	O

5.3	O
Hepatotoxicity	O
In	O
clinical	B-D016430
trials,	I-D016430
of	O
oral	O
diclofenac-containing	B-D004008
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
with	O
oral	O
diclofenac	B-D004008
for	O
2	O
to	O
6	O
months,	O
patients	B-D010361
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
tests	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

In	O
a	O
European	B-D005060
retrospective	O
population-based,	B-D011153
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	B-D004008
associated	O
drug-induced	O
liver	B-D008099
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	B-D004008
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	B-D016017
ratio	I-D016017
of	O
liver	B-D008099
injury	O

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	B-D016424
number	O
of	O
10	O
cases	O
of	O
liver	B-D008099
injury	O
associated	O
with	O
diclofenac,	B-D004008
the	O
adjusted	O
odds	B-D016017
ratio	I-D016017
increased	O
further	O
with	O
female	B-D005260
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
then	O
90	O
days	O

Physicians	B-D010820
should	O
measure	O
transaminases	B-D000637
at	O
baseline	O
and	O
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
transaminases	B-D000637
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
diclofenac	B-D004008
sodium	B-D012964
should	O
be	O
discontinued	O
immediately	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
diclofenac	B-D004008
sodium	B-D012964
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver-related	B-D008099
event	O
in	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium,	B-D012964
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	B-D004008
sodium	B-D012964
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	B-D000082
antibiotics,	O
antiepileptics)	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension,	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotension	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
DRUG	B-D004347
INTERACTIONS	I-D004347
(7)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
diclofenac	B-D004008
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
DRUG	B-D004347
INTERACTIONS	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
diclofenac	B-D004008
sodium	B-D012964
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
diclofenac	B-D004008
sodium	B-D012964
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
[see	O
DRUG	B-D004347
INTERACTIONS	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
diclofenac	B-D004008
sodium	B-D012964
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
diclofenac	B-D004008
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
(see	O
CONTRAINDICATIONS	B-D000075202
(4)	O
and	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.8)]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
diclofenac	B-D004008
sodium	B-D012964
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
CONTRAINDICATIONS	B-D000075202
(4)]	O

When	O
diclofenac	B-D004008
sodium	B-D012964
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Diclofenac	B-D004008
sodium	B-D012964
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
CONTRAINDICATIONS	B-D000075202
(4)]	O

Do	O
not	O
apply	O
diclofenac	B-D004008
sodium	B-D012964
to	O
open	O
skin	B-D012867
wounds,	O
infections,	B-D007239
inflammations,	B-D007249
or	O
exfoliative	O
dermatitis,	B-D003872
as	O
it	O
may	O
affect	B-D000339
absorption	B-D000042
and	O
tolerability	O
of	O
the	O
drug	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium,	B-D012964
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
USE	O
IN	O
SPECIFIC	O
POPULATIONS	B-D011153
(8.1)]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
diclofenac	B-D004008
sodium,	B-D012964
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
DRUG	B-D004347
INTERACTIONS	I-D004347
(7)]	O

The	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	B-D006262
subjects	O
administered	O
80	O
drops	O
four	O
times	B-D013995
a	O
day	O
for	O
7	O
days	O

There	O
was	O
no	O
significant	O
change	O
in	O
platelet	B-D010974
aggregation	I-D010974
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	B-D004008
sodium	B-D012964
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2,	O
5.3,	O
5.6)]	O

5.14	O
Sun	O
Exposure	O
Instruct	O
patients	B-D010361
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
on	O
treated	O
knee(s)	B-D007717
because	O
studies	O
in	O
animals	B-D000818
indicated	O
topical	O
diclofenac	B-D004008
treatment	O
resulted	O
in	O
an	O
earlier	B-D004423
onset	O
of	O
ultraviolet	O
light-induced	B-D008027
skin	B-D012867
tumors	O

The	O
potential	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
on	O
skin	B-D012867
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	B-D006801
are	O
not	O
known	O

5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	B-D004008
sodium	B-D012964
with	O
eyes	B-D005123
and	O
mucosa	O

Advise	O
patients	B-D010361
that	O
if	O
eye	B-D005123
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	B-D005123
with	O
water	B-D014867
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour	O

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	B-D004008
sodium	B-D012964
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	B-D006470
more	O
frequent	O
abnormal	O
creatinine,	B-D003404
urea	B-D014508
and	O
hemoglobin	O

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	B-D012306
and	O
conduct	O
periodic	O
laboratory	O
evaluations	O

The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O
Hepatotoxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.3)]	O
Hypertension	B-D006973
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.11)]	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
of	O
911	O
patients	B-D010361
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	B-D010361
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	B-D010361
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	B-D010361
treated	O
for	O
at	O
least	O
12	O
months	O

The	O
population	B-D011153
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	B-D010361
were	O
Caucasians,	O
64%	O
were	O
females,	B-D005260
and	O
all	O
patients	B-D010361
had	O
primary	O
osteoarthritis	B-D010003
	O

The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

Application	O
site	O
reactions	O
were	O
characterized	B-D002605
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	B-D004890
induration,	O
vesicles,	O
paresthesia,	B-D010292
pruritus,	B-D011537
vasodilation,	B-D014664
acne,	O
and	O
urticaria	B-D014581
	O

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	B-D012867
(32%),	O
contact	O
dermatitis	B-D003872
characterized	B-D002605
by	O
skin	B-D012867
erythema	B-D004890
and	O
induration	O
(9%),	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
(2%)	O
and	O
pruritus	B-D011537
(4%)	O

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
oral	O
diclofenac	B-D004008
	O

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	B-D012449
study,	O
contact	O
dermatitis	B-D003872
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
in	O
10%	O
of	O
patients,	B-D010361
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	B-D007854
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%	O

Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	B-D003967
dyspepsia,	B-D004415
nausea,	B-D009325
flatulence,	B-D005414
abdominal	B-D015746
pain,	I-D015746
edema;	B-D004487
see	O
TABLE	O
1)	O

The	O
combination	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
oral	O
diclofenac,	B-D004008
compared	O
to	O
oral	O
diclofenac	B-D004008
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	B-D006470
(3%	O
vs	O

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	B-D003404
(12%	O
vs	O

7%),	O
urea	B-D014508
(20%	O
vs	O

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	B-D008099
transaminases	B-D000637
	O

Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
	O

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	B-D010361
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	B-D004008
trials	O

Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction*	O
N	O
(%)	O
N	O
(%)	O
*	O
Preferred	O
Term	O
according	O
to	O
COSTART	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis,	B-D003872
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

Body	O
as	O
a	O
Whole:	O
abdominal	B-D015746
pain,	I-D015746
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	B-D001247
back	B-D001416
pain,	I-D001416
body	O
odor,	O
chest	B-D002637
pain,	I-D002637
edema,	B-D004487
face	B-D005145
edema,	B-D004487
halitosis,	B-D006209
headache,	B-D006261
lack	O
of	O
drug	O
effect,	O
neck	B-D009333
rigidity,	O
pain	B-D010146
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	B-D003967
dry	O
mouth,	B-D009055
dyspepsia,	B-D004415
gastroenteritis,	B-D005759
decreased	O
appetite,	B-D001066
mouth	B-D009055
ulceration,	B-D014456
nausea,	B-D009325
rectal	O
hemorrhage,	B-D006470
ulcerative	B-D014456
stomatitis	B-D013280
Metabolic	O
and	O
Nutritional:	O
creatinine	B-D003404
increased	O
Musculoskeletal:	O
leg	B-D007866
cramps,	O
myalgia	B-D063806
Nervous:	O
depression,	B-D003863
dizziness,	B-D004244
drowsiness,	O
lethargy,	B-D053609
paresthesia,	B-D010292
paresthesia	B-D010292
at	O
application	O
site	O
Respiratory:	O
asthma,	B-D001249
dyspnea,	B-D004417
laryngismus,	B-D007826
laryngitis,	B-D007827
pharyngitis	B-D010612
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	B-D003877
contact	I-D003877
dermatitis	B-D003872
with	O
vesicles,	O
dry	O
skin,	B-D012867
pruritus,	B-D011537
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	B-D004485
rash,	O
pruritus,	B-D011537
skin	B-D012867
discoloration,	O
urticaria	B-D014581
Special	O
Senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	B-D002386
ear	B-D004423
pain,	B-D010146
eye	B-D005123
disorder,	O
eye	B-D058447
pain,	I-D058447
taste	B-D013649
perversion	O
BOXED	O
WARNING	O
SECTION	O
CONTRAINDICATIONS	B-D000075202
AND	O
WARNINGS	O
DICLOFENAC	B-D004008
SODIUM/MISOPROSTOL	B-D012964
TABLETS	B-D013607
CONTAIN	O
DICLOFENAC	B-D004008
SODIUM	B-D012964
AND	O
MISOPROSTOL	B-D016595
	O

ADMINISTRATION	O
OF	O
MISOPROSTOL	B-D016595
TO	O
WOMEN	B-D014930
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	B-D047928
BIRTH,	I-D047928
OR	O
BIRTH	O
DEFECTS	O

UTERINE	B-D014597
RUPTURE	I-D014597
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	B-D016595
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	B-D037841
WOMEN	I-D037841
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY	B-D011247
(see	O
also	O
PRECAUTIONS)	O

DICLOFENAC	B-D004008
SODIUM/MISOPROSTOL	B-D012964
TABLETS	B-D013607
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	B-D037841
WOMEN	I-D037841
(see	O
CONTRAINDICATIONS,	B-D000075202
WARNINGS	O
and	O
PRECAUTIONS)	O

PATIENTS	B-D010361
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS	O

Diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
should	O
not	O
be	O
used	O
in	O
women	B-D014930
of	O
childbearing	B-D002648
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	B-D012306
of	O
developing	O
gastric	O
or	O
duodenal	B-D004381
ulceration	I-D004381
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	B-D004381
ulcers	I-D004381
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID	O
(see	O
WARNINGS)	O

In	O
such	O
patients,	B-D010361
diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
has	O
had	O
a	O
negative	O
serum	B-D044967
pregnancy	B-D011247
test	B-C004551
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy	O

is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	B-D016595
the	O
risk	B-D012306
of	O
possible	O
contraception	B-D003267
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	B-D014930
of	O
childbearing	B-D002648
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake	O

will	O
begin	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	B-D008571
period	O

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
(see	O
WARNINGS)	O

Diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
are	O
contraindicated	O
for	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
SECTION	O
Adverse	O
reactions	O
associated	O
with	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
Adverse	O
reaction	O
information	O
for	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
is	O
derived	O
from	O
Phase	O
III	O
multinational	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
in	O
over	O
2,000	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
50	O
or	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
75,	O
as	O
well	O
as	O
from	O
blinded,	O
controlled	O
trials	O
of	O
Voltaren®	O
Delayed-Release	O
tablets	B-D013607
(diclofenac)	O
and	O
Cytotec®	O
tablets	B-D013607
(misoprostol)	O

Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
incidence	B-D015994
of	O
adverse	O
events	O
for	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
	O

These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
patients	B-D010361
on	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
and	O
5%	O
of	O
patients	B-D010361
on	O
diclofenac	B-D004008
	O

For	O
GI	O
ulcer	B-D014456
rates,	O
see	O
CLINICAL	O
STUDIES—Upper	O
gastrointestinal	O
safety	B-D012449
	O

GI	O
disorder	O
Diclofenac	B-D004008
sodium/misoprostol	B-D012964
Diclofenac	B-D004008
Abdominal	B-D015746
pain	I-D015746
21%	O
15%	O
Diarrhea	B-D003967
19%	O
11%	O
Dyspepsia	B-D004415
14%	O
11%	O
Nausea	B-D009325
11%	O
6%	O
Flatulence	B-D005414
9%	O
4%	O
Diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
can	O
cause	O
more	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
and	O
other	O
GI	O
symptoms	O
than	O
diclofenac	B-D004008
alone	O

Diarrhea	B-D003967
and	O
abdominal	B-D015746
pain	I-D015746
developed	O
early	B-D004423
in	O
the	O
course	O
of	O
therapy,	O
and	O
were	O
usually	O
self-limited	O
(resolved	O
after	O
2	O
to	O
7	O
days)	O

Rare	O
instances	O
of	O
profound	O
diarrhea	B-D003967
leading	B-D007854
to	O
severe	O
dehydration	B-D003681
have	O
been	O
reported	O
in	O
patients	B-D010361
receiving	O
misoprostol	B-D016595
	O

Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
disease,	B-D004194
or	O
those	O
in	O
whom	O
dehydration,	B-D003681
were	O
it	O
to	O
occur,	O
would	O
be	O
dangerous,	O
should	O
be	O
monitored	O
carefully	O
if	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
are	O
prescribed	O

The	O
incidence	B-D015994
of	O
diarrhea	B-D003967
can	O
be	O
minimized	O
by	O
administering	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
with	O
food	B-D005502
and	O
by	O
avoiding	O
coadministration	O
with	O
magnesium-containing	B-D008274
antacids	B-D000863
	O

Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
misoprostol	B-D016595
use	O
have	O
also	O
been	O
reported	O
for	O
women	B-D014930
receiving	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
(see	O
below)	O

Postmenopausal	O
vaginal	B-D014621
bleeding	O
may	O
be	O
related	O
to	O
administration	O
of	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
	O

If	O
it	O
occurs,	O
diagnostic	O
workup	B-D014937
should	O
be	O
undertaken	O
to	O
rule	O
out	O
gynecological	O
pathology	B-D010336
(see	O
boxed	O
CONTRAINDICATIONS	B-D000075202
AND	O
WARNINGS)	O

Elderly	O
Overall,	B-D016424
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
safety	B-D012449
profile	B-C546490
of	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets	B-D013607
in	O
over	O
500	O
patients	B-D010361
65	O
years	O
of	O
age	O
or	O
older	O
compared	O
with	O
younger	O
patients	B-D010361
	O

Other	O
adverse	O
experiences	O
reported	O
occasionally	O
or	O
rarely	O
with	O
diclofenac	B-D004008
sodium/misoprostol	B-D012964
tablets,	B-D013607
diclofenac	B-D004008
or	O
other	O
NSAIDs,	O
or	O
misoprostol	B-D016595
are:	O
Body	O
as	O
a	O
whole:	O
Asthenia,	B-D001247
death,	B-D003643
fatigue,	B-D005221
fever,	B-D005334
infection,	O
malaise,	O
sepsis,	B-D018805
chills	B-D023341
	O

Cardiovascular	B-D002319
system:	I-D002319
Arrhythmia,	O
atrial	B-D001281
fibrillation,	I-D001281
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
hypotension,	B-D007022
increased	O
CPK,	O
increased	O
LDH,	O
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
phlebitis,	B-D010689
premature	B-C070504
ventricular	O
contractions,	O
syncope,	B-D013575
tachycardia,	B-D013610
vasculitis	B-D014657
	O

Central	O
and	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Coma,	B-D003128
convulsions,	O
dizziness,	B-D004244
drowsiness,	O
headache,	B-D006261
hyperesthesia,	B-D006941
hypertonia,	O
hypoesthesia,	O
insomnia,	O
meningitis,	B-D008581
migraine,	O
neuralgia,	B-D009437
paresthesia,	B-D010292
somnolence,	O
stroke,	B-D020521
tremor,	B-D014202
vertigo	B-D014717
	O

Digestive:	O
Anorexia,	B-D000855
appetite	B-D001066
changes,	O
constipation,	B-D003248
dry	O
mouth,	B-D009055
dysphagia,	O
enteritis,	B-D004751
esophageal	O
ulceration,	B-D014456
esophagitis,	B-D004941
eructation,	B-D004884
gastritis,	B-D005756
gastroesophageal	B-D005764
reflux,	I-D005764
GI	O
bleeding,	O
GI	O
neoplasm	O
benign,	O
glossitis,	B-D005928
heartburn,	B-D006356
hematemesis,	B-D006396
hemorrhoids,	B-D006484
intestinal	B-D007416
perforation,	I-D007416
peptic	B-D010437
ulcer,	I-D010437
stomatitis	B-D013280
and	O
ulcerative	B-D014456
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
	O

Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940
pain,	B-D010146
dysmenorrhea,	B-D004412
intermenstrual	O
bleeding,	O
leukorrhea,	B-D007973
menstrual	B-D008571
disorder,	O
menorrhagia,	B-D008595
vaginal	B-D014621
hemorrhage	B-D006470
	O

Hemic	O
and	O
lymphatic	B-D008208
system:	I-D008208
Agranulocytosis,	B-D000380
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
coagulation	O
time	B-D013995
increased,	O
ecchymosis,	B-D004438
eosinophilia,	B-D004802
epistaxis,	B-D004844
hemolytic	O
anemia,	B-D000740
leukocytosis,	B-D007964
leukopenia,	B-D007970
lymphadenopathy,	B-D000072281
melena,	B-D008551
pancytopenia,	B-D010198
pulmonary	B-D011655
embolism,	I-D011655
purpura,	B-D011693
rectal	O
bleeding,	O
thrombocythemia,	O
thrombocytopenia	B-D013921
	O

Hypersensitivity:	B-D006967
Angioedema,	B-D000799
laryngeal/pharyngeal	O
edema,	B-D004487
urticaria	B-D014581
	O

Liver	B-D008099
and	O
biliary	O
system:	O
Abnormal	O
hepatic	O
function,	O
bilirubinemia,	B-D001663
hepatitis,	B-D006505
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
pancreatitis	B-D010195
	O

Male	B-D008297
reproductive	O
disorders:	O
Impotence,	O
perineal	O
pain	B-D010146
	O

Metabolic	O
and	O
nutritional:	O
Alanine	B-D000409
aminotransferase	O
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
aspartate	O
aminotransferase	O
increased,	O
BUN	O
increased,	O
dehydration,	B-D003681
glycosuria,	B-D006029
gout,	B-D006073
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hyperuricemia,	B-D033461
hypoglycemia,	B-D007003
hyponatremia,	B-D007010
periorbital	O
edema,	B-D004487
porphyria,	O
weight	O
changes	O

Musculoskeletal	B-D009141
system:	I-D009141
Arthralgia,	B-D018771
myalgia	B-D063806
	O

Psychiatric:	O
Anxiety,	B-D001007
concentration	O
impaired,	O
confusion,	B-D003221
depression,	B-D003863
disorientation,	O
dream	O
abnormalities,	O
hallucinations,	B-D006212
irritability,	O
nervousness,	O
paranoia,	O
psychotic	O
reaction	O

Respiratory	B-D012137
system:	I-D012137
Asthma,	B-D001249
coughing,	B-D003371
dyspnea,	B-D004417
hyperventilation,	B-D006985
pneumonia,	B-D011014
respiratory	O
depression	B-D003863
	O

Skin	B-D012867
and	O
appendages:	O
Acne,	O
alopecia,	B-D000505
bruising,	O
eczema,	B-D004485
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
pemphigoid	O
reaction,	O
photosensitivity,	O
pruritus,	B-D011537
pruritus	B-D011538
ani,	I-D011538
rash,	O
skin	B-D012883
ulceration,	I-D012883
Stevens-Johnson	B-D013262
syndrome,	I-D013262
sweating	B-D013546
increased,	O
toxic	O
epidermal	O
necrolysis	O

Special	O
senses:	O
Hearing	B-D006309
impairment,	O
taste	B-D013649
loss,	O
taste	B-D013649
perversion,	O
tinnitus	B-D014012
	O

Urinary	O
system:	O
Cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
micturition	O
frequency,	O
nocturia,	B-D053158
nephrotic	B-D009404
syndrome,	I-D009404
oliguria/polyuria,	B-D009846
papillary	O
necrosis,	B-D009336
proteinuria,	B-D011507
renal	O
failure,	O
urinary	B-D014551
tract	I-D014551
infection,	O
glomerulonephritis	B-D005921
membranous,	O
glomerulonephritis	B-D005921
minimal	O
lesion	O

Vision:	O
Amblyopia,	B-D000550
blurred	O
vision,	O
conjunctivitis,	B-D003231
diplopia,	B-D004172
glaucoma,	B-D005901
iritis,	B-D007500
lacrimation	O
abnormal,	O
night	B-D009755
blindness,	I-D009755
vision	O
abnormal	O

BOXED	O
WARNING	O
SECTION	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(See	O
WARNINGS)	O

Diclofenac	B-D004008
sodium	B-D012964
extended-release	O
tablets,	B-D013607
USP	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(See	O
ADVERSE	O
REACTIONS	O
SECTION	O
In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
sodium	B-D012964
extended-release	O
tablets,	B-D013607
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

•Diclofenac	O
sodium	B-D012964
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
•NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NASAID-treated	B-C015378
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	B-D004008
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.3	O
Hepatotoxicity	O
In	O
clinical	B-D016430
trials,	I-D016430
of	O
oral	O
diclofenac-containing	B-D004008
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
with	O
oral	O
diclofenac	B-D004008
for	O
2	O
to	O
6	O
months,	O
patients	B-D010361
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
tests	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

In	O
a	O
European	B-D005060
retrospective	O
population-based,	B-D011153
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	B-D004008
associated	O
drug-induced	O
liver	B-D008099
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	B-D004008
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	B-D016017
ratio	I-D016017
of	O
liver	B-D008099
injury	O

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	B-D016424
number	O
of	O
10	O
cases	O
of	O
liver	B-D008099
injury	O
associated	O
with	O
diclofenac,	B-D004008
the	O
adjusted	O
odds	B-D016017
ratio	I-D016017
increased	O
further	O
with	O
female	B-D005260
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days	O

Physicians	B-D010820
should	O
measure	O
transaminases	B-D000637
at	O
baseline	O
and	O
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
transaminases	B-D000637
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
should	O
be	O
discontinued	O
immediately	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver-related	B-D008099
event	O
in	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	B-D000082
antibiotics,	O
antiepileptics)	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension,	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
diclofenac	B-D004008
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
diclofenac	B-D004008
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)]	O

When	O
diclofenac	B-D004008
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)]	O

Do	O
not	O
apply	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
to	O
open	O
skin	B-D012867
wounds,	O
infections,	B-D007239
inflammations,	B-D007249
or	O
exfoliative	O
dermatitis,	B-D003872
as	O
it	O
may	O
affect	B-D000339
absorption	B-D000042
and	O
tolerability	O
of	O
the	O
drug	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
diclofenac,	B-D004008
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

The	O
effects	O
of	O
diclofenac	B-D004008
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	B-D006262
subjects	O
administered	O
80	O
drops	O
four	O
times	B-D013995
a	O
day	O
for	O
7	O
days	O

There	O
was	O
no	O
significant	O
change	O
in	O
platelet	B-D010974
aggregation	I-D010974
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	B-D004008
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)]	O

5.14	O
Sun	O
Exposure	O
Instruct	O
patients	B-D010361
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
on	O
treated	O
knee(s)	B-D007717
because	O
studies	O
in	O
animals	B-D000818
indicated	O
topical	O
diclofenac	B-D004008
treatment	O
resulted	O
in	O
an	O
earlier	B-D004423
onset	O
of	O
ultraviolet	O
light-induced	B-D008027
skin	B-D012867
tumors	O

The	O
potential	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
on	O
skin	B-D012867
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	B-D006801
are	O
not	O
known	O

5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
eyes	B-D005123
and	O
mucosa	O

Advise	O
patients	B-D010361
that	O
if	O
eye	B-D005123
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	B-D005123
with	O
water	B-D014867
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour	O

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	B-D006470
more	O
frequent	O
abnormal	O
creatinine,	B-D003404
urea	B-D014508
and	O
hemoglobin	O

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	B-D012306
and	O
conduct	O
periodic	O
laboratory	O
evaluations.Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	B-D006470
more	O
frequent	O
abnormal	O
creatinine,	B-D003404
urea	B-D014508
and	O
hemoglobin	O

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	B-D012306
and	O
conduct	O
periodic	O
laboratory	O
evaluations	O

The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
of	O
911	O
patients	B-D010361
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	B-D010361
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	B-D010361
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	B-D010361
treated	O
for	O
at	O
least	O
12	O
months	O

The	O
population	B-D011153
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	B-D010361
were	O
Caucasians,	O
64%	O
were	O
females,	B-D005260
and	O
all	O
patients	B-D010361
had	O
primary	O
osteoarthritis	B-D010003
	O

The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

Application	O
site	O
reactions	O
were	O
characterized	B-D002605
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	B-D004890
induration,	O
vesicles,	O
paresthesia,	B-D010292
pruritus,	B-D011537
vasodilation,	B-D014664
acne,	O
and	O
urticaria	B-D014581
	O

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	B-D012867
(32%),	O
contact	O
dermatitis	B-D003872
characterized	B-D002605
by	O
skin	B-D012867
erythema	B-D004890
and	O
induration	O
(9%),	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
(2%)	O
and	O
pruritus	B-D011537
(4%)	O

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
oral	O
diclofenac	B-D004008
	O

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	B-D012449
study,	O
contact	O
dermatitis	B-D003872
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
in	O
10%	O
of	O
patients,	B-D010361
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	B-D007854
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%	O

Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	B-D003967
dyspepsia,	B-D004415
nausea,	B-D009325
flatulence,	B-D005414
abdominal	B-D015746
pain,	I-D015746
edema;	B-D004487
see	O
Table	O
1)	O

The	O
combination	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
oral	O
diclofenac,	B-D004008
compared	O
to	O
oral	O
diclofenac	B-D004008
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	B-D006470
(3%	O
vs	O

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	B-D003404
(12%	O
vs	O

7%),	O
urea	B-D014508
(20%	O
vs	O

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	B-D008099
transaminases	B-D000637
	O

Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
	O

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥	O
1%	O
of	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	B-D004008
trials	O

Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction†	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis,	B-D003872
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
†Preferred	O
Term	O
according	O
to	O
COSTART	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

Body	O
as	O
a	O
Whole:	O
abdominal	B-D015746
pain,	I-D015746
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	B-D001247
back	B-D001416
pain,	I-D001416
body	O
odor,	O
chest	B-D002637
pain,	I-D002637
edema,	B-D004487
face	B-D005145
edema,	B-D004487
halitosis,	B-D006209
headache,	B-D006261
lack	O
of	O
drug	O
effect,	O
neck	B-D009333
rigidity,	O
pain	B-D010146
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	B-D003967
dry	O
mouth,	B-D009055
dyspepsia,	B-D004415
gastroenteritis,	B-D005759
decreased	O
appetite,	B-D001066
mouth	B-D009055
ulceration,	B-D014456
nausea,	B-D009325
rectal	O
hemorrhage,	B-D006470
ulcerative	B-D014456
stomatitis	B-D013280
Metabolic	O
and	O
Nutritional:	O
creatinine	B-D003404
increased	O
Musculoskeletal:	O
leg	B-D007866
cramps,	O
myalgia	B-D063806
Nervous:	O
depression,	B-D003863
dizziness,	B-D004244
drowsiness,	O
lethargy,	B-D053609
paresthesia,	B-D010292
paresthesia	B-D010292
at	O
application	O
site	O
Respiratory:	O
asthma,	B-D001249
dyspnea,	B-D004417
laryngismus,	B-D007826
laryngitis,	B-D007827
pharyngitis	B-D010612
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	B-D003877
contact	I-D003877
dermatitis	B-D003872
with	O
vesicles,	O
dry	O
skin,	B-D012867
pruritus,	B-D011537
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	B-D004485
rash,	O
pruritus,	B-D011537
skin	B-D012867
discoloration,	O
urticaria	B-D014581
Special	O
Senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	B-D002386
ear	B-D004423
pain,	B-D010146
eye	B-D005123
disorder,	O
eye	B-D058447
pain,	I-D058447
taste	B-D013649
perversion	O
Boxed	O
Warning	O
boxed	O
warning	O
Adverse	O
Reactions	O
ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
Diclofenac	B-D004008
Sodium	B-D012964
Delayed-Release	O
Tablets,	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Rising	O
Pharmaceuticals,	O
Inc	O

at	O
1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch.1	O
1	O
-	O
to	O
report	O
suspected	O
adverse	O
reactions	O
call	O
1-800-332-1088	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O

Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
a	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS)	O

In	O
patients	B-D010361
taking	O
etodolac	B-D017308
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal),	O
vomiting	B-D014839
	O

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritis,	O
rashes,	O
tinnitus	B-D014012
	O

Adverse-reaction	O
information	O
for	O
etodolac	B-D017308
was	O
derived	O
from	O
2,629	O
arthritic	B-D001154
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
in	O
double-blind	O
and	O
open-label	O
clinical	B-D016430
trials	I-D016430
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies	O

In	O
clinical	B-D016430
trials,	I-D016430
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient	O

The	O
discontinuation	O
rate	O
in	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

New	O
patient	O
complaints	O
(with	O
an	O
incidence	B-D015994
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system	O

The	O
incidences	B-D015994
were	O
determined	O
from	O
clinical	B-D016430
trials	I-D016430
involving	O
465	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	B-D017308
b.i.d	O

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever	B-D005334
	O

Digestive	B-D004064
system	I-D004064
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	B-D015746
pain*,	I-D015746
diarrhea*,	B-D003967
flatulence*,	B-D005414
nausea*,	B-D009325
constipation,	B-D003248
gastritis,	B-D005756
melena,	B-D008551
vomiting	B-D014839
	O

Nervous	B-D009420
system	I-D009420
-	O
Asthenia/malaise*,	B-D001247
dizziness*,	B-D004244
depression,	B-D003863
nervousness	O

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus,	B-D011537
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus	B-D014012
	O

Urogenital	B-D014566
system	I-D014566
-	O
Dysuria,	B-D053159
urinary	O
frequency	O

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	B-D016430
trials,	I-D016430
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock)	B-D012769
	O

Cardiovascular	B-D002319
system	I-D002319
-	O
Hypertension,	B-D006973
congestive	O
heart	B-D006333
failure,	I-D006333
flushing,	B-D005483
palpitations,	O
syncope,	B-D013575
vasculitis	B-D014657
(including	O
necrotizing	O
and	O
allergic)	O

Digestive	B-D004064
system	I-D004064
-	O
Thirst,	B-D013894
dry	O
mouth,	B-D009055
ulcerative	B-D014456
stomatitis,	B-D013280
anorexia,	B-D000855
eructation,	B-D004884
elevated	O
liver	B-D008099
enzymes,	B-D004798
cholestatic	O
hepatitis,	B-D006505
hepatitis,	B-D006505
cholestatic	O
jaundice,	B-D007565
duodenitis,	B-D004382
jaundice,	B-D007565
hepatic	O
failure,	O
liver	B-D008099
necrosis,	B-D009336
peptic	B-D010437
ulcer	I-D010437
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	B-D014456
pancreatitis	B-D010195
	O

Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
Ecchymosis,	B-D004438
anemia,	B-D000740
thrombocytopenia,	B-D013921
bleeding	B-D001760
time	I-D001760
increased,	O
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000740
leukopenia,	B-D007970
neutropenia,	B-D009503
pancytopenia	B-D010198
	O

Metabolic	O
and	O
nutritional	O
-	O
Edema,	B-D004487
serum	B-D044967
creatinine	B-D003404
increase,	O
hyperglycemia	B-D006943
in	O
previously	O
controlled	O
diabetic	O
patients	B-D010361
	O

Nervous	B-D009420
system	I-D009420
-	O
Insomnia,	O
somnolence	O

Respiratory	B-D012137
system	I-D012137
-	O
Asthma,	B-D001249
pulmonary	O
infiltration	O
with	O
eosinophilia	B-D004802
	O

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema,	B-D000799
sweating,	B-D013546
urticaria,	B-D014581
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	B-D014657
with	O
purpura,	B-D011693
Stevens-Johnson	B-D013262
Syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis,	O
hyperpigmentation,	B-D017495
erythema	B-D004892
multiforme	I-D004892
	O

Special	O
senses	O
-	O
Photophobia,	B-D020795
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
system	I-D014566
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	B-D051437
insufficiency,	I-D051437
renal	O
papillary	O
necrosis	B-D009336
	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	B-D017308
is	O
uncertain	O

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	B-D010820
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache	B-D006261
	O

Cardiovascular	B-D002319
system	I-D002319
-	O
Arrhythmias,	O
myocardial	B-D009203
infarction,	I-D009203
cerebrovascular	B-C079279
accident	O

Digestive	B-D004064
system	I-D004064
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis	B-D003092
	O

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
system	I-D009420
-	O
Paresthesia,	B-D010292
confusion	B-D003221
	O

Respiratory	B-D012137
system	I-D012137
-	O
Bronchitis,	B-D001991
dyspnea,	B-D004417
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis	B-D012852
	O

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia,	B-D000505
maculopapular	O
rash,	O
photosensitivity,	O
skin	B-D012867
peeling	O

Special	O
senses	O
-	O
Conjunctivitis,	B-D003231
deafness,	B-D003638
taste	B-D013649
perversion	O

Urogenital	B-D014566
system	I-D014566
-	O
Cystitis,	B-D003556
hematuria,	B-D006417
leukorrhea,	B-D007973
renal	O
calculus,	O
interstitial	O
nephritis,	B-D009393
uterine	O
bleeding	O
irregularities	O

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis,	B-D018805
death	B-D003643
Cardiovascular	B-D002319
system	I-D002319
-	O
Tachycardia	B-D013610
Digestive	B-D004064
system	I-D004064
-	O
Gastric	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis	B-D006396
Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
Lymphadenopathy	B-D000072281
Nervous	B-D009420
system	I-D009420
-	O
Anxiety,	B-D001007
dream	O
abnormalities,	O
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis,	B-D008581
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
system	I-D012137
-	O
Respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Urogenital	B-D014566
system	I-D014566
-	O
Oliguria/polyuria,	B-D009846
proteinuria	B-D011507
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O

Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
indomethacin,	B-D007213
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2	O
)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4	O
)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
indomethacin	B-D007213
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
indomethacin,	B-D007213
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
indomethacin	B-D007213
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
indomethacin	B-D007213
	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
indomethacin	B-D007213
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
indomethacin	B-D007213
capsules,	B-D002214
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
pre-existing	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7	O
)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
indomethacin	B-D007213
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7	O
)]	O

Avoid	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
indomethacin	B-D007213
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
indomethacin	B-D007213
capsules	B-D002214
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
indomethacin	B-D007213
capsules	B-D002214
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7	O
)]	O

Avoid	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
indomethacin	B-D007213
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
the	O
potassium-sparing	B-D011188
diuretic,	O
triamterene,	B-D014223
to	O
a	O
maintenance	B-D008283
schedule	O
of	O
indomethacin	B-D007213
resulted	O
in	O
reversible	O
acute	O
renal	O
failure	O
in	O
two	O
of	O
four	O
healthy	B-D064368
volunteers	I-D064368
	O

Indomethacin	B-D007213
and	O
triamterene	B-D014223
should	O
not	O
be	O
administered	O
together	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

Both	O
indomethacin	B-D007213
and	O
potassium-sparing	B-D011188
diuretics	B-D004232
may	O
be	O
associated	O
with	O
increased	O
serum	B-D044967
potassium	B-D011188
levels	O

The	O
potential	O
effects	O
of	O
indomethacin	B-D007213
and	O
potassium-sparing	B-D011188
diuretics	B-D004232
on	O
potassium	B-D011188
levels	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O

5.7	O
Anaphylactic	O
Reactions	O
Indomethacin	B-D007213
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
indomethacin	B-D007213
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[	O
see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8	O
)]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
indomethacin	B-D007213
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(4	O
)]	O

When	O
indomethacin	B-D007213
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
indomethacin,	B-D007213
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Indomethacin	B-D007213
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4	O
)]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Indomethacin	B-D007213
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
indomethacin	B-D007213
capsules,	B-D002214
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1	O
)]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
indomethacin	B-D007213
capsules	B-D002214
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
indomethacin	B-D007213
capsules,	B-D002214
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7	O
)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6	O
)]	O

5.14	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects:	O
Indomethacin	B-D007213
may	O
aggravate	O
depression	B-D003863
or	O
other	O
psychiatric	O
disturbances,	O
epilepsy,	B-D004827
and	O
parkinsonism,	O
and	O
should	O
be	O
used	O
with	O
considerable	O
caution	O
in	O
patients	B-D010361
with	O
these	O
conditions	O

If	O
severe	O
CNS	O
adverse	O
reactions	O
develop,	O
indomethacin	B-D007213
should	O
be	O
discontinued	O

Indomethacin	B-D007213
may	O
cause	O
drowsiness;	O
therefore,	O
patients	B-D010361
should	O
be	O
cautioned	O
about	O
engaging	O
in	O
activities	O
requiring	O
mental	B-D008571
alertness	O
and	O
motor	O
coordination,	O
such	O
as	O
driving	O
a	O
car	O

Indomethacin	B-D007213
may	O
also	O
cause	O
headache	B-D006261
	O

Headache	B-D006261
which	O
persists	O
despite	O
dosage	O
reduction	O
requires	O
cessation	O
of	O
therapy	O
with	O
indomethacin	B-D007213
	O

5.15	O
Ocular	O
Effects:	O
Corneal	B-D003315
deposits	B-C020884
and	O
retinal	B-D012160
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
who	O
had	O
received	O
prolonged	O
therapy	O
with	O
indomethacin	B-D007213
	O

The	O
prescribing	O
physician	O
should	O
be	O
alert	O
to	O
the	O
possible	O
association	B-D001244
between	O
the	O
changes	O
noted	O
and	O
indomethacin	B-D007213
	O

It	O
is	O
advisable	O
to	O
discontinue	O
therapy	O
if	O
such	O
changes	O
are	O
observed	O

Blurred	O
vision	O
may	O
be	O
a	O
significant	O
symptom	O
and	O
warrants	O
a	O
thorough	O
ophthalmological	O
examination	O

Since	O
these	O
changes	O
may	O
be	O
asymptomatic,	O
ophthalmologic	O
examination	O
at	O
periodic	O
intervals	O
is	O
desirable	O
in	O
patients	B-D010361
where	O
therapy	O
is	O
prolonged	O

The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)]	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O

In	O
a	O
gastroscopic	O
study	O
in	O
45	O
healthy	B-D006262
subjects,	O
the	O
number	O
of	O
gastric	B-D005753
mucosal	I-D005753
abnormalities	O
was	O
significantly	O
higher	O
in	O
the	O
group	O
receiving	O
indomethacin	B-D007213
capsules	B-D002214
than	O
in	O
the	O
group	O
taking	O
indomethacin	B-D007213
Suppositories	B-D013488
or	O
placebo	O

In	O
a	O
double-blind	O
comparative	O
clinical	B-D000068397
study	I-D000068397
involving	O
175	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis,	B-D001168
however,	O
the	O
incidence	B-D015994
of	O
upper	O
gastrointestinal	O
adverse	O
effects	O
with	O
indomethacin	B-D007213
Suppositories	B-D013488
or	O
Capsules	B-D002214
was	O
comparable	O

The	O
incidence	B-D015994
of	O
lower	O
gastrointestinal	O
adverse	O
effects	O
was	O
greater	O
in	O
the	O
suppository	O
group	O

The	O
adverse	O
reactions	O
for	O
indomethacin	B-D007213
capsules	B-D002214
listed	O
in	O
the	O
following	O
table	O
have	O
been	O
arranged	O
into	O
two	O
groups:	O
(1)	O
incidence	B-D015994
greater	O
than	O
1%;	O
and	O
(2)	O
incidence	B-D015994
less	O
than	O
1%	O

The	O
incidence	B-D015994
for	O
group	O
(1)	O
was	O
obtained	O
from	O
33	O
double-blind	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
reported	O
in	O
the	O
literature	B-D008091
(1,092	O
patients)	B-D010361
	O

The	O
incidence	B-D015994
for	O
group	O
(2)	O
was	O
based	O
on	O
reports	O
in	O
clinical	B-D016430
trials,	I-D016430
in	O
the	O
literature,	B-D008091
and	O
on	O
voluntary	O
reports	O
since	O
marketing	B-D040541
	O

The	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists	O
between	O
indomethacin	B-D007213
and	O
these	O
adverse	O
reactions,	O
some	O
of	O
which	O
have	O
been	O
reported	O
only	O
rarely	O

Table	O
1:	O
Summary	O
of	O
Adverse	O
reactions	O
for	O
Indomethacin	B-D007213
Capsules	B-D002214
Incidence	B-D015994
greater	O
than	O
1%	O
Incidence	B-D015994
less	O
than	O
1%	O
GASTROINTESTINAL	O
nausea*	B-D009325
with	O
or	O
without	O
vomiting	B-D014839
dyspepsia*	B-D004415
(including	O
indigestion,	O
heartburn	B-D006356
and	O
epigastric	O
pain)	B-D010146
diarrhea	B-D003967
abdominal	O
distress	O
or	O
pain	B-D010146
constipation	B-D003248
Anorexia	B-D000855
bloating	O
(includes	O
distension)	O
flatulence	B-D005414
peptic	B-D010437
ulcer	I-D010437
gastroenteritis	B-D005759
rectal	O
bleeding	O
proctitis	B-D011349
single	O
or	O
multiple	O
ulcerations,	B-D014456
including	O
perforation	O
and	O
hemorrhage	B-D006470
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
duodenum	B-D004386
or	O
small	O
and	O
large	O
intestines	B-D007422
intestinal	O
ulceration	B-D014456
associated	O
with	O
stenosis	O
and	O
obstruction	O
gastrointestinal	O
bleeding	O
without	O
obvious	O
ulcer	B-D014456
formation	B-D020478
and	O
perforation	O
of	O
pre-existing	O
sigmoid	O
lesions	O
(diverticulum,	O
carcinoma,	B-D002277
etc.)	O
development	O
of	O
ulcerative	B-D014456
colitis	B-D003092
and	O
regional	O
ileitis	B-D007079
ulcerative	B-D014456
stomatitis	B-D013280
toxic	O
hepatitis	B-D006506
and	I-D006506
jaundice	B-D007565
(some	O
fatal	O
cases	O
have	O
been	O
reported)	O
intestinal	O
strictures	O
(diaphragms)	O
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
headache	B-D006261
(11.7%)	O
dizziness*	B-D004244
vertigo	B-D014717
somnolence	O
depression	B-D003863
and	O
fatigue	B-D005221
(including	O
malaise	O
and	O
listlessness)	O
anxiety	B-D001007
(includes	O
nervousness)	O
muscle	B-D018908
weakness	I-D018908
involuntary	O
muscle	O
movements	B-D009068
insomnia	O
muzziness	O
psychic	O
disturbances	O
including	O
psychotic	O
episodes	O
mental	B-D008571
confusion	B-D003221
drowsiness	O
light-headedness	B-D008027
syncope	B-D013575
paresthesia	B-D010292
aggravation	O
of	O
epilepsy	B-D004827
and	O
parkinsonism	O
depersonalization	B-D003861
coma	B-D003128
peripheral	O
neuropathy	O
convulsion	O
dysarthria	B-D004401
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
ocular	O
—	O
corneal	B-D003315
deposits	B-C020884
and	O
retinal	B-D012160
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
reported	O
in	O
some	O
patients	B-D010361
on	O
prolonged	O
therapy	O
with	O
indomethacin	B-D007213
blurred	O
vision	O
diplopia	B-D004172
hearing	B-D006309
disturbances,	O
deafness	B-D003638
CARDIOVASCULAR	O
None	O
Hypertension	B-D006973
hypotension	B-D007022
tachycardia	B-D013610
chest	B-D002637
pain	I-D002637
congestive	O
heart	B-D006333
failure	I-D006333
arrhythmia;	O
palpitations	O
METABOLIC	O
none	O
Edema	B-D004487
weight	B-D015430
gain	I-D015430
fluid	O
retention	O
flushing	B-D005483
or	O
sweating	B-D013546
Hyperglycemia	B-D006943
glycosuria	B-D006029
hyperkalemia	B-D006947
INTEGUMENTARY	O
None	O
Pruritus	B-D011537
rash;	O
urticaria	B-D014581
petechiae	O
or	O
ecchymosis	B-D004438
exfoliative	O
dermatitis	B-D003872
erythema	B-D004893
nodosum	I-D004893
loss	O
of	O
hair	B-D006197
Stevens-Johnson	B-D013262
syndrome	I-D013262
erythema	B-D004892
multiforme	I-D004892
toxic	O
epidermal	O
necrolysis	O
HEMATOLOGIC	O
None	O
Leucopenia	O
bone	B-D001853
marrow	I-D001853
depression	B-D003863
anemia	B-D000740
secondary	O
to	O
obvious	O
or	O
occult	O
gastrointestinal	O
bleeding	O
aplastic	O
anemia	B-D000740
hemolytic	O
anemia	B-D000740
agranulocytosis	B-D000380
thrombocytopenic	O
purpura	B-D011693
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
HYPERSENSITIVITY	B-D006967
None	O
acute	O
anaphylaxis	B-D000707
acute	O
respiratory	O
distress	O
rapid	O
fall	O
in	O
blood	B-D001794
pressure	I-D001794
resembling	O
a	O
shock-like	B-D012769
state	O
angioedema	B-D000799
Dyspnea	B-D004417
asthma	B-D001249
purpura	B-D011693
angiitis	O
pulmonary	B-D011654
edema	I-D011654
fever	B-D005334
GENITOURINARY	O
None	O
Hematuria	B-D006417
vaginal	B-D014621
bleeding	O
proteinuria	B-D011507
nephrotic	B-D009404
syndrome	I-D009404
interstitial	O
nephritis	B-D009393
BUN	O
elevation	O
renal	B-D051437
insufficiency,	I-D051437
including	O
renal	O
failure	O
MISCELLANEOUS	O
None	O
Epistaxis	B-D004844
breast	B-D001940
changes,	O
including	O
enlargement	O
and	O
tenderness,	O
or	O
gynecomastia	B-D006177
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
indomethacin	B-D007213
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
Causal	O
relationship	O
unknown	O
:	O
Other	O
reactions	O
have	O
been	O
reported	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established	O

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
the	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
observations	B-D019370
are	O
being	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians:	B-D010820
Cardiovascular	O
:	O
Thrombophlebitis	B-D013924
Hematologic	O
:	O
Although	O
there	O
have	O
been	O
several	O
reports	O
of	O
leukemia,	B-D007938
the	O
supporting	O
information	O
is	O
weak	O

Genitourinary	O
:	O
Urinary	O
frequency	O

A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	B-D005208
particularly	O
in	O
association	B-D001244
with	O
Group	O
Aß	O
hemolytic	O
streptococcus,	B-D013291
has	O
been	O
described	O
in	O
persons	B-D009272
treated	O
with	O
nonsteroidal	O
anti-inflammatory	B-D000893
agents,	I-D000893
including	O
indomethacin,	B-D007213
sometimes	O
with	O
fatal	B-D017809
outcome	I-D017809
	O

BOXED	O
WARNING	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(See	O
WARNINGS	O
and	O
PRECAUTIONS)	O

IBU	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(See	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinaladverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforationof	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
eventscan	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms.Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinalevents	O

(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
withIbuprofen	O
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
thepercentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaintsranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
toaspirin	O
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidenceof	B-D015994
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
eitherthe	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
anincidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listedin	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000patients	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
ofat	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
werereported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience.These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
twoof	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
wherethe	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
inColumn	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
has	O
notbeen	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
thanat	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
withrheumatoid	O
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
stillwithin	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

BOXED	O
WARNING	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(See	O
WARNINGS	O
and	O
PRECAUTIONS)	O

IBU	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(See	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinaladverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforationof	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
eventscan	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms.Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinalevents	O

(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
withIbuprofen	O
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
thepercentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaintsranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
toaspirin	O
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidenceof	B-D015994
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
eitherthe	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
anincidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listedin	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000patients	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
ofat	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
werereported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience.These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
twoof	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
wherethe	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
inColumn	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
has	O
notbeen	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
thanat	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
withrheumatoid	O
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
stillwithin	O
the	O
ranges	O
reported	O
in	O
the	O
table	O
BOXED	O
WARNING	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O

Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
indomethacin,	B-D007213
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2	O
)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4	O
)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
indomethacin	B-D007213
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
indomethacin,	B-D007213
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
indomethacin	B-D007213
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
indomethacin	B-D007213
	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
indomethacin	B-D007213
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
indomethacin	B-D007213
capsules,	B-D002214
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
pre-existing	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7	O
)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
indomethacin	B-D007213
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7	O
)]	O

Avoid	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
indomethacin	B-D007213
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
indomethacin	B-D007213
capsules	B-D002214
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
indomethacin	B-D007213
capsules	B-D002214
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7	O
)]	O

Avoid	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
indomethacin	B-D007213
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
the	O
potassium-sparing	B-D011188
diuretic,	O
triamterene,	B-D014223
to	O
a	O
maintenance	B-D008283
schedule	O
of	O
indomethacin	B-D007213
resulted	O
in	O
reversible	O
acute	O
renal	O
failure	O
in	O
two	O
of	O
four	O
healthy	B-D064368
volunteers	I-D064368
	O

Indomethacin	B-D007213
and	O
triamterene	B-D014223
should	O
not	O
be	O
administered	O
together	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

Both	O
indomethacin	B-D007213
and	O
potassium-sparing	B-D011188
diuretics	B-D004232
may	O
be	O
associated	O
with	O
increased	O
serum	B-D044967
potassium	B-D011188
levels	O

The	O
potential	O
effects	O
of	O
indomethacin	B-D007213
and	O
potassium-sparing	B-D011188
diuretics	B-D004232
on	O
potassium	B-D011188
levels	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O

5.7	O
Anaphylactic	O
Reactions	O
Indomethacin	B-D007213
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
indomethacin	B-D007213
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[	O
see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8	O
)]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
indomethacin	B-D007213
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(4	O
)]	O

When	O
indomethacin	B-D007213
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
indomethacin,	B-D007213
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Indomethacin	B-D007213
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4	O
)]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Indomethacin	B-D007213
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
indomethacin	B-D007213
capsules,	B-D002214
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1	O
)]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
indomethacin	B-D007213
capsules	B-D002214
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
indomethacin	B-D007213
capsules,	B-D002214
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7	O
)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6	O
)]	O

5.14	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects:	O
Indomethacin	B-D007213
may	O
aggravate	O
depression	B-D003863
or	O
other	O
psychiatric	O
disturbances,	O
epilepsy,	B-D004827
and	O
parkinsonism,	O
and	O
should	O
be	O
used	O
with	O
considerable	O
caution	O
in	O
patients	B-D010361
with	O
these	O
conditions	O

If	O
severe	O
CNS	O
adverse	O
reactions	O
develop,	O
indomethacin	B-D007213
should	O
be	O
discontinued	O

Indomethacin	B-D007213
may	O
cause	O
drowsiness;	O
therefore,	O
patients	B-D010361
should	O
be	O
cautioned	O
about	O
engaging	O
in	O
activities	O
requiring	O
mental	B-D008571
alertness	O
and	O
motor	O
coordination,	O
such	O
as	O
driving	O
a	O
car	O

Indomethacin	B-D007213
may	O
also	O
cause	O
headache	B-D006261
	O

Headache	B-D006261
which	O
persists	O
despite	O
dosage	O
reduction	O
requires	O
cessation	O
of	O
therapy	O
with	O
indomethacin	B-D007213
	O

5.15	O
Ocular	O
Effects:	O
Corneal	B-D003315
deposits	B-C020884
and	O
retinal	B-D012160
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
who	O
had	O
received	O
prolonged	O
therapy	O
with	O
indomethacin	B-D007213
	O

The	O
prescribing	O
physician	O
should	O
be	O
alert	O
to	O
the	O
possible	O
association	B-D001244
between	O
the	O
changes	O
noted	O
and	O
indomethacin	B-D007213
	O

It	O
is	O
advisable	O
to	O
discontinue	O
therapy	O
if	O
such	O
changes	O
are	O
observed	O

Blurred	O
vision	O
may	O
be	O
a	O
significant	O
symptom	O
and	O
warrants	O
a	O
thorough	O
ophthalmological	O
examination	O

Since	O
these	O
changes	O
may	O
be	O
asymptomatic,	O
ophthalmologic	O
examination	O
at	O
periodic	O
intervals	O
is	O
desirable	O
in	O
patients	B-D010361
where	O
therapy	O
is	O
prolonged	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)]	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O

In	O
a	O
gastroscopic	O
study	O
in	O
45	O
healthy	B-D006262
subjects,	O
the	O
number	O
of	O
gastric	B-D005753
mucosal	I-D005753
abnormalities	O
was	O
significantly	O
higher	O
in	O
the	O
group	O
receiving	O
indomethacin	B-D007213
capsules	B-D002214
than	O
in	O
the	O
group	O
taking	O
indomethacin	B-D007213
Suppositories	B-D013488
or	O
placebo	O

In	O
a	O
double-blind	O
comparative	O
clinical	B-D000068397
study	I-D000068397
involving	O
175	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis,	B-D001168
however,	O
the	O
incidence	B-D015994
of	O
upper	O
gastrointestinal	O
adverse	O
effects	O
with	O
indomethacin	B-D007213
Suppositories	B-D013488
or	O
Capsules	B-D002214
was	O
comparable	O

The	O
incidence	B-D015994
of	O
lower	O
gastrointestinal	O
adverse	O
effects	O
was	O
greater	O
in	O
the	O
suppository	O
group	O

The	O
adverse	O
reactions	O
for	O
indomethacin	B-D007213
capsules	B-D002214
listed	O
in	O
the	O
following	O
table	O
have	O
been	O
arranged	O
into	O
two	O
groups:	O
(1)	O
incidence	B-D015994
greater	O
than	O
1%;	O
and	O
(2)	O
incidence	B-D015994
less	O
than	O
1%	O

The	O
incidence	B-D015994
for	O
group	O
(1)	O
was	O
obtained	O
from	O
33	O
double-blind	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
reported	O
in	O
the	O
literature	B-D008091
(1,092	O
patients)	B-D010361
	O

The	O
incidence	B-D015994
for	O
group	O
(2)	O
was	O
based	O
on	O
reports	O
in	O
clinical	B-D016430
trials,	I-D016430
in	O
the	O
literature,	B-D008091
and	O
on	O
voluntary	O
reports	O
since	O
marketing	B-D040541
	O

The	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists	O
between	O
indomethacin	B-D007213
and	O
these	O
adverse	O
reactions,	O
some	O
of	O
which	O
have	O
been	O
reported	O
only	O
rarely	O

Table	O
1:	O
Summary	O
of	O
Adverse	O
reactions	O
for	O
Indomethacin	B-D007213
Capsules	B-D002214
Incidence	B-D015994
greater	O
than	O
1%	O
Incidence	B-D015994
less	O
than	O
1%	O
GASTROINTESTINAL	O
nausea*	B-D009325
with	O
or	O
without	O
vomiting	B-D014839
dyspepsia*	B-D004415
(including	O
indigestion,	O
heartburn	B-D006356
and	O
epigastric	O
pain)	B-D010146
diarrhea	B-D003967
abdominal	O
distress	O
or	O
pain	B-D010146
constipation	B-D003248
Anorexia	B-D000855
bloating	O
(includes	O
distension)	O
flatulence	B-D005414
peptic	B-D010437
ulcer	I-D010437
gastroenteritis	B-D005759
rectal	O
bleeding	O
proctitis	B-D011349
single	O
or	O
multiple	O
ulcerations,	B-D014456
including	O
perforation	O
and	O
hemorrhage	B-D006470
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
duodenum	B-D004386
or	O
small	O
and	O
large	O
intestines	B-D007422
intestinal	O
ulceration	B-D014456
associated	O
with	O
stenosis	O
and	O
obstruction	O
gastrointestinal	O
bleeding	O
without	O
obvious	O
ulcer	B-D014456
formation	B-D020478
and	O
perforation	O
of	O
pre-existing	O
sigmoid	O
lesions	O
(diverticulum,	O
carcinoma,	B-D002277
etc.)	O
development	O
of	O
ulcerative	B-D014456
colitis	B-D003092
and	O
regional	O
ileitis	B-D007079
ulcerative	B-D014456
stomatitis	B-D013280
toxic	O
hepatitis	B-D006506
and	I-D006506
jaundice	B-D007565
(some	O
fatal	O
cases	O
have	O
been	O
reported)	O
intestinal	O
strictures	O
(diaphragms)	O
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
headache	B-D006261
(11.7%)	O
dizziness*	B-D004244
vertigo	B-D014717
somnolence	O
depression	B-D003863
and	O
fatigue	B-D005221
(including	O
malaise	O
and	O
listlessness)	O
anxiety	B-D001007
(includes	O
nervousness)	O
muscle	B-D018908
weakness	I-D018908
involuntary	O
muscle	O
movements	B-D009068
insomnia	O
muzziness	O
psychic	O
disturbances	O
including	O
psychotic	O
episodes	O
mental	B-D008571
confusion	B-D003221
drowsiness	O
light-headedness	B-D008027
syncope	B-D013575
paresthesia	B-D010292
aggravation	O
of	O
epilepsy	B-D004827
and	O
parkinsonism	O
depersonalization	B-D003861
coma	B-D003128
peripheral	O
neuropathy	O
convulsion	O
dysarthria	B-D004401
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
ocular	O
—	O
corneal	B-D003315
deposits	B-C020884
and	O
retinal	B-D012160
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
reported	O
in	O
some	O
patients	B-D010361
on	O
prolonged	O
therapy	O
with	O
indomethacin	B-D007213
blurred	O
vision	O
diplopia	B-D004172
hearing	B-D006309
disturbances,	O
deafness	B-D003638
CARDIOVASCULAR	O
None	O
Hypertension	B-D006973
hypotension	B-D007022
tachycardia	B-D013610
chest	B-D002637
pain	I-D002637
congestive	O
heart	B-D006333
failure	I-D006333
arrhythmia;	O
palpitations	O
METABOLIC	O
none	O
Edema	B-D004487
weight	B-D015430
gain	I-D015430
fluid	O
retention	O
flushing	B-D005483
or	O
sweating	B-D013546
Hyperglycemia	B-D006943
glycosuria	B-D006029
hyperkalemia	B-D006947
INTEGUMENTARY	O
None	O
Pruritus	B-D011537
rash;	O
urticaria	B-D014581
petechiae	O
or	O
ecchymosis	B-D004438
exfoliative	O
dermatitis	B-D003872
erythema	B-D004893
nodosum	I-D004893
loss	O
of	O
hair	B-D006197
Stevens-Johnson	B-D013262
syndrome	I-D013262
erythema	B-D004892
multiforme	I-D004892
toxic	O
epidermal	O
necrolysis	O
HEMATOLOGIC	O
None	O
Leucopenia	O
bone	B-D001853
marrow	I-D001853
depression	B-D003863
anemia	B-D000740
secondary	O
to	O
obvious	O
or	O
occult	O
gastrointestinal	O
bleeding	O
aplastic	O
anemia	B-D000740
hemolytic	O
anemia	B-D000740
agranulocytosis	B-D000380
thrombocytopenic	O
purpura	B-D011693
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
HYPERSENSITIVITY	B-D006967
None	O
acute	O
anaphylaxis	B-D000707
acute	O
respiratory	O
distress	O
rapid	O
fall	O
in	O
blood	B-D001794
pressure	I-D001794
resembling	O
a	O
shock-like	B-D012769
state	O
angioedema	B-D000799
Dyspnea	B-D004417
asthma	B-D001249
purpura	B-D011693
angiitis	O
pulmonary	B-D011654
edema	I-D011654
fever	B-D005334
GENITOURINARY	O
None	O
Hematuria	B-D006417
vaginal	B-D014621
bleeding	O
proteinuria	B-D011507
nephrotic	B-D009404
syndrome	I-D009404
interstitial	O
nephritis	B-D009393
BUN	O
elevation	O
renal	B-D051437
insufficiency,	I-D051437
including	O
renal	O
failure	O
MISCELLANEOUS	O
None	O
Epistaxis	B-D004844
breast	B-D001940
changes,	O
including	O
enlargement	O
and	O
tenderness,	O
or	O
gynecomastia	B-D006177
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
indomethacin	B-D007213
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
Causal	O
relationship	O
unknown	O
:	O
Other	O
reactions	O
have	O
been	O
reported	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established	O

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
the	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
observations	B-D019370
are	O
being	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians:	B-D010820
Cardiovascular	O
:	O
Thrombophlebitis	B-D013924
Hematologic	O
:	O
Although	O
there	O
have	O
been	O
several	O
reports	O
of	O
leukemia,	B-D007938
the	O
supporting	O
information	O
is	O
weak	O

Genitourinary	O
:	O
Urinary	O
frequency	O

A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	B-D005208
particularly	O
in	O
association	B-D001244
with	O
Group	O
Aß	O
hemolytic	O
streptococcus,	B-D013291
has	O
been	O
described	O
in	O
persons	B-D009272
treated	O
with	O
nonsteroidal	O
anti-inflammatory	B-D000893
agents,	I-D000893
including	O
indomethacin,	B-D007213
sometimes	O
with	O
fatal	B-D017809
outcome	I-D017809
	O

BOXED	O
WARNING	O
CARDIOVASCULAR	O
RISK	B-D012306
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS]	O

Diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS]	O

GASTROINTESTINAL	O
RISK	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

[see	O
WARNINGS]	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets,	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS]	O

Diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS]	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
Diclofenac	B-D004008
Sodium	B-D012964
Delayed-Release	O
Tablets,	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Rising	O
Pharmaceuticals,	O
Inc	O

at	O
1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

BOXED	O
WARNING	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O

Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
indomethacin,	B-D007213
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2	O
)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4	O
)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
indomethacin	B-D007213
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
indomethacin,	B-D007213
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
indomethacin	B-D007213
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
indomethacin	B-D007213
	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
indomethacin	B-D007213
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
indomethacin	B-D007213
capsules,	B-D002214
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
pre-existing	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7	O
)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
indomethacin	B-D007213
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7	O
)]	O

Avoid	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
indomethacin	B-D007213
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
indomethacin	B-D007213
capsules	B-D002214
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
indomethacin	B-D007213
capsules	B-D002214
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7	O
)]	O

Avoid	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
indomethacin	B-D007213
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
the	O
potassium-sparing	B-D011188
diuretic,	O
triamterene,	B-D014223
to	O
a	O
maintenance	B-D008283
schedule	O
of	O
indomethacin	B-D007213
resulted	O
in	O
reversible	O
acute	O
renal	O
failure	O
in	O
two	O
of	O
four	O
healthy	B-D064368
volunteers	I-D064368
	O

Indomethacin	B-D007213
and	O
triamterene	B-D014223
should	O
not	O
be	O
administered	O
together	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

Both	O
indomethacin	B-D007213
and	O
potassium-sparing	B-D011188
diuretics	B-D004232
may	O
be	O
associated	O
with	O
increased	O
serum	B-D044967
potassium	B-D011188
levels	O

The	O
potential	O
effects	O
of	O
indomethacin	B-D007213
and	O
potassium-sparing	B-D011188
diuretics	B-D004232
on	O
potassium	B-D011188
levels	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O

5.7	O
Anaphylactic	O
Reactions	O
Indomethacin	B-D007213
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
indomethacin	B-D007213
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[	O
see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8	O
)]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
indomethacin	B-D007213
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(4	O
)]	O

When	O
indomethacin	B-D007213
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
indomethacin,	B-D007213
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Indomethacin	B-D007213
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4	O
)]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Indomethacin	B-D007213
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
indomethacin	B-D007213
capsules,	B-D002214
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1	O
)]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
indomethacin	B-D007213
capsules	B-D002214
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
indomethacin	B-D007213
capsules,	B-D002214
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7	O
)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6	O
)]	O

5.14	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects:	O
Indomethacin	B-D007213
may	O
aggravate	O
depression	B-D003863
or	O
other	O
psychiatric	O
disturbances,	O
epilepsy,	B-D004827
and	O
parkinsonism,	O
and	O
should	O
be	O
used	O
with	O
considerable	O
caution	O
in	O
patients	B-D010361
with	O
these	O
conditions	O

If	O
severe	O
CNS	O
adverse	O
reactions	O
develop,	O
indomethacin	B-D007213
should	O
be	O
discontinued	O

Indomethacin	B-D007213
may	O
cause	O
drowsiness;	O
therefore,	O
patients	B-D010361
should	O
be	O
cautioned	O
about	O
engaging	O
in	O
activities	O
requiring	O
mental	B-D008571
alertness	O
and	O
motor	O
coordination,	O
such	O
as	O
driving	O
a	O
car	O

Indomethacin	B-D007213
may	O
also	O
cause	O
headache	B-D006261
	O

Headache	B-D006261
which	O
persists	O
despite	O
dosage	O
reduction	O
requires	O
cessation	O
of	O
therapy	O
with	O
indomethacin	B-D007213
	O

5.15	O
Ocular	O
Effects:	O
Corneal	B-D003315
deposits	B-C020884
and	O
retinal	B-D012160
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
who	O
had	O
received	O
prolonged	O
therapy	O
with	O
indomethacin	B-D007213
	O

The	O
prescribing	O
physician	O
should	O
be	O
alert	O
to	O
the	O
possible	O
association	B-D001244
between	O
the	O
changes	O
noted	O
and	O
indomethacin	B-D007213
	O

It	O
is	O
advisable	O
to	O
discontinue	O
therapy	O
if	O
such	O
changes	O
are	O
observed	O

Blurred	O
vision	O
may	O
be	O
a	O
significant	O
symptom	O
and	O
warrants	O
a	O
thorough	O
ophthalmological	O
examination	O

Since	O
these	O
changes	O
may	O
be	O
asymptomatic,	O
ophthalmologic	O
examination	O
at	O
periodic	O
intervals	O
is	O
desirable	O
in	O
patients	B-D010361
where	O
therapy	O
is	O
prolonged	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)]	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O

In	O
a	O
gastroscopic	O
study	O
in	O
45	O
healthy	B-D006262
subjects,	O
the	O
number	O
of	O
gastric	B-D005753
mucosal	I-D005753
abnormalities	O
was	O
significantly	O
higher	O
in	O
the	O
group	O
receiving	O
indomethacin	B-D007213
capsules	B-D002214
than	O
in	O
the	O
group	O
taking	O
indomethacin	B-D007213
Suppositories	B-D013488
or	O
placebo	O

In	O
a	O
double-blind	O
comparative	O
clinical	B-D000068397
study	I-D000068397
involving	O
175	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis,	B-D001168
however,	O
the	O
incidence	B-D015994
of	O
upper	O
gastrointestinal	O
adverse	O
effects	O
with	O
indomethacin	B-D007213
Suppositories	B-D013488
or	O
Capsules	B-D002214
was	O
comparable	O

The	O
incidence	B-D015994
of	O
lower	O
gastrointestinal	O
adverse	O
effects	O
was	O
greater	O
in	O
the	O
suppository	O
group	O

The	O
adverse	O
reactions	O
for	O
indomethacin	B-D007213
capsules	B-D002214
listed	O
in	O
the	O
following	O
table	O
have	O
been	O
arranged	O
into	O
two	O
groups:	O
(1)	O
incidence	B-D015994
greater	O
than	O
1%;	O
and	O
(2)	O
incidence	B-D015994
less	O
than	O
1%	O

The	O
incidence	B-D015994
for	O
group	O
(1)	O
was	O
obtained	O
from	O
33	O
double-blind	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
reported	O
in	O
the	O
literature	B-D008091
(1,092	O
patients)	B-D010361
	O

The	O
incidence	B-D015994
for	O
group	O
(2)	O
was	O
based	O
on	O
reports	O
in	O
clinical	B-D016430
trials,	I-D016430
in	O
the	O
literature,	B-D008091
and	O
on	O
voluntary	O
reports	O
since	O
marketing	B-D040541
	O

The	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists	O
between	O
indomethacin	B-D007213
and	O
these	O
adverse	O
reactions,	O
some	O
of	O
which	O
have	O
been	O
reported	O
only	O
rarely	O

Table	O
1:	O
Summary	O
of	O
Adverse	O
reactions	O
for	O
Indomethacin	B-D007213
Capsules	B-D002214
Incidence	B-D015994
greater	O
than	O
1%	O
Incidence	B-D015994
less	O
than	O
1%	O
GASTROINTESTINAL	O
nausea*	B-D009325
with	O
or	O
without	O
vomiting	B-D014839
dyspepsia*	B-D004415
(including	O
indigestion,	O
heartburn	B-D006356
and	O
epigastric	O
pain)	B-D010146
diarrhea	B-D003967
abdominal	O
distress	O
or	O
pain	B-D010146
constipation	B-D003248
Anorexia	B-D000855
bloating	O
(includes	O
distension)	O
flatulence	B-D005414
peptic	B-D010437
ulcer	I-D010437
gastroenteritis	B-D005759
rectal	O
bleeding	O
proctitis	B-D011349
single	O
or	O
multiple	O
ulcerations,	B-D014456
including	O
perforation	O
and	O
hemorrhage	B-D006470
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
duodenum	B-D004386
or	O
small	O
and	O
large	O
intestines	B-D007422
intestinal	O
ulceration	B-D014456
associated	O
with	O
stenosis	O
and	O
obstruction	O
gastrointestinal	O
bleeding	O
without	O
obvious	O
ulcer	B-D014456
formation	B-D020478
and	O
perforation	O
of	O
pre-existing	O
sigmoid	O
lesions	O
(diverticulum,	O
carcinoma,	B-D002277
etc.)	O
development	O
of	O
ulcerative	B-D014456
colitis	B-D003092
and	O
regional	O
ileitis	B-D007079
ulcerative	B-D014456
stomatitis	B-D013280
toxic	O
hepatitis	B-D006506
and	I-D006506
jaundice	B-D007565
(some	O
fatal	O
cases	O
have	O
been	O
reported)	O
intestinal	O
strictures	O
(diaphragms)	O
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
headache	B-D006261
(11.7%)	O
dizziness*	B-D004244
vertigo	B-D014717
somnolence	O
depression	B-D003863
and	O
fatigue	B-D005221
(including	O
malaise	O
and	O
listlessness)	O
anxiety	B-D001007
(includes	O
nervousness)	O
muscle	B-D018908
weakness	I-D018908
involuntary	O
muscle	O
movements	B-D009068
insomnia	O
muzziness	O
psychic	O
disturbances	O
including	O
psychotic	O
episodes	O
mental	B-D008571
confusion	B-D003221
drowsiness	O
light-headedness	B-D008027
syncope	B-D013575
paresthesia	B-D010292
aggravation	O
of	O
epilepsy	B-D004827
and	O
parkinsonism	O
depersonalization	B-D003861
coma	B-D003128
peripheral	O
neuropathy	O
convulsion	O
dysarthria	B-D004401
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
ocular	O
—	O
corneal	B-D003315
deposits	B-C020884
and	O
retinal	B-D012160
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
reported	O
in	O
some	O
patients	B-D010361
on	O
prolonged	O
therapy	O
with	O
indomethacin	B-D007213
blurred	O
vision	O
diplopia	B-D004172
hearing	B-D006309
disturbances,	O
deafness	B-D003638
CARDIOVASCULAR	O
None	O
Hypertension	B-D006973
hypotension	B-D007022
tachycardia	B-D013610
chest	B-D002637
pain	I-D002637
congestive	O
heart	B-D006333
failure	I-D006333
arrhythmia;	O
palpitations	O
METABOLIC	O
none	O
Edema	B-D004487
weight	B-D015430
gain	I-D015430
fluid	O
retention	O
flushing	B-D005483
or	O
sweating	B-D013546
Hyperglycemia	B-D006943
glycosuria	B-D006029
hyperkalemia	B-D006947
INTEGUMENTARY	O
None	O
Pruritus	B-D011537
rash;	O
urticaria	B-D014581
petechiae	O
or	O
ecchymosis	B-D004438
exfoliative	O
dermatitis	B-D003872
erythema	B-D004893
nodosum	I-D004893
loss	O
of	O
hair	B-D006197
Stevens-Johnson	B-D013262
syndrome	I-D013262
erythema	B-D004892
multiforme	I-D004892
toxic	O
epidermal	O
necrolysis	O
HEMATOLOGIC	O
None	O
Leucopenia	O
bone	B-D001853
marrow	I-D001853
depression	B-D003863
anemia	B-D000740
secondary	O
to	O
obvious	O
or	O
occult	O
gastrointestinal	O
bleeding	O
aplastic	O
anemia	B-D000740
hemolytic	O
anemia	B-D000740
agranulocytosis	B-D000380
thrombocytopenic	O
purpura	B-D011693
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
HYPERSENSITIVITY	B-D006967
None	O
acute	O
anaphylaxis	B-D000707
acute	O
respiratory	O
distress	O
rapid	O
fall	O
in	O
blood	B-D001794
pressure	I-D001794
resembling	O
a	O
shock-like	B-D012769
state	O
angioedema	B-D000799
Dyspnea	B-D004417
asthma	B-D001249
purpura	B-D011693
angiitis	O
pulmonary	B-D011654
edema	I-D011654
fever	B-D005334
GENITOURINARY	O
None	O
Hematuria	B-D006417
vaginal	B-D014621
bleeding	O
proteinuria	B-D011507
nephrotic	B-D009404
syndrome	I-D009404
interstitial	O
nephritis	B-D009393
BUN	O
elevation	O
renal	B-D051437
insufficiency,	I-D051437
including	O
renal	O
failure	O
MISCELLANEOUS	O
None	O
Epistaxis	B-D004844
breast	B-D001940
changes,	O
including	O
enlargement	O
and	O
tenderness,	O
or	O
gynecomastia	B-D006177
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
indomethacin	B-D007213
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
Causal	O
relationship	O
unknown	O
:	O
Other	O
reactions	O
have	O
been	O
reported	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established	O

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
the	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
observations	B-D019370
are	O
being	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians:	B-D010820
Cardiovascular	O
:	O
Thrombophlebitis	B-D013924
Hematologic	O
:	O
Although	O
there	O
have	O
been	O
several	O
reports	O
of	O
leukemia,	B-D007938
the	O
supporting	O
information	O
is	O
weak	O

Genitourinary	O
:	O
Urinary	O
frequency	O

A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	B-D005208
particularly	O
in	O
association	B-D001244
with	O
Group	O
Aß	O
hemolytic	O
streptococcus,	B-D013291
has	O
been	O
described	O
in	O
persons	B-D009272
treated	O
with	O
nonsteroidal	O
anti-inflammatory	B-D000893
agents,	I-D000893
including	O
indomethacin,	B-D007213
sometimes	O
with	O
fatal	B-D017809
outcome	I-D017809
	O

BOXED	O
WARNING	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(See	O
WARNINGS	O
and	O
PRECAUTIONS)	O

IBU	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(See	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinaladverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforationof	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
eventscan	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms.Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinalevents	O

(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
withIbuprofen	O
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
thepercentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaintsranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
toaspirin	O
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidenceof	B-D015994
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
eitherthe	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
anincidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listedin	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000patients	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
ofat	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
werereported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience.These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
twoof	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
wherethe	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
inColumn	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
has	O
notbeen	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
thanat	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
withrheumatoid	O
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
stillwithin	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

[table]	O
CLOSE	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O

Diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets,	B-D013607
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
EVENTS,	O
contact	O
Actavis	O
at	O
1-800-432-8534	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
http://www.fda.gov/	O
for	O
voluntary	O
reporting	O
of	O
adverse	O
reactions	O

ADVERSE	O
REACTIONS	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
administered	O
to	O
approximately	O
300	O
pain	B-D010146
patients	B-D010361
in	O
a	O
safety	B-D012449
study	O
that	O
employed	O
dosages	O
and	O
a	O
duration	O
of	O
treatment	O
sufficient	O
to	O
encompass	O
the	O
recommended	O
usage	O
(see	O
DOSAGE	O
AND	O
ADMINISTRATION)	O

Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose	O

The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
patients	B-D010361
who	O
were	O
in	O
a	O
group	O
that	O
received	O
one	O
tablet	O
of	O
hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	B-D007052
an	O
average	O
of	O
three	O
to	O
four	O
times	B-D013995
daily	O

The	O
overall	B-D016424
incidence	B-D015994
rates	O
of	O
adverse	O
experiences	O
in	O
the	O
trials	O
were	O
fairly	O
similar	O
for	O
this	O
patient	O
group	O
and	O
those	O
who	O
received	O
the	O
comparison	O
treatment,	O
acetaminophen	B-D000082
600	O
mg	O
with	O
codeine	B-D003061
60	O
mg	O

The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
incidence	B-D015994
of	O
1%	O
or	O
greater	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	B-D007052
tablets,	B-D013607
without	O
regard	O
to	O
the	O
causal	O
relationship	O
of	O
the	O
events	O
to	O
the	O
drug	O

To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk	O
*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses	O

Body	O
as	O
a	O
Whole	O
Abdominal	B-D015746
pain*;	I-D015746
Asthenia*;	B-D001247
Fever;	B-D005334
Flu	O
syndrome;	B-D013577
Headache	B-D006261
(27%);	O
Infection*;	O
Pain	B-D010146
	O

Cardiovascular	O
Palpitations;	O
Vasodilation	B-D014664
	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Anxiety*;	B-D001007
Confusion;	B-D003221
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia;	B-D010292
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities	O

Digestive	O
Anorexia;	B-D000855
Constipation	B-D003248
(22%);	O
Diarrhea*;	B-D003967
Dry	O
mouth*;	B-D009055
Dyspepsia	B-D004415
(12%);	O
Flatulence*;	B-D005414
Gastritis;	B-D005756
Melena;	B-D008551
Mouth	B-D009055
ulcers;	B-D014456
Nausea	B-D009325
(21%);	O
Thirst;	B-D013894
Vomiting*	B-D014839
	O

Metabolic	O
and	O
Nutritional	O
Disorders	O
Edema*	B-D004487
	O

Respiratory	O
Dyspnea;	B-D004417
Hiccups;	B-D006606
Pharyngitis;	B-D010612
Rhinitis	B-D012220
	O

Skin	B-D012867
and	O
Appendages	O
Pruritus*;	B-D011537
Sweating*	B-D013546
	O

Special	O
Senses	O
Tinnitus	B-D014012
	O

Urogenital	O
Urinary	O
frequency	O

Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole	O
Allergic	O
reaction	O

Cardiovascular	O
Arrhythmia;	O
Hypotension;	B-D007022
Tachycardia	B-D013610
	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Agitation;	O
Abnormal	O
dreams;	B-D004325
Decreased	O
libido;	B-D007989
Depression;	B-D003863
Euphoria;	B-D005059
Mood	O
changes;	O
Neuralgia;	B-D009437
Slurred	O
speech;	B-D013060
Tremor,	B-D014202
Vertigo	B-D014717
	O

Digestive	O
Chalky	O
stool;	O
"Clenching	O
teeth";	O
Dysphagia;	O
Esophageal	O
spasm;	B-D013035
Esophagitis;	B-D004941
Gastroenteritis;	B-D005759
Glossitis;	B-D005928
Liver	B-D008099
enzyme	O
elevation	O

Metabolic	O
and	O
Nutritional	O
Weight	O
decrease	O

Musculoskeletal	O
Arthralgia;	B-D018771
Myalgia	B-D063806
	O

Respiratory	O
Asthma;	B-D001249
Bronchitis;	B-D001991
Hoarseness;	B-D006685
Increased	O
cough;	B-D003371
Pulmonary	O
congestion;	O
Pneumonia;	B-D011014
Shallow	O
breathing;	O
Sinusitis	B-D012852
	O

Skin	B-D012867
and	O
Appendages	O
Rash;	O
Urticaria	B-D014581
	O

Special	O
Senses	O
Altered	O
vision;	O
Bad	O
taste;	B-D013649
Dry	O
eyes	B-D005123
	O

Urogenital	O
Cystitis;	B-D003556
Glycosuria;	B-D006029
Impotence;	O
Urinary	B-D014549
incontinence;	I-D014549
Urinary	B-D016055
retention	I-D016055
	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
EVENTS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
HTTP://WWW.FDA.GOV/	O
for	O
voluntary	O
reporting	O
of	O
adverse	O
reactions	O

BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs	O
1)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(See	O
WARNINGS)	O

•	O
Etodolac	B-D017308
capsules	B-D002214
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(See	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O

(See	O
WARNINGS)	O

1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
nonsteroidal	O
anti-inflammatory	O
drug	O

ADVERSE	O
REACTIONS	O
BOXED	O
WARNING	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS)	O

•	O
Diclofenac	B-D004008
potassium	B-D011188
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	B-D000075202
WARNINGS)	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
•	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
(see	O
WARNINGS)	O
•	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
•	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
•	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
•	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
•	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
•	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
•	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

In	O
718	O
patients	B-D010361
treated	O
for	O
shorter	O
periods,	O
i.e.,	O
2	O
weeks	O
or	O
less,	O
with	O
diclofenac	B-D004008
tablets,	B-D013607
adverse	O
reactions	O
were	O
reported	O
one-half	O
to	O
one-tenth	O
as	O
frequently	O
as	O
by	O
patients	B-D010361
treated	O
for	O
longer	O
periods	O

In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
diclofenac	B-D004008
potassium	B-D011188
tablets	B-D013607
(N	O
=	O
196)	O
versus	O
diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
(N	O
=	O
197)	O
versus	O
ibuprofen	B-D007052
(N	O
=	O
197),	O
adverse	O
reactions	O
were	O
similar	O
in	O
nature	B-D019368
and	O
frequency	O

In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
potassium	B-D011188
tablets	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
BOXED	O
WARNING	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O

Ibuprofen	B-D007052
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
than	O
1%(but	O
less	O
than	O
3%)	O
probable	O
casual	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
probable	O
Casual	O
Relationship*	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Casual	O
Relationship	O
Unknown*	O
GASTROINTESTINAL	O
Nausea†,	B-D009325
epigastric	O
paint†,	B-D010150
heartburn,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
Pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatis	O
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness†,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash†	O
(including	O
maculopapular	O
type),	O
pruritis	O
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
(see	O
PRECAUTIONS)	O
Conjuctivitis,	O
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(eg	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function	O
elevated	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRADICATIONS)	O
Serum	B-D012713
sickness,	I-D012713
lupuserythematosus	O
syndrome,	B-D013577
Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
see	O
PRECAUTIONS	O
),	O
decreased	O
creatinine	B-D003404
clearance,	O
polyuria,	B-D011141
azotemia,	B-D053099
cystitis,	B-D003556
Hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
*Reactions	O
are	O
classified	O
under	O
"Probable	O
Causal	O
Relationship	O
(PCR)"	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
"Causal	O
Relationship	O
Unknown"	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

†Reactions	O
occurring	O
in	O
3%to	O
9%of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%of	O
the	O
patients	B-D010361
are	O
unmarked)	O

BOXED	O
WARNING	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
..	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
-	O
8.5)	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
-	O
7.2)	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(14.6	O
)]	O
To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants;	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)]	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
celecoxib	B-D000068579
capsules,	B-D002214
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules	B-D002214
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

The	O
rates	O
of	O
hypertension	B-D006973
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	B-D000068579
ibuprofen	B-D007052
and	O
diclofenac-treated	B-D004008
patients	B-D010361
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	B-D000078682
[see	O
Clinical	O
Studies	O
(14.6)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
celecoxib	B-D000068579
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
celecoxib	B-D000068579
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoadosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
celecoxib	B-D000068579
and	O
in	O
patients	B-D010361
with	O
aspirin	B-D001241
sensitive	O
asthma	B-D001249
	O

Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	B-D013449
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	B-D019369
or	O
less	O
severe	O
asthmatic	B-D001249
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)]	O

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)]	O

When	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	B-D012867
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib	B-D000068579
capsules,	B-D002214
including	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	B-D056150
generalized	I-D056150
exanthematous	I-D056150
pustulosis	I-D056150
(AGEP)	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)]	O

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	B-D000068579
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
capsules	B-D002214
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
with	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	B-D010361
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	B-D010361
and	O
their	O
caregivers	B-D017028
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labelling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Of	O
the	O
celecoxib-treated	B-D000068579
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
capsules	B-D002214
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Celecoxib	B-D000068579
=	O
Celecoxib	B-D000068579
capsules	B-D002214
100	O
-	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

Celecoxib	B-D000068579
(N=4146)	O
Placebo	O
(N=1864)	O
NAP	O
(N=1366)	O
DCF	O
(N=387)	O
IBU	O
(N=345)	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	B-D000068579
capsules	B-D002214
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	B-D000068579
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
-	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
Capsules	B-D002214
(100	O
-	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
Allergy	O
General:	O
Hypersensitivity,	B-D006967
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	B-D010361
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis	B-D013924
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis	B-D010195
ileus	B-D045823
General:	O
Sepsis,	B-D018805
sudden	O
death	B-D003643
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis,	B-D002769
Hemic	O
and	O
lymphatic:	B-D008196
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia,	B-D001259
suicide	B-D013405
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)]	O
Hematological	O
Events:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
was	O
maintained	O
with	O
or	O
without	O
aspirin	B-D001241
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	B-D000068579
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
twice	O
daily	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
*Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.6)]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	B-D000068579
capsules	B-D002214
pre-marketing	O
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
Capsules	B-D002214
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
capsules,	B-D002214
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post	O
approval	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
General:	O
Anaphylactoid	O
reaction,	O
angioedema	B-D000799
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	B-D009336
hepatitis,	B-D006505
jaundice,	B-D007565
hepatic	O
failure	O
Hemic	O
and	O
lymphatic	B-D008196
Agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
Renal	O
Interstitial	O
nephritis	B-D009393
BOXED	O
WARNING	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
·	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O

·	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
than	O
1%(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash*,	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and	O
/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
(see	O
PRECAUTIONS)	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevate	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS)	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythematosus	B-D004890
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
poliuria,	O
azotemia,	B-D053099
cystitis,	B-D003556
hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked)	O

**Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“CausalRelationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(See	O
WARNINGS	O
and	O
PRECAUTIONS)	O

Ibuprofen	B-D007052
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(See	O
WARNINGS	O
and	O
PRECAUTIONS)	O

IBU	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(See	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinaladverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforationof	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
eventscan	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms.Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinalevents	O

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
withIbuprofen	O
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
thepercentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaintsranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
toaspirin	O
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidenceof	B-D015994
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
eitherthe	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
anincidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listedin	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000patients	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
ofat	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
werereported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience.These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
twoof	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
wherethe	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
inColumn	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
has	O
notbeen	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
thanat	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
withrheumatoid	O
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
stillwithin	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

table	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS)	O

Diclofenac	B-D004008
potassium	B-D011188
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	B-D000075202
WARNINGS)	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

In	O
718	O
patients	B-D010361
treated	O
for	O
shorter	O
periods,	O
i.e.,	O
2	O
weeks	O
or	O
less,	O
with	O
diclofenac	B-D004008
tablets,	B-D013607
adverse	O
reactions	O
were	O
reported	O
one-half	O
to	O
one-tenth	O
as	O
frequently	O
as	O
by	O
patients	B-D010361
treated	O
for	O
longer	O
periods	O

In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
diclofenac	B-D004008
potassium	B-D011188
tablets	B-D013607
(N	O
=	O
196)	O
versus	O
diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
(N	O
=	O
197)	O
versus	O
ibuprofen	B-D007052
(N	O
=	O
197),	O
adverse	O
reactions	O
were	O
similar	O
in	O
nature	B-D019368
and	O
frequency	O

In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
potassium	B-D011188
tablets	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS	O
]	O

Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
]	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
]	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“	O
Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“	O
Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
Pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash*	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
neuritis,	B-D009443
cataracts	B-D002386
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
(see	O
PRECAUTIONS)	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(eg	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevated	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS)	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythe-	O
matosus	O
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
polyuria,	B-D011141
azotemia,	B-D053099
cystitis,	B-D003556
Hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
tests	B-C004551
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(See	O
WARNINGS	O
and	O
PRECAUTIONS)	O

IBU	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(See	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinaladverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforationof	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
eventscan	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms.Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinalevents	O

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
withIbuprofen	O
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
thepercentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaintsranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
toaspirin	O
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidenceof	B-D015994
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
eitherthe	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
anincidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listedin	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000patients	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
ofat	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
werereported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience.These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
twoof	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
wherethe	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
inColumn	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
has	O
notbeen	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
thanat	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
withrheumatoid	O
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
stillwithin	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

table	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(5.1)	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
NSAIDs,	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(5.11,	O
7)	O
Exposure	O
to	O
light:	B-D008027
Avoid	O
exposure	O
of	O
treated	O
knee(s)	B-D007717
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
	O

(5.14)	O
Eye	B-D005123
Contact:	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
with	O
eyes	B-D005123
and	O
mucosa	O

(5.15)	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	B-D004008
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.3	O
Hepatotoxicity	O
In	O
clinical	B-D016430
trials,	I-D016430
of	O
oral	O
diclofenac-containing	B-D004008
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
with	O
oral	O
diclofenac	B-D004008
for	O
2	O
to	O
6	O
months,	O
patients	B-D010361
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
tests	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

In	O
a	O
European	B-D005060
retrospective	O
population-based,	B-D011153
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	B-D004008
associated	O
drug-induced	O
liver	B-D008099
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	B-D004008
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	B-D016017
ratio	I-D016017
of	O
liver	B-D008099
injury	O

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	B-D016424
number	O
of	O
10	O
cases	O
of	O
liver	B-D008099
injury	O
associated	O
with	O
diclofenac,	B-D004008
the	O
adjusted	O
odds	B-D016017
ratio	I-D016017
increased	O
further	O
with	O
female	B-D005260
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days	O

Physicians	B-D010820
should	O
measure	O
transaminases	B-D000637
at	O
baseline	O
and	O
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
transaminases	B-D000637
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
should	O
be	O
discontinued	O
immediately	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver-related	B-D008099
event	O
in	O
patients	B-D010361
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	B-D000082
antibiotics,	O
antiepileptics)	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w,	O
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension,	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
diclofenac	B-D004008
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
diclofenac	B-D004008
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)]	O

When	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)]	O

Do	O
not	O
apply	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
to	O
open	O
skin	B-D012867
wounds,	O
infections,	B-D007239
inflammations,	B-D007249
or	O
exfoliative	O
dermatitis,	B-D003872
as	O
it	O
may	O
affect	B-D000339
absorption	B-D000042
and	O
tolerability	O
of	O
the	O
drug	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w,	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w,	O
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

The	O
effects	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	B-D006262
subjects	O
administered	O
80	O
drops	O
four	O
times	B-D013995
a	O
day	O
for	O
7	O
days	O

There	O
was	O
no	O
significant	O
change	O
in	O
platelet	B-D010974
aggregation	I-D010974
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)]	O

5.14	O
Sun	O
Exposure	O
Instruct	O
patients	B-D010361
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
on	O
treated	O
knee(s)	B-D007717
because	O
studies	O
in	O
animals	B-D000818
indicated	O
topical	O
diclofenac	B-D004008
treatment	O
resulted	O
in	O
an	O
earlier	B-D004423
onset	O
of	O
ultraviolet	O
light-induced	B-D008027
skin	B-D012867
tumors	O

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
on	O
skin	B-D012867
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	B-D006801
are	O
not	O
known	O

5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
with	O
eyes	B-D005123
and	O
mucosa	O

Advise	O
patients	B-D010361
that	O
if	O
eye	B-D005123
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	B-D005123
with	O
water	B-D014867
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour	O

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	B-D006470
more	O
frequent	O
abnormal	O
creatinine,	B-D003404
urea	B-D014508
and	O
hemoglobin	O

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	B-D012306
and	O
conduct	O
periodic	O
laboratory	O
evaluations	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
are	O
application	O
site	O
reactions	O

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Ingenus	O
Pharmaceuticals,	O
LLC	O
at	O
1-877-748-1970	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
of	O
911	O
patients	B-D010361
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	B-D010361
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	B-D010361
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	B-D010361
treated	O
for	O
at	O
least	O
12	O
months	O

The	O
population	B-D011153
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	B-D010361
were	O
Caucasians,	O
64%	O
were	O
females,	B-D005260
and	O
all	O
patients	B-D010361
had	O
primary	O
osteoarthritis	B-D010003
	O

The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
patients	B-D010361
receiving	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

Application	O
site	O
reactions	O
were	O
characterized	B-D002605
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	B-D004890
induration,	O
vesicles,	O
paresthesia,	B-D010292
pruritus,	B-D011537
vasodilation,	B-D014664
acne,	O
and	O
urticaria	B-D014581
	O

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	B-D012867
(32%),	O
contact	O
dermatitis	B-D003872
characterized	B-D002605
by	O
skin	B-D012867
erythema	B-D004890
and	O
induration	O
(9%),	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
(2%)	O
and	O
pruritus	B-D011537
(4%)	O

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
and	O
oral	O
diclofenac	B-D004008
	O

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	B-D012449
study,	O
contact	O
dermatitis	B-D003872
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
in	O
10%	O
of	O
patients,	B-D010361
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	B-D007854
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%	O

Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	B-D003967
dyspepsia,	B-D004415
nausea,	B-D009325
flatulence,	B-D005414
abdominal	B-D015746
pain,	I-D015746
edema;	B-D004487
see	O
Table	O
1)	O

The	O
combination	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
and	O
oral	O
diclofenac,	B-D004008
compared	O
to	O
oral	O
diclofenac	B-D004008
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	B-D006470
(3%	O
vs	O

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	B-D003404
(12%	O
vs	O

7%),	O
urea	B-D014508
(20%	O
vs	O

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	B-D008099
transaminases	B-D000637
	O

Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	B-D010361
receiving	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w,	O
where	O
the	O
rate	O
in	O
the	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
	O

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	B-D010361
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	B-D004008
trials	O

Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/wN=911	O
Topical	O
PlaceboN=332	O
Adverse	O
Reaction†	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis,	B-D003872
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
†Preferred	O
Term	O
according	O
to	O
COSTART	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
topical	O
solution,	O
1.5%	O
w/w	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

Body	O
as	O
a	O
Whole:	O
abdominal	B-D015746
pain,	I-D015746
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	B-D001247
back	B-D001416
pain,	I-D001416
body	O
odor,	O
chest	B-D002637
pain,	I-D002637
edema,	B-D004487
face	B-D005145
edema,	B-D004487
halitosis,	B-D006209
headache,	B-D006261
lack	O
of	O
drug	O
effect,	O
neck	B-D009333
rigidity,	O
pain	B-D010146
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	B-D003967
dry	O
mouth,	B-D009055
dyspepsia,	B-D004415
gastroenteritis,	B-D005759
decreased	O
appetite,	B-D001066
mouth	B-D009055
ulceration,	B-D014456
nausea,	B-D009325
rectal	O
hemorrhage,	B-D006470
ulcerative	B-D014456
stomatitis	B-D013280
Metabolic	O
and	O
Nutritional:	O
creatinine	B-D003404
increased	O
Musculoskeletal:	O
leg	B-D007866
cramps,	O
myalgia	B-D063806
Nervous:	O
depression,	B-D003863
dizziness,	B-D004244
drowsiness,	O
lethargy,	B-D053609
paresthesia,	B-D010292
paresthesia	B-D010292
at	O
application	O
site	O
Respiratory:	O
asthma,	B-D001249
dyspnea,	B-D004417
laryngismus,	B-D007826
laryngitis,	B-D007827
pharyngitis	B-D010612
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	B-D003877
contact	I-D003877
dermatitis	B-D003872
with	O
vesicles,	O
dry	O
skin,	B-D012867
pruritus,	B-D011537
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	B-D004485
rash,	O
pruritus,	B-D011537
skin	B-D012867
discoloration,	O
urticaria	B-D014581
Special	O
Senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	B-D002386
ear	B-D004423
pain,	B-D010146
eye	B-D005123
disorder,	O
eye	B-D058447
pain,	I-D058447
taste	B-D013649
perversion	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
]	O

Etodolac	B-D017308
capsules,	B-D002214
200	O
mg	O
and	O
300	O
mg,	O
and	O
Etodolac	B-D017308
tablets,	B-D013607
400	O
mg	O
and	O
500	O
mg	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
and	O
Warnings	O
]	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
etodolac	B-D017308
capsules	B-D002214
and	O
tablets	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1-10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal),	O
vomiting	B-D014839
	O

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritis,	O
rashes,	O
tinnitus	B-D014012
	O

Adverse-reaction	O
information	O
for	O
etodolac	B-D017308
was	O
derived	O
from	O
2,629	O
arthritic	B-D001154
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
capsules	B-D002214
and	O
tablets	B-D013607
in	O
double-blind	O
and	O
open-label	O
clinical	B-D016430
trials	I-D016430
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies	O

In	O
clinical	B-D016430
trials,	I-D016430
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient	O

The	O
discontinuation	O
rate	O
in	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

New	O
patient	O
complaints	O
(with	O
an	O
incidence	B-D015994
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system	O

The	O
incidences	B-D015994
were	O
determined	O
from	O
clinical	B-D016430
trials	I-D016430
involving	O
465	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	B-D017308
b.i.d	O

(i.e.,	O
600	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever	B-D005334
	O

Digestive	B-D004064
system	I-D004064
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	B-D015746
pain	I-D015746
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked.,	O
diarrhea	B-D003967
,	O
flatulence	B-D005414
,	O
nausea	B-D009325
,	O
abdominal	O
distension,	O
epigastric	O
pain,	B-D010146
abnormal	O
stools,	O
constipation,	B-D003248
gastritis,	B-D005756
melena,	B-D008551
vomiting	B-D014839
	O

Nervous	B-D009420
system	I-D009420
-	O
Asthenia/malaise	B-D001247
,	O
dizziness	B-D004244
,	O
depression,	B-D003863
nervousness,	O
fatigue	B-D005221
	O

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus,	B-D011537
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus	B-D014012
	O

Urogenital	B-D014566
system	I-D014566
-	O
Dysuria,	B-D053159
urinary	O
frequency	O

Musculoskeletal—Arthralgia	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	B-D016430
trials,	I-D016430
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock)	B-D012769
	O

Cardiovascular	B-D002319
system	I-D002319
-	O
Hypertension,	B-D006973
congestive	O
heart	B-D006333
failure,	I-D006333
flushing,	B-D005483
palpitations,	O
syncope,	B-D013575
vasculitis	B-D014657
(including	O
necrotizing	O
and	O
allergic)	O

Digestive	B-D004064
system	I-D004064
-	O
Thirst,	B-D013894
dry	O
mouth,	B-D009055
ulcerative	B-D014456
stomatitis,	B-D013280
anorexia,	B-D000855
eructation,	B-D004884
elevated	O
liver	B-D008099
enzymes,	B-D004798
cholestatic	O
hepatitis,	B-D006505
hepatitis,	B-D006505
cholestatic	O
jaundice,	B-D007565
duodenitis,	B-D004382
jaundice,	B-D007565
hepatic	O
failure,	O
liver	B-D008099
necrosis,	B-D009336
peptic	B-D010437
ulcer	I-D010437
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	B-D014456
pancreatitis	B-D010195
	O

Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
Ecchymosis,	B-D004438
anemia,	B-D000740
thrombocytopenia,	B-D013921
bleeding	B-D001760
time	I-D001760
increased,	O
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
leukopenia,	B-D007970
neutropenia,	B-D009503
pancytopenia	B-D010198
	O

Metabolic	O
and	O
nutritional	O
-	O
Edema,	B-D004487
serum	B-D044967
creatinine	B-D003404
increase,	O
hyperglycemia	B-D006943
in	O
previously	O
controlled	O
diabetic	O
patients	B-D010361
	O

Nervous	B-D009420
system	I-D009420
-	O
Insomnia,	O
somnolence	O

Respiratory	B-D012137
system	I-D012137
-	O
Asthma,	B-D001249
pulmonary	O
infiltration	O
with	O
eosinophilia	B-D004802
	O

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema,	B-D000799
sweating,	B-D013546
urticaria,	B-D014581
exfoliative	O
dermatitis,	B-D003872
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	B-D014657
with	O
purpura,	B-D011693
Stevens-Johnson	B-D013262
Syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	B-D014657
hyperpigmentation	B-D017495
,	O
erythema	B-D004892
multiforme	I-D004892
	O

Special	O
senses	O
-	O
Photophobia,	B-D020795
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
system	I-D014566
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	B-D051437
insufficiency,	I-D051437
renal	O
papillary	O
necrosis	B-D009336
	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	B-D017308
is	O
uncertain	O

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	B-D010820
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache	B-D006261
	O

Cardiovascular	B-D002319
system	I-D002319
-	O
Arrhythmias,	O
myocardial	B-D009203
infarction,	I-D009203
cerebrovascular	B-C079279
accident	O

Digestive	B-D004064
system	I-D004064
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	B-D003092
GI	O
discomfort,	O
burning	O
sensation,	B-D012677
blood	B-D001769
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort	O

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
system	I-D009420
-	O
Paresthesia,	B-D010292
confusion,	B-D003221
irritability	O

Respiratory	B-D012137
system	I-D012137
-	O
Bronchitis,	B-D001991
bronchospasm,	O
dyspnea,	B-D004417
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis	B-D012852
	O

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia,	B-D000505
maculopapular	O
rash,	O
photosensitivity,	O
skin	B-D012867
peeling	O

Special	O
senses	O
-	O
Conjunctivitis,	B-D003231
deafness,	B-D003638
taste	B-D013649
perversion,	O
loss	O
of	O
taste	B-D013649
	O

Urogenital	B-D014566
system	I-D014566
-	O
Cystitis,	B-D003556
hematuria,	B-D006417
leukorrhea,	B-D007973
renal	O
calculus,	O
interstitial	O
nephritis,	B-D009393
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment	O

Musculoskeletal—Muscle	O
pain	B-D010146
	O

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis,	B-D018805
death	B-D003643
Cardiovascular	B-D002319
system	I-D002319
-	O
Tachycardia	B-D013610
Digestive	B-D004064
system	I-D004064
-	O
Gastric	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis	B-D006396
Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
Lymphadenopathy	B-D000072281
Nervous	B-D009420
system	I-D009420
-	O
Anxiety,	B-D001007
dream	O
abnormalities,	O
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis,	B-D008581
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
system	I-D012137
-	O
Respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Urogenital	B-D014566
system	I-D014566
-	O
Oliguria/polyuria,	B-D009846
proteinuria	B-D011507
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS)	O

Diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	B-D000075202
WARNINGS)	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets,	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuriarenal	B-D011507
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
EVENTS,	O
contact	O
Actavis	O
at	O
1-800-432-8534	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
http://www.fda.gov/	O
for	O
voluntary	O
reporting	O
of	O
adverse	O
reactions	O

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(See	O
WARNINGS	O
and	O
PRECAUTIONS	O
)	O

Ibuprofen	B-D007052
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O

(5.4)	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke	B-D020521
	O

Patients	B-D010361
with	O
known	O
CV	O
disease/risk	B-D004194
factors	O
may	O
be	O
at	O
greater	O
risk	B-D012306
(5.1,	O
14.6,	O
17.2)	O

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
risk	B-D012306
is	O
greater	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
GI	O
bleeding,	O
and	O
in	O
patients	B-D010361
at	O
high	O
risk	B-D012306
for	O
GI	O
events,	O
especially	O
the	O
elderly	O

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	B-D010361
(5.4,	O
8.5,	O
14.6,	O
17.3)	O

Elevated	O
liver	B-D008099
enzymes	B-D004798
and,	O
rarely,	O
severe	O
hepatic	O
reactions	O

Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
liver	B-D008099
enzymes	B-D004798
persist	O
or	O
worsen	O
(5.5,	O
17.4)	O

New	O
onset	O
or	O
worsening	O
of	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
CELEBREX	O
(5.2,	O
7.4,	O
17.2)	O

Fluid	O
retention	O
and	O
edema	B-D004487
	O

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
(5.3,	O
17.6)	O

Renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use	O

Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
and	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
or	O
angiotensin	B-D000804
II	I-D000804
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6)	O

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
CELEBREX	O
in	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O
(5.7,	O
10,	O
17.7)	O

Serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy	O

Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	B-D012867
reactions	O
(5.8,	O
17.5)	O

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
CELEBREX	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
CELEBREX,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
CELEBREX	O
does	O
increase	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O

Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)	O
]	O

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
lead	B-D007854
to	O
the	O
onset	O
of	O
new	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
CELEBREX	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

The	O
rates	O
of	O
hypertension	B-D006973
from	O
the	O
CLASS	O
trial	O
in	O
the	O
CELEBREX,	O
ibuprofen	B-D007052
and	O
diclofenac-treated	B-D004008
patients	B-D010361
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	B-D000078682
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
taking	O
NSAIDs,	O
including	O
CELEBREX	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
]	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulceration,	B-D014456
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	B-D013995
during	O
the	O
course	O
of	O
therapy	O

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
with	O
neither	O
of	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population	B-D011153
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
CELEBREX	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

For	O
high-risk	O
patients,	B-D010361
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered	O

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	B-D008099
enzymes	B-D004798
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
with	O
NSAIDs	O

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	B-D007565
and	O
fatal	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis	B-D009336
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	B-D017809
outcome)	I-D017809
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
CELEBREX	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
CELEBREX,	O
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
CELEBREX	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
CELEBREX	O
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	B-D008099
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	B-D008099
test	B-C004551
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
CELEBREX	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
CELEBREX	O
should	O
be	O
discontinued	O

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
angiotensin	B-D000804
II	I-D000804
receptor	O
antagonists,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
trials	I-D016430
with	O
CELEBREX	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	B-D010361
without	O
known	O
prior	O
exposure	O
to	O
CELEBREX	O

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	B-D000799
have	O
been	O
reported	O
in	O
patients	B-D010361
receiving	O
CELEBREX	O

CELEBREX	O
should	O
not	O
be	O
given	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	B-D010361
without	O
prior	O
known	O
sulfa	O
allergy	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012877
manifestations	I-D012877
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	B-D011247
starting	O
at	O
30	O
weeks	O
gestation,	O
CELEBREX	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	B-D007854
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness	O

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	B-D010361
receiving	O
CELEBREX	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
CELEBREX	O
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

CELEBREX	O
does	O
not	O
generally	O
affect	B-D000339
platelet	B-D010976
counts,	I-D010976
prothrombin	B-D011517
time	I-D011517
(PT),	O
or	O
partial	B-D010314
thromboplastin	I-D010314
time	I-D010314
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	B-D010974
aggregation	I-D010974
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
	O

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

The	O
use	O
of	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal	O

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	B-D001241
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
CELEBREX	O
should	O
not	O
be	O
administered	O
to	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

5.14	O
Laboratory	O
Tests	B-C004551
Because	O
serious	O
GI	O
tract	O
ulcerations	B-D014456
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	B-D010820
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
checked	O
periodically	B-D020492
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
or	O
renal	O
tests	B-C004551
persist	O
or	O
worsen,	O
CELEBREX	O
should	O
be	O
discontinued	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
CELEBREX	O
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	B-D010146
conditions	O

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	B-D012306
of	O
adverse	O
reactions	O

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
CELEBREX	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
CELEBREX	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
CELEBREX	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
CELEBREX	O
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
CELEBREX	O
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
CELEBREX	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia	O
Psychiatric	O
:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders	O
:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary	O
:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	B-D010361
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis,	B-D013924
vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
Gastrointestinal	O
:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis,	B-D002769
hepatitis,	B-D006505
jaundice,	B-D007565
liver	B-D017093
failure	I-D017093
Hemic	O
and	O
lymphatic	B-D008196
:	O
Thrombocytopenia,	B-D013921
agranulocytosis,aplastic	B-D000380
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous	O
:	O
Ataxia,	B-D001259
suicide,	B-D013405
aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	B-D009393
Skin:	B-D012867
Erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis	O
General	O
:	O
Sepsis,	B-D018805
sudden	O
death,	B-D003643
anaphylactoid	O
reaction,	O
angioedema	B-D000799
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
CELEBREX	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

6.3	O
Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
BID,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
BID	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib3	B-D000068579
mg/kgN=77	O
Celecoxib6	B-D000068579
mg/kgN=82	O
Naproxen7.5	B-D009288
mg/kgN=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
InvestigationsAbnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
CELEBREX	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
CELEBREX	O
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
CELEBREX	O
pre-marketing	O
controlled	O
arthritis	B-D001168
trials	O
,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
CELEBREX	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
CELEBREX(400	O
to	O
800	O
mg	O
daily)N	O
=	O
2285	O
PlaceboN=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
CELEBREX,	O
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders	O
:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
(see	O
WARNINGS	O
)	O

Diclofenac	B-D004008
sodium	B-D012964
extended-release	O
tablets,	B-D013607
USP	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
sodium	B-D012964
extended-release	O
tablets,	B-D013607
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O

Other	O
adverse	O
reactions	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
EVENTS,	O
contact	O
Watson	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
http://www.fda.gov/	O
for	O
voluntary	O
reporting	O
of	O
adverse	O
reactions	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

4	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(5.1)	O
5	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4	O
,	O
5.1)	O
6	O

NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
1	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O

2	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
1	O

NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
10	O

Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(5.3)	O
11	O

Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(5.4,	O
7)	O
12	O

Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(5.5)	O
13	O

Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(5.6)	O
14	O

Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
15	O

Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(5.8)	O
16	O

Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(5.9)	O
17	O

Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
18	O

Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	B-D012306
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
for	O
the	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
and	O
celecoxib	B-D000068579
capsules	B-D002214
200	O
mg	O
twice	O
daily	O
treatment	O
arms	B-D001132
compared	O
to	O
placebo	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(14.7)]	O

A	O
randomized	B-D016449
controlled	I-D016449
trial	I-D016449
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs	O

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	B-D012306
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	B-D000068579
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	B-D009288
and	O
ibuprofen	B-D007052
	O

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	B-D009288
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	B-D007052
600	O
to	O
800	O
mg	O
three	O
times	B-D013995
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists’	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	B-D003643
(including	O
hemorrhagic	O
death),	B-D003643
non-fatal	O
myocardial	B-D009203
infarction,	I-D009203
and	O
non-fatal	O
stroke	B-D020521
[See	O
Clinical	O
Studies	O
(14.6)]	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
celecoxib	B-D000068579
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	B-D001241
anticoagulants;	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.7)]	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
1.Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

2.Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

3.Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

4.Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

5.If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

6.In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
celecoxib	B-D000068579
capsules,	B-D002214
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash),	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
blood	B-D001794
pressure	I-D001794
data	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
celecoxib	B-D000068579
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoaldosteronism	B-D006994
state	O

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
celecoxib	B-D000068579
and	O
in	O
patients	B-D010361
with	O
aspirin	B-D001241
sensitive	O
asthma	B-D001249
	O

Celecoxib	B-D000068579
capsules	B-D002214
are	O
sulfonamides	B-D013449
and	O
both	O
NSAIDs	O
and	O
sulfonamides	B-D013449
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	B-D019369
or	O
less	O
severe	O
asthmatic	B-D001249
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
]	O

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

When	O
celecoxib	B-D000068579
capsules	B-D002214
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	B-D012867
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib	B-D000068579
capsules,	B-D002214
including	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	B-D056150
generalized	I-D056150
exanthematous	I-D056150
pustulosis	I-D056150
(AGEP)	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
celecoxib	B-D000068579
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	B-D000068579
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	B-D001241
SSRIs	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	B-D000068579
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
Warnings	O
and	O
Precautions	O
(5.2	O
,	O
5.3,	O
5.6)]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
capsules	B-D002214
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
with	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	B-D010361
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	B-D010361
and	O
their	O
caregivers	B-D017028
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
1.Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
2.GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
3.Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
4.Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
5.Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
6.Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
7.Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
8.Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
9.Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Of	O
the	O
celecoxib-treated	B-D000068579
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	B-D000068579
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
celecoxib	B-D000068579
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
celecoxib	B-D000068579
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	B-D000068579
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	B-D000068579
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
%	O
to	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General:	O
Hypersensitivity,	B-D006967
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
blood	B-D001806
urea	I-D001806
nitrogen	I-D001806
(BUN)	O
increased,	O
creatine	B-D003401
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia,	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	B-D010361
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis	B-D013924
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
General:	O
Sepsis,	B-D018805
sudden	O
death	B-D003643
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	B-D008196
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia,	B-D001259
suicide	B-D013405
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Clinical	O
Studies	O
(	O
14.7	O
)]	O
Hematological	O
Events:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
celecoxib	B-D000068579
was	O
maintained	O
with	O
or	O
without	O
aspirin	B-D001241
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	B-D000068579
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
twice	O
daily	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Celecoxib	B-D000068579
3	O
mg/kg	O
Celecoxib	B-D000068579
6	O
mg/kg	O
Naproxen	B-D009288
7.5	O
mg/kg	O
Preferred	O
Term	O
N=77	O
N=82	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*	O
Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	B-D000068579
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	B-D000068579
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.7)]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	B-D000068579
pre-marketing	O
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
Placebo	O
N=	O
2285	O
N=	O
1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
celecoxib,	B-D000068579
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning,	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post	O
approval	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
General:	O
Anaphylactoid	O
reaction,	O
angioedema	B-D000799
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	B-D009336
hepatitis,	B-D006505
jaundice,	B-D007565
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	B-D008196
Agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
Renal:	O
Interstitial	O
nephritis	B-D009393
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	B-D012306
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
perioperative	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)]	O
	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	B-D012306
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(	O
5.1)	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(	O
4)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(	O
5.2)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke	B-D020521
can	O
occur	O
with	O
NSAID	O
treatment	O

Use	O
the	O
lowest	O
effective	O
dose	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

(	O
5.1)	O
NSAIDs	O
can	O
cause	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O

Prescribe	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

(	O
5.2)	O
Elevation	O
of	O
one	O
or	O
more	O
liver	B-D008099
tests	B-C004551
may	O
occur	O
during	O
therapy	O
with	O
NSAIDs	O

Discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
immediately	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O

(	O
5.3)	O
Hypertension	B-D006973
can	O
occur	O
with	O
NSAID	O
treatment	O

Monitor	O
blood	B-D001794
pressure	I-D001794
closely	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
treatment	O

(	O
5.4)	O
Use	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

(	O
5.5)	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Use	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
caution	O
in	O
patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
and	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE-inhibitors	O

(	O
5.6)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O
or	O
in	O
patients	B-D010361
without	O
prior	O
exposure	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

(	O
5.7)	O
NSAIDs	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

(	O
5.8)	O
Not	O
for	O
use	O
during	O
pregnancy	B-D011247
	O

(	O
5.9)	O
Do	O
not	O
administer	O
to	O
patients	B-D010361
with	O
aspirin	B-D001241
sensitive	O
asthma	B-D001249
and	O
use	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

(	O
5.10)	O
Avoid	O
exposure	O
of	O
treated	O
knee(s)	B-D007717
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
	O

(	O
5.11)	O
Avoid	O
contact	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
eyes	B-D005123
and	O
mucosa	O

(	O
5.12)	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(	O
5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
oral	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction	I-D009203
(MI),	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
COX-2	O
selective	O
and	O
nonselective	O
orally	O
administered	O
NSAIDs,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Inform	O
patients	B-D010361
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
an	O
orally	O
administered	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)]	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
NSAIDS,	O
such	O
as	O
diclofenac,	B-D004008
does	O
increase	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulceration,	B-D014456
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	B-D013995
during	O
the	O
course	O
of	O
therapy	O

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Prescribe	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
with	O
neither	O
of	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
and	O
therefore,	O
use	O
special	O
care	O
when	O
treating	O
this	O
population	B-D011153
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
diclofencac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

For	O
high-risk	O
patients,	B-D010361
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O

5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
the	O
normal	O
[ULN]	O
range)	O
or	O
greater	O
elevations	O
of	O
transaminases	B-D000637
occurred	O
in	O
about	O
15%	O
of	O
oral	O
diclofenac-treated	B-D004008
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
of	O
indications	O
other	O
than	O
acute	B-D059787
pain	I-D059787
	O

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	B-D008099
injury	O

In	O
clinical	B-D016430
trials	I-D016430
of	O
an	O
oral	O
diclofenac	B-D004008
–	O
misoprostol	B-D016595
combination	O
product,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O

In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
for	O
2	O
to	O
6	O
months,	O
patients	B-D010361
with	O
oral	O
diclofenac	B-D004008
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(>8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
this	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(>8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
test	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
oral	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
sever	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

In	O
a	O
European	B-D005060
retrospective	O
population-based,	B-D011153
case-controlled	O
study,	O
10	O
cases	O
of	O
oral	O
diclofenac	B-D004008
associated	O
drug-induced	O
liver	B-D008099
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	B-D004008
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	B-D016017
ratio	I-D016017
of	O
liver	B-D008099
injury	O

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	B-D016424
number	O
of	O
10	O
cases	O
of	O
liver	B-D008099
injury	O
associated	O
with	O
diclofenac,	B-D004008
the	O
adjusted	O
odds	B-D016017
ratio	I-D016017
increased	O
further	O
with	O
female	B-D005260
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days	O

Measure	O
transaminases	B-D000637
(ALT	O
and	O
AST)	O
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
monitor	O
transaminases	B-D000637
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g	O

eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
immediately	O

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
to	O
take	O
if	O
these	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
appear	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver-related	B-D008099
event	O
in	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	B-D000082
certain	O
antibiotics,	O
antiepileptics)	O

Caution	O
patients	B-D010361
to	O
avoid	O
taking	O
unprescribed	O
acetaminophen	B-D000082
while	O
using	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
lead	B-D007854
to	O
new	O
onset	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Use	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
with	O
caution	O
in	O
patients	B-D010361
with	O
hypertension	B-D006973
	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

Patients	B-D010361
taking	O
ACE-inhibitors,	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

Use	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
considerable	O
dehydration	B-D003681
	O

Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE-inhibitors,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

Therefore,	O
treatment	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
not	O
recommended	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

If	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	B-D010361
without	O
prior	O
exposure	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

Do	O
not	O
prescribe	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.10)]	O

Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
to	O
open	O
skin	B-D012867
wounds,	O
infections,	B-D007239
inflammations,	B-D007249
or	O
exfoliative	O
dermatitis,	B-D003872
as	O
it	O
may	O
affect	B-D000339
absorption	B-D000042
and	O
tolerability	O
of	O
the	O
drug	O

NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012877
manifestations,	I-D012877
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
	O

5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
should	O
not	O
be	O
used	O
by	O
pregnant	O
or	O
nursing	B-D009729
women	B-D014930
or	O
those	O
intending	O
to	O
become	O
pregnant	O

5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

The	O
use	O
of	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal	O

Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	B-D001241
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
do	O
not	O
administer	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
to	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
and	O
use	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

5.11	O
Sun	O
Exposure	O
Instruct	O
patients	B-D010361
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
on	O
treated	O
knee(s)	B-D007717
because	O
studies	O
in	O
animals	B-D000818
indicated	O
topical	O
diclofenac	B-D004008
treatment	O
resulted	O
in	O
an	O
earlier	B-D004423
onset	O
of	O
ultraviolet	O
light-induced	B-D008027
skin	B-D012867
tumors	O

The	O
potential	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
on	O
skin	B-D012867
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	B-D006801
are	O
not	O
known	O

5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
eyes	B-D005123
and	O
mucosa	O

Advise	O
patients	B-D010361
that	O
if	O
eye	B-D005123
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	B-D005123
with	O
water	B-D014867
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour	O

5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	B-D006470
more	O
frequent	O
abnormal	O
creatinine,	B-D003404
urea	B-D014508
and	O
hemoglobin	O

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	B-D012306
and	O
conduct	O
periodic	O
laboratory	O
evaluations	O

5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	B-D007854
to	O
exacerbation	O
of	O
corticosteroid-response	O
illness	O

For	O
patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy,	O
taper	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	B-D010146
conditions	O

5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	B-D006262
subjects	O
administered	O
80	O
drops	O
four	O
times	B-D013995
a	O
day	O
for	O
7	O
days	O

There	O
was	O
no	O
significant	O
change	O
in	O
platelet	B-D010974
aggregation	I-D010974
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)]	O

Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	B-D010361
receiving	O
NSAIDs	O

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	B-D001769
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis	B-D004920
	O

Check	O
hemoglobin	O
or	O
hematocrit	B-D006400
of	O
patients	B-D010361
on	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

NSAIDs	O
inhibit	O
platelet	B-D010974
aggregation	I-D010974
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	B-D001760
time	I-D001760
in	O
some	O
patients	B-D010361
	O

Unlike	O
aspirin,	B-D001241
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration	O
and	O
reversible	O

Carefully	O
monitor	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
who	O
may	O
be	O
adversely	O
affected	B-D000339
by	O
alteration	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	B-D010361
receiving	O
anticoagulants	B-D000925
	O

5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	B-D014456
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms	O
in	O
patients	B-D010361
taking	O
NSAIDs,	O
monitor	O
patients	B-D010361
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding	O

Check	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
in	O
patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O

Discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
or	O
renal	O
tests	B-C004551
persist	O
or	O
worsen	O

6	O

ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
are	O
application	O
site	O
reactions	O

(	O
6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
IGI	O
Laboratories,	B-D007753
Inc	O

at	O
1-856-697-1441,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trial	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
of	O
911	O
patients	B-D010361
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	B-D010361
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	B-D010361
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	B-D010361
treated	O
for	O
at	O
least	O
12	O
months	O

The	O
population	B-D011153
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	B-D010361
were	O
Caucasians,	O
64%	O
were	O
females,	B-D005260
and	O
all	O
patients	B-D010361
had	O
primary	O
osteoarthritis	B-D010003
	O

The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
site	O
reactions:	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment	O
related	O
adverse	O
events	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

Application	O
site	O
reactions	O
were	O
characterized	B-D002605
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	B-D004890
induration,	O
vesicles,	O
paresthesia,	B-D010292
pruritus,	B-D011537
vasodilation,	B-D014664
acne,	O
and	O
urticaria	B-D014581
	O

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	B-D012867
(32%),	O
contact	O
dermatitis	B-D003872
characterized	B-D002605
by	O
skin	B-D012867
erythema	B-D004890
and	O
induration	O
(9%),	O
contact	O
dermatitis	B-D003872
with	O
vescicles	O
(2%)	O
and	O
pruritus	B-D011537
(4%)	O

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
oral	O
diclofenac	B-D004008
	O

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	B-D012449
study,	O
contact	O
dermatitis	B-D003872
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
in	O
10%	O
of	O
patients,	B-D010361
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	B-D007854
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%	O

Adverse	O
events	O
common	O
to	O
the	O
NSAID	O
class:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	B-D003967
dyspepsia,	B-D004415
nausea,	B-D009325
flatulence,	B-D005414
abdominal	B-D015746
pain,	I-D015746
edema;	B-D004487
see	O
Table	O
1)	O

The	O
combination	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
oral	O
diclofenac,	B-D004008
compared	O
to	O
oral	O
diclofenac	B-D004008
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	B-D006470
(3%	O
vs	O

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	B-D003404
(12%	O
vs	O

7%),	O
urea	B-D014508
(20%	O
vs	O

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	B-D008099
transaminases	B-D000637
	O

Table	O
1:	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
	O

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	B-D010361
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	B-D004008
trials	O

Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction	O
Preferred	O
Term	O
according	O
to	O
COSTART	O
N(%)	O
N(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis,	B-D003872
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non	O
–	O
U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

Body	O
as	O
a	O
Whole:	O
abdominal	B-D015746
pain,	I-D015746
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	B-D001247
back	B-D001416
pain,	I-D001416
body	O
odor,	O
chest	B-D002637
pain,	I-D002637
edema,	B-D004487
face	B-D005145
edema,	B-D004487
halitosis,	B-D006209
headache,	B-D006261
lack	O
of	O
drug	O
effect,	O
neck	B-D009333
rigidity,	O
pain	B-D010146
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	B-D003967
dry	O
mouth,	B-D009055
dyspepsia,	B-D004415
gastroenteritis,	B-D005759
decreased	O
appetite,	B-D001066
mouth	B-D009055
ulceration,	B-D014456
nausea,	B-D009325
rectal	O
hemorrhage,	B-D006470
ulcerative	B-D014456
stomatitis	B-D013280
Metabolic	O
and	O
Nutritional:	O
creatinine	B-D003404
increased	O
Musculoskeletal:	O
leg	B-D007866
cramps,	O
myalgia	B-D063806
Nervous:	O
depression,	B-D003863
dizziness,	B-D004244
drowsiness,	O
lethargy,	B-D053609
paresthesia,	B-D010292
paresthesia	B-D010292
at	O
application	O
site	O
Respiratory:	O
asthma,	B-D001249
dyspnea,	B-D004417
laryngismus,	B-D007826
laryngitis,	B-D007827
pharyngitis	B-D010612
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	B-D003877
contact	I-D003877
dermatitis	B-D003872
with	O
vesicles,	O
dry	O
skin,	B-D012867
pruritus,	B-D011537
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	B-D004485
rash,	O
pruritus,	B-D011537
skin	B-D012867
discoloration,	O
urticaria	B-D014581
Special	O
senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	B-D002386
ear	B-D004423
pain,	B-D010146
eye	B-D005123
disorder,	O
eye	B-D058447
pain,	I-D058447
taste	B-D013649
perversion	O
ADVERSE	O
REACTIONS	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
administered	O
to	O
approximately	O
300	O
pain	B-D010146
patients	B-D010361
in	O
a	O
safety	B-D012449
study	O
that	O
employed	O
dosages	O
and	O
a	O
duration	O
of	O
treatment	O
sufficient	O
to	O
encompass	O
the	O
recommended	O
usage	O
(see	O
DOSAGE	O
AND	O
ADMINISTRATION)	O

Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose	O

The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
patients	B-D010361
who	O
were	O
in	O
a	O
group	O
that	O
received	O
one	O
tablet	O
of	O
hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	B-D007052
an	O
average	O
of	O
three	O
to	O
four	O
times	B-D013995
daily	O

The	O
overall	B-D016424
incidence	B-D015994
rates	O
of	O
adverse	O
experiences	O
in	O
the	O
trials	O
were	O
fairly	O
similar	O
for	O
this	O
patient	O
group	O
and	O
those	O
who	O
received	O
the	O
comparison	O
treatment,	O
acetaminophen	B-D000082
600	O
mg	O
with	O
codeine	B-D003061
60	O
mg	O

The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
incidence	B-D015994
of	O
1%	O
or	O
greater	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	B-D007052
tablets,	B-D013607
without	O
regard	O
to	O
the	O
causal	O
relationship	O
of	O
the	O
events	O
to	O
the	O
drug	O

To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk	O
*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses	O

Body	O
as	O
a	O
Whole	O
Abdominal	B-D015746
pain*;	I-D015746
Asthenia*;	B-D001247
Fever;	B-D005334
Flu	O
syndrome;	B-D013577
Headache	B-D006261
(27%);	O
Infection*;	O
Pain	B-D010146
	O

Cardiovascular	O
Palpitations;	O
Vasodilation	B-D014664
	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Anxiety*;	B-D001007
Confusion;	B-D003221
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia;	B-D010292
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities	O

Digestive	O
Anorexia;	B-D000855
Constipation	B-D003248
(22%);	O
Diarrhea*;	B-D003967
Dry	O
mouth*;	B-D009055
Dyspepsia	B-D004415
(12%);	O
Flatulence*;	B-D005414
Gastritis;	B-D005756
Melena;	B-D008551
Mouth	B-D009055
ulcers;	B-D014456
Nausea	B-D009325
(21%);	O
Thirst;	B-D013894
Vomiting*	B-D014839
	O

Metabolic	O
and	O
Nutritional	O
Disorders	O
Edema*	B-D004487
	O

Respiratory	O
Dyspnea;	B-D004417
Hiccups;	B-D006606
Pharyngitis;	B-D010612
Rhinitis	B-D012220
	O

Skin	B-D012867
and	O
Appendages	O
Pruritus*;	B-D011537
Sweating*	B-D013546
	O

Special	O
Senses	O
Tinnitus	B-D014012
	O

Urogenital	O
Urinary	O
frequency	O

Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole	O
Allergic	O
reaction	O

Cardiovascular	O
Arrhythmia;	O
Hypotension;	B-D007022
Tachycardia	B-D013610
	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Agitation;	O
Abnormal	O
dreams;	B-D004325
Decreased	O
libido;	B-D007989
Depression;	B-D003863
Euphoria;	B-D005059
Mood	O
changes;	O
Neuralgia;	B-D009437
Slurred	O
speech;	B-D013060
Tremor,	B-D014202
Vertigo	B-D014717
	O

Digestive	O
Chalky	O
stool;	O
"Clenching	O
teeth";	O
Dysphagia;	O
Esophageal	O
spasm;	B-D013035
Esophagitis;	B-D004941
Gastroenteritis;	B-D005759
Glossitis;	B-D005928
Liver	B-D008099
enzyme	O
elevation	O

Metabolic	O
and	O
Nutritional	O
Weight	O
decrease	O

Musculoskeletal	O
Arthralgia;	B-D018771
Myalgia	B-D063806
	O

Respiratory	O
Asthma;	B-D001249
Bronchitis;	B-D001991
Hoarseness;	B-D006685
Increased	O
cough;	B-D003371
Pulmonary	O
congestion;	O
Pneumonia;	B-D011014
Shallow	O
breathing;	O
Sinusitis	B-D012852
	O

Skin	B-D012867
and	O
Appendages	O
Rash;	O
Urticaria	B-D014581
	O

Special	O
Senses	O
Altered	O
vision;	O
Bad	O
taste;	B-D013649
Dry	O
eyes	B-D005123
	O

Urogenital	O
Cystitis;	B-D003556
Glycosuria;	B-D006029
Impotence;	O
Urinary	B-D014549
incontinence;	I-D014549
Urinary	B-D016055
retention	I-D016055
	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Non-Steroidal	O
Anti-Inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(5.1)	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
(5.2)	O
Cardiovascular	O
Thrombic	O
Events	O
Non-Steroidal	O
Anti-Inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O

FENOPROFEN	B-D005279
CALCIUM®	B-D002118
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
precautions	O
(5.1)	O
]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
fenoprofen,	B-D005279
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
FENOPROFEN	B-D005279
CALCIUM,	B-D002118
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDS	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
of	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
for	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
Patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
theincreased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GIbleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
fenoprofen	B-D005279
	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
FENOPROFEN	B-D005279
CALCIUM,	B-D002118
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
pre-existing	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
fenoprofen	B-D005279
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Avoid	O
the	O
use	O
of	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
pre-existing	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Avoid	O
the	O
use	O
of	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
fenoprofen	B-D005279
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[	O
see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
FENOPROFEN	B-D005279
CALCIUM	B-D002118
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

When	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenopropfen,	B-C009264
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

FENOPROFEN	B-D005279
CALCIUM	B-D002118
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
FENOPROFEN	B-D005279
CALCIUM,	B-D002118
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
FENOPROFEN	B-D005279
CALCIUM,	B-D002118
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
]	O

5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
eyes	B-D005123
attributable	O
to	O
the	O
administration	O
of	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
	O

However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs	O

Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
patients	B-D010361
taking	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
	O

5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
exercised	B-D015444
by	O
patients	B-D010361
whose	O
activities	O
require	O
alertness	O
if	O
they	O
experience	O
CNS	O
side	O
effects	O
while	O
taking	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
	O

5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
safety	B-D012449
of	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
has	O
not	O
been	O
established	O
in	O
patients	B-D010361
with	O
impaired	O
hearing,	B-D006309
these	O
patients	B-D010361
should	O
have	O
periodic	O
tests	B-C004551
of	O
auditory	O
function	O
during	O
prolonged	O
therapy	O
with	O
FENOPROFEN	B-D005279
CALCIUM	B-D002118
	O

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia,	B-D004415
headache,	B-D006261
somnolence,	O
nausea,	B-D009325
dizziness,	B-D004244
constipation,	B-D003248
nervousness,	O
asthenia,	B-D001247
and	O
peripheral	O
edema	B-D004487
	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
BPI	O
Labs,	O
LLC	O
at	O
(727)	O
471-0850	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
(6)	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

During	O
clinical	O
studies	O
for	O
rheumatoid	B-D012250
arthritis,	B-D001168
osteoarthritis,	B-D010003
or	O
mild	O
to	O
moderate	O
pain	B-D010146
and	O
studies	O
of	O
pharmacokinetics,	B-D010599
complaints	O
were	O
compiled	O
from	O
a	O
checklist	B-D057189
of	O
potential	O
adverse	O
reactions,	O
and	O
the	O
following	O
data	O
emerged	O

These	O
encompass	O
observations	B-D019370
in	O
6,786	O
patients,	B-D010361
including	O
188	O
observed	O
for	O
at	O
least	O
52	O
weeks	O

For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
patients	B-D010361
who	O
received	O
placebo	O
in	O
these	O
same	O
trials	O

During	O
short-term	O
studies	O
for	O
analgesia,	B-D000698
the	O
incidence	B-D015994
of	O
adverse	O
reactions	O
was	O
markedly	O
lower	O
than	O
that	O
seen	O
in	O
longer-term	O
studies	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trials	I-D016430
Digestive	B-D004064
System	I-D004064
—	O
During	O
clinical	B-D016430
trials	I-D016430
with	O
Fenoprofen	B-D005279
Calcium,	B-D002118
the	O
most	O
common	O
adverse	O
reactions	O
were	O
gastrointestinal	O
in	O
nature	B-D019368
and	O
occurred	O
in	O
20.8%	O
of	O
patients	B-D010361
receiving	O
Fenoprofen	B-D005279
Calcium	B-D002118
as	O
compared	O
to	O
16.9%	O
of	O
patients	B-D010361
receiving	O
placebo	O

In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
dyspepsia	B-D004415
(10.3%	O
Fenoprofen	B-D005279
Calcium	B-D002118
vs	O

2.3%	O
placebo),	O
nausea	B-D009325
(7.7%	O
vs	O

7.1%),	O
constipation	B-D003248
(7%	O
vs	O

1.5%),	O
vomiting	B-D014839
(2.6%	O
vs	O

1.9%),	O
abdominal	B-D015746
pain	I-D015746
(2%	O
vs	O

1.1%),	O
and	O
diarrhea	B-D003967
(1.8%	O
vs	O

4.1%)	O

The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
patients	B-D010361
during	O
premarketing	B-C070504
studies	O

Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
headache	B-D006261
(8.7%	O
vs	O

7.5%)	O
and	O
somnolence	O
(8.5%	O
vs	O

6.4%)	O

Dizziness	B-D004244
(6.5%	O
vs	O

5.6%),	O
tremor	B-D014202
(2.2%	O
vs	O

0.4%),	O
and	O
confusion	B-D003221
(1.4%	O
vs	O

none)	O
were	O
noted	O
less	O
frequently	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
patients	B-D010361
because	O
of	O
these	O
side	O
effects	O
during	O
premarketing	B-C070504
studies	O

Skin	B-D012867
and	O
Appendages—	O
Increased	O
sweating	B-D013546
(4.6%	O
vs	O

0.4%),	O
pruritus	B-D011537
(4.2%	O
vs	O

0.8%),	O
and	O
rash	O
(3.7%	O
vs	O

0.4%)	O
were	O
reported	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
about	O
1%	O
of	O
patients	B-D010361
because	O
of	O
an	O
adverse	O
effect	O
related	O
to	O
the	O
skin	B-D012867
during	O
premarketing	B-C070504
studies	O

Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs	O

0.4%),	O
blurred	O
vision	O
(2.2%	O
vs	O

none),	O
and	O
decreased	O
hearing	B-D006309
(1.6%	O
vs	O

none)	O
were	O
reported	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
patients	B-D010361
because	O
of	O
adverse	O
effects	O
related	O
to	O
the	O
special	O
senses	O
during	O
premarketing	B-C070504
studies	O

Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs	O

0.4%)	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
patients	B-D010361
because	O
of	O
adverse	O
cardiovascular	O
reactions	O
during	O
premarketing	B-C070504
studies	O

Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs	O

1.5%),	O
asthenia	B-D001247
(5.4%	O
vs	O

0.4%),	O
peripheral	O
edema	B-D004487
(5.0%	O
vs	O

0.4%),	O
dyspnea	B-D004417
(2.8%	O
vs	O

none),	O
fatigue	B-D005221
(1.7%	O
vs	O

1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs	O

5.6%),	O
and	O
nasopharyngitis	B-C015378
(1.2%	O
vs	O

none)	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trials	I-D016430
Digestive	B-D004064
System—Gastritis,	I-D004064
peptic	B-D010437
ulcer	I-D010437
with/without	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
anorexia,	B-D000855
flatulence,	B-D005414
dry	O
mouth,	B-D009055
and	O
blood	B-D001769
in	O
the	O
stool	O

Increases	O
in	O
alkaline	B-D000469
phosphatase,	I-D000469
LDH,	O
SGOT,	O
jaundice,	B-D007565
and	O
cholestatic	O
hepatitis,	B-D006505
aphthous	O
ulcerations	B-D014456
of	O
the	O
buccal	O
mucosa,	O
metallic	O
taste,	B-D013649
and	O
pancreatitis	B-D010195
	O

Cardiovascular—Atrial	O
fibrillation,	O
pulmonary	B-D011654
edema,	I-D011654
electrocardiographic	O
changes,	O
and	O
supraventricular	O
tachycardia	B-D013610
	O

Genitourinary	O
Tract—Renal	O
failure,	O
dysuria,	B-D053159
cystitis,	B-D003556
hematuria,	B-D006417
oliguria,	B-D009846
azotemia,	B-D053099
anuria,	B-D001002
interstitial	O
nephritis,	B-D009393
nephrosis,	B-D009401
and	O
papillary	O
necrosis	B-D009336
	O

Hypersensitivity—Angioedema	B-D006967
(angioneurotic	O
edema)	B-D004487
	O

Hematologic—Purpura,	O
bruising,	O
hemorrhage,	B-D006470
thrombocytopenia,	B-D013921
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
agranulocytosis,	B-D000380
and	O
pancytopenia	B-D010198
	O

Nervous	B-D009420
System—Depression,	I-D009420
disorientation,	O
seizures,	B-D012640
and	O
trigeminal	B-D014277
neuralgia	I-D014277
	O

Special	O
Senses—Burning	O
tongue,	B-D014059
diplopia,	B-D004172
and	O
optic	B-D009902
neuritis	I-D009902
	O

Skin	B-D012867
and	O
Appendages—Exfoliative	O
dermatitis,	B-D003872
toxic	O
epidermal	O
necrolysis,	O
Stevens-Johnson	B-D013262
syndrome,	I-D013262
and	O
alopecia	B-D000505
	O

Miscellaneous—Anaphylaxis,	O
urticaria,	B-D014581
malaise,	O
insomnia,	O
tachycardia,	B-D013610
personality	B-D010551
change,	O
lymphadenopathy,	B-D000072281
mastodynia,	B-D059373
and	O
fever	B-D005334
	O

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS	O
]	O

Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
]	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
]	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
pain,	B-D010146
fullness	O
of	O
Gl	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
[see	O
PRECAUTIONS]	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudotumor	B-D011559
cerebri	I-D011559
DERMATOLOGIC	O
Rash*	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
[see	O
PRECAUTIONS]	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
[see	O
PRECAUTIONS]	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
[see	O
PRECAUTIONS]	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevated	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
[see	O
CONTRAINDICATIONS]	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythematosus	B-D004890
syndrome,	B-D013577
Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
[see	O
PRECAUTIONS],	O
decreased	O
creatinine	B-D003404
clearance,	O
polyuria,	B-D011141
azotemia,	B-D053099
cystitis,	B-D003556
hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
tests	B-C004551
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Amneal	O
Pharmaceuticals	O
at	O
1-877-835-5472	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS	O
]	O

Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
]	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
]	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
pain,	B-D010146
fullness	O
of	O
Gl	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
[see	O
PRECAUTIONS]	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudotumor	B-D011559
cerebri	I-D011559
DERMATOLOGIC	O
Rash*	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
[see	O
PRECAUTIONS]	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
[see	O
PRECAUTIONS]	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
[see	O
PRECAUTIONS]	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevated	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
[see	O
CONTRAINDICATIONS]	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythematosus	B-D004890
syndrome,	B-D013577
Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
[see	O
PRECAUTIONS],	O
decreased	O
creatinine	B-D003404
clearance,	O
polyuria,	B-D011141
azotemia,	B-D053099
cystitis,	B-D003556
hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
tests	B-C004551
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Amneal	O
Pharmaceuticals	O
at	O
1-877-835-5472	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS	O
]	O

Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
]	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
]	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
pain,	B-D010146
fullness	O
of	O
Gl	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
[see	O
PRECAUTIONS]	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudotumor	B-D011559
cerebri	I-D011559
DERMATOLOGIC	O
Rash*	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
[see	O
PRECAUTIONS]	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
[see	O
PRECAUTIONS]	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
[see	O
PRECAUTIONS]	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevated	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
[see	O
CONTRAINDICATIONS]	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythematosus	B-D004890
syndrome,	B-D013577
Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
[see	O
PRECAUTIONS],	O
decreased	O
creatinine	B-D003404
clearance,	O
polyuria,	B-D011141
azotemia,	B-D053099
cystitis,	B-D003556
hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
tests	B-C004551
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Amneal	O
Pharmaceuticals	O
at	O
1-877-835-5472	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
ADVERSE	O
REACTIONS	O
Hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
administered	O
to	O
approximately	O
300	O
pain	B-D010146
patients	B-D010361
in	O
a	O
safety	B-D012449
study	O
that	O
employed	O
dosages	O
and	O
a	O
duration	O
of	O
treatment	O
sufficient	O
to	O
encompass	O
the	O
recommended	O
usage	O
(see	O
DOSAGE	O
AND	O
ADMINISTRATION	O
)	O

Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose	O

The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
patients	B-D010361
who	O
were	O
in	O
a	O
group	O
that	O
received	O
one	O
tablet	O
of	O
hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	B-D007052
an	O
average	O
of	O
three	O
to	O
four	O
times	B-D013995
daily	O

The	O
overall	B-D016424
incidence	B-D015994
rates	O
of	O
adverse	O
experiences	O
in	O
the	O
trials	O
were	O
fairly	O
similar	O
for	O
this	O
patient	O
group	O
and	O
those	O
who	O
received	O
the	O
comparison	O
treatment,	O
acetaminophen	B-D000082
600	O
mg	O
with	O
codeine	B-D003061
60	O
mg	O

The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
incidence	B-D015994
of	O
1%	O
or	O
greater	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
hydrocodone	B-D006853
bitartrate	O
and	O
ibuprofen	B-D007052
tablets,	B-D013607
without	O
regard	O
to	O
the	O
causal	O
relationship	O
of	O
the	O
events	O
to	O
the	O
drug	O

To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk	O
*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses	O

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
pain*;	I-D015746
Asthenia*;	B-D001247
Fever;	B-D005334
Flu	O
syndrome;	B-D013577
Headache	B-D006261
(27%);	O
Infection*;	O
Pain	B-D010146
	O

Cardiovascular:	O
Palpitations;	O
Vasodilation	B-D014664
	O

Central	B-D002490
Nervous	I-D002490
System:	I-D002490
Anxiety*;	B-D001007
Confusion;	B-D003221
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia;	B-D010292
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities	O

Digestive:	O
Anorexia;	B-D000855
Constipation	B-D003248
(22%);	O
Diarrhea*;	B-D003967
Dry	O
mouth*;	B-D009055
Dyspepsia	B-D004415
(12%);	O
Flatulence*;	B-D005414
Gastritis;	B-D005756
Melena;	B-D008551
Mouth	B-D009055
ulcers;	B-D014456
Nausea	B-D009325
(21%);	O
Thirst;	B-D013894
Vomiting*	B-D014839
	O

Metabolic	O
and	O
Nutritional	O
Disorders:	O
Edema*	B-D004487
	O

Respiratory:	O
Dyspnea;	B-D004417
Hiccups;	B-D006606
Pharyngitis;	B-D010612
Rhinitis	B-D012220
	O

Skin	B-D012867
and	O
Appendages:	O
Pruritus*;	B-D011537
Sweating*	B-D013546
	O

Special	O
Senses:	O
Tinnitus	B-D014012
	O

Urogenital:	O
Urinary	O
frequency	O

Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole:	O
Allergic	O
reaction	O

Cardiovascular:	O
Arrhythmia;	O
Hypotension;	B-D007022
Tachycardia	B-D013610
	O

Central	B-D002490
Nervous	I-D002490
System:	I-D002490
Agitation;	O
Abnormal	O
dreams;	B-D004325
Decreased	O
libido;	B-D007989
Depression;	B-D003863
Euphoria;	B-D005059
Mood	O
changes;	O
Neuralgia;	B-D009437
Slurred	O
speech;	B-D013060
Tremor,	B-D014202
Vertigo	B-D014717
	O

Digestive:	O
Chalky	O
stool;	O
"Clenching	O
teeth";	O
Dysphagia;	O
Esophageal	O
spasm;	B-D013035
Esophagitis;	B-D004941
Gastroenteritis;	B-D005759
Glossitis;	B-D005928
Liver	B-D008099
enzyme	O
elevation	O

Metabolic	O
and	O
Nutritional:	O
Weight	O
decrease	O

Musculoskeletal:	O
Arthralgia;	B-D018771
Myalgia	B-D063806
	O

Respiratory:	O
Asthma;	B-D001249
Bronchitis;	B-D001991
Hoarseness;	B-D006685
Increased	O
cough;	B-D003371
Pulmonary	O
congestion;	O
Pneumonia;	B-D011014
Shallow	O
breathing;	O
Sinusitis	B-D012852
	O

Skin	B-D012867
and	O
Appendages:	O
Rash;	O
Urticaria	B-D014581
	O

Special	O
Senses:	O
Altered	O
vision;	O
Bad	O
taste;	B-D013649
Dry	O
eyes	B-D005123
	O

Urogenital:	O
Cystitis;	B-D003556
Glycosuria;	B-D006029
Impotence;	O
Urinary	B-D014549
incontinence;	I-D014549
Urinary	B-D016055
retention	I-D016055
	O

Cardiovascular	O
Risk	B-D012306
•NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(see	O
WARNINGS.)	O
•Diclofenac	O
sodium	B-D012964
delayed-release	O
tablets	B-D013607
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(see	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets,	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%–10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
atulence,	O
gross	O
bleeding/	O
perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
liver	B-D017093
failure,	I-D017093
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
adverse	O
reactions	O
are	O
drowsiness	O
and	O
dizziness	B-D004244
	O

Less	O
frequent	O
adverse	O
reactions	O
are	O
lightheadedness	B-D008027
and	O
gastrointestinal	O
disturbances	O
including	O
nausea,	B-D009325
vomiting,	B-D014839
and	O
flatulence	B-D005414
	O

A	O
single	O
incidence	B-D015994
of	O
bone	B-D001853
marrow	I-D001853
suppression	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
butalbital,	B-C004470
aspirin,	B-D001241
and	O
caffeine	B-D002110
capsules	B-D002214
	O

Several	O
cases	O
of	O
dermatological	O
reactions	O
including	O
toxic	O
epidermal	O
necrolysis	O
and	O
erythema	B-D004892
multiforme	I-D004892
have	O
been	O
reported	O

ADVERSE	O
REACTIONS:	O
Clinical	O
Practice:	O
The	O
following	O
events	O
have	O
been	O
identified	B-D007060
during	O
postmarketing	O
use	O
of	O
topical	O
diclofenac	B-D004008
sodium	B-D012964
ophthalmic	O
solution,	O
0.1%	O
in	O
clinical	O
practice	O

Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
unknown	O
size,	O
estimates	O
of	O
frequency	O
cannot	O
be	O
made	O

The	O
events	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
diclofenac	B-D004008
sodium	B-D012964
ophthalmic	O
Solution,	O
0.1%,	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
corneal	B-D003315
erosion,	O
corneal	B-D003315
infiltrates,	O
corneal	B-D057112
perforation,	I-D057112
corneal	B-D003315
thinning,	O
corneal	B-D003320
ulceration,	I-D003320
epithelial	O
breakdown,	O
and	O
superficial	O
punctate	O
keratitis	B-D007634
(see	O
Precautions,	O
General)	O

Ocular:	O
Transient	O
burning	O
and	O
stinging	O
were	O
reported	O
in	O
approximately	O
15%	O
of	O
patients	B-D010361
across	O
studies	O
with	O
the	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Ophthalmic	O
Solution	O

In	O
cataract	B-D002386
surgery	O
studies,	O
keratitis	B-D007634
was	O
reported	O
in	O
up	O
to	O
28%	O
of	O
patients	B-D010361
receiving	O
Diclofenac	B-D004008
Sodium	B-D012964
Ophthalmic	O
Solution,	O
although	O
in	O
many	O
of	O
these	O
cases	O
keratitis	B-D007634
was	O
initially	O
noted	O
prior	O
to	O
the	O
initiation	O
of	O
treatment	O

Elevated	O
intraocular	B-D007429
pressure	I-D007429
following	O
cataract	B-D002386
surgery	O
was	O
reported	O
in	O
approximately	O
15%	O
of	O
patients	B-D010361
undergoing	O
cataract	B-D002386
surgery	O

Lacrimation	O
complaints	O
were	O
reported	O
in	O
approximately	O
30%	O
of	O
case	O
studies	O
undergoing	O
incisional	O
refractive	O
surgery	O

The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
approximately	O
5%	O
or	O
less	O
of	O
the	O
patients:	B-D010361
abnormal	O
vision,	O
acute	O
elevated	O
IOP,	O
blurred	O
vision,	O
conjunctivitis,	B-D003231
corneal	B-D003315
deposits,	B-C020884
corneal	B-D015715
edema,	I-D015715
corneal	B-D003318
opacity,	I-D003318
corneal	B-D003315
lesions,	O
discharge,	O
eyelid	B-D005123
swelling,	O
injection,	O
iritis,	B-D007500
irritation,	O
itching,	O
lacrimation	O
disorder	O
and	O
ocular	O
allergy	O

Systemic:	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
3%	O
or	O
less	O
of	O
the	O
patients:	B-D010361
abdominal	B-D015746
pain,	I-D015746
asthenia,	B-D001247
chills,	B-D023341
dizziness,	B-D004244
facial	O
edema,	B-D004487
fever,	B-D005334
headache,	B-D006261
insomnia,	O
nausea,	B-D009325
pain,	B-D010146
rhinitis,	B-D012220
viral	O
infection,	O
and	O
vomiting	B-D014839
	O

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

[See	O
WARNINGS	O
and	O
PRECAUTIONS	O
]	O

Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O
	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

[See	O
WARNINGS	O
]	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship	O
Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown	O
GASTROINTESTINAL	O
Nausea	B-D009325
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
,	O
epigastric	O
pain	B-D010146
,	O
heartburn	B-D006356
,	O
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
Pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness	B-D004244
,	O
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
[see	O
PRECAUTIONS	O
]	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
[see	O
PRECAUTIONS	O
]	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
[see	O
PRECAUTIONS	O
]	O
Bleeding	O
episodes	O
(eg	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
[see	O
PRECAUTIONS	O
]	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevated	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
[see	O
CONTRAINDICATIONS	B-D000075202
]	O
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythe-	O
matosus	O
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
[see	O
PRECAUTIONS	O
],	O
decreased	O
creatinine	B-D003404
clearance,	O
polyuria,	B-D011141
azotemia,	B-D053099
cystitis,	B-D003556
Hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
tests	B-C004551
CARDIOVASCULAR	O
RISK	B-D012306
NSAIDs1	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
(see	O
WARNINGS)	O

Diclofenac	B-D004008
potassium	B-D011188
tablets	B-D013607
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS)	O

GASTROINTESTINAL	O
RISK	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS)	O

1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug	O

ADVERSE	O
REACTIONS	O
In	O
718	O
patients	B-D010361
treated	O
for	O
shorter	O
periods,	O
i.e.,	O
2	O
weeks	O
or	O
less,	O
with	O
diclofenac	B-D004008
potassium	B-D011188
tablets,	B-D013607
adverse	O
reactions	O
were	O
reported	O
one-half	O
to	O
one-tenth	O
as	O
frequently	O
as	O
by	O
patients	B-D010361
treated	O
for	O
longer	O
periods	O

In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
diclofenac	B-D004008
potassium	B-D011188
tablets	B-D013607
(N	O
=	O
196)	O
versus	O
diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
(N	O
=	O
197)	O
versus	O
ibuprofen	B-D007052
(N	O
=	O
197),	O
adverse	O
reactions	O
were	O
similar	O
in	O
nature	B-D019368
and	O
frequency	O

In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
potassium	B-D011188
tablets	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
·	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O

·	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash*,	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and	O
/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
(see	O
PRECAUTIONS)	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevate	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS)	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythematosus	B-D004890
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
poliuria,	O
azotemia,	B-D053099
cystitis,	B-D003556
hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked)	O

**Reactions	O
are	O
classified	O
under	O
“	O
Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
·	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O

·	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash*,	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and	O
/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
(see	O
PRECAUTIONS)	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevate	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS)	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythematosus	B-D004890
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
poliuria,	O
azotemia,	B-D053099
cystitis,	B-D003556
hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked)	O

**Reactions	O
are	O
classified	O
under	O
“	O
Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O

(5.4)	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke	B-D020521
	O

Patients	B-D010361
with	O
known	O
CV	O
disease/risk	B-D004194
factors	O
may	O
be	O
at	O
greater	O
risk	B-D012306
(5.1,	O
14.6,	O
17.2)	O

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
risk	B-D012306
is	O
greater	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
GI	O
bleeding,	O
and	O
in	O
patients	B-D010361
at	O
high	O
risk	B-D012306
for	O
GI	O
events,	O
especially	O
the	O
elderly	O

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	B-D010361
(5.4,	O
8.5,	O
14.6,	O
17.3)	O

Elevated	O
liver	B-D008099
enzymes	B-D004798
and,	O
rarely,	O
severe	O
hepatic	O
reactions	O

Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
liver	B-D008099
enzymes	B-D004798
persist	O
or	O
worsen	O
(5.5,	O
17.4)	O

New	O
onset	O
or	O
worsening	O
of	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
CELEBREX	O
(5.2,	O
7.4,	O
17.2)	O

Fluid	O
retention	O
and	O
edema	B-D004487
	O

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
(5.3,	O
17.6)	O

Renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use	O

Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
and	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
or	O
angiotensin	B-D000804
II	I-D000804
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6)	O

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
CELEBREX	O
in	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O
(5.7,	O
10,	O
17.7)	O

Serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy	O

Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	B-D012867
reactions	O
(5.8,	O
17.5)	O

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
CELEBREX	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
CELEBREX,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
CELEBREX	O
does	O
increase	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O

Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)	O
]	O

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
lead	B-D007854
to	O
the	O
onset	O
of	O
new	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
CELEBREX	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

The	O
rates	O
of	O
hypertension	B-D006973
from	O
the	O
CLASS	O
trial	O
in	O
the	O
CELEBREX,	O
ibuprofen	B-D007052
and	O
diclofenac-treated	B-D004008
patients	B-D010361
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	B-D000078682
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
taking	O
NSAIDs,	O
including	O
CELEBREX	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
]	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulceration,	B-D014456
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	B-D013995
during	O
the	O
course	O
of	O
therapy	O

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
with	O
neither	O
of	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population	B-D011153
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
CELEBREX	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

For	O
high-risk	O
patients,	B-D010361
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered	O

Celebrex	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
active	O
GI	O
bleeding	O

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	B-D008099
enzymes	B-D004798
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
with	O
NSAIDs	O

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	B-D007565
and	O
fatal	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis	B-D009336
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	B-D017809
outcome)	I-D017809
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
CELEBREX	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
CELEBREX,	O
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
CELEBREX	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
CELEBREX	O
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	B-D008099
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	B-D008099
test	B-C004551
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
CELEBREX	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
CELEBREX	O
should	O
be	O
discontinued	O

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
angiotensin	B-D000804
II	I-D000804
receptor	O
antagonists,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
trials	I-D016430
with	O
CELEBREX	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	B-D010361
without	O
known	O
prior	O
exposure	O
to	O
CELEBREX	O

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	B-D000799
have	O
been	O
reported	O
in	O
patients	B-D010361
receiving	O
CELEBREX	O

CELEBREX	O
should	O
not	O
be	O
given	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	B-D010361
without	O
prior	O
known	O
sulfa	O
allergy	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012877
manifestations	I-D012877
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	B-D011247
starting	O
at	O
30	O
weeks	O
gestation,	O
CELEBREX	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	B-D007854
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness	O

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	B-D010361
receiving	O
CELEBREX	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
CELEBREX	O
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

CELEBREX	O
does	O
not	O
generally	O
affect	B-D000339
platelet	B-D010976
counts,	I-D010976
prothrombin	B-D011517
time	I-D011517
(PT),	O
or	O
partial	B-D010314
thromboplastin	I-D010314
time	I-D010314
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	B-D010974
aggregation	I-D010974
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
	O

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

The	O
use	O
of	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal	O

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	B-D001241
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
CELEBREX	O
should	O
not	O
be	O
administered	O
to	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

5.14	O
Laboratory	O
Tests	B-C004551
Because	O
serious	O
GI	O
tract	O
ulcerations	B-D014456
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	B-D010820
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
checked	O
periodically	B-D020492
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
or	O
renal	O
tests	B-C004551
persist	O
or	O
worsen,	O
CELEBREX	O
should	O
be	O
discontinued	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
CELEBREX	O
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	B-D010146
conditions	O

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	B-D012306
of	O
adverse	O
reactions	O

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
CELEBREX	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
CELEBREX	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
CELEBREX	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
CELEBREX	O
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
CELEBREX	O
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
CELEBREX	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia	O
Psychiatric	O
:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders	O
:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary	O
:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	B-D010361
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis,	B-D013924
vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
Gastrointestinal	O
:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis,	B-D002769
hepatitis,	B-D006505
jaundice,	B-D007565
liver	B-D017093
failure	I-D017093
Hemic	O
and	O
lymphatic	B-D008196
:	O
Thrombocytopenia,	B-D013921
agranulocytosis,aplastic	B-D000380
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous	O
:	O
Ataxia,	B-D001259
suicide,	B-D013405
aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	B-D009393
Skin:	B-D012867
Erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	B-D006967
syndrome)	B-D013577
General	O
:	O
Sepsis,	B-D018805
sudden	O
death,	B-D003643
anaphylactoid	O
reaction,	O
angioedema	B-D000799
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
CELEBREX	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

6.3	O
Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
BID,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
BID	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib3	B-D000068579
mg/kgN=77	O
Celecoxib6	B-D000068579
mg/kgN=82	O
Naproxen7.5	B-D009288
mg/kgN=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
InvestigationsAbnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
CELEBREX	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
CELEBREX	O
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
CELEBREX	O
pre-marketing	O
controlled	O
arthritis	B-D001168
trials	O
,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
CELEBREX	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
CELEBREX(400	O
to	O
800	O
mg	O
daily)N	O
=	O
2285	O
PlaceboN=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
CELEBREX,	O
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders	O
:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
Allergy	O
alert:	O
Ibuprofen	B-D007052
may	O
cause	O
a	O
severe	O
allergic	O
reaction,	O
especially	O
in	O
people	O
allergic	O
to	O
Aspirin	B-D001241
	O

Symptoms	O
may	O
include	O
hives	B-D006678
facial	O
swelling	O
asthma	B-D001249
(wheezing)	O
shock	B-D012769
skin	B-D012867
reddening	O
rash	O
blisters	B-D001768
If	O
an	O
allergic	O
reaction	O
occurs,	O
stop	O
use	O
and	O
seek	O
medical	O
help	O
right	O
away	O

Stomach	B-D013270
bleeding	O
warning:	O
This	O
product	O
contains	O
an	O
NSAID,	O
which	O
may	O
cause	O
severe	O
stomach	B-D013270
bleeding	O

The	O
chance	O
is	O
higher	O
if	O
you	O
are	O
age	O
60	O
or	O
older	O
have	O
had	O
stomach	B-D013276
ulcers	I-D013276
or	O
bleeding	O
problems	O
take	O
a	O
blood	B-D001769
thinning	O
(anticoagulant)	O
or	O
steroid	O
drug	O
take	O
other	O
drugs	O
containing	O
prescription	O
or	O
non	O
prescription	O
NSAIDs	O
(aspirin,	O
ibuprofen,	B-D007052
naproxen,	B-D009288
or	O
others)	O
have	O
3	O
or	O
more	O
alcoholic	O
drinks	O
everyday	O
while	O
using	O
this	O
product	O
take	O
more	O
or	O
for	O
a	O
longer	O
time	B-D013995
than	O
directed	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)]	O
	O

•	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)]	O
	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(	O
5.1)	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(	O
4	O
,	O
5.1)	O
NSAIDs,	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(	O
5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(	O
5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(	O
5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
gestation	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
lsymptoms	O
of	O
anemia	B-D000740
(	O
5.11,	O
7)	O
Exposure	O
to	O
light:	B-D008027
Avoid	O
exposure	O
of	O
treated	O
knee(s)	B-D007717
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
	O

(	O
5.14)	O
Eye	B-D005123
Contact:	O
Avoid	O
contact	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
eyes	B-D005123
and	O
mucosa	O

(	O
5.15)	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDS	O

(	O
5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NASAID-treated	B-C015378
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	B-D004008
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)]	O
	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(	O
4)]	O
	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)]	O
	O

5.3	O
Hepatotoxicity	O
In	O
clinical	B-D016430
trials,	I-D016430
of	O
oral	O
diclofenac-containing	B-D004008
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
with	O
oral	O
diclofenac	B-D004008
for	O
2	O
to	O
6	O
months,	O
patients	B-D010361
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
tests	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

In	O
a	O
European	B-D005060
retrospective	O
population-based,	B-D011153
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	B-D004008
associated	O
drug-induced	O
liver	B-D008099
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	B-D004008
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	B-D016017
ratio	I-D016017
of	O
liver	B-D008099
injury	O

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	B-D016424
number	O
of	O
10	O
cases	O
of	O
liver	B-D008099
injury	O
associated	O
with	O
diclofenac,	B-D004008
the	O
adjusted	O
odds	B-D016017
ratio	I-D016017
increased	O
further	O
with	O
female	B-D005260
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days	O

Physicians	B-D010820
should	O
measure	O
transaminases	B-D000637
at	O
baseline	O
and	O
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
transaminases	B-D000637
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
should	O
be	O
discontinued	O
immediately	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver-related	B-D008099
event	O
in	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	B-D000082
antibiotics,	O
antiepileptics)	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension,	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)]	O
	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
diclofenac	B-D004008
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)]	O
	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)]	O
	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
diclofenac	B-D004008
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.8)]	O
	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
Contraindications	B-D000075202
(	O
4)]	O
	O

When	O
diclofenac	B-D004008
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(	O
4)]	O
	O

Do	O
not	O
apply	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
to	O
open	O
skin	B-D012867
wounds,	O
infections,	B-D007239
inflammations,	B-D007249
or	O
exfoliative	O
dermatitis,	B-D003872
as	O
it	O
may	O
affect	B-D000339
absorption	B-D000042
and	O
tolerability	O
of	O
the	O
drug	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(	O
8.1)]	O
	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
diclofenac,	B-D004008
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)]	O
	O

The	O
effects	O
of	O
diclofenac	B-D004008
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	B-D006262
subjects	O
administered	O
80	O
drops	O
four	O
times	B-D013995
a	O
day	O
for	O
7	O
days	O

There	O
was	O
no	O
significant	O
change	O
in	O
platelet	B-D010974
aggregation	I-D010974
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(	O
12.4)]	O
	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	B-D004008
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2,	O
5.3,	O
5.6)]	O
	O

5.14	O
Sun	O
Exposure	O
Instruct	O
patients	B-D010361
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
on	O
treated	O
knee(s)	B-D007717
because	O
studies	O
in	O
animals	B-D000818
indicated	O
topical	O
diclofenac	B-D004008
treatment	O
resulted	O
in	O
an	O
earlier	B-D004423
onset	O
of	O
ultraviolet	O
light-induced	B-D008027
skin	B-D012867
tumors	O

The	O
potential	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
on	O
skin	B-D012867
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	B-D006801
are	O
not	O
known	O

5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
eyes	B-D005123
and	O
mucosa	O

Advise	O
patients	B-D010361
that	O
if	O
eye	B-D005123
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	B-D005123
with	O
water	B-D014867
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour	O

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	B-D006470
more	O
frequent	O
abnormal	O
creatinine,	B-D003404
urea	B-D014508
and	O
hemoglobin	O

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	B-D012306
and	O
conduct	O
periodic	O
laboratory	O
evaluations.Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	B-D006470
more	O
frequent	O
abnormal	O
creatinine,	B-D003404
urea	B-D014508
and	O
hemoglobin	O

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	B-D012306
and	O
conduct	O
periodic	O
laboratory	O
evaluations	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)]	O
Most	O
common	O
adverse	O
reactions	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
are	O
application	O
site	O
reactions	O

(	O
6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
	O

6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
of	O
911	O
patients	B-D010361
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	B-D010361
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	B-D010361
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	B-D010361
treated	O
for	O
at	O
least	O
12	O
months	O

The	O
population	B-D011153
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	B-D010361
were	O
Caucasians,	O
64%	O
were	O
females,	B-D005260
and	O
all	O
patients	B-D010361
had	O
primary	O
osteoarthritis	B-D010003
	O

The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

Application	O
site	O
reactions	O
were	O
characterized	B-D002605
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	B-D004890
induration,	O
vesicles,	O
paresthesia,	B-D010292
pruritus,	B-D011537
vasodilation,	B-D014664
acne,	O
and	O
urticaria	B-D014581
	O

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	B-D012867
(32%),	O
contact	O
dermatitis	B-D003872
characterized	B-D002605
by	O
skin	B-D012867
erythema	B-D004890
and	O
induration	O
(9%),	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
(2%)	O
and	O
pruritus	B-D011537
(4%)	O

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
oral	O
diclofenac	B-D004008
	O

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	B-D012449
study,	O
contact	O
dermatitis	B-D003872
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
in	O
10%	O
of	O
patients,	B-D010361
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	B-D007854
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%	O

Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	B-D003967
dyspepsia,	B-D004415
nausea,	B-D009325
flatulence,	B-D005414
abdominal	B-D015746
pain,	I-D015746
edema;	B-D004487
see	O
Table	O
1)	O

The	O
combination	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
oral	O
diclofenac,	B-D004008
compared	O
to	O
oral	O
diclofenac	B-D004008
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	B-D006470
(3%	O
vs	O

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	B-D003404
(12%	O
vs	O

7%),	O
urea	B-D014508
(20%	O
vs	O

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	B-D008099
transaminases	B-D000637
	O

Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
	O

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥	O
1%	O
of	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	B-D004008
trials	O

Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
N=911	O
Topical	O
Placebo	O
N=332	O
Adverse	O
Reaction	O
†	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis,	B-D003872
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
†Preferred	O
Term	O
according	O
to	O
COSTART	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

Body	O
as	O
a	O
Whole:	O
abdominal	B-D015746
pain,	I-D015746
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	B-D001247
back	B-D001416
pain,	I-D001416
body	O
odor,	O
chest	B-D002637
pain,	I-D002637
edema,	B-D004487
face	B-D005145
edema,	B-D004487
halitosis,	B-D006209
headache,	B-D006261
lack	O
of	O
drug	O
effect,	O
neck	B-D009333
rigidity,	O
pain	B-D010146
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	B-D003967
dry	O
mouth,	B-D009055
dyspepsia,	B-D004415
gastroenteritis,	B-D005759
decreased	O
appetite,	B-D001066
mouth	B-D009055
ulceration,	B-D014456
nausea,	B-D009325
rectal	O
hemorrhage,	B-D006470
ulcerative	B-D014456
stomatitis	B-D013280
Metabolic	O
and	O
Nutritional:	O
creatinine	B-D003404
increased	O
Musculoskeletal:	O
leg	B-D007866
cramps,	O
myalgia	B-D063806
Nervous:	O
depression,	B-D003863
dizziness,	B-D004244
drowsiness,	O
lethargy,	B-D053609
paresthesia,	B-D010292
paresthesia	B-D010292
at	O
application	O
site	O
Respiratory:	O
asthma,	B-D001249
dyspnea,	B-D004417
laryngismus,	B-D007826
laryngitis,	B-D007827
pharyngitis	B-D010612
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	B-D003877
contact	I-D003877
dermatitis	B-D003872
with	O
vesicles,	O
dry	O
skin,	B-D012867
pruritus,	B-D011537
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	B-D004485
rash,	O
pruritus,	B-D011537
skin	B-D012867
discoloration,	O
urticaria	B-D014581
Special	O
Senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	B-D002386
ear	B-D004423
pain,	B-D010146
eye	B-D005123
disorder,	O
eye	B-D058447
pain,	I-D058447
taste	B-D013649
perversion	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(See	O
WARNINGS	O
.)	O
Diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets,	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/	B-D009846
polyuria,	B-D011141
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS)	O

Diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	B-D000075202
WARNINGS)	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets,	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional	O
:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System	I-D012137
:	O
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages	O
:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole	O
:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System	I-D004064
:	O
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional	O
:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System	I-D009420
:	O
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages	O
:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses	O
:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS	O
]	O

Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
]	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
]	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“	O
Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“	O
Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
Pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash*	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
neuritis,	B-D009443
cataracts	B-D002386
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
(see	O
PRECAUTIONS)	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(eg	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevated	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS)	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythe-	O
matosus	O
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
polyuria,	B-D011141
azotemia,	B-D053099
cystitis,	B-D003556
Hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
tests	B-C004551
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
AvKARE,	O
Inc	O

at	O
1-855-361-3993;	O
email	O
drugsafety@avkare.com;	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
·	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O

·	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash*,	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and	O
/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
(see	O
PRECAUTIONS)	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevate	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS)	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythematosus	B-D004890
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
poliuria,	O
azotemia,	B-D053099
cystitis,	B-D003556
hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked)	O

**Reactions	O
are	O
classified	O
under	O
“	O
Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O
BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(See	O
WARNINGS	O
and	O
PRECAUTIONS)	O

•	O
Ibuprofen	B-D007052
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)Probable	O
Causal	O
Relationship*	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)Probable	O
Causal	O
Relationship**[/	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINALNausea*,	O
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
Pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEMDizziness*,	I-D002490
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudotumor	B-D011559
cerebri	I-D011559
DERMATOLOGICRash*,	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-	O
Johnson	O
syndrome,	B-D013577
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSESTinnitus	O
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-	O
Johnson	O
syndrome,	B-D013577
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
HEMATOLOGIC	O
Neutropenia,agranulocytosis,	B-D009503
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(eg	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINEDecreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAREdema,	O
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevate	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS)	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythematosus	B-D004890
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
poliuria,	O
azotemia,	B-D053099
cystitis,	B-D003556
Hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O
DUEXIS	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

DUEXIS	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O

(5.4)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
	O

(5.5,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
DUEXIS	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

(5.6)	O
Active	O
Bleeding:	O
Active	O
and	O
clinically	O
significant	O
bleeding	O
from	O
any	O
source	O
can	O
occur;	O
discontinue	O
DUEXIS	O
if	O
active	O
bleeding	O
occurs	O

(5.3)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
DUEXIS	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

(5.7)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

(5.8)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
DUEXIS	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin-sensitivity)	B-D001241
	O

(5.10)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
DUEXIS	O
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
	O

(5.11)	O
Premature	B-C070504
Closure	O
of	O
the	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
gestation	O

(5.12,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patient	O
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
	O

(5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI),	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDS	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
ibuprofen,	B-D007052
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
DUEXIS	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
DUEXIS	O
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
ibuprofen,	B-D007052
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDS	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

NSAIDs	O
should	O
be	O
given	O
with	O
care	O
to	O
patients	B-D010361
with	O
a	O
history	B-D006664
of	O
inflammatory	O
bowel	O
disease	B-D004194
(ulcerative	O
colitis,	B-D003092
Crohn's	O
disease)	B-D004194
as	O
their	O
condition	O
may	O
be	O
exacerbated	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
DUEXIS	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.3	O
Active	O
Bleeding	O
When	O
active	O
and	O
clinically	O
significant	O
bleeding	O
from	O
any	O
source	O
occurs	O
in	O
patients	B-D010361
receiving	O
DUEXIS,	O
the	O
treatment	O
should	O
be	O
withdrawn	O

Patients	B-D010361
with	O
initial	O
hemoglobin	O
values	O
of	O
10	O
g	O
or	O
less	O
who	O
are	O
to	O
receive	O
long-term	O
therapy	O
should	O
have	O
hemoglobin	O
values	O
determined	O
periodically	B-D020492
	O

5.4	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
ibuprofen	B-D007052
	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
DUEXIS	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.5	O
Hypertension	B-D006973
NSAIDs,	O
including	O
DUEXIS,	O
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
pre-existing	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.6	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective	O
treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
ibuprofen	B-D007052
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
DUEXIS	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
DUEXIS	O
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.7	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE-inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
DUEXIS	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
DUEXIS	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
pre-existing	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
DUEXIS	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
DUEXIS	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
DUEXIS	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
failure	O

If	O
DUEXIS	O
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.8	O
Anaphylactic	O
Reactions	O
Ibuprofen	B-D007052
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
ibuprofen	B-D007052
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.8)]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.9	O
Seizures	B-D012640
Central	B-D002490
nervous	I-D002490
system	I-D002490
(CNS)	O
adverse	O
effects	O
including	O
seizures,	B-D012640
delirium,	B-D003693
and	O
coma	B-D003128
have	O
been	O
reported	O
with	O
famotidine	B-D015738
in	O
patients	B-D010361
with	O
moderate	O
(creatinine	O
clearance	O
<50	O
mL/min)	O
and	O
severe	O
renal	B-D051437
insufficiency	I-D051437
(creatinine	O
clearance	O
<10	O
mL/min),	O
and	O
the	O
dosage	O
of	O
the	O
famotidine	B-D015738
component	O
in	O
DUEXIS	O
is	O
fixed	O

Therefore,	O
DUEXIS	O
is	O
not	O
recommended	O
in	O
patients	B-D010361
with	O
creatinine	B-D003404
clearance	O
<	O
50	O
mL/min	O

5.10	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
DUEXIS	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)]	O

When	O
DUEXIS	O
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.11	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
ibuprofen,	B-D007052
which	O
is	O
a	O
component	O
of	O
DUEXIS	O
tablets,	B-D013607
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
DUEXIS	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

DUEXIS	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)]	O

5.12	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Ibuprofen	B-D007052
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
DUEXIS,	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Population	B-D011153
(8.1)]	O

5.13	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
DUEXIS	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
DUEXIS,	O
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
and	O
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
the	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.14	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
DUEXIS	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.15	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.4,	O
5.7)	O
]	O

5.16	O
Concomitant	O
NSAID	O
Use	O
DUEXIS	O
contains	O
ibuprofen	B-D007052
as	O
one	O
of	O
its	O
active	O
ingredients	O

It	O
should	O
not	O
be	O
used	O
with	O
other	O
ibuprofen-containing	B-D007052
products	O

The	O
concomitant	O
use	O
of	O
NSAIDs,	O
including	O
aspirin,	B-D001241
with	O
DUEXIS	O
may	O
increase	O
the	O
risk	B-D012306
of	O
adverse	O
reactions	O
[see	O
Adverse	O
Reactions	O
(6),	O
Drug	B-D004347
Interactions	I-D004347
(7),	O
Clinical	O
Studies	O
(14)	O
]	O

5.17	O
Aseptic	O
Meningitis	B-D008581
Aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
has	O
been	O
observed	O
on	O
rare	O
occasions	O
in	O
patients	B-D010361
on	O
ibuprofen,	B-D007052
which	O
is	O
a	O
component	O
of	O
DUEXIS	O

Although	O
it	O
is	O
probably	O
more	O
likely	O
to	O
occur	O
in	O
patients	B-D010361
with	O
systemic	O
lupus	O
erythematosus	B-D004890
(SLE)	O
and	O
related	O
connective	B-D003240
tissue	I-D003240
diseases,	I-D003240
it	O
has	O
been	O
reported	O
in	O
patients	B-D010361
who	O
do	O
not	O
have	O
an	O
underlying	O
chronic	B-D002908
disease	I-D002908
	O

If	O
signs	O
or	O
symptoms	O
of	O
meningitis	B-D008581
develop	O
in	O
a	O
patient	O
on	O
DUEXIS,	O
the	O
possibility	O
of	O
its	O
being	O
related	O
to	O
ibuprofen	B-D007052
should	O
be	O
considered	O

5.18	O
Ophthalmological	O
Effects	O
Blurred	O
and/or	O
diminished	O
vision,	O
scotomata,	B-D012607
and/or	O
changes	O
in	O
color	B-D055253
vision	I-D055253
have	O
been	O
reported	O

If	O
a	O
patient	O
develops	O
such	O
complaints	O
while	O
receiving	O
DUEXIS,	O
the	O
drug	O
should	O
be	O
discontinued,	O
and	O
the	O
patient	O
should	O
have	O
an	O
ophthalmologic	O
examination	O
which	O
includes	O
central	O
visual	B-D014794
fields	I-D014794
and	O
color	B-D055253
vision	I-D055253
testing	B-C004551
	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5	O

8)]	O
Seizures	B-D012640
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.13)]	O
Aseptic	O
Meningitis	B-D008581
[see	O
Warnings	O
and	O
Precautions	O
(5.17)]	O
Ophthalmological	O
Effects	O
[see	O
Warnings	O
and	O
Precautions	O
(5.18)]	O
Most	O
common	O
adverse	O
reactions	O
(≥1%	O
and	O
greater	O
than	O
ibuprofen	B-D007052
alone)	O
are	O
nausea,	B-D009325
diarrhea,	B-D003967
constipation,	B-D003248
upper	O
abdominal	B-D015746
pain,	I-D015746
and	O
headache	B-D006261
	O

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Horizon	O
at	O
(1-866-479-6742)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
	O

6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
safety	B-D012449
of	O
DUEXIS	O
was	O
evaluated	O
in	O
1022	O
patients	B-D010361
in	O
controlled	O
clinical	O
studies,	O
including	O
508	O
patients	B-D010361
treated	O
for	O
at	O
least	O
6	O
months	O
and	O
107	O
patients	B-D010361
treated	O
for	O
approximately	O
1	O
year	O

Patients	B-D010361
treated	O
with	O
DUEXIS	O
ranged	O
in	O
age	O
from	O
39	O
to	O
80	O
years	O
(median	O
age	O
55	O
years),	O
with	O
67%	O
female,	B-D005260
79%	O
Caucasian,	O
18%	O
African-American,	B-D000349
and	O
3%	O
other	O
races	O

Two	O
randomized,	O
active-controlled	O
clinical	O
studies	O
(Study	O
301	O
and	O
Study	O
303)	O
were	O
conducted	O
for	O
the	O
reduction	O
of	O
the	O
risk	B-D012306
of	O
development	O
of	O
ibuprofen-associated,	B-D007052
upper	O
gastrointestinal	O
ulcers	B-D014456
in	O
patients	B-D010361
who	O
required	O
use	O
of	O
ibuprofen,	B-D007052
which	O
included	O
1022	O
patients	B-D010361
on	O
DUEXIS	O
and	O
511	O
patients	B-D010361
on	O
ibuprofen	B-D007052
alone	O

Approximately	O
15%	O
of	O
patients	B-D010361
were	O
on	O
low-	O
dose	O
aspirin	B-D001241
	O

Patients	B-D010361
were	O
assigned	O
randomly,	O
in	O
a	O
2:1	O
ratio,	O
to	O
treatment	O
with	O
either	O
DUEXIS	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
a	O
day	O
for	O
24	O
consecutive	O
weeks	O

Three	O
serious	O
cases	O
of	O
acute	O
renal	O
failure	O
were	O
observed	O
in	O
patients	B-D010361
treated	O
with	O
DUEXIS	O
in	O
the	O
two	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
	O

All	O
three	O
patients	B-D010361
recovered	O
to	O
baseline	O
levels	O
after	O
discontinuation	O
of	O
DUEXIS	O

Additionally,	O
increases	O
in	O
serum	B-D044967
creatinine	B-D003404
were	O
observed	O
in	O
both	O
treatment	O
arms	B-D001132
in	O
the	O
two	O
clinical	O
studies	O

Many	O
of	O
these	O
patients	B-D010361
were	O
taking	O
concomitant	O
diuretics	B-D004232
and/or	O
angiotensin-converting	B-D000806
enzyme	I-D000806
inhibitors,	I-D000806
or	O
angiotensin	O
receptor	O
blockers	O

There	O
were	O
patients	B-D010361
with	O
a	O
normal	O
baseline	O
serum	B-D044967
creatinine	B-D003404
level	O
who	O
developed	O
abnormal	O
values	O
in	O
the	O
controlled	O
trials	O
as	O
presented	O
in	O
Table	O
1	O

Table	O
1:	O
Shift	O
Table	O
of	O
Serum	B-D044967
Creatinine,	B-D003404
Normalserum	O
creatinine	B-D003404
normal	O
range	O
is	O
0.5	O
–	O
1.4	O
mg/dL	O
or	O
44-124	O
micromol/L	O
to	O
Abnormalserum	O
creatinine	B-D003404
>1.4	O
mg/dL	O
in	O
Controlled	O
Studies	O
Study	O
301	O
Study	O
303	O
Baseline	O
Post-BaselineAt	O
any	O
point	O
after	O
baseline	O
level	O
DUEXISN=414%	O
(n)	O
IbuprofenN=207%	B-D007052
(n)	O
DUEXISN=598%	O
(n)	O
IbuprofenN=296%	B-D007052
(n)	O
Normal	O
Abnormal	O
4%	O
(17)	O
2%	O
(4)	O
2%(15)	O
4%	O
(12)	O
Most	O
Commonly	O
Reported	O
Adverse	O
Reactions	O
The	O
most	O
common	O
adverse	O
reactions	O
(≥2%),	O
from	O
pooled	O
data	O
from	O
the	O
two	O
controlled	O
studies	O
are	O
presented	O
in	O
Table	O
2	O

Table	O
2:	O
Incidence	B-D015994
of	O
Adverse	O
Reactions	O
in	O
Controlled	O
Studies	O
DUEXISN=1022	O
IbuprofenN=511	B-D007052
%	O
%	O
Blood	B-D001769
and	O
lymphatic	B-D008208
system	I-D008208
disorders	O
Anemia	B-D000740
2	O
1	O
Gastrointestinal	O
disorders	O
Nausea	B-D009325
6	O
5	O
Dyspepsia	B-D004415
5	O
8	O
Diarrhea	B-D003967
5	O
4	O
Constipation	B-D003248
4	O
4	O
Abdominal	B-D015746
pain	I-D015746
upper	O
3	O
3	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
2	O
3	O
Vomiting	B-D014839
2	O
2	O
Stomach	B-D013270
discomfort	O
2	O
2	O
Abdominal	B-D015746
pain	I-D015746
2	O
2	O
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
Edema	B-D004487
peripheral	O
2	O
2	O
Infections	B-D007239
and	O
infestations	O
Upper	O
respiratory	O
tract	O
infection	O
4	O
4	O
Nasopharyngitis	B-C015378
2	O
3	O
Sinusitis	B-D012852
2	O
3	O
Bronchitis	B-D001991
2	O
1	O
Urinary	B-D014551
tract	I-D014551
infection	O
2	O
2	O
Influenza	O
2	O
2	O
Musculoskeletal	O
and	O
connective	B-D003238
tissue	I-D003238
disorders	O
Arthralgia	B-D018771
1	O
2	O
Back	B-D001416
pain	I-D001416
2	O
1	O
Nervous	B-D009420
system	I-D009420
disorders	O
Headache	B-D006261
3	O
3	O
Respiratory,	O
thoracic	O
and	O
mediastinal	O
disorders	O
Cough	B-D003371
2	O
2	O
Pharyngolaryngeal	O
pain	B-D010146
2	O
1	O
Vascular	O
disorders	O
Hypertension	B-D006973
3	O
2	O
In	O
controlled	O
clinical	O
studies,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
for	O
patients	B-D010361
receiving	O
DUEXIS	O
and	O
ibuprofen	B-D007052
alone	O
were	O
similar	O

The	O
most	O
common	O
adverse	O
reactions	O
leading	B-D007854
to	O
discontinuation	O
from	O
DUEXIS	O
therapy	O
were	O
nausea	B-D009325
(0.9%)	O
and	O
upper	O
abdominal	B-D015746
pain	I-D015746
(0.9%)	O

There	O
were	O
no	O
differences	O
in	O
types	O
of	O
related	O
adverse	O
reactions	O
seen	O
during	O
maintenance	B-D008283
treatment	O
up	O
to	O
12	O
months	O
compared	O
to	O
short-term	O
treatment	O

6.2	O
Postmarketing	O
Experience	O
Ibuprofen	B-D007052
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post-approval	O
use	O
of	O
ibuprofen	B-D007052
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

These	O
reports	O
are	O
listed	O
below	O
by	O
body	O
system:	O
Cardiac	B-D002299
disorders:	O
myocardial	B-D009203
infarction	I-D009203
Gastrointestinal	O
disorders:	O
nausea,	B-D009325
vomiting,	B-D014839
diarrhea,	B-D003967
abdominal	B-D015746
pain	I-D015746
General	O
disorders	O
and	O
administration	O
site	O
conditions:	O
pyrexia,	O
pain,	B-D010146
fatigue,	B-D005221
asthenia,	B-D001247
chest	B-D002637
pain,	I-D002637
drug	O
ineffective,	O
edema	B-D004487
peripheral	O
Musculoskeletal	O
and	O
connective	B-D003238
tissue	I-D003238
disorders:	O
arthralgia	B-D018771
Nervous	B-D009420
system	I-D009420
disorders:	O
headache,	B-D006261
dizziness	B-D004244
Psychiatric	O
disorders:	O
depression,	B-D003863
anxiety	B-D001007
Renal	O
and	O
urinary	O
disorders:	O
renal	O
failure	O
acute	O
Respiratory,	O
thoracic,	O
and	O
mediastinal	O
disorders:	O
dyspnea	B-D004417
Vascular	O
disorders:	O
hypertension	B-D006973
Famotidine	B-D015738
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post-approval	O
use	O
of	O
famotidine	B-D015738
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

These	O
reports	O
are	O
listed	O
below	O
by	O
body	O
system:	O
Blood	B-D001769
and	O
lymphatic	B-D008208
system	I-D008208
disorders:	O
anemia,	B-D000740
thrombocytopenia	B-D013921
Gastrointestinal	O
disorders:	O
nausea,	B-D009325
diarrhea,	B-D003967
vomiting,	B-D014839
abdominal	B-D015746
pain	I-D015746
General	O
disorders	O
and	O
administration	O
site	O
conditions:	O
pyrexia,	O
condition	O
aggravated,	O
asthenia,	B-D001247
drug	O
ineffective,	O
chest	B-D002637
pain,	I-D002637
fatigue,	B-D005221
pain,	B-D010146
edema	B-D004487
peripheral	O
Hepatobiliary	O
disorders:	O
hepatic	O
function	O
abnormal	O
Infections	B-D007239
and	O
infestations:	O
pneumonia,	B-D011014
sepsis	B-D018805
Investigations:	O
platelet	B-D010976
count	I-D010976
decreased,	O
aspartate	O
aminotransferase	O
increased,	O
alanine	B-D000409
aminotransferase	O
increased,	O
hemoglobin	B-C032001
decreased	I-C032001
Metabolism	B-D008660
and	O
nutrition	B-D009748
disorders:	I-D009748
decreased	O
appetite	B-D001066
Nervous	B-D009420
system	I-D009420
disorders:	O
dizziness,	B-D004244
headache	B-D006261
Respiratory,	O
thoracic,	O
and	O
mediastinal	O
disorders:	O
dyspnea	B-D004417
Vascular	O
disorders:	O
hypotension	B-D007022
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(	O
5.1)	O
CELEBREX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(	O
4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(	O
5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
CELEBREX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

[	O
see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(	O
5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
CELEBREX	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(	O
5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	B-D012306
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
for	O
the	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
and	O
CELEBREX	O
200	O
mg	O
twice	O
daily	O
treatment	O
arms	B-D001132
compared	O
to	O
placebo	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[	O
see	O
Clinical	O
Studies	O
(14.7)	O
]	O

A	O
randomized	B-D016449
controlled	I-D016449
trial	I-D016449
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs	O

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	B-D012306
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	B-D000068579
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	B-D009288
and	O
ibuprofen	B-D007052
	O

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	B-D009288
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	B-D007052
600	O
to	O
800	O
mg	O
three	O
times	B-D013995
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists'	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	B-D003643
(including	O
hemorrhagic	O
death),	B-D003643
non-fatal	O
myocardial	B-D009203
infarction,	I-D009203
and	O
non-fatal	O
stroke	B-D020521
[	O
See	O
Clinical	O
Studies	O
(14.6)	O
]	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
]	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
CELEBREX	O
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
CELEBREX	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	B-D001241
anticoagulants;	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
]	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
see	O
Clinical	O
Studies	O
(14.7)	O
]	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
CELEBREX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
CELEBREX,	O
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
CELEBREX	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
CELEBREX	O
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash),	O
discontinue	O
CELEBREX	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
CELEBREX,	O
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
blood	B-D001794
pressure	I-D001794
data	O
for	O
CELEBREX	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
celecoxib	B-D000068579
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

In	O
the	O
CLASS	O
study	O
[	O
see	O
Clinical	O
Studies	O
(14.7)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Avoid	O
the	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
CELEBREX	O
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia	B-D020896
,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
CELEBREX	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
CELEBREX	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
CELEBREX	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O
	O

Avoid	O
the	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
CELEBREX	O
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoaldosteronism	B-D006994
state	O

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
celecoxib	B-D000068579
and	O
in	O
patients	B-D010361
with	O
aspirin	B-D001241
sensitive	O
asthma	B-D001249
	O

CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	B-D013449
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	B-D019369
or	O
less	O
severe	O
asthmatic	B-D001249
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
]	O

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
CELEBREX	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

When	O
CELEBREX	O
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	B-D012867
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
CELEBREX,	O
including	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	B-D056150
generalized	I-D056150
exanthematous	I-D056150
pustulosis	I-D056150
(AGEP)	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
CELEBREX	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

CELEBREX	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
CELEBREX,	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
CELEBREX	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
CELEBREX	O
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

NSAIDs,	O
including	O
CELEBREX,	O
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	B-D001241
SSRIs	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
CELEBREX	O
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
with	O
use	O
of	O
CELEBREX	O
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	B-D010361
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	B-D010361
and	O
their	O
caregivers	B-D017028
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible	O

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(	O
6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Of	O
the	O
CELEBREX-treated	O
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
CELEBREX	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
CELEBREX	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
CELEBREX	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CBX	O
=	O
CELEBREX	O
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
CELEBREX	O
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
CELEBREX	O
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
CELEBREX	O
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General:	O
Hypersensitivity,	B-D006967
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
blood	B-D001806
urea	I-D001806
nitrogen	I-D001806
(BUN)	O
increased,	O
creatine	B-D003401
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia,	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	B-D010361
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis	B-D013924
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
General:	O
Sepsis,	B-D018805
sudden	O
death	B-D003643
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	B-D008196
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia,	B-D001259
suicide	B-D013405
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[	O
see	O
Clinical	O
Studies	O
(14.7)	O
]	O
Hematological	O
Events:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
CELEBREX	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	B-D001241
use	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
twice	O
daily	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations	O
Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
CELEBREX	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
CELEBREX	O
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[	O
see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.7)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
CELEBREX	O
pre-marketing	O
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
CELEBREX	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
CELEBREX	O
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
CELEBREX,	O
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning,	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post	O
approval	O
use	O
of	O
CELEBREX	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
General:	O
Anaphylactoid	O
reaction,	O
angioedema	B-D000799
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	B-D009336
hepatitis,	B-D006505
jaundice,	B-D007565
hepatic	O
failure	O
Hemic	O
and	O
lymphatic	B-D008196
:	O
Agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
Renal:	O
Interstitial	O
nephritis	B-D009393
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS	O
]	O

Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
]	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
]	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“	O
Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“	O
Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
Pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash*	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
neuritis,	B-D009443
cataracts	B-D002386
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
(see	O
PRECAUTIONS)	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(eg	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevated	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS)	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythe-	O
matosus	O
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
polyuria,	B-D011141
azotemia,	B-D053099
cystitis,	B-D003556
Hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
tests	B-C004551
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(	O
5.1)	O
DAYPRO	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(	O
4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
(	O
5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O

DAYPRO	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(	O
5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
DAYPRO	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
DAYPRO	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
DAYPRO	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
DAYPRO	O
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(	O
5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
gestation	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
oxaprozin,	B-D000077431
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
DAYPRO	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
DAYPRO	O
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
DAYPRO,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients,	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy,	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-times	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
DAYPRO	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
alanine	B-D000409
aminotransferase	O
(ALT)	O
or	O
aspartate	O
aminotransferase	O
(AST)	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
oxaprozin	B-D000077431
	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash),	O
discontinue	O
DAYPRO	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
DAYPRO,	O
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
oxaprozin	B-D000077431
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Avoid	O
the	O
use	O
of	O
DAYPRO	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
DAYPRO	O
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
DAYPRO	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
DAYPRO	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
DAYPRO	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
DAYPRO	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O
	O

Avoid	O
the	O
use	O
of	O
DAYPRO	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
DAYPRO	O
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Oxaprozin	B-D000077431
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
oxaprozin	B-D000077431
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[	O
see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
DAYPRO	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

When	O
DAYPRO	O
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
oxaprozin,	B-D000077431
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
DAYPRO	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

DAYPRO	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Oxaprozin	B-D000077431
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
DAYPRO,	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
DAYPRO	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
DAYPRO,	O
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	B-D001241
SSRIs,	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
DAYPRO	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
complete	O
blood	B-D001769
count	O
(CBC)	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
]	O

5.14	O
Photosensitivity	O
Oxaprozin	B-D000077431
has	O
been	O
associated	O
with	O
rash	O
and/or	O
mild	O
photosensitivity	O
in	O
dermatologic	O
testing	B-C004551
	O

An	O
increased	O
incidence	B-D015994
of	O
rash	O
on	O
sun-exposed	O
skin	B-D012867
was	O
seen	O
in	O
some	O
patients	B-D010361
in	O
the	O
clinical	B-D016430
trials	I-D016430
	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(>3	O
%)	O
are:	O
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
nausea,	B-D009325
rash	O
(	O
6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

Adverse	O
reaction	O
data	O
were	O
derived	O
from	O
patients	B-D010361
who	O
received	O
DAYPRO	O
in	O
multidose,	O
controlled,	O
and	O
open-label	O
clinical	B-D016430
trials	I-D016430
	O

Rates	O
for	O
events	O
from	O
clinical	B-D016430
trial	I-D016430
experience	O
are	O
based	O
on	O
2253	O
patients	B-D010361
who	O
took	O
1200	O
mg	O
to	O
1800	O
mg	O
DAYPRO	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
	O

Of	O
these,	O
1721	O
patients	B-D010361
were	O
treated	O
for	O
at	O
least	O
1	O
month,	O
971	O
patients	B-D010361
for	O
at	O
least	O
3	O
months,	O
and	O
366	O
patients	B-D010361
for	O
more	O
than	O
1	O
year	O

Incidence	B-D015994
Greater	O
than	O
1%:	O
In	O
clinical	B-D016430
trials	I-D016430
of	O
DAYPRO	O
or	O
in	O
patients	B-D010361
taking	O
other	O
NSAIDs,	O
the	O
following	O
adverse	O
reactions	O
occurred	O
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O

Cardiovascular	B-D002319
system:	I-D002319
edema	B-D004487
	O

Digestive	B-D004064
system:	I-D004064
abdominal	B-D015746
pain/distress,	I-D015746
anorexia,	B-D000855
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gastrointestinal	O
ulcers	B-D014456
(gastric/duodenal),	O
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
liver	B-D008099
enzyme	O
elevations,	O
nausea,	B-D009325
vomiting	B-D014839
	O

Hematologic	O
system:	O
anemia,	B-D000740
increased	O
bleeding	B-D001760
time	I-D001760
	O

Nervous	B-D009420
system:	I-D009420
CNS	O
inhibition	O
(depression,	O
sedation,	O
somnolence,	O
or	O
confusion),	B-D003221
disturbance	O
of	O
sleep,	B-D012890
dizziness,	B-D004244
headache	B-D006261
	O

Skin	B-D012867
and	O
appendages:	O
pruritus,	B-D011537
rash	O

Special	O
senses:	O
tinnitus	B-D014012
	O

Urogenital	B-D014566
system:	I-D014566
abnormal	O
renal	O
function,	O
dysuria	B-D053159
or	O
frequency	O

Incidence	B-D015994
Greater	O
than	O
1%:	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
clinical	B-D016430
trials	I-D016430
or	O
in	O
patients	B-D010361
taking	O
other	O
NSAIDs	O

Body	O
as	O
a	O
whole:	O
appetite	B-D001066
changes,	O
death,	B-D003643
drug	B-D004342
hypersensitivity	I-D004342
reactions	O
including	O
anaphylaxis,	B-D000707
fever,	B-D005334
infection,	O
sepsis	B-D018805
	O

Cardiovascular	B-D002319
system:	I-D002319
arrhythmia,	O
blood	B-D001794
pressure	I-D001794
changes,	O
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
tachycardia,	B-D013610
syncope,	B-D013575
vasculitis	B-D014657
	O

Digestive	B-D004064
system:	I-D004064
alteration	O
in	O
taste,	B-D013649
dry	O
mouth,	B-D009055
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
glossitis,	B-D005928
hematemesis,	B-D006396
jaundice,	B-D007565
liver	B-D008099
function	O
abnormalities	O
including	O
liver	B-D017093
failure,	I-D017093
stomatitis,	B-D013280
hemorrhoidal	O
or	O
rectal	O
bleeding	O
	O

Hematologic	O
system:	O
aplastic	O
anemia,	B-D000740
ecchymoses,	O
eosinophilia,	B-D004802
hemolytic	O
anemia,	B-D000740
lymphadenopathy,	B-D000072281
melena,	B-D008551
purpura,	B-D011693
thrombocytopenia,	B-D013921
leukopenia	B-D007970
	O

Metabolic	O
system:	O
hyperglycemia,	B-D006943
weight	O
changes	O

Nervous	B-D009420
system:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
coma,	B-D003128
convulsions,	O
dream	O
abnormalities,	O
drowsiness,	O
hallucinations,	B-D006212
insomnia,	O
malaise,	O
meningitis,	B-D008581
nervousness,	O
paresthesia,	B-D010292
tremors,	B-D014202
vertigo,	B-D014717
weakness	O

Respiratory	B-D012137
system:	I-D012137
asthma,	B-D001249
dyspnea,	B-D004417
pulmonary	O
infections,	B-D007239
pneumonia,	B-D011014
sinusitis,	B-D012852
symptoms	O
of	O
upper	O
respiratory	O
tract	O
infection,	O
respiratory	O
depression	B-D003863
	O

Skin:	B-D012867
alopecia,	B-D000505
angioedema,	B-D000799
urticaria,	B-D014581
photosensitivity,	O
sweat	B-D013542
	O

Special	O
senses:	O
blurred	O
vision,	O
conjunctivitis,	B-D003231
hearing	B-D006309
decrease	O

Urogenital:	O
cystitis,	B-D003556
hematuria,	B-D006417
increase	O
in	O
menstrual	B-D008571
flow,	O
oliguria/	B-D009846
polyuria,	B-D011141
proteinuria,	B-D011507
renal	B-D051437
insufficiency,	I-D051437
decreased	O
menstrual	B-D008571
flow	O

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post	O
approval	O
use	O
of	O
DAYPRO	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

Body	O
as	O
a	O
whole:	O
serum	B-D012713
sickness	I-D012713
	O

Digestive	B-D004064
system:	I-D004064
hepatitis,	B-D006505
pancreatitis	B-D010195
	O

Hematologic	O
system:	O
agranulocytosis,	B-D000380
pancytopenia	B-D010198
	O

Skin:	B-D012867
pseudoporphyria,	O
exfoliative	O
dermatitis,	B-D003872
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis	O
(Lyell's	O
syndrome)	B-D013577
	O

Urogenital:	O
acute	O
interstitial	O
nephritis,	B-D009393
nephrotic	B-D009404
syndrome,	I-D009404
acute	O
renal	O
failure	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(	O
5.1)	O
CELEBREX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(	O
4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(	O
5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
CELEBREX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

[	O
see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(	O
5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
CELEBREX	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(	O
5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	B-D012306
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
for	O
the	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
and	O
CELEBREX	O
200	O
mg	O
twice	O
daily	O
treatment	O
arms	B-D001132
compared	O
to	O
placebo	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[	O
see	O
Clinical	O
Studies	O
(14.7)	O
]	O

A	O
randomized	B-D016449
controlled	I-D016449
trial	I-D016449
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs	O

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	B-D012306
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	B-D000068579
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	B-D009288
and	O
ibuprofen	B-D007052
	O

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	B-D009288
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	B-D007052
600	O
to	O
800	O
mg	O
three	O
times	B-D013995
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists'	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	B-D003643
(including	O
hemorrhagic	O
death),	B-D003643
non-fatal	O
myocardial	B-D009203
infarction,	I-D009203
and	O
non-fatal	O
stroke	B-D020521
[	O
See	O
Clinical	O
Studies	O
(14.6)	O
]	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur.To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
]	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
CELEBREX	O
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
CELEBREX	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	B-D001241
anticoagulants;	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
]	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
see	O
Clinical	O
Studies	O
(14.7)	O
]	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
CELEBREX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
CELEBREX,	O
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
CELEBREX	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
CELEBREX	O
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash),	O
discontinue	O
CELEBREX	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
CELEBREX,	O
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
blood	B-D001794
pressure	I-D001794
data	O
for	O
CELEBREX	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
celecoxib	B-D000068579
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

In	O
the	O
CLASS	O
study	O
[	O
see	O
Clinical	O
Studies	O
(14.7)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Avoid	O
the	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
CELEBREX	O
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia	B-D020896
,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
CELEBREX	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
CELEBREX	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
CELEBREX	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O
	O

Avoid	O
the	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
CELEBREX	O
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoaldosteronism	B-D006994
state	O

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
celecoxib	B-D000068579
and	O
in	O
patients	B-D010361
with	O
aspirin	B-D001241
sensitive	O
asthma	B-D001249
	O

CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	B-D013449
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	B-D019369
or	O
less	O
severe	O
asthmatic	B-D001249
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
]	O

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
CELEBREX	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

When	O
CELEBREX	O
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	B-D012867
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
CELEBREX,	O
including	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	B-D056150
generalized	I-D056150
exanthematous	I-D056150
pustulosis	I-D056150
(AGEP)	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
CELEBREX	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

CELEBREX	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
CELEBREX,	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
CELEBREX	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
CELEBREX	O
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

NSAIDs,	O
including	O
CELEBREX,	O
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	B-D001241
SSRIs	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)	O
]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
CELEBREX	O
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
with	O
use	O
of	O
CELEBREX	O
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	B-D010361
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	B-D010361
and	O
their	O
caregivers	B-D017028
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible	O

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(	O
6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Of	O
the	O
CELEBREX-treated	O
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
CELEBREX	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
CELEBREX	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
CELEBREX	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CBX	O
=	O
CELEBREX	O
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
CELEBREX	O
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
CELEBREX	O
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
CELEBREX	O
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General:	O
Hypersensitivity,	B-D006967
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
blood	B-D001806
urea	I-D001806
nitrogen	I-D001806
(BUN)	O
increased,	O
creatine	B-D003401
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia,	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	B-D010361
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis	B-D013924
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
General:	O
Sepsis,	B-D018805
sudden	O
death	B-D003643
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	B-D008196
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia,	B-D001259
suicide	B-D013405
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[	O
see	O
Clinical	O
Studies	O
(14.7)	O
]	O
Hematological	O
Events:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
CELEBREX	O
was	O
maintained	O
with	O
or	O
without	O
aspirin	B-D001241
use	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
twice	O
daily	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations	O
Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
CELEBREX	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
CELEBREX	O
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[	O
see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.7)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
CELEBREX	O
pre-marketing	O
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
CELEBREX	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
CELEBREX	O
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
CELEBREX,	O
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning,	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post	O
approval	O
use	O
of	O
CELEBREX	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
General:	O
Anaphylactoid	O
reaction,	O
angioedema	B-D000799
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	B-D009336
hepatitis,	B-D006505
jaundice,	B-D007565
hepatic	O
failure	O
Hemic	O
and	O
lymphatic	B-D008196
:	O
Agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
Renal:	O
Interstitial	O
nephritis	B-D009393
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O

MOBIC	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O

MOBIC	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O

NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(	O
5.1)	O
MOBIC	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(	O
4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
(	O
5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(	O
5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
MOBIC	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
MOBIC	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
MOBIC	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
MOBIC	O
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(	O
5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
gestation	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
meloxicam,	B-D000077239
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
MOBIC	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
MOBIC	O
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
meloxicam,	B-D000077239
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2-4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10‑fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
MOBIC	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
meloxicam	B-D000077239
	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
MOBIC	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(	O
8.6)	O
and	O
Clinical	O
Pharmacology	B-D010600
(	O
12.3)	O
]	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
MOBIC,	O
can	O
lead	B-D007854
to	O
new	O
onset	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
meloxicam	B-D000077239
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O

Avoid	O
the	O
use	O
of	O
MOBIC	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
MOBIC	O
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs,	O
including	O
MOBIC,	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis,	B-D009336
renal	B-D051437
insufficiency,	I-D051437
acute	O
renal	O
failure,	O
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

The	O
renal	O
effects	O
of	O
MOBIC	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Because	O
some	O
MOBIC	O
metabolites	O
are	O
excreted	O
by	O
the	O
kidney,	B-D007668
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
MOBIC	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
MOBIC	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
MOBIC	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

Avoid	O
the	O
use	O
of	O
MOBIC	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
MOBIC	O
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(	O
12.3)	O
]	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Meloxicam	B-D000077239
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
meloxicam	B-D000077239
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.8)	O
]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
MOBIC	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

When	O
MOBIC	O
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
meloxicam,	B-D000077239
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
MOBIC	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

MOBIC	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Meloxicam	B-D000077239
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
MOBIC,	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(	O
8.1)	O
]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
MOBIC	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
MOBIC,	O
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
MOBIC	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2,	O
5.3,	O
5.6)	O
]	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
(≥5%	O
and	O
greater	O
than	O
placebo)	O
adverse	O
events	O
in	O
adults	B-D000328
are	O
diarrhea,	B-D003967
upper	O
respiratory	B-D012141
tract	I-D012141
infections,	I-D012141
dyspepsia,	B-D004415
and	O
influenza-like	O
symptoms	O
(	O
6.1)	O
Adverse	O
events	O
observed	O
in	O
pediatric	O
studies	O
were	O
similar	O
in	O
nature	B-D019368
to	O
the	O
adult	B-D000328
clinical	B-D016430
trial	I-D016430
experience	O
(	O
6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Boehringer	O
Ingelheim	O
Pharmaceuticals,	O
Inc	O

at	O
(800)	O
542-6257	O
or	O
(800)	O
459-9906	O
TTY	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

Adults	B-D000328
Osteoarthritis	B-D010003
and	O
Rheumatoid	B-D012250
Arthritis	B-D001168
The	O
MOBIC	O
Phase	O
2/3	O
clinical	B-D016430
trial	I-D016430
database	B-D019991
includes	O
10,122	O
OA	O
patients	B-D010361
and	O
1012	O
RA	O
patients	B-D010361
treated	O
with	O
MOBIC	O
7.5	O
mg/day,	O
3505	O
OA	O
patients	B-D010361
and	O
1351	O
RA	O
patients	B-D010361
treated	O
with	O
MOBIC	O
15	O
mg/day	O

MOBIC	O
at	O
these	O
doses	O
was	O
administered	O
to	O
661	O
patients	B-D010361
for	O
at	O
least	O
6	O
months	O
and	O
to	O
312	O
patients	B-D010361
for	O
at	O
least	O
one	O
year	O

Approximately	O
10,500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
in	O
ten	O
placebo-	O
and/or	O
active-controlled	O
osteoarthritis	B-D010003
trials	O
and	O
2363	O
of	O
these	O
patients	B-D010361
were	O
treated	O
in	O
ten	O
placebo-	O
and/or	O
active-controlled	O
rheumatoid	B-D012250
arthritis	B-D001168
trials	O

Gastrointestinal	O
(GI)	O
adverse	O
events	O
were	O
the	O
most	O
frequently	O
reported	O
adverse	O
events	O
in	O
all	O
treatment	O
groups	O
across	O
MOBIC	O
trials	O

A	O
12-week	O
multicenter,	O
double-blind,	O
randomized	O
trial	O
was	O
conducted	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
of	O
the	O
knee	B-D007717
or	O
hip	B-D006615
to	O
compare	O
the	O
efficacy	O
and	O
safety	B-D012449
of	O
MOBIC	O
with	O
placebo	O
and	O
with	O
an	O
active	O
control	O

Two	O
12-week	O
multicenter,	O
double-blind,	O
randomized	O
trials	O
were	O
conducted	O
in	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
to	O
compare	O
the	O
efficacy	O
and	O
safety	B-D012449
of	O
MOBIC	O
with	O
placebo	O

Table	O
1a	O
depicts	O
adverse	O
events	O
that	O
occurred	O
in	O
≥2%	O
of	O
the	O
MOBIC	O
treatment	O
groups	O
in	O
a	O
12-week	O
placebo-	O
and	O
active-controlled	O
osteoarthritis	B-D010003
trial	O

Table	O
1b	O
depicts	O
adverse	O
events	O
that	O
occurred	O
in	O
≥2%	O
of	O
the	O
MOBIC	O
treatment	O
groups	O
in	O
two	O
12-week	O
placebo-controlled	O
rheumatoid	B-D012250
arthritis	B-D001168
trials	O

Table	O
1a	O
Adverse	O
Events	O
(%)	O
Occurring	O
in	O
≥	O
2%	O
of	O
MOBIC	O
Patients	B-D010361
in	O
a	O
12-Week	O
Osteoarthritis	B-D010003
Placebo-	O
and	O
Active-Controlled	O
Trial	O
1	O
WHO	O
preferred	O
terms	O
edema,	B-D004487
edema	B-D004487
dependent,	O
edema	B-D004487
peripheral,	O
and	O
edema	B-D004487
legs	B-D007866
combined	O
2	O
WHO	O
preferred	O
terms	O
rash,	O
rash	O
erythematous,	B-D004890
and	O
rash	O
maculo-papular	O
combined	O
Placebo	O
MOBIC	O
7.5	O
mg	O
daily	O
MOBIC	O
15	O
mg	O
daily	O
Diclofenac	B-D004008
100	O
mg	O
daily	O
No	O

of	O
Patients	B-D010361
157	O
154	O
156	O
153	O
Gastrointestinal	O
17.2	O
20.1	O
17.3	O
28.1	O
Abdominal	B-D015746
pain	I-D015746
2.5	O
1.9	O
2.6	O
1.3	O
Diarrhea	B-D003967
3.8	O
7.8	O
3.2	O
9.2	O
Dyspepsia	B-D004415
4.5	O
4.5	O
4.5	O
6.5	O
Flatulence	B-D005414
4.5	O
3.2	O
3.2	O
3.9	O
Nausea	B-D009325
3.2	O
3.9	O
3.8	O
7.2	O
Body	O
as	O
a	O
Whole	O
Accident	O
household	O
1.9	O
4.5	O
3.2	O
2.6	O
Edema	B-D004487
1	O
2.5	O
1.9	O
4.5	O
3.3	O
Fall	O
0.6	O
2.6	O
0.0	O
1.3	O
Influenza-like	O
symptoms	O
5.1	O
4.5	O
5.8	O
2.6	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
3.2	O
2.6	O
3.8	O
2.0	O
Headache	B-D006261
10.2	O
7.8	O
8.3	O
5.9	O
Respiratory	O
Pharyngitis	B-D010612
1.3	O
0.6	O
3.2	O
1.3	O
Upper	O
respiratory	O
tract	O
infection	O
1.9	O
3.2	O
1.9	O
3.3	O
Skin	B-D012867
Rash	O
2	O
2.5	O
2.6	O
0.6	O
2.0	O
Table	O
1b	O
Adverse	O
Events	O
(%)	O
Occurring	O
in	O
≥2%	O
of	O
MOBIC	O
Patients	B-D010361
in	O
two	O
12-Week	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Placebo-Controlled	O
Trials	O
1	O
MedDRA	O
high	O
level	O
term	O
(preferred	O
terms):	O
dyspeptic	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
(dyspepsia,	O
dyspepsia	B-D004415
aggravated,	O
eructation,	B-D004884
gastrointestinal	O
irritation),	O
upper	O
respiratory	B-D012141
tract	I-D012141
infections-pathogen	I-D012141
unspecified	O
(laryngitis	O
NOS,	O
pharyngitis	B-D010612
NOS,	O
sinusitis	B-D012852
NOS),	O
joint	O
related	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
(arthralgia,	O
arthralgia	B-D018771
aggravated,	O
joint	O
crepitation,	O
joint	O
effusion,	O
joint	O
swelling)	O
2	O
MedDRA	O
preferred	O
term:	O
nausea,	B-D009325
abdominal	B-D015746
pain	I-D015746
NOS,	O
influenza-like	O
illness,	O
headaches	B-D006261
NOS,	O
and	O
rash	O
NOS	O
Placebo	O
MOBIC	O
7.5	O
mg	O
daily	O
MOBIC	O
15	O
mg	O
daily	O
No	O

of	O
Patients	B-D010361
469	O
481	O
477	O
Gastrointestinal	O
Disorders	O
14.1	O
18.9	O
16.8	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
2	O
0.6	O
2.9	O
2.3	O
Dyspeptic	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
1	O
3.8	O
5.8	O
4.0	O
Nausea	B-D009325
2	O
2.6	O
3.3	O
3.8	O
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
Influenza-like	O
illness	O
2	O
2.1	O
2.9	O
2.3	O
Infection	O
and	O
Infestations	O
Upper	O
respiratory	B-D012141
tract	I-D012141
infections-pathogen	I-D012141
class	O
unspecified	O
1	O
4.1	O
7.0	O
6.5	O
Musculoskeletal	O
and	O
Connective	B-D003238
Tissue	I-D003238
Disorders	O
Joint	O
related	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
1	O
1.9	O
1.5	O
2.3	O
Nervous	B-D009420
System	I-D009420
Disorders	O
Headaches	B-D006261
NOS	O
2	O
6.4	O
6.4	O
5.5	O
Skin	B-D012867
and	O
Subcutaneous	B-D040521
Tissue	I-D040521
Disorders	O
Rash	O
NOS	O
2	O
1.7	O
1.0	O
2.1	O
The	O
adverse	O
events	O
that	O
occurred	O
with	O
MOBIC	O
in	O
≥2%	O
of	O
patients	B-D010361
treated	O
short-term	O
(4	O
to	O
6	O
weeks)	O
and	O
long-term	O
(6	O
months)	O
in	O
active-controlled	O
osteoarthritis	B-D010003
trials	O
are	O
presented	O
in	O
Table	O
2	O

Table	O
2	O
Adverse	O
Events	O
(%)	O
Occurring	O
in	O
≥2%	O
of	O
MOBIC	O
Patients	B-D010361
in	O
4	O
to	O
6	O
Weeks	O
and	O
6	O
Month	O
Active-Controlled	O
Osteoarthritis	B-D010003
Trials	O
1	O
WHO	O
preferred	O
terms	O
edema,	B-D004487
edema	B-D004487
dependent,	O
edema	B-D004487
peripheral,	O
and	O
edema	B-D004487
legs	B-D007866
combined	O
2	O
WHO	O
preferred	O
terms	O
rash,	O
rash	O
erythematous,	B-D004890
and	O
rash	O
maculo-papular	O
combined	O
4	O
to	O
6	O
Weeks	O
Controlled	O
Trials	O
6	O
Month	O
Controlled	O
Trials	O
MOBIC	O
7.5	O
mg	O
daily	O
MOBIC	O
15	O
mg	O
daily	O
MOBIC	O
7.5	O
mg	O
daily	O
MOBIC	O
15	O
mg	O
daily	O
No	O

of	O
Patients	B-D010361
8955	O
256	O
169	O
306	O
Gastrointestinal	O
11.8	O
18.0	O
26.6	O
24.2	O
Abdominal	B-D015746
pain	I-D015746
2.7	O
2.3	O
4.7	O
2.9	O
Constipation	B-D003248
0.8	O
1.2	O
1.8	O
2.6	O
Diarrhea	B-D003967
1.9	O
2.7	O
5.9	O
2.6	O
Dyspepsia	B-D004415
3.8	O
7.4	O
8.9	O
9.5	O
Flatulence	B-D005414
0.5	O
0.4	O
3.0	O
2.6	O
Nausea	B-D009325
2.4	O
4.7	O
4.7	O
7.2	O
Vomiting	B-D014839
0.6	O
0.8	O
1.8	O
2.6	O
Body	O
as	O
a	O
Whole	O
Accident	O
household	O
0.0	O
0.0	O
0.6	O
2.9	O
Edema	B-D004487
1	O
0.6	O
2.0	O
2.4	O
1.6	O
Pain	B-D010146
0.9	O
2.0	O
3.6	O
5.2	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
1.1	O
1.6	O
2.4	O
2.6	O
Headache	B-D006261
2.4	O
2.7	O
3.6	O
2.6	O
Hematologic	O
Anemia	B-D000740
0.1	O
0.0	O
4.1	O
2.9	O
Musculoskeletal	O
Arthralgia	B-D018771
0.5	O
0.0	O
5.3	O
1.3	O
Back	B-D001416
pain	I-D001416
0.5	O
0.4	O
3.0	O
0.7	O
Psychiatric	O
Insomnia	O
0.4	O
0.0	O
3.6	O
1.6	O
Respiratory	O
Coughing	B-D003371
0.2	O
0.8	O
2.4	O
1.0	O
Upper	O
respiratory	O
tract	O
infection	O
0.2	O
0.0	O
8.3	O
7.5	O
Skin	B-D012867
Pruritus	B-D011537
0.4	O
1.2	O
2.4	O
0.0	O
Rash	O
2	O
0.3	O
1.2	O
3.0	O
1.3	O
Urinary	O
Micturition	O
frequency	O
0.1	O
0.4	O
2.4	O
1.3	O
Urinary	B-D014551
tract	I-D014551
infection	O
0.3	O
0.4	O
4.7	O
6.9	O
Higher	O
doses	O
of	O
MOBIC	O
(22.5	O
mg	O
and	O
greater)	O
have	O
been	O
associated	O
with	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
GI	O
events;	O
therefore,	O
the	O
daily	O
dose	O
of	O
MOBIC	O
should	O
not	O
exceed	O
15	O
mg	O

Pediatrics	B-D010372
Pauciarticular	O
and	O
Polyarticular	O
Course	O
Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
(JRA)	O
Three	O
hundred	O
and	O
eighty-seven	O
patients	B-D010361
with	O
pauciarticular	O
and	O
polyarticular	O
course	O
JRA	O
were	O
exposed	O
to	O
MOBIC	O
with	O
doses	O
ranging	O
from	O
0.125	O
to	O
0.375	O
mg/kg	O
per	O
day	O
in	O
three	O
clinical	B-D016430
trials	I-D016430
	O

These	O
studies	O
consisted	O
of	O
two	O
12-week	O
multicenter,	O
double-blind,	O
randomized	O
trials	O
(one	O
with	O
a	O
12-week	O
open-label	O
extension	O
and	O
one	O
with	O
a	O
40-week	O
extension)	O
and	O
one	O
1-year	O
open-label	O
PK	O
study	O

The	O
adverse	O
events	O
observed	O
in	O
these	O
pediatric	O
studies	O
with	O
MOBIC	O
were	O
similar	O
in	O
nature	B-D019368
to	O
the	O
adult	B-D000328
clinical	B-D016430
trial	I-D016430
experience,	O
although	O
there	O
were	O
differences	O
in	O
frequency	O

In	O
particular,	O
the	O
following	O
most	O
common	O
adverse	O
events,	O
abdominal	B-D015746
pain,	I-D015746
vomiting,	B-D014839
diarrhea,	B-D003967
headache,	B-D006261
and	O
pyrexia,	O
were	O
more	O
common	O
in	O
the	O
pediatric	O
than	O
in	O
the	O
adult	B-D000328
trials	O

Rash	O
was	O
reported	O
in	O
seven	O
(<2%)	O
patients	B-D010361
receiving	O
MOBIC	O

No	O
unexpected	O
adverse	O
events	O
were	O
identified	B-D007060
during	O
the	O
course	O
of	O
the	O
trials	O

The	O
adverse	O
events	O
did	O
not	O
demonstrate	O
an	O
age	O
or	O
gender-specific	O
subgroup	O
effect	O

The	O
following	O
is	O
a	O
list	O
of	O
adverse	O
drug	O
reactions	O
occurring	O
in	O
<2%	O
of	O
patients	B-D010361
receiving	O
MOBIC	O
in	O
clinical	B-D016430
trials	I-D016430
involving	O
approximately	O
16,200	O
patients	B-D010361
	O

Body	O
as	O
a	O
Whole	O
allergic	O
reaction,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
malaise,	O
syncope,	B-D013575
weight	O
decrease,	O
weight	O
increase	O
Cardiovascular	O
angina	B-D000787
pectoris,	I-D000787
cardiac	B-D002299
failure,	O
hypertension,	B-D006973
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
vasculitis	B-D014657
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
convulsions,	O
paresthesia,	B-D010292
tremor,	B-D014202
vertigo	B-D014717
Gastrointestinal	O
colitis,	B-D003092
dry	O
mouth,	B-D009055
duodenal	B-D004381
ulcer,	I-D004381
eructation,	B-D004884
esophagitis,	B-D004941
gastric	O
ulcer,	B-D014456
gastritis,	B-D005756
gastroesophageal	B-D005764
reflux,	I-D005764
gastrointestinal	B-D006471
hemorrhage,	I-D006471
hematemesis,	B-D006396
hemorrhagic	O
duodenal	B-D004381
ulcer,	I-D004381
hemorrhagic	O
gastric	O
ulcer,	B-D014456
intestinal	B-D007416
perforation,	I-D007416
melena,	B-D008551
pancreatitis,	B-D010195
perforated	O
duodenal	B-D004381
ulcer,	I-D004381
perforated	O
gastric	O
ulcer,	B-D014456
stomatitis	B-D013280
ulcerative	B-D014456
Heart	B-D006339
Rate	I-D006339
and	O
Rhythm	O
arrhythmia,	O
palpitation,	O
tachycardia	B-D013610
Hematologic	O
leukopenia,	B-D007970
purpura,	B-D011693
thrombocytopenia	B-D013921
Liver	B-D008099
and	O
Biliary	O
System	O
ALT	O
increased,	O
AST	O
increased,	O
bilirubinemia,	B-D001663
GGT	O
increased,	O
hepatitis	B-D006505
Metabolic	O
and	O
Nutritional	O
dehydration	B-D003681
Psychiatric	O
abnormal	O
dreaming,	O
anxiety,	B-D001007
appetite	B-D001066
increased,	O
confusion,	B-D003221
depression,	B-D003863
nervousness,	O
somnolence	O
Respiratory	O
asthma,	B-D001249
bronchospasm,	O
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages	O
alopecia,	B-D000505
angioedema,	B-D000799
bullous	O
eruption,	O
photosensitivity	O
reaction,	O
pruritus,	B-D011537
sweating	B-D013546
increased,	O
urticaria	B-D014581
Special	O
Senses	O
abnormal	O
vision,	O
conjunctivitis,	B-D003231
taste	B-D013649
perversion,	O
tinnitus	B-D014012
Urinary	O
System	O
albuminuria,	B-D000419
BUN	O
increased,	O
creatinine	B-D003404
increased,	O
hematuria,	B-D006417
renal	O
failure	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post	O
approval	O
use	O
of	O
MOBIC	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

Decisions	O
about	O
whether	O
to	O
include	O
an	O
adverse	O
event	O
from	O
spontaneous	O
reports	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
event,	O
(2)	O
number	O
of	O
reports,	O
or	O
(3)	O
strength	O
of	O
causal	O
relationship	O
to	O
the	O
drug	O

Adverse	O
reactions	O
reported	O
in	O
worldwide	O
post	O
marketing	B-D040541
experience	O
or	O
the	O
literature	B-D008091
include:	O
acute	O
urinary	B-D016055
retention;	I-D016055
agranulocytosis;	B-D000380
alterations	O
in	O
mood	O
(such	O
as	O
mood	O
elevation);	O
anaphylactoid	O
reactions	O
including	O
shock;	B-D012769
erythema	B-D004892
multiforme;	I-D004892
exfoliative	O
dermatitis;	B-D003872
interstitial	O
nephritis;	B-D009393
jaundice;	B-D007565
liver	B-D017093
failure;	I-D017093
Stevens-Johnson	B-D013262
syndrome;	I-D013262
toxic	O
epidermal	O
necrolysis,	O
and	O
infertility	B-D007246
female	B-D005260
	O

BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(See	O
WARNINGS	O
and	O
PRECAUTIONS)	O

IBU	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(See	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinaladverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforationof	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
eventscan	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms.Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinalevents	O

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
withIbuprofen	O
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
thepercentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaintsranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
toaspirin	O
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidenceof	B-D015994
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
eitherthe	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
anincidence	O
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listedin	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000patients	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
ofat	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
werereported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience.These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
twoof	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
wherethe	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
inColumn	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
has	O
notbeen	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
thanat	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
withrheumatoid	O
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
stillwithin	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
·	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O

·	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash*,	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and	O
/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
(see	O
PRECAUTIONS)	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevate	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS)	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythematosus	B-D004890
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
poliuria,	O
azotemia,	B-D053099
cystitis,	B-D003556
hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked)	O

**Reactions	O
are	O
classified	O
under	O
“	O
Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O
BOXED	O
WARNING	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
(see	O
WARNINGS	O
)	O

Ibuprofen	B-D007052
tablets	B-D013607
are	O
contraindicated	O
for	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship­	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS	O
)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash*,	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and	O
/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
(see	O
PRECAUTIONS	O
)	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS	O
)	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation	O
)	O
(see	O
PRECAUTIONS	O
)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevate	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS	B-D000075202
)	O
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythematosus	B-D004890
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS	O
),	O
decreased	O
creatinine	B-D003404
clearance,	O
poliuria,	O
azotemia,	B-D053099
cystitis,	B-D003556
hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked)	O

**Reactions	O
are	O
classified	O
under	O
“	O
Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

•	O
VOLTAREN	O
GEL	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(5.1)	O
•	O
VOLTAREN	O
GEL	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O

(5.3)	O
•	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
	O

(5.4,	O
7)	O
•	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
VOLTAREN	O
GEL	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

(5.5)	O
•	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
VOLTAREN	O
GEL	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

(5.6)	O
•	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

(5.7)	O
•	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
VOLTAREN	O
GEL	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O

(5.8)	O
•	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
VOLTAREN	O
GEL	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
	O

(5.9)	O
•	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
gestation	O

(5.10,	O
8.1)	O
•	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
	O

(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	B-D004008
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
VOLTAREN	O
GEL	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
VOLTAREN	O
GEL	O
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
•Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

•Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

•Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
VOLTAREN	O
GEL	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.3	O
Hepatotoxicity	O
In	O
clinical	B-D016430
trials,	I-D016430
of	O
oral	O
diclofenac-containing	B-D004008
products,	O
meaningful	O
elevations	O
(i.e	O

more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
with	O
oral	O
diclofenac	B-D004008
sodium	B-D012964
for	O
2-6	O
months,	O
patients	B-D010361
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3-8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
tests	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

In	O
a	O
European	B-D005060
retrospective	O
population-based,	B-D011153
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	B-D004008
associated	O
drug-induced	O
liver	B-D008099
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	B-D004008
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	B-D016017
ratio	I-D016017
of	O
liver	B-D008099
injury	O

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	B-D016424
number	O
of	O
10	O
cases	O
of	O
liver	B-D008099
injury	O
associated	O
with	O
diclofenac,	B-D004008
the	O
adjusted	O
odds	B-D016017
ratio	I-D016017
increased	O
further	O
with	O
female	B-D005260
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days	O

Physicians	B-D010820
should	O
measure	O
transaminases	B-D000637
at	O
baseline	O
and	O
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
transaminases	B-D000637
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
VOLTAREN	O
GEL	O
should	O
be	O
discontinued	O
immediately	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
VOLTAREN	O
GEL	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver	B-D008099
related	O
event	O
in	O
patients	B-D010361
treated	O
with	O
VOLTAREN	O
GEL,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Exercise	B-D015444
caution	O
when	O
prescribing	O
VOLTAREN	O
GEL	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	B-D000082
antibiotics,	O
anti-epileptics)	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
VOLTAREN	O
GEL,	O
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
diclofenac	B-D004008
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
VOLTAREN	O
GEL	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
VOLTAREN	O
GEL	O
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE-inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
VOLTAREN	O
GEL	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
VOLTAREN	O
GEL	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
VOLTAREN	O
GEL	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
VOLTAREN	O
GEL	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
VOLTAREN	O
GEL	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
VOLTAREN	O
GEL	O
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
diclofenac	B-D004008
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
VOLTAREN	O
GEL	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)]	O

When	O
VOLTAREN	O
GEL	O
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
VOLTAREN	O
GEL	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

VOLTAREN	O
GEL	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
VOLTAREN	O
GEL,	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
VOLTAREN	O
GEL	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
VOLTAREN	O
GEL,	O
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
VOLTAREN	O
GEL	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)]	O

5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	B-D000818
indicated	O
topical	O
diclofenac	B-D004008
treatment	O
resulted	O
in	O
an	O
earlier	B-D004423
onset	O
of	O
ultraviolet	O
light	B-D008027
induced	O
skin	B-D012867
tumors	O

The	O
potential	O
effects	O
of	O
VOLTAREN	O
GEL	O
on	O
skin	B-D012867
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	B-D006801
are	O
not	O
known	O

5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
VOLTAREN	O
GEL	O
with	O
eyes	B-D005123
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided	O

Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	B-D005123
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	B-D005123
with	O
water	B-D014867
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour	O

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
hemorrhage,	B-D006470
more	O
frequent	O
abnormal	O
creatinine,	B-D003404
urea,	B-D014508
and	O
hemoglobin	O

Do	O
not	O
use	O
combination	O
therapy	O
with	O
VOLTAREN	O
GEL	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	B-D012306
	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
patients	B-D010361
treated	O
with	O
VOLTAREN	O
GEL	O
and	O
greater	O
than	O
placebo)	O
are	O
application	O
site	O
reactions,	O
including	O
dermatitis	B-D003872
	O

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
GlaxoSmithKline	O
Consumer	O
Healthcare	B-D006262
at	O
1-855-297-3031	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

During	O
clinical	O
development,	O
913	O
patients	B-D010361
were	O
exposed	O
to	O
VOLTAREN	O
GEL	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	B-D010003
of	O
the	O
superficial	O
joints	B-D007596
of	O
the	O
extremities	B-D005121
	O

Of	O
these,	O
513	O
patients	B-D010361
received	O
VOLTAREN	O
GEL	O
for	O
osteoarthritis	B-D010003
of	O
the	O
knee	B-D007717
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	B-D010003
of	O
the	O
hand	B-D006225
	O

Additionally,	O
583	O
patients	B-D010361
were	O
exposed	O
to	O
VOLTAREN	O
GEL	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	B-D012449
trial	O
in	O
osteoarthritis	B-D010003
of	O
the	O
knee	B-D007717
	O

Of	O
these,	O
355	O
patients	B-D010361
were	O
treated	O
for	O
osteoarthritis	B-D010003
of	O
1	O
knee	B-D007717
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	B-D010003
of	O
both	O
knees	B-D007717
	O

Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	B-D012449
trial	O

Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	B-D010361
treated	O
with	O
VOLTAREN	O
GEL:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
VOLTAREN	O
GEL	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions	O

These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>1%	O
of	O
treated	O
patients	B-D010361
with	O
a	O
greater	O
frequency	O
in	O
the	O
VOLTAREN	O
GEL	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%)	O

Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported	O

Application	O
site	O
dermatitis	B-D003872
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	B-D010361
treated	O
with	O
VOLTAREN	O
GEL,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients	B-D010361
	O

Table	O
	O

Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
VOLTAREN	O
GEL	O
Patients)	B-D010361
–	O
Short-term	O
Controlled	O
Trials	O
†Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1	O
Adverse	O
Reaction†	O
VOLTAREN	O
GEL	O
N=913	O
Placebo	O
(Vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	B-D003872
32	O
(4)	O
6	O
(<1)	O
Application	O
site	O
pruritus	B-D011537
7	O
(<1)	O
1	O
(<1)	O
Application	O
site	O
erythema	B-D004890
6	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
paresthesia	B-D010292
5	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
dryness	O
4	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
vesicles	O
3	O
(<1)	O
0	O
Application	O
site	O
irritation	O
2	O
(<1)	O
0	O
Application	O
site	O
papules	O
1	O
(<1)	O
0	O
In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	B-D010361
treated	O
with	O
VOLTAREN	O
GEL,	O
and	O
3%	O
for	O
patients	B-D010361
in	O
the	O
placebo	O
group	O

Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	B-D003872
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation	O

Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:In	O
the	O
open-label,	O
long-term	O
safety	B-D012449
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies	O

In	O
this	O
study,	O
where	O
patients	B-D010361
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
VOLTAREN	O
GEL	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	B-D003872
was	O
observed	O
in	O
11%	O
of	O
patients	B-D010361
	O

Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients	B-D010361
	O

The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	B-D003872
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients	B-D010361
	O

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	B-D012306
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	B-D012306
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1)	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(5.2)	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1)	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(5.2)	O
Warnings	O
and	O
Precautions	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
oral	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction	I-D009203
(MI),	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
COX-2	O
selective	O
and	O
nonselective	O
orally	O
administered	O
NSAIDs,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
an	O
NSAID,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Inform	O
patients	B-D010361
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
an	O
orally	O
administered	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)]	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
NSAIDS,	O
such	O
as	O
diclofenac,	B-D004008
does	O
increase	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulceration,	B-D014456
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	B-D013995
during	O
the	O
course	O
of	O
therapy	O

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Prescribe	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
with	O
neither	O
of	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
and	O
therefore,	O
use	O
special	O
care	O
when	O
treating	O
this	O
population	B-D011153
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
diclofencac	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

For	O
high-risk	O
patients,	B-D010361
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O

5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
the	O
normal	O
[ULN]	O
range)	O
or	O
greater	O
elevations	O
of	O
transaminases	B-D000637
occurred	O
in	O
about	O
15%	O
of	O
oral	O
diclofenac-treated	B-D004008
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
of	O
indications	O
other	O
than	O
acute	B-D059787
pain	I-D059787
	O

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	B-D008099
injury	O

In	O
clinical	B-D016430
trials	I-D016430
of	O
an	O
oral	O
diclofenac	B-D004008
–	O
misoprostol	B-D016595
combination	O
product,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O

In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
for	O
2	O
to	O
6	O
months,	O
patients	B-D010361
with	O
oral	O
diclofenac	B-D004008
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(>8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
this	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(>8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
test	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
oral	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
druginduced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
sever	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

In	O
a	O
European	B-D005060
retrospective	O
population-based,	B-D011153
case-controlled	O
study,	O
10	O
cases	O
of	O
oral	O
diclofenac	B-D004008
associated	O
drug-induced	O
liver	B-D008099
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	B-D004008
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	B-D016017
ratio	I-D016017
of	O
liver	B-D008099
injury	O

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	B-D016424
number	O
of	O
10	O
cases	O
of	O
liver	B-D008099
injury	O
associated	O
with	O
diclofenac,	B-D004008
the	O
adjusted	O
odds	B-D016017
ratio	I-D016017
increased	O
further	O
with	O
female	B-D005260
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days	O

Measure	O
transaminases	B-D000637
(ALT	O
and	O
AST)	O
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
monitor	O
transaminases	B-D000637
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g	O

eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
immediately	O

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flulike"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
to	O
take	O
if	O
these	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
appear	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver-related	B-D008099
event	O
in	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	B-D000082
certain	O
antibiotics,	O
antiepileptics)	O

Caution	O
patients	B-D010361
to	O
avoid	O
taking	O
unprescribed	O
acetaminophen	B-D000082
while	O
using	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
lead	B-D007854
to	O
new	O
onset	O
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Use	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
with	O
caution	O
in	O
patients	B-D010361
with	O
hypertension	B-D006973
	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

Patients	B-D010361
taking	O
ACE-inhibitors,	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

Use	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
considerable	O
dehydration	B-D003681
	O

Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dosedependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE-inhibitors,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

Therefore,	O
treatment	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
is	O
not	O
recommended	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

If	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	B-D010361
without	O
prior	O
exposure	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

Do	O
not	O
prescribe	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.10)]	O

Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
to	O
open	O
skin	B-D012867
wounds,	O
infections,	B-D007239
inflammations,	B-D007249
or	O
exfoliative	O
dermatitis,	B-D003872
as	O
it	O
may	O
affect	B-D000339
absorption	B-D000042
and	O
tolerability	O
of	O
the	O
drug	O

NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012877
manifestations,	I-D012877
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
	O

5.9	O
Pregnancy	B-D011247
Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
should	O
not	O
be	O
used	O
by	O
pregnant	O
or	O
nursing	B-D009729
women	B-D014930
or	O
those	O
intending	O
to	O
become	O
pregnant	O

5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

The	O
use	O
of	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
aspirinsensitive	B-D001241
asthma	B-D001249
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal	O

Since	O
crossreactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	B-D001241
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
do	O
not	O
administer	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
to	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
and	O
use	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

5.11	O
Sun	O
Exposure	O
Instruct	O
patients	B-D010361
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
on	O
treated	O
knee(s)	B-D007717
because	O
studies	O
in	O
animals	B-D000818
indicated	O
topical	O
diclofenac	B-D004008
treatment	O
resulted	O
in	O
an	O
earlier	B-D004423
onset	O
of	O
ultraviolet	O
light-induced	B-D008027
skin	B-D012867
tumors	O

The	O
potential	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
on	O
skin	B-D012867
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	B-D006801
are	O
not	O
known	O

5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
eyes	B-D005123
and	O
mucosa	O

Advise	O
patients	B-D010361
that	O
if	O
eye	B-D005123
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	B-D005123
with	O
water	B-D014867
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour	O

5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	B-D006470
more	O
frequent	O
abnormal	O
creatinine,	B-D003404
urea	B-D014508
and	O
hemoglobin	O

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	B-D012306
and	O
conduct	O
periodic	O
laboratory	O
evaluations	O

5.14	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	B-D007854
to	O
exacerbation	O
of	O
corticosteroid-response	O
illness	O

For	O
patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy,	O
taper	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	B-D010146
conditions	O

5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	B-D006262
subjects	O
administered	O
80	O
drops	O
four	O
times	B-D013995
a	O
day	O
for	O
7	O
days	O

There	O
was	O
no	O
significant	O
change	O
in	O
platelet	B-D010974
aggregation	I-D010974
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)]	O

Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	B-D010361
receiving	O
NSAIDs	O

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	B-D001769
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis	B-D004920
	O

Check	O
hemoglobin	O
or	O
hematocrit	B-D006400
of	O
patients	B-D010361
on	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

NSAIDs	O
inhibit	O
platelet	B-D010974
aggregation	I-D010974
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	B-D001760
time	I-D001760
in	O
some	O
patients	B-D010361
	O

Unlike	O
aspirin,	B-D001241
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration	O
and	O
reversible	O

Carefully	O
monitor	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
who	O
may	O
be	O
adversely	O
affected	B-D000339
by	O
alteration	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	B-D010361
receiving	O
anticoagulants	B-D000925
	O

5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
ulcerations	B-D014456
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms	O
in	O
patients	B-D010361
taking	O
NSAIDs,	O
monitor	O
patients	B-D010361
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding	O

Check	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
in	O
patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O

Discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
or	O
renal	O
tests	B-C004551
persist	O
or	O
worsen	O

Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke	B-D020521
can	O
occur	O
with	O
NSAID	O
treatment	O

Use	O
the	O
lowest	O
effective	O
dose	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
in	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

(5.1)	O
NSAIDs	O
can	O
cause	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O

Prescribe	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

(5.2)	O
Elevation	O
of	O
one	O
or	O
more	O
liver	B-D008099
tests	B-C004551
may	O
occur	O
during	O
therapy	O
with	O
NSAIDs	O

Discontinue	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
immediately	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O

(5.3)	O
Hypertension	B-D006973
can	O
occur	O
with	O
NSAID	O
treatment	O

Monitor	O
blood	B-D001794
pressure	I-D001794
closely	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
treatment	O

(5.4)	O
Use	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

(5.5)	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Use	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
caution	O
in	O
patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
and	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE-inhibitors	O

(5.6)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O
or	O
in	O
patients	B-D010361
without	O
prior	O
exposure	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

(5.7)	O
NSAIDs	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

(5.8)	O
Not	O
for	O
use	O
during	O
pregnancy	B-D011247
	O

(5.9)	O
Do	O
not	O
administer	O
to	O
patients	B-D010361
with	O
aspirin	B-D001241
sensitive	O
asthma	B-D001249
and	O
use	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

(5.10)	O
Avoid	O
exposure	O
of	O
treated	O
knee(s)	B-D007717
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
	O

(5.11)	O
Avoid	O
contact	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
with	O
eyes	B-D005123
and	O
mucosa	O

(5.12)	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(5.13)	O
Adverse	O
Reactions	O
6	O

ADVERSE	O
REACTIONS	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trial	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
of	O
911	O
patients	B-D010361
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	B-D010361
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	B-D010361
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	B-D010361
treated	O
for	O
at	O
least	O
12	O
months	O

The	O
population	B-D011153
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	B-D010361
were	O
Caucasians,	O
64%	O
were	O
females,	B-D005260
and	O
all	O
patients	B-D010361
had	O
primary	O
osteoarthritis	B-D010003
	O

The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
site	O
reactions:	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment	O
related	O
adverse	O
events	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

Application	O
site	O
reactions	O
were	O
characterized	B-D002605
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	B-D004890
induration,	O
vesicles,	O
paresthesia,	B-D010292
pruritus,	B-D011537
vasodilation,	B-D014664
acne,	O
and	O
urticaria	B-D014581
	O

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	B-D012867
(32%),	O
contact	O
dermatitis	B-D003872
characterized	B-D002605
by	O
skin	B-D012867
erythema	B-D004890
and	O
induration	O
(9%),	O
contact	O
dermatitis	B-D003872
with	O
vescicles	O
(2%)	O
and	O
pruritus	B-D011537
(4%)	O

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
oral	O
diclofenac	B-D004008
	O

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	B-D012449
study,	O
contact	O
dermatitis	B-D003872
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
in	O
10%	O
of	O
patients,	B-D010361
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	B-D007854
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%	O

Adverse	O
events	O
common	O
to	O
the	O
NSAID	O
class:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	B-D003967
dyspepsia,	B-D004415
nausea,	B-D009325
flatulence,	B-D005414
abdominal	B-D015746
pain,	I-D015746
edema;	B-D004487
see	O
Table	O
1)	O

The	O
combination	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
oral	O
diclofenac,	B-D004008
compared	O
to	O
oral	O
diclofenac	B-D004008
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	B-D006470
(3%	O
vs	O

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	B-D003404
(12%	O
vs	O

7%),	O
urea	B-D014508
(20%	O
vs	O

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	B-D008099
transaminases	B-D000637
	O

Table	O
1:	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
	O

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	B-D010361
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	B-D004008
trials	O

6.2	O
Postmarketing	O
Experience	O
In	O
non	O
–	O
U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

Body	O
as	O
a	O
Whole:	O
abdominal	B-D015746
pain,	I-D015746
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	B-D001247
back	B-D001416
pain,	I-D001416
body	O
odor,	O
chest	B-D002637
pain,	I-D002637
edema,	B-D004487
face	B-D005145
edema,	B-D004487
halitosis,	B-D006209
headache,	B-D006261
lack	O
of	O
drug	O
effect,	O
neck	B-D009333
rigidity,	O
pain	B-D010146
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	B-D003967
dry	O
mouth,	B-D009055
dyspepsia,	B-D004415
gastroenteritis,	B-D005759
decreased	O
appetite,	B-D001066
mouth	B-D009055
ulceration,	B-D014456
nausea,	B-D009325
rectal	O
hemorrhage,	B-D006470
ulcerative	B-D014456
stomatitis	B-D013280
Metabolic	O
and	O
Nutritional:	O
creatinine	B-D003404
increased	O
Musculoskeletal:	O
leg	B-D007866
cramps,	O
myalgia	B-D063806
Nervous:	O
depression,	B-D003863
dizziness,	B-D004244
drowsiness,	O
lethargy,	B-D053609
paresthesia,	B-D010292
paresthesia	B-D010292
at	O
application	O
site	O
Respiratory:	O
asthma,	B-D001249
dyspnea,	B-D004417
laryngismus,	B-D007826
laryngitis,	B-D007827
pharyngitis	B-D010612
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	B-D003877
contact	I-D003877
dermatitis	B-D003872
with	O
vesicles,	O
dry	O
skin,	B-D012867
pruritus,	B-D011537
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	B-D004485
rash,	O
pruritus,	B-D011537
skin	B-D012867
discoloration,	O
urticaria	B-D014581
Special	O
senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	B-D002386
ear	B-D004423
pain,	B-D010146
eye	B-D005123
disorder,	O
eye	B-D058447
pain,	I-D058447
taste	B-D013649
perversion	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Teligent	O
Pharma,	O
Inc	O

at	O
1-856-697-1441	O
or	O
FDA	O
at	O
1-800-332-1088	O
or	O
www.fda.gov/medwatch	O

The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.1)]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.2)]	O
Hepatotoxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.3)]	O
Hypertension	B-D006973
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
WARNINGS	O
AND	O
PRECAUTIONS	O
(5.11)]	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Teligent	O
Pharma,	O
Inc	O

at	O
1-856-697-1441	O
or	O
FDA	O
at	O
1-800-332-1088	O
or	O
www.fda.gov/medwatch	O

table	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	B-D000068579
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O

(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
CardiovascularRisk	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	B-D000068579
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke	B-D020521
	O

Patients	B-D010361
with	O
known	O
CV	O
disease/risk	B-D004194
factors	O
may	O
be	O
at	O
greater	O
risk	B-D012306
(5.1,	O
14.6,	O
17.2)	O

•	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
risk	B-D012306
is	O
greater	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
GI	O
bleeding,	O
and	O
in	O
patients	B-D010361
at	O
high	O
risk	B-D012306
for	O
GI	O
events,	O
especially	O
the	O
elderly	O

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	B-D010361
(5.4,	O
8.5,	O
14.6,	O
17.3)	O

•	O
Elevated	O
liver	B-D008099
enzymes	B-D004798
and,	O
rarely,	O
severe	O
hepatic	O
reactions	O

Discontinue	O
use	O
of	O
celecoxibimmediately	B-D000068579
if	O
abnormal	O
liver	B-D008099
enzymes	B-D004798
persist	O
or	O
worsen	O
(5.5,	O
17.4)	O

•	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
duringtreatment	O
with	O
celecoxib	B-D000068579
(5.2,	O
7.4,	O
17.2)	O

•	O
Fluid	O
retention	O
and	O
edema	B-D004487
	O

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retentionor	O
heart	B-D006333
failure	I-D006333
(5.3,	O
17.6)	O

•	O
Renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use	O

Use	O
celecoxib	B-D000068579
with	O
caution	O
inthe	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
and	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
or	O
angiotensin	B-D000804
II	I-D000804
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6)	O

•	O
Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O
(5.7,	O
10,	O
17.7)	O

•	O
Serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
evenwithout	O
known	O
prior	O
sulfa	O
allergy	O

Discontinue	O
celecoxib	B-D000068579
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	B-D012867
reactions	O
(5.8,	O
17.5)	O

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovasculardeath,	O
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
to	O
8.5)	O
for	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
to	O
7.2)	O
with	O
celecoxib	B-D000068579
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(14.6)]	O

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib,	B-D000068579
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/orsymptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
celecoxib	B-D000068579
does	O
increase	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O

Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)]	O

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	B-D000068579
can	O
lead	B-D007854
to	O
the	O
onset	O
of	O
new	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

NSAIDs,	O
including	O
celecoxib,	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	B-D000068579
and	O
throughout	O
the	O
course	O
of	O
therapy	O

The	O
rates	O
of	O
hypertension	B-D006973
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	B-D000068579
ibuprofen	B-D007052
and	O
diclofenac-treated	B-D004008
patients	B-D010361
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	B-D000078682
[see	O
Clinical	O
Studies	O
(14.6)]	O

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
taking	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
[see	O
Adverse	O
Reactions	O
(6.1)]	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulceration,	B-D014456
Bleeding,	O
and	O
PerforationNSAIDs,	O
including	O
celecoxib,	B-D000068579
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)]	O

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	B-D013995
during	O
the	O
course	O
of	O
therapy	O

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
with	O
neither	O
of	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population	B-D011153
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
duringcelecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

For	O
high-risk	O
patients,	B-D010361
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered	O

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	B-D008099
enzymes	B-D004798
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
with	O
NSAIDs	O

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	B-D007565
and	O
fatal	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis	B-D009336
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	B-D017809
outcome)	I-D017809
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
[see	O
Adverse	O
Reactions	O
(6.1)]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
celecoxib,	B-D000068579
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
celecoxib	B-D000068579
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	B-D008099
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	B-D008099
test	B-C004551
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib	B-D000068579
	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptomsconsistent	I-D012816
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
celecoxib	B-D000068579
should	O
be	O
discontinued	O

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
ofan	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liverdysfunction,	B-D008099
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
angiotensin	B-D000804
II	I-D000804
receptor	O
antagonists,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
trials	I-D016430
with	O
celecoxib	B-D000068579
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

Therefore,	O
treatment	O
with	O
celecoxib	B-D000068579
is	O
not	O
recommended	O
in	O
these	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

If	O
celecoxib	B-D000068579
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	B-D010361
without	O
known	O
prior	O
exposure	O
to	O
celecoxib	B-D000068579
	O

In	O
postmarketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	B-D000799
have	O
been	O
reported	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
	O

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),Warnings	O
and	O
Precautions	O
(5.7)]	O

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	B-D010361
without	O
prior	O
known	O
sulfa	O
allergy	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012877
manifestations	I-D012877
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	B-D011247
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	B-D000068579
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)]	O

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	B-D007854
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness	O

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
celecoxib	B-D000068579
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	B-D000068579
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	B-D000339
platelet	B-D010976
counts,	I-D010976
prothrombin	B-D011517
time	I-D011517
(PT),	O
or	O
partial	B-D010314
thromboplastin	I-D010314
time	I-D010314
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	B-D010974
aggregation	I-D010974
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)]	O

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
	O

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

The	O
use	O
of	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal	O

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	B-D001241
and	O
other	O
nonsteroidal	O
antiinflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
celecoxib	B-D000068579
should	O
not	O
be	O
administered	O
to	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

5.14	O
Laboratory	O
Tests	B-C004551
Because	O
serious	O
GI	O
tract	O
ulcerations	B-D014456
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	B-D010820
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
checked	O
periodically	B-D020492
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
or	O
renal	O
tests	B-C004551
persist	O
or	O
worsen,	O
celecoxib	B-D000068579
should	O
be	O
discontinued	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	B-D000068579
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	B-D010146
conditions	O

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	B-D000068579
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	B-D012306
of	O
adverse	O
reactions	O

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	B-D000068579
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	B-D000068579
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
celecoxib	B-D000068579
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reactioninformation	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sydon	O
Labs,	O
LLC	O
at	O
1	O
866-487-4695	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
>2%	O
of	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4,	O
146	O
Placebo	O
N=1,	O
864	O
NAP	O
N=1,	O
366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%3.8%	O
6.2%	O
1%	O
4.2%	O
7.7%5.3%	O
12.2%	O
3.6%	O
6%	O
9%9.3%	O
10.9%	O
4.1%	O
3.4%	O
9%5.8%	O
12.8%	O
3.5%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%2.1%	O
2.9%	O
3.6%1.1%	O
2.3%	O
2.2%2.1%	O
3%	O
2.6%1%	O
2.6%	O
0.9%3.5%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
Headache	B-D006261
2%15.8%	O
1.7%20.2%	O
2.6%14.5%	O
1.3%15.5%	O
2.3%15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
Rhinitis	B-D012220
Sinusitis	B-D012852
Upper	O
Respiratory	O
Infection	O
2.3%2%	O
5%	O
8.1%	O
1.1%1.3%	O
4.3%	O
6.7%	O
1.7%2.4%	O
4%	O
9.9%	O
1.6%2.3%	O
5.4%	O
9.8%	O
2.6%0.6%	O
5.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	B-D000068579
treatmentgroups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	B-D000068579
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinineincreased,	B-D003404
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	B-D010361
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis,	B-D013924
vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis,	B-D002769
hepatitis,	B-D006505
jaundice,	B-D007565
liver	B-D017093
failure	I-D017093
Hemic	O
alymphatic:	O
Thrombocytopenia,	B-D013921
agranulocytosis,aplastic	B-D000380
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Ataxia,	B-D001259
suicide,	B-D013405
aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	B-D009393
Skin:	B-D012867
Erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
StevensJohnson	O
syndrome,	B-D013577
toxic	O
epidermal	O
necrolysis	O
General:	O
Sepsis,	B-D018805
sudden	O
death,	B-D003643
anaphylactoid	O
reaction,	O
angioedema	B-D000799
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
Hematological	O
Events	O
:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

Thelower	O
incidence	B-D015994
of	O
events	O
with	O
celecoxib	B-D000068579
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	B-D000068579
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
tobe	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

6.3	O
Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
BID,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
BID	O

The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
doubleblind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
>5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
ClassPreferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kgN=77	O
Celecoxib	B-D000068579
6	O
mg/kgN=82	O
Naproxen	B-D009288
7.5	O
mg/kgN=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
36	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocritdecreased,	B-D006400
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600mg/day	O
of	O
celecoxib	B-D000068579
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
postdental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	B-D000068579
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.6)].Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
premarketing	B-C070504
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	B-D000068579
premarketing	B-C070504
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N=2,285	O
Placebo	O
N=1,303	O
Diarrhea	B-D003967
10.5%	O
7%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
>0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
celecoxib,	B-D000068579
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS	O
]	O

Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
]	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
]	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“	O
Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“	O
Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
Pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash*	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
neuritis,	B-D009443
cataracts	B-D002386
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
(see	O
PRECAUTIONS)	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(eg	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevated	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS)	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythe-	O
matosus	O
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
polyuria,	B-D011141
azotemia,	B-D053099
cystitis,	B-D003556
Hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
tests	B-C004551
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use.(	O
5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(	O
4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(	O
5.2)	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)]	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity	O
:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(	O
5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(	O
5.5)	O
Renal	O
Toxicity	O
:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions	O
:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
:	O
Celecoxib	B-D000068579
capsules	B-D002214
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions	O
:	O
Discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(	O
5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity	O
:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses.Clinical	O
trials	O
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	B-D012306
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
for	O
the	O
celecoxib	B-D000068579
capsules	B-D002214
400mg	O
twice	O
daily	O
and	O
celecoxib	B-D000068579
capsules	B-D002214
200	O
mg	O
twice	O
daily	O
treatment	O
arms	B-D001132
compared	O
to	O
placebo	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(	O
14.7)]	O

A	O
randomized	B-D016449
controlled	I-D016449
trial	I-D016449
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs	O

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	B-D012306
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	B-D000068579
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	B-D009288
and	O
ibuprofen	B-D007052
	O

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	B-D009288
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	B-D007052
600	O
to	O
800	O
mg	O
three	O
times	B-D013995
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists'	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	B-D003643
(including	O
hemorrhagic	O
death),	B-D003643
non-fatal	O
myocardial	B-D009203
infarction,	I-D009203
and	O
non-fatal	O
stroke	B-D020521
[	O
See	O
Clinical	O
Studies	O
(	O
14.6)	O
]	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(	O
4)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	B-D001241
anticoagulants;	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding.Patients	O
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	B-D001241
anticoagulants;	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
]	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[	O
see	O
Clinical	O
Studies	O
(14.7)]	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
celecoxib	B-D000068579
capsules,	B-D002214
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash),	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules	B-D002214
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
]	O

NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules	B-D002214
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O

See	O
Clinical	O
Studies	O
(	O
14.6,	O
14.7)	O
for	O
additional	O
blood	B-D001794
pressure	I-D001794
data	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
celecoxib	B-D000068579
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(	O
14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia	B-D020896
,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
celecoxib	B-D000068579
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoaldosteronism	B-D006994
state	O

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
celecoxib	B-D000068579
and	O
in	O
patients	B-D010361
with	O
aspirin	B-D001241
sensitive	O
asthma	B-D001249
	O

Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	B-D013449
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	B-D019369
or	O
less	O
severe	O
asthmatic	B-D001249
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.8)	O
]	O

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

When	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	B-D012867
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib	B-D000068579
capsules,	B-D002214
including	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	B-D056150
generalized	I-D056150
exanthematous	I-D056150
pustulosis	I-D056150
(AGEP)	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(	O
8.1)	O
]	O

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	B-D001241
SSRIs	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)	O
]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	B-D000068579
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2,	O
5.3,	O
5.6)	O
]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
capsules	B-D002214
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
with	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	B-D010361
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	B-D010361
and	O
their	O
caregivers	B-D017028
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible	O

6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(	O
6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Cipla	O
Ltd,	O
at	O
1-866-604-3268	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labelling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Of	O
the	O
celecoxib-treated	B-D000068579
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
capsules	B-D002214
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Celecoxib	B-D000068579
=	O
Celecoxib	B-D000068579
capsules	B-D002214
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

Celecoxib	B-D000068579
(N=4146)	O
Placebo	O
(N=1864)	O
NAP	O
(N=1366)	O
DCF	O
(N=387)	O
IBU	O
(N=345)	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	B-D000068579
capsules	B-D002214
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	B-D000068579
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
Capsules	B-D002214
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
Allergy	O
General:	O
Hypersensitivity,	B-D006967
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
blood	B-D001806
urea	I-D001806
nitrogen	I-D001806
(BUN)	O
increased,	O
creatine	B-D003401
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	B-D010361
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis	B-D013924
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis	B-D010195
ileus	B-D045823
General:	O
Sepsis,	B-D018805
sudden	O
death	B-D003643
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis,	B-D002769
Hemic	O
and	O
lymphatic:	B-D008196
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia,	B-D001259
suicide	B-D013405
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7.1)	O
]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[	O
see	O
Special	O
Studies	O
(	O
14.7)]	O
Hematological	O
Events:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
was	O
maintained	O
with	O
or	O
without	O
aspirin	B-D001241
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(	O
12.2)]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	B-D000068579
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
twice	O
daily	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

$	O
Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
*Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(	O
14.7)]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	B-D000068579
capsules	B-D002214
pre-marketing	O
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
Capsules	B-D002214
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
capsules,	B-D002214
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post	O
approval	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
General:	O
Anaphylactoid	O
reaction,	O
angioedema	B-D000799
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	B-D009336
hepatitis,	B-D006505
jaundice,	B-D007565
hepatic	O
failure	O
Hemic	O
and	O
lymphatic	B-D008196
Agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
Renal	O
Interstitial	O
nephritis	B-D009393
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
WARNINGS	O
and	O
PRECAUTIONS	O
]	O

Ibuprofen	B-D007052
Tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
]	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
[see	O
WARNINGS	O
]	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
Than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“	O
Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“	O
Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
Pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash*	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
neuritis,	B-D009443
cataracts	B-D002386
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and/or	O
changes	O
in	O
color	B-D055253
vision)	I-D055253
(see	O
PRECAUTIONS)	O
Conjunctivitis,	B-D003231
diplopia,	B-D004172
optic	B-D009902
neuritis,	I-D009902
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(eg	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevated	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS)	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythe-	O
matosus	O
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
polyuria,	B-D011141
azotemia,	B-D053099
cystitis,	B-D003556
Hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
tests	B-C004551
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O
	O

Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
a	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
etodolac	B-D017308
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal),	O
vomiting	B-D014839
	O

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritis,	O
rashes,	O
tinnitus	B-D014012
	O

Adverse-reaction	O
information	O
for	O
etodolac	B-D017308
was	O
derived	O
from	O
2,629	O
arthritic	B-D001154
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
in	O
double-blind	O
and	O
open-label	O
clinical	B-D016430
trials	I-D016430
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies	O

In	O
clinical	B-D016430
trials,	I-D016430
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient	O

The	O
discontinuation	O
rate	O
in	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

New	O
patient	O
complaints	O
(with	O
an	O
incidence	B-D015994
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system	O

The	O
incidences	B-D015994
were	O
determined	O
from	O
clinical	B-D016430
trials	I-D016430
involving	O
465	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	B-D017308
b.i.d	O

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever	B-D005334
	O

Digestive	B-D004064
system	I-D004064
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	B-D015746
pain*,	I-D015746
diarrhea*,	B-D003967
flatulence*,	B-D005414
nausea*,	B-D009325
constipation,	B-D003248
gastritis,	B-D005756
melena,	B-D008551
vomiting	B-D014839
	O

Nervous	B-D009420
system	I-D009420
-	O
Asthenia/malaise*,	B-D001247
dizziness*,	B-D004244
depression,	B-D003863
nervousness	O

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus,	B-D011537
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus	B-D014012
	O

Urogenital	B-D014566
system	I-D014566
-	O
Dysuria,	B-D053159
urinary	O
frequency	O

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	B-D016430
trials,	I-D016430
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock)	B-D012769
	O

Cardiovascular	B-D002319
system	I-D002319
-	O
Hypertension,	B-D006973
congestive	O
heart	B-D006333
failure,	I-D006333
flushing,	B-D005483
palpitations,	O
syncope,	B-D013575
vasculitis	B-D014657
(including	O
necrotizing	O
and	O
allergic)	O

Digestive	B-D004064
system	I-D004064
-	O
Thirst,	B-D013894
dry	O
mouth,	B-D009055
ulcerative	B-D014456
stomatitis,	B-D013280
anorexia,	B-D000855
eructation,	B-D004884
elevated	O
liver	B-D008099
enzymes,	B-D004798
cholestatic	O
hepatitis,	B-D006505
hepatitis,	B-D006505
cholestatic	O
jaundice,	B-D007565
duodenitis,	B-D004382
jaundice,	B-D007565
hepatic	O
failure,	O
liver	B-D008099
necrosis,	B-D009336
peptic	B-D010437
ulcer	I-D010437
with	O
or	O
without	O
bleeding	O
and/or	O
perforation	O
,	O
intestinal	O
ulceration,	B-D014456
pancreatitis	B-D010195
	O

Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
Ecchymosis,	B-D004438
anemia,	B-D000740
thrombocytopenia,	B-D013921
bleeding	B-D001760
time	I-D001760
increased,	O
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000740
leukopenia,	B-D007970
neutropenia,	B-D009503
pancytopenia	B-D010198
	O

Metabolic	O
and	O
nutritional	O
-	O
Edema,	B-D004487
serum	B-D044967
creatinine	B-D003404
increase,	O
hyperglycemia	B-D006943
in	O
previously	O
controlled	O
diabetic	O
patients	B-D010361
	O

Nervous	B-D009420
system	I-D009420
-	O
Insomnia,	O
somnolence	O

Respiratory	B-D012137
system	I-D012137
-	O
Asthma,	B-D001249
pulmonary	O
infiltration	O
with	O
eosinophilia	B-D004802
	O

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema,	B-D000799
sweating,	B-D013546
urticaria,	B-D014581
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	B-D014657
with	O
purpura,	B-D011693
Stevens-Johnson	B-D013262
Syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis,	O
hyperpigmentation	B-D017495
,	O
erythema	B-D004892
multiforme	I-D004892
	O

Special	O
senses	O
-	O
Photophobia,	B-D020795
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
system	I-D014566
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	B-D051437
insufficiency,	I-D051437
renal	O
papillary	O
necrosis	B-D009336
	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	B-D017308
is	O
uncertain	O

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	B-D010820
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache	B-D006261
	O

Cardiovascular	B-D002319
system	I-D002319
-	O
Arrhythmias,	O
myocardial	B-D009203
infarction,	I-D009203
cerebrovascular	B-C079279
accident	O

Digestive	B-D004064
system	I-D004064
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis	B-D003092
	O

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
system	I-D009420
-	O
Paresthesia,	B-D010292
confusion	B-D003221
	O

Respiratory	B-D012137
system	I-D012137
-	O
Bronchitis,	B-D001991
dyspnea,	B-D004417
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis	B-D012852
	O

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia,	B-D000505
maculopapular	O
rash,	O
photosensitivity,	O
skin	B-D012867
peeling	O

Special	O
senses	O
-	O
Conjunctivitis,	B-D003231
deafness,	B-D003638
taste	B-D013649
perversion	O

Urogenital	B-D014566
system	I-D014566
-	O
Cystitis,	B-D003556
hematuria,	B-D006417
leukorrhea,	B-D007973
renal	O
calculus,	O
interstitial	O
nephritis,	B-D009393
uterine	O
bleeding	O
irregularities	O

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis,	B-D018805
death	B-D003643
Cardiovascular	B-D002319
system	I-D002319
-	O
Tachycardia	B-D013610
Digestive	B-D004064
system	I-D004064
-	O
Gastric	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis	B-D006396
Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
Lymphadenopathy	B-D000072281
Nervous	B-D009420
system	I-D009420
-	O
Anxiety,	B-D001007
dream	O
abnormalities,	O
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis,	B-D008581
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
system	I-D012137
-	O
Respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Urogenital	B-D014566
system	I-D014566
-	O
Oliguria/polyuria,	B-D009846
proteinuria	B-D011507
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS	O
)	O

Etodolac	B-D017308
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
etodolac	B-D017308
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal),	O
vomiting	B-D014839
	O

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritis,	O
rashes,	O
tinnitus	B-D014012
	O

Adverse	O
reaction	O
information	O
for	O
etodolac	B-D017308
was	O
derived	O
from	O
2,629	O
arthritic	B-D001154
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
in	O
double-blind	O
and	O
open-label	O
clinical	B-D016430
trials	I-D016430
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
post-marketing	O
surveillance	O
studies	O

In	O
clinical	B-D016430
trials,	I-D016430
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient	O

The	O
discontinuation	O
rate	O
in	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

New	O
patient	O
complaints	O
(with	O
an	O
incidence	B-D015994
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system	O

The	O
incidences	B-D015994
were	O
determined	O
from	O
clinical	B-D016430
trials	I-D016430
involving	O
465	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
treated	O
with	O
300	O
mg	O
to	O
500	O
mg	O
of	O
etodolac	B-D017308
b.i.d	O

(i.e.,	O
600	O
mg/day	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
Whole	O
Chills	B-D023341
and	O
fever	B-D005334
	O

Digestive	B-D004064
System	I-D004064
Dyspepsia	B-D004415
(10%),	O
abdominal	B-D015746
pain	I-D015746
1,	O
diarrhea	B-D003967
2,	O
flatulence	B-D005414
3,	O
nausea	B-D009325
4,	O
abdominal	O
distension,	O
epigastric	O
pain,	B-D010146
abnormal	O
stools,	O
constipation,	B-D003248
gastritis,	B-D005756
melena,	B-D008551
vomiting	B-D014839
	O

Nervous	B-D009420
System	I-D009420
Asthenia/malaise	B-D001247
5,	O
dizziness	B-D004244
6,	O
depression,	B-D003863
nervousness,	O
fatigue	B-D005221
	O

Skin	B-D012867
and	O
Appendages	O
Pruritus,	B-D011537
rash	O

Special	O
Senses	O
Blurred	O
vision,	O
tinnitus	B-D014012
	O

Urogenital	B-D014566
System	I-D014566
Dysuria,	B-D053159
urinary	O
frequency	O

Musculoskeletal	O
Arthralgia	B-D018771
1Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

2Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

3Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

4Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

5Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

6Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
post-marketing	O
experience,	O
not	O
seen	O
in	O
clinical	B-D016430
trials,	I-D016430
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
Whole:	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock)	B-D012769
	O

Cardiovascular	B-D002319
System:	I-D002319
Hypertension,	B-D006973
congestive	O
heart	B-D006333
failure,	I-D006333
flushing,	B-D005483
palpitations,	O
syncope,	B-D013575
vasculitis	B-D014657
(including	O
necrotizing	O
and	O
allergic)	O

Digestive	B-D004064
System:	I-D004064
Thirst,	B-D013894
dry	O
mouth,	B-D009055
ulcerative	B-D014456
stomatitis,	B-D013280
anorexia,	B-D000855
eructation,	B-D004884
elevated	O
liver	B-D008099
enzymes,	B-D004798
cholestatic	O
hepatitis,	B-D006505
hepatitis,	B-D006505
cholestatic	O
jaundice,	B-D007565
duodenitis,	B-D004382
jaundice,	B-D007565
hepatic	O
failure,	O
liver	B-D008099
necrosis,	B-D009336
peptic	B-D010437
ulcer	I-D010437
with	O
or	O
without	O
bleeding	O
and/or	O
perforation	O
,	O
intestinal	O
ulceration,	B-D014456
pancreatitis	B-D010195
	O

Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
Ecchymosis,	B-D004438
anemia,	B-D000740
thrombocytopenia,	B-D013921
bleeding	B-D001760
time	I-D001760
increased,	O
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
leukopenia,	B-D007970
neutropenia,	B-D009503
pancytopenia	B-D010198
	O

Metabolic	O
and	O
Nutritional:	O
Edema,	B-D004487
serum	B-D044967
creatinine	B-D003404
increase,	O
hyperglycemia	B-D006943
in	O
previously	O
controlled	O
diabetic	O
patients	B-D010361
	O

Nervous	B-D009420
System:	I-D009420
Insomnia,	O
somnolence	O

Respiratory	B-D012137
System:	I-D012137
Asthma,	B-D001249
pulmonary	O
infiltration	O
with	O
eosinophilia	B-D004802
	O

Skin	B-D012867
and	O
Appendages:	O
Angioedema,	B-D000799
sweating,	B-D013546
urticaria,	B-D014581
exfoliative	O
dermatitis,	B-D003872
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	B-D014657
with	O
purpura,	B-D011693
Stevens-Johnson	B-D013262
Syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis,	O
leukocytoclastic	O
vasculitis,	B-D014657
hyperpigmentation	B-D017495
,	O
erythema	B-D004892
multiforme	I-D004892
	O

Special	O
Senses:	O
Photophobia,	B-D020795
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System:	I-D014566
Elevated	O
BUN,	O
renal	O
failure,	O
renal	B-D051437
insufficiency,	I-D051437
renal	O
papillary	O
necrosis	B-D009336
	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	B-D017308
is	O
uncertain	O

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	B-D010820
Body	O
as	O
a	O
Whole:	O
Infection,	O
headache	B-D006261
	O

Cardiovascular	B-D002319
System:	I-D002319
Arrhythmias,	O
myocardial	B-D009203
infarction,	I-D009203
cerebrovascular	B-C079279
accident	O

Digestive	B-D004064
System:	I-D004064
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis,	B-D003092
GI	O
discomfort,	O
burning	O
sensation,	B-D012677
blood	B-D001769
in	O
stools,	O
gastralgia,	O
upper	O
abdominal	O
discomfort	O

Metabolic	O
and	O
Nutritional:	O
Change	O
in	O
weight	O

Nervous	B-D009420
System:	I-D009420
Paresthesia,	B-D010292
confusion,	B-D003221
irritability	O

Respiratory	B-D012137
System:	I-D012137
Bronchitis,	B-D001991
bronchospasm,	O
dyspnea,	B-D004417
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis	B-D012852
	O

Skin	B-D012867
and	O
Appendages:	O
Alopecia,	B-D000505
maculopapular	O
rash,	O
photosensitivity,	O
skin	B-D012867
peeling	O

Special	O
Senses:	O
Conjunctivitis,	B-D003231
deafness,	B-D003638
taste	B-D013649
perversion,	O
loss	O
of	O
taste	B-D013649
	O

Urogenital	B-D014566
System:	I-D014566
Cystitis,	B-D003556
hematuria,	B-D006417
leukorrhea,	B-D007973
renal	O
calculus,	O
interstitial	O
nephritis,	B-D009393
uterine	O
bleeding	O
irregularities,	O
renal	O
impairment	O

Musculoskeletal:	O
Muscle	O
pain	B-D010146
	O

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
Whole:	O
Sepsis,	B-D018805
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
Tachycardia	B-D013610
Digestive	B-D004064
System:	I-D004064
Gastric	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis	B-D006396
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
Lymphadenopathy	B-D000072281
Nervous	B-D009420
System:	I-D009420
Anxiety,	B-D001007
dream	O
abnormalities,	O
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis,	B-D008581
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
Respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Urogenital	B-D014566
System:	I-D014566
Oliguria/polyuria,	B-D009846
proteinuria	B-D011507
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O

Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUD	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(	O
5.1	O
)	O
Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(	O
4	O
,	O
5.1	O
)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
(	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity	O
:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(	O
5.3	O
)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(	O
5.4	O
,	O
7	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(	O
5.5	O
)	O
Renal	O
Toxicity	O
:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(	O
5.6	O
)	O
Anaphylactic	O
Reactions	O
:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7	O
)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
:	O
Indomethacin	B-D007213
Capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(	O
5.8	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
:	O
Discontinue	O
indomethacin	B-D007213
capsules	B-D002214
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(	O
5.9	O
)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
gestation	O
(	O
5.10	O
,	O
8.1	O
)	O
Hematologic	O
Toxicity	O
:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(	O
5.11	O
,	O
7	O
)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
indomethacin,	B-D007213
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
indomethacin	B-D007213
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
indomethacin,	B-D007213
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
indomethacin	B-D007213
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
indomethacin	B-D007213
	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
indomethacin	B-D007213
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
indomethacin	B-D007213
capsules,	B-D002214
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
pre-existing	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
indomethacin	B-D007213
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)]	O

Avoid	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
indomethacin	B-D007213
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
indomethacin	B-D007213
capsules	B-D002214
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
indomethacin	B-D007213
capsules	B-D002214
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)]	O

Avoid	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
indomethacin	B-D007213
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
the	O
potassium-sparing	B-D011188
diuretic,	O
triamterene,	B-D014223
to	O
a	O
maintenance	B-D008283
schedule	O
of	O
indomethacin	B-D007213
resulted	O
in	O
reversible	O
acute	O
renal	O
failure	O
in	O
two	O
of	O
four	O
healthy	B-D064368
volunteers	I-D064368
	O

Indomethacin	B-D007213
and	O
triamterene	B-D014223
should	O
not	O
be	O
administered	O
together	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

Both	O
indomethacin	B-D007213
and	O
potassium-sparing	B-D011188
diuretics	B-D004232
may	O
be	O
associated	O
with	O
increased	O
serum	B-D044967
potassium	B-D011188
levels	O

The	O
potential	O
effects	O
of	O
indomethacin	B-D007213
and	O
potassium-sparing	B-D011188
diuretics	B-D004232
on	O
potassium	B-D011188
levels	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O

5.7	O
Anaphylactic	O
Reactions	O
Indomethacin	B-D007213
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
indomethacin	B-D007213
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
indomethacin	B-D007213
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)]	O

When	O
indomethacin	B-D007213
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
indomethacin,	B-D007213
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
indomethacin	B-D007213
capsules	B-D002214
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Indomethacin	B-D007213
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(	O
4	O
)]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Indomethacin	B-D007213
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
indomethacin	B-D007213
capsules,	B-D002214
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(	O
8.1	O
)]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
indomethacin	B-D007213
capsules	B-D002214
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
indomethacin	B-D007213
capsules,	B-D002214
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7	O
)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
indomethacin	B-D007213
capsules	B-D002214
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.3	O
,	O
5.6	O
)]	O

5.14	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects:	O
Indomethacin	B-D007213
may	O
aggravate	O
depression	B-D003863
or	O
other	O
psychiatric	O
disturbances,	O
epilepsy,	B-D004827
and	O
parkinsonism,	O
and	O
should	O
be	O
used	O
with	O
considerable	O
caution	O
in	O
patients	B-D010361
with	O
these	O
conditions	O

If	O
severe	O
CNS	O
adverse	O
reactions	O
develop,	O
indomethacin	B-D007213
should	O
be	O
discontinued	O

Indomethacin	B-D007213
may	O
cause	O
drowsiness;	O
therefore,	O
patients	B-D010361
should	O
be	O
cautioned	O
about	O
engaging	O
in	O
activities	O
requiring	O
mental	B-D008571
alertness	O
and	O
motor	O
coordination,	O
such	O
as	O
driving	O
a	O
car	O

Indomethacin	B-D007213
may	O
also	O
cause	O
headache	B-D006261
	O

Headache	B-D006261
which	O
persists	O
despite	O
dosage	O
reduction	O
requires	O
cessation	O
of	O
therapy	O
with	O
indomethacin	B-D007213
	O

5.15	O
Ocular	O
Effects:	O
Corneal	B-D003315
deposits	B-C020884
and	O
retinal	B-D012160
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
who	O
had	O
received	O
prolonged	O
therapy	O
with	O
indomethacin	B-D007213
	O

The	O
prescribing	O
physician	O
should	O
be	O
alert	O
to	O
the	O
possible	O
association	B-D001244
between	O
the	O
changes	O
noted	O
and	O
indomethacin	B-D007213
	O

It	O
is	O
advisable	O
to	O
discontinue	O
therapy	O
if	O
such	O
changes	O
are	O
observed	O

Blurred	O
vision	O
may	O
be	O
a	O
significant	O
symptom	O
and	O
warrants	O
a	O
thorough	O
ophthalmological	O
examination	O

Since	O
these	O
changes	O
may	O
be	O
asymptomatic,	O
ophthalmologic	O
examination	O
at	O
periodic	O
intervals	O
is	O
desirable	O
in	O
patients	B-D010361
where	O
therapy	O
is	O
prolonged	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)]	O
Most	O
common	O
adverse	O
(incidence	O
≥	O
3%)	O
are	O
headache,	B-D006261
dizziness,	B-D004244
dyspepsia	B-D004415
and	O
nausea	B-D009325
	O

(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Heritage	O
Pharmaceuticals	O
Inc	O

at	O
1.866.901.DRUG	O
(3784)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O

In	O
a	O
gastroscopic	O
study	O
in	O
45	O
healthy	B-D006262
subjects,	O
the	O
number	O
of	O
gastric	B-D005753
mucosal	I-D005753
abnormalities	O
was	O
significantly	O
higher	O
in	O
the	O
group	O
receiving	O
indomethacin	B-D007213
capsules	B-D002214
than	O
in	O
the	O
group	O
taking	O
indomethacin	B-D007213
Suppositories	B-D013488
or	O
placebo	O

In	O
a	O
double-blind	O
comparative	O
clinical	B-D000068397
study	I-D000068397
involving	O
175	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis,	B-D001168
however,	O
the	O
incidence	B-D015994
of	O
upper	O
gastrointestinal	O
adverse	O
effects	O
with	O
indomethacin	B-D007213
Suppositories	B-D013488
or	O
Capsules	B-D002214
was	O
comparable	O

The	O
incidence	B-D015994
of	O
lower	O
gastrointestinal	O
adverse	O
effects	O
was	O
greater	O
in	O
the	O
suppository	O
group	O

The	O
adverse	O
reactions	O
for	O
indomethacin	B-D007213
capsules	B-D002214
listed	O
in	O
the	O
following	O
table	O
have	O
been	O
arranged	O
into	O
two	O
groups:	O
(1)	O
incidence	B-D015994
greater	O
than	O
1%;	O
and	O
(2)	O
incidence	B-D015994
less	O
than	O
1%	O

The	O
incidence	B-D015994
for	O
group	O
(1)	O
was	O
obtained	O
from	O
33	O
double-blind	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
reported	O
in	O
the	O
literature	B-D008091
(1,092	O
patients)	B-D010361
	O

The	O
incidence	B-D015994
for	O
group	O
(2)	O
was	O
based	O
on	O
reports	O
in	O
clinical	B-D016430
trials,	I-D016430
in	O
the	O
literature,	B-D008091
and	O
on	O
voluntary	O
reports	O
since	O
marketing	B-D040541
	O

The	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists	O
between	O
indomethacin	B-D007213
and	O
these	O
adverse	O
reactions,	O
some	O
of	O
which	O
have	O
been	O
reported	O
only	O
rarely	O

Table	O
1:	O
Summary	O
of	O
Adverse	O
reactions	O
for	O
Indomethacin	B-D007213
Capsules	B-D002214
Incidence	B-D015994
greater	O
than	O
1%	O
Incidence	B-D015994
less	O
than	O
1%	O
GASTROINTESTINAL	O
nausea*	B-D009325
with	O
or	O
without	O
vomiting	B-D014839
dyspepsia*	B-D004415
(including	O
indigestion,	O
heartburn	B-D006356
and	O
epigastric	O
pain)	B-D010146
diarrhea	B-D003967
abdominal	O
distress	O
or	O
pain	B-D010146
constipation	B-D003248
Anorexia	B-D000855
bloating	O
(includes	O
distension)	O
flatulence	B-D005414
peptic	B-D010437
ulcer	I-D010437
gastroenteritis	B-D005759
rectal	O
bleeding	O
proctitis	B-D011349
single	O
or	O
multiple	O
ulcerations,	B-D014456
including	O
perforation	O
and	O
hemorrhage	B-D006470
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
duodenum	B-D004386
or	O
small	O
and	O
large	O
intestines	B-D007422
intestinal	O
ulceration	B-D014456
associated	O
with	O
stenosis	O
and	O
obstruction	O
gastrointestinal	O
bleeding	O
without	O
obvious	O
ulcer	B-D014456
formation	B-D020478
and	O
perforation	O
of	O
pre-existing	O
sigmoid	O
lesions	O
(diverticulum,	O
carcinoma,	B-D002277
etc.)	O
development	O
of	O
ulcerative	B-D014456
colitis	B-D003092
and	O
regional	O
ileitis	B-D007079
ulcerative	B-D014456
stomatitis	B-D013280
toxic	O
hepatitis	B-D006506
and	I-D006506
jaundice	B-D007565
(some	O
fatal	O
cases	O
have	O
been	O
reported)	O
intestinal	O
strictures	O
(diaphragms)	O
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
headache	B-D006261
(11.7%)	O
dizziness*	B-D004244
vertigo	B-D014717
somnolence	O
depression	B-D003863
and	O
fatigue	B-D005221
(including	O
malaise	O
and	O
listlessness)	O
anxiety	B-D001007
(includes	O
nervousness)	O
muscle	B-D018908
weakness	I-D018908
involuntary	O
muscle	O
movements	B-D009068
insomnia	O
muzziness	O
psychic	O
disturbances	O
including	O
psychotic	O
episodes	O
mental	B-D008571
confusion	B-D003221
drowsiness	O
light-headedness	B-D008027
syncope	B-D013575
paresthesia	B-D010292
aggravation	O
of	O
epilepsy	B-D004827
and	O
parkinsonism	O
depersonalization	B-D003861
coma	B-D003128
peripheral	O
neuropathy	O
convulsion	O
dysarthria	B-D004401
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
ocular	O
—	O
corneal	B-D003315
deposits	B-C020884
and	O
retinal	B-D012160
disturbances,	O
including	O
those	O
of	O
the	O
macula,	O
have	O
been	O
reported	O
in	O
some	O
patients	B-D010361
on	O
prolonged	O
therapy	O
with	O
indomethacin	B-D007213
blurred	O
vision	O
diplopia	B-D004172
hearing	B-D006309
disturbances,	O
deafness	B-D003638
CARDIOVASCULAR	O
None	O
Hypertension	B-D006973
hypotension	B-D007022
tachycardia	B-D013610
chest	B-D002637
pain	I-D002637
congestive	O
heart	B-D006333
failure	I-D006333
arrhythmia;	O
palpitations	O
METABOLIC	O
none	O
Edema	B-D004487
weight	B-D015430
gain	I-D015430
fluid	O
retention	O
flushing	B-D005483
or	O
sweating	B-D013546
Hyperglycemia	B-D006943
glycosuria	B-D006029
hyperkalemia	B-D006947
INTEGUMENTARY	O
None	O
Pruritus	B-D011537
rash;	O
urticaria	B-D014581
petechiae	O
or	O
ecchymosis	B-D004438
exfoliative	O
dermatitis	B-D003872
erythema	B-D004893
nodosum	I-D004893
loss	O
of	O
hair	B-D006197
Stevens-Johnson	B-D013262
syndrome	I-D013262
erythema	B-D004892
multiforme	I-D004892
toxic	O
epidermal	O
necrolysis	O
HEMATOLOGIC	O
None	O
Leucopenia	O
bone	B-D001853
marrow	I-D001853
depression	B-D003863
anemia	B-D000740
secondary	O
to	O
obvious	O
or	O
occult	O
gastrointestinal	O
bleeding	O
aplastic	O
anemia	B-D000740
hemolytic	O
anemia	B-D000740
agranulocytosis	B-D000380
thrombocytopenic	O
purpura	B-D011693
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
HYPERSENSITIVITY	B-D006967
None	O
acute	O
anaphylaxis	B-D000707
acute	O
respiratory	O
distress	O
rapid	O
fall	O
in	O
blood	B-D001794
pressure	I-D001794
resembling	O
a	O
shock-like	B-D012769
state	O
angioedema	B-D000799
Dyspnea	B-D004417
asthma	B-D001249
purpura	B-D011693
angiitis	O
pulmonary	B-D011654
edema	I-D011654
fever	B-D005334
GENITOURINARY	O
None	O
Hematuria	B-D006417
vaginal	B-D014621
bleeding	O
proteinuria	B-D011507
nephrotic	B-D009404
syndrome	I-D009404
interstitial	O
nephritis	B-D009393
BUN	O
elevation	O
renal	B-D051437
insufficiency,	I-D051437
including	O
renal	O
failure	O
MISCELLANEOUS	O
None	O
Epistaxis	B-D004844
breast	B-D001940
changes,	O
including	O
enlargement	O
and	O
tenderness,	O
or	O
gynecomastia	B-D006177
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
indomethacin	B-D007213
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
Causal	O
relationship	O
unknown	O
:	O
Other	O
reactions	O
have	O
been	O
reported	O
but	O
occurred	O
under	O
circumstances	O
where	O
a	O
causal	O
relationship	O
could	O
not	O
be	O
established	O

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
the	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
observations	B-D019370
are	O
being	O
listed	O
to	O
serve	O
as	O
alerting	O
information	O
to	O
physicians:	B-D010820
Cardiovascular	O
:	O
Thrombophlebitis	B-D013924
Hematologic	O
:	O
Although	O
there	O
have	O
been	O
several	O
reports	O
of	O
leukemia,	B-D007938
the	O
supporting	O
information	O
is	O
weak	O

Genitourinary	O
:	O
Urinary	O
frequency	O

A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
fasciitis,	B-D005208
particularly	O
in	O
association	B-D001244
with	O
Group	O
Aß	O
hemolytic	O
streptococcus,	B-D013291
has	O
been	O
described	O
in	O
persons	B-D009272
treated	O
with	O
nonsteroidal	O
anti-inflammatory	B-D000893
agents,	I-D000893
including	O
indomethacin,	B-D007213
sometimes	O
with	O
fatal	B-D017809
outcome	I-D017809
	O

BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O
	O

Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O
	O

Gastrointestinal	O
Risk	B-D012306
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea*,	B-D009325
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
comstipation,	O
abdominal	O
cramps	O
or	O
pain,	B-D010146
fulness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence)	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatiis,	O
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEM	I-D002490
Dizziness*,	B-D004244
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
Confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS	O
)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudo-	O
tumor	O
cerebri	B-C079279
DERMATOLOGIC	O
Rash*,	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-Johnson	B-D013262
syndrome,	I-D013262
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSES	O
Tinnitus	B-D014012
Hearing	B-D034381
loss,	I-D034381
amblyopia	B-D000550
(blurred	O
and/or	O
diminished	O
vision,	O
scotomata	B-D012607
and	O
/or	O
changes	O
in	O
colour	O
vision)	O
(see	O
PRECAUTIONS	O
)	O
Conjuctivitis,	O
diplopia,optic	B-D004172
neuritis,	B-D009443
cataracts	B-D002386
HEMATOLOGIC	O
Neutropenia,	B-D009503
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS	O
)	O
Bleeding	O
episodes	O
(e.g.,	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINE	O
Decreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAR	O
Edema,	B-D004487
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS	O
)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,elevate	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,sinus	B-D013610
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATION	O
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythematous	B-D004890
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
poliuria,	O
azotemia,	B-D053099
cystitis,	B-D003556
hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitits	O
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patietnts	O
treated	O
with	O
ibuprofe.(Those	O
reactions	O
occuring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked)	O
**Reactions	O
are	O
classified	O
under	O
“	O
Probable	O
Causal	O
Relationship	O
(PCR)”if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
there	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related.Reactions	O
are	O
classified	O
under	O
“	O
Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
Cardiovascular	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
celecoxib,	B-D000068579
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O

(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
CardiovascularRisk	O
•	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,	O
14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
celecoxib,	B-D000068579
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke	B-D020521
	O

Patients	B-D010361
with	O
known	O
CV	O
disease/risk	B-D004194
factors	O
may	O
be	O
at	O
greater	O
risk	B-D012306
(5.1,	O
14.6,	O
17.2)	O

•	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
risk	B-D012306
is	O
greater	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
GI	O
bleeding,	O
and	O
in	O
patients	B-D010361
at	O
high	O
risk	B-D012306
for	O
GI	O
events,	O
especially	O
the	O
elderly	O

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	B-D010361
(5.4,	O
8.5,	O
14.6,	O
17.3)	O

•	O
Elevated	O
liver	B-D008099
enzymes	B-D004798
and,	O
rarely,	O
severe	O
hepatic	O
reactions	O

Discontinue	O
use	O
of	O
celecoxibimmediately	B-D000068579
if	O
abnormal	O
liver	B-D008099
enzymes	B-D004798
persist	O
or	O
worsen	O
(5.5,	O
17.4)	O

•	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
duringtreatment	O
with	O
celecoxib	B-D000068579
(5.2,	O
7.4,	O
17.2)	O

•	O
Fluid	O
retention	O
and	O
edema	B-D004487
	O

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retentionor	O
heart	B-D006333
failure	I-D006333
(5.3,	O
17.6)	O

•	O
Renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use	O

Use	O
celecoxib	B-D000068579
with	O
caution	O
inthe	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
and	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
or	O
angiotensin	B-D000804
II	I-D000804
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6)	O

•	O
Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O
(5.7,	O
10,	O
17.7)	O

•	O
Serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
evenwithout	O
known	O
prior	O
sulfa	O
allergy	O

Discontinue	O
celecoxib	B-D000068579
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	B-D012867
reactions	O
(5.8,	O
17.5)	O

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovasculardeath,	O
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
to	O
8.5)	O
for	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
to	O
7.2)	O
with	O
celecoxib	B-D000068579
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(14.6)]	O

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib,	B-D000068579
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/orsymptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
celecoxib	B-D000068579
does	O
increase	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O

Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)]	O

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	B-D000068579
can	O
lead	B-D007854
to	O
the	O
onset	O
of	O
new	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

NSAIDs,	O
including	O
celecoxib,	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	B-D000068579
and	O
throughout	O
the	O
course	O
of	O
therapy	O

The	O
rates	O
of	O
hypertension	B-D006973
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	B-D000068579
ibuprofen	B-D007052
and	O
diclofenac-treated	B-D004008
patients	B-D010361
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	B-D000078682
[see	O
Clinical	O
Studies	O
(14.6)]	O

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
taking	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
[see	O
Adverse	O
Reactions	O
(6.1)]	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulceration,	B-D014456
Bleeding,	O
and	O
PerforationNSAIDs,	O
including	O
celecoxib,	B-D000068579
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)]	O

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	B-D013995
during	O
the	O
course	O
of	O
therapy	O

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
with	O
neither	O
of	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population	B-D011153
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
duringcelecoxib	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

For	O
high-risk	O
patients,	B-D010361
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered	O

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	B-D008099
enzymes	B-D004798
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
with	O
NSAIDs	O

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	B-D007565
and	O
fatal	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis	B-D009336
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	B-D017809
outcome)	I-D017809
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
[see	O
Adverse	O
Reactions	O
(6.1)]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
celecoxib,	B-D000068579
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
celecoxib	B-D000068579
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	B-D008099
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	B-D008099
test	B-C004551
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib	B-D000068579
	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptomsconsistent	I-D012816
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
celecoxib	B-D000068579
should	O
be	O
discontinued	O

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
ofan	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liverdysfunction,	B-D008099
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
angiotensin	B-D000804
II	I-D000804
receptor	O
antagonists,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
trials	I-D016430
with	O
celecoxib	B-D000068579
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

Therefore,	O
treatment	O
with	O
celecoxib	B-D000068579
is	O
not	O
recommended	O
in	O
these	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

If	O
celecoxib	B-D000068579
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	B-D010361
without	O
known	O
prior	O
exposure	O
to	O
celecoxib	B-D000068579
	O

In	O
postmarketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	B-D000799
have	O
been	O
reported	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
	O

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),Warnings	O
and	O
Precautions	O
(5.7)]	O

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	B-D010361
without	O
prior	O
known	O
sulfa	O
allergy	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012877
manifestations	I-D012877
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	B-D011247
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	B-D000068579
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)]	O

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	B-D007854
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness	O

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
celecoxib	B-D000068579
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	B-D000068579
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	B-D000339
platelet	B-D010976
counts,	I-D010976
prothrombin	B-D011517
time	I-D011517
(PT),	O
or	O
partial	B-D010314
thromboplastin	I-D010314
time	I-D010314
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	B-D010974
aggregation	I-D010974
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)]	O

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
	O

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

The	O
use	O
of	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal	O

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	B-D001241
and	O
other	O
nonsteroidal	O
antiinflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
celecoxib	B-D000068579
should	O
not	O
be	O
administered	O
to	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

5.14	O
Laboratory	O
Tests	B-C004551
Because	O
serious	O
GI	O
tract	O
ulcerations	B-D014456
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	B-D010820
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
checked	O
periodically	B-D020492
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
or	O
renal	O
tests	B-C004551
persist	O
or	O
worsen,	O
celecoxib	B-D000068579
should	O
be	O
discontinued	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	B-D000068579
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	B-D010146
conditions	O

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	B-D000068579
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	B-D012306
of	O
adverse	O
reactions	O

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	B-D000068579
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	B-D000068579
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
celecoxib	B-D000068579
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reactioninformation	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sydon	O
Labs,	O
LLC	O
at	O
1	O
866-487-4695	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
>2%	O
of	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4,	O
146	O
Placebo	O
N=1,	O
864	O
NAP	O
N=1,	O
366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%	O
5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%	O
3.8%	O
6.2%	O
1%	O
4.2%	O
7.7%	O
5.3%	O
12.2%	O
3.6%	O
6%	O
9%	O
9.3%	O
10.9%	O
4.1%	O
3.4%	O
9%	O
5.8%	O
12.8%	O
3.5%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%	O
2.1%	O
2.9%	O
3.6%	O
1.1%	O
2.3%	O
2.2%	O
2.1%	O
3%	O
2.6%	O
1%	O
2.6%	O
0.9%	O
3.5%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
Headache	B-D006261
2%	O
15.8%	O
1.7%	O
20.2%	O
2.6%	O
14.5%	O
1.3%	O
15.5%	O
2.3%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
Rhinitis	B-D012220
Sinusitis	B-D012852
Upper	O
Respiratory	O
Infection	O
2.3%	O
2%	O
5%	O
8.1%	O
1.1%	O
1.3%	O
4.3%	O
6.7%	O
1.7%	O
2.4%	O
4%	O
9.9%	O
1.6%	O
2.3%	O
5.4%	O
9.8%	O
2.6%	O
0.6%	O
5.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	B-D000068579
treatmentgroups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	B-D000068579
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinineincreased,	B-D003404
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	B-D010361
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis,	B-D013924
vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis,	B-D002769
hepatitis,	B-D006505
jaundice,	B-D007565
liver	B-D017093
failure	I-D017093
Hemic	O
alymphatic:	O
Thrombocytopenia,	B-D013921
agranulocytosis,aplastic	B-D000380
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Ataxia,	B-D001259
suicide,	B-D013405
aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	B-D009393
Skin:	B-D012867
Erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
StevensJohnson	O
syndrome,	B-D013577
toxic	O
epidermal	O
necrolysis	O
General:	O
Sepsis,	B-D018805
sudden	O
death,	B-D003643
anaphylactoid	O
reaction,	O
angioedema	B-D000799
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
Hematological	O
Events	O
:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

Thelower	O
incidence	B-D015994
of	O
events	O
with	O
celecoxib	B-D000068579
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	B-D000068579
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
tobe	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

6.3	O
Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
BID,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
BID	O

The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
doubleblind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups.In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
>5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
ClassPreferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kgN=77	O
Celecoxib	B-D000068579
6	O
mg/kgN=82	O
Naproxen	B-D009288
7.5mg/kgN=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
36	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocritdecreased,	B-D006400
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600mg/day	O
of	O
celecoxib	B-D000068579
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
postdental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	B-D000068579
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.6)].Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
premarketing	B-C070504
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	B-D000068579
premarketing	B-C070504
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N=2,285	O
Placebo	O
N=1,303	O
Diarrhea	B-D003967
10.5%	O
7%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
>0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
celecoxib,	B-D000068579
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
CONTRAINDICATIONS	B-D000075202
AND	O
WARNINGS	O
DICLOFENAC	B-D004008
SODIUM	B-D012964
AND	O
MISOPROSTOL	B-D016595
DELAYED-RELEASE	O
TABLETS	B-D013607
CONTAIN	O
DICLOFENAC	B-D004008
SODIUM	B-D012964
AND	O
MISOPROSTOL	B-D016595
	O

ADMINISTRATION	O
OF	O
MISOPROSTOL	B-D016595
TO	O
WOMEN	B-D014930
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	B-D047928
BIRTH,	I-D047928
OR	O
BIRTH	O
DEFECTS	O

UTERINE	B-D014597
RUPTURE	I-D014597
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	B-D016595
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	B-D037841
WOMEN	I-D037841
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O
BEYOND	O
THE	O
EIGHTH	O
WEEK	O
OF	O
PREGNANCY	B-D011247
(see	O
also	O
PRECAUTIONS	O
)	O

DICLOFENAC	B-D004008
SODIUM	B-D012964
AND	O
MISOPROSTOL	B-D016595
DELAYED-RELEASE	O
TABLETS	B-D013607
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	B-D037841
WOMEN	I-D037841
(see	O
CONTRAINDICATIONS,	B-D000075202
WARNINGS	O
and	O
PRECAUTIONS	O
)	O

PATIENTS	B-D010361
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS	O

DICLOFENAC	B-D004008
SODIUM	B-D012964
AND	O
MISOPROSTOL	B-D016595
DELAYED-RELEASE	O
TABLETS	B-D013607
should	O
not	O
be	O
used	O
in	O
women	B-D014930
of	O
childbearing	B-D002648
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	B-D012306
of	O
developing	O
gastric	O
or	O
duodenal	B-D004381
ulceration	I-D004381
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	B-D004381
ulcers	I-D004381
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID	O
(see	O
WARNINGS	O
)	O

In	O
such	O
patients,	B-D010361
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
has	O
had	O
a	O
negative	O
serum	B-D044967
pregnancy	B-D011247
test	B-C004551
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy	O

is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	B-D016595
the	O
risk	B-D012306
of	O
possible	O
contraception	B-D003267
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	B-D014930
of	O
childbearing	B-D002648
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake	O

will	O
begin	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	B-D008571
period	O

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
(see	O
WARNINGS	O
)	O

Diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
are	O
contraindicated	O
for	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS	O
)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(see	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
Adverse	O
reactions	O
associated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
Adverse	O
reaction	O
information	O
for	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
are	O
derived	O
from	O
Phase	O
III	O
multinational	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
in	O
over	O
2,000	O
patients,	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets,	B-D013607
50/0.2	O
mg	O
or	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
75/0.2	O
mg	O
,	O
as	O
well	O
as	O
from	O
blinded,	O
controlled	O
trials	O
of	O
Voltaren®	O
Delayed-Release	O
Tablets(diclofenac)	B-D013607
and	O
Cytotec®	O
Tablets	B-D013607
(misoprostol)	O

Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
incidence	B-D015994
of	O
adverse	O
events	O
for	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
	O

These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
patients	B-D010361
on	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
and	O
5%	O
of	O
patients	B-D010361
on	O
diclofenac	B-D004008
	O

For	O
GI	O
ulcer	B-D014456
rates,	O
see	O
CLINICAL	O
STUDIES—Upper	O
gastrointestinal	O
safety	B-D012449
	O

GI	O
disorder	O
Diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
Diclofenac	B-D004008
Abdominal	B-D015746
pain	I-D015746
21%	O
15%	O
Diarrhea	B-D003967
19%	O
11%	O
Dyspepsia	B-D004415
14%	O
11%	O
Nausea	B-D009325
11%	O
6%	O
Flatulence	B-D005414
9%	O
4%	O
Diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
can	O
cause	O
more	O
abdominal	B-D015746
pain,	I-D015746
diarrhea	B-D003967
and	O
other	O
GI	O
symptoms	O
than	O
diclofenac	B-D004008
alone	O

Diarrhea	B-D003967
and	O
abdominal	B-D015746
pain	I-D015746
developed	O
early	B-D004423
in	O
the	O
course	O
of	O
therapy,	O
and	O
were	O
usually	O
self-limited	O
(resolved	O
after	O
2	O
to	O
7	O
days)	O

Rare	O
instances	O
of	O
profound	O
diarrhea	B-D003967
leading	B-D007854
to	O
severe	O
dehydration	B-D003681
have	O
been	O
reported	O
in	O
patients	B-D010361
receiving	O
misoprostol	B-D016595
	O

Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
disease,	B-D004194
or	O
those	O
in	O
whom	O
dehydration,	B-D003681
were	O
it	O
to	O
occur,	O
would	O
be	O
dangerous,	O
should	O
be	O
monitored	O
carefully	O
if	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
is	O
prescribed	O

The	O
incidence	B-D015994
of	O
diarrhea	B-D003967
can	O
be	O
minimized	O
by	O
administering	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
with	O
food	B-D005502
and	O
by	O
avoiding	O
coadministration	O
with	O
magnesium-containing	B-D008274
antacids	B-D000863
	O

Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
misoprostol	B-D016595
use	O
have	O
also	O
been	O
reported	O
for	O
women	B-D014930
receiving	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
(see	O
below)	O

Postmenopausal	O
vaginal	B-D014621
bleeding	O
may	O
be	O
related	O
to	O
administration	O
of	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
	O

If	O
it	O
occurs,	O
diagnostic	O
workup	B-D014937
should	O
be	O
undertaken	O
to	O
rule	O
out	O
gynecological	O
pathology	B-D010336
(see	O
boxed	O
CONTRAINDICATIONS	B-D000075202
AND	O
WARNINGS	O
)	O

Elderly	O
Overall,	B-D016424
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
safety	B-D012449
profile	B-C546490
of	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets	B-D013607
in	O
over	O
500	O
patients	B-D010361
65	O
years	O
of	O
age	O
or	O
older	O
compared	O
with	O
younger	O
patients	B-D010361
	O

Other	O
adverse	O
experiences	O
reported	O
occasionally	O
or	O
rarely	O
with	O
diclofenac	B-D004008
sodium	B-D012964
and	O
misoprostol	B-D016595
delayed-release	O
tablets,	B-D013607
diclofenac	B-D004008
or	O
other	O
NSAIDs,	O
or	O
misoprostol	B-D016595
are:	O
Body	O
as	O
a	O
whole:	O
Asthenia,	B-D001247
death,	B-D003643
fatigue,	B-D005221
fever,	B-D005334
infection,	O
malaise,	O
sepsis,	B-D018805
chills	B-D023341
	O

Cardiovascular	B-D002319
system:	I-D002319
Arrhythmia,	O
atrial	B-D001281
fibrillation,	I-D001281
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
hypotension,	B-D007022
increased	O
CPK,	O
increased	O
LDH,	O
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
phlebitis,	B-D010689
premature	B-C070504
ventricular	O
contractions,	O
syncope,	B-D013575
tachycardia,	B-D013610
vasculitis	B-D014657
	O

Central	O
and	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Coma,	B-D003128
convulsions,	O
dizziness,	B-D004244
drowsiness,	O
headache,	B-D006261
hyperesthesia,	B-D006941
hypertonia,	O
hypoesthesia,	O
insomnia,	O
meningitis,	B-D008581
migraine,	O
neuralgia,	B-D009437
paresthesia,	B-D010292
somnolence,	O
stroke,	B-D020521
tremor,	B-D014202
vertigo	B-D014717
	O

Digestive:	O
Anorexia,	B-D000855
appetite	B-D001066
changes,	O
constipation,	B-D003248
dry	O
mouth,	B-D009055
dysphagia,	O
enteritis,	B-D004751
esophageal	O
ulceration,	B-D014456
esophagitis,	B-D004941
eructation,	B-D004884
gastritis,	B-D005756
gastroesophageal	B-D005764
reflux,	I-D005764
GI	O
bleeding,	O
GI	O
neoplasm	O
benign,	O
glossitis,	B-D005928
heartburn,	B-D006356
hematemesis,	B-D006396
hemorrhoids,	B-D006484
intestinal	B-D007416
perforation,	I-D007416
peptic	B-D010437
ulcer,	I-D010437
stomatitis	B-D013280
and	O
ulcerative	B-D014456
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
	O

Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940
pain,	B-D010146
dysmenorrhea,	B-D004412
intermenstrual	O
bleeding,	O
leukorrhea,	B-D007973
menstrual	B-D008571
disorder,	O
menorrhagia,	B-D008595
vaginal	B-D014621
hemorrhage	B-D006470
	O

Hemic	O
and	O
lymphatic	B-D008208
system:	I-D008208
Agranulocytosis,	B-D000380
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
coagulation	O
time	B-D013995
increased,	O
ecchymosis,	B-D004438
eosinophilia,	B-D004802
epistaxis,	B-D004844
hemolytic	O
anemia,	B-D000740
leukocytosis,	B-D007964
leukopenia,	B-D007970
lymphadenopathy,	B-D000072281
melena,	B-D008551
pancytopenia,	B-D010198
pulmonary	B-D011655
embolism,	I-D011655
purpura,	B-D011693
rectal	O
bleeding,	O
thrombocythemia,	O
thrombocytopenia	B-D013921
	O

Hypersensitivity:	B-D006967
Angioedema,	B-D000799
laryngeal/pharyngeal	O
edema,	B-D004487
urticaria	B-D014581
	O

Liver	B-D008099
and	O
biliary	O
system:	O
Abnormal	O
hepatic	O
function,	O
bilirubinemia,	B-D001663
hepatitis,	B-D006505
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
pancreatitis	B-D010195
	O

Male	B-D008297
reproductive	O
disorders:	O
Impotence,	O
perineal	O
pain	B-D010146
	O

Metabolic	O
and	O
nutritional:	O
Alanine	B-D000409
aminotransferase	O
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
aspartate	O
aminotransferase	O
increased,	O
BUN	O
increased,	O
dehydration,	B-D003681
glycosuria,	B-D006029
gout,	B-D006073
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hyperuricemia,	B-D033461
hypoglycemia,	B-D007003
hyponatremia,	B-D007010
periorbital	O
edema,	B-D004487
porphyria,	O
weight	O
changes	O

Musculoskeletal	B-D009141
system:	I-D009141
Arthralgia,	B-D018771
myalgia	B-D063806
	O

Psychiatric:	O
Anxiety,	B-D001007
concentration	O
impaired,	O
confusion,	B-D003221
depression,	B-D003863
disorientation,	O
dream	O
abnormalities,	O
hallucinations,	B-D006212
irritability,	O
nervousness,	O
paranoia,	O
psychotic	O
reaction	O

Respiratory	B-D012137
system:	I-D012137
Asthma,	B-D001249
coughing,	B-D003371
dyspnea,	B-D004417
hyperventilation,	B-D006985
pneumonia,	B-D011014
respiratory	O
depression	B-D003863
Skin	B-D012867
and	O
appendages:	O
Acne,	O
alopecia,	B-D000505
bruising,	O
eczema,	B-D004485
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
pemphigoid	O
reaction,	O
photosensitivity,	O
pruritus,	B-D011537
pruritus	B-D011538
ani,	I-D011538
rash,	O
skin	B-D012883
ulceration,	I-D012883
Stevens-Johnson	B-D013262
syndrome,	I-D013262
sweating	B-D013546
increased,	O
toxic	O
epidermal	O
necrolysis	O

Special	O
senses:	O
Hearing	B-D006309
impairment,	O
taste	B-D013649
loss,	O
taste	B-D013649
perversion,	O
tinnitus	B-D014012
	O

Urinary	O
system:	O
Cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
micturition	O
frequency,	O
nocturia,	B-D053158
nephrotic	B-D009404
syndrome,	I-D009404
oliguria/polyuria,	B-D009846
papillary	O
necrosis,	B-D009336
proteinuria,	B-D011507
renal	O
failure,	O
urinary	B-D014551
tract	I-D014551
infection	O

Vision:	O
Amblyopia,	B-D000550
blurred	O
vision,	O
conjunctivitis,	B-D003231
diplopia,	B-D004172
glaucoma,	B-D005901
iritis,	B-D007500
lacrimation	O
abnormal,	O
night	B-D009755
blindness,	I-D009755
vision	O
abnormal	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Events	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(5.1)	O
Diclofenac	B-D004008
Sodium	B-D012964
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
NSAIDs,	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
]	O

Diclofenac	B-D004008
Sodium	B-D012964
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and	O
or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
sodium	B-D012964
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
diclofenac	B-D004008
sodium	B-D012964
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(5.11,	O
7)	O
Exposure	O
to	O
light:	B-D008027
Avoid	O
exposure	O
of	O
treated	O
knee(s)	B-D007717
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
	O

(5.14)	O
Eye	B-D005123
Contact:	O
Avoid	O
contact	O
of	O
diclofenac	B-D004008
sodium	B-D012964
with	O
eyes	B-D005123
and	O
mucosa	O

(5.15)	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	B-D004008
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
diclofenac	B-D004008
sodium	B-D012964
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2	O
%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
diclofenac	B-D004008
sodium	B-D012964
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.3	O
Hepatotoxicity	O
In	O
clinical	B-D016430
trials,	I-D016430
of	O
oral	O
diclofenac-containing	B-D004008
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
with	O
oral	O
diclofenac	B-D004008
for	O
2	O
to	O
6	O
months,	O
patients	B-D010361
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3	O
to	O
8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
tests	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

In	O
a	O
European	B-D005060
retrospective	O
population-based,	B-D011153
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	B-D004008
associated	O
drug-induced	O
liver	B-D008099
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	B-D004008
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	B-D016017
ratio	I-D016017
of	O
liver	B-D008099
injury	O

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	B-D016424
number	O
of	O
10	O
cases	O
of	O
liver	B-D008099
injury	O
associated	O
with	O
diclofenac,	B-D004008
the	O
adjusted	O
odds	B-D016017
ratio	I-D016017
increased	O
further	O
with	O
female	B-D005260
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
then	O
90	O
days	O

Physicians	B-D010820
should	O
measure	O
transaminases	B-D000637
at	O
baseline	O
and	O
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
transaminases	B-D000637
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
diclofenac	B-D004008
sodium	B-D012964
should	O
be	O
discontinued	O
immediately	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
diclofenac	B-D004008
sodium	B-D012964
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver-related	B-D008099
event	O
in	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium,	B-D012964
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Exercise	B-D015444
caution	O
when	O
prescribing	O
diclofenac	B-D004008
sodium	B-D012964
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	B-D000082
antibiotics,	O
antiepileptics)	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension,	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotension	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
closely	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
diclofenac	B-D004008
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
diclofenac	B-D004008
sodium	B-D012964
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
diclofenac	B-D004008
sodium	B-D012964
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Avoid	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
diclofenac	B-D004008
sodium	B-D012964
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
diclofenac	B-D004008
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
(see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
diclofenac	B-D004008
sodium	B-D012964
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

When	O
diclofenac	B-D004008
sodium	B-D012964
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Diclofenac	B-D004008
sodium	B-D012964
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Do	O
not	O
apply	O
diclofenac	B-D004008
sodium	B-D012964
to	O
open	O
skin	B-D012867
wounds,	O
infections,	B-D007239
inflammations,	B-D007249
or	O
exfoliative	O
dermatitis,	B-D003872
as	O
it	O
may	O
affect	B-D000339
absorption	B-D000042
and	O
tolerability	O
of	O
the	O
drug	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium,	B-D012964
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
diclofenac	B-D004008
sodium,	B-D012964
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

The	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
healthy	B-D006262
subjects	O
administered	O
80	O
drops	O
four	O
times	B-D013995
a	O
day	O
for	O
7	O
days	O

There	O
was	O
no	O
significant	O
change	O
in	O
platelet	B-D010974
aggregation	I-D010974
following	O
one	O
week	O
of	O
treatment	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
diclofenac	B-D004008
sodium	B-D012964
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)]	O

5.14	O
Sun	O
Exposure	O
Instruct	O
patients	B-D010361
to	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
on	O
treated	O
knee(s)	B-D007717
because	O
studies	O
in	O
animals	B-D000818
indicated	O
topical	O
diclofenac	B-D004008
treatment	O
resulted	O
in	O
an	O
earlier	B-D004423
onset	O
of	O
ultraviolet	O
light-induced	B-D008027
skin	B-D012867
tumors	O

The	O
potential	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
on	O
skin	B-D012867
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	B-D006801
are	O
not	O
known	O

5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
diclofenac	B-D004008
sodium	B-D012964
with	O
eyes	B-D005123
and	O
mucosa	O

Advise	O
patients	B-D010361
that	O
if	O
eye	B-D005123
contact	O
occurs,	O
immediately	O
wash	O
out	O
the	O
eye	B-D005123
with	O
water	B-D014867
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour	O

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
diclofenac	B-D004008
sodium	B-D012964
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage,	B-D006470
more	O
frequent	O
abnormal	O
creatinine,	B-D003404
urea	B-D014508
and	O
hemoglobin	O

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
risk	B-D012306
and	O
conduct	O
periodic	O
laboratory	O
evaluations	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
The	O
most	O
common	O
adverse	O
reactions	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
are	O
application	O
site	O
reactions	O

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Taro	O
Pharmaceuticals	O
U.S.A.,	O
Inc	O

at	O
1-866-923-4914	O
or	O
the	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
of	O
911	O
patients	B-D010361
treated	O
between	O
4	O
and	O
12	O
weeks	O
(mean	O
duration	O
of	O
49	O
days)	O
in	O
seven	O
Phase	O
3	O
controlled	O
trials,	O
as	O
well	O
as	O
exposure	O
of	O
793	O
patients	B-D010361
treated	O
in	O
an	O
open-label	O
study,	O
including	O
463	O
patients	B-D010361
treated	O
for	O
at	O
least	O
6	O
months,	O
and	O
144	O
patients	B-D010361
treated	O
for	O
at	O
least	O
12	O
months	O

The	O
population	B-D011153
mean	O
age	O
was	O
approximately	O
60	O
years,	O
89%	O
of	O
patients	B-D010361
were	O
Caucasians,	O
64%	O
were	O
females,	B-D005260
and	O
all	O
patients	B-D010361
had	O
primary	O
osteoarthritis	B-D010003
	O

The	O
most	O
common	O
adverse	O
events	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
were	O
application	O
site	O
skin	B-D012867
reactions	O

Application	O
site	O
reactions	O
were	O
characterized	B-D002605
by	O
one	O
or	O
more	O
of	O
the	O
following:	O
dryness,	O
erythema,	B-D004890
induration,	O
vesicles,	O
paresthesia,	B-D010292
pruritus,	B-D011537
vasodilation,	B-D014664
acne,	O
and	O
urticaria	B-D014581
	O

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
skin	B-D012867
(32%),	O
contact	O
dermatitis	B-D003872
characterized	B-D002605
by	O
skin	B-D012867
erythema	B-D004890
and	O
induration	O
(9%),	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
(2%)	O
and	O
pruritus	B-D011537
(4%)	O

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
(4%)	O
was	O
observed	O
after	O
treatment	O
of	O
152	O
subjects	O
with	O
the	O
combination	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
oral	O
diclofenac	B-D004008
	O

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
safety	B-D012449
study,	O
contact	O
dermatitis	B-D003872
occurred	O
in	O
13%	O
and	O
contact	O
dermatitis	B-D003872
with	O
vesicles	O
in	O
10%	O
of	O
patients,	B-D010361
generally	O
within	O
the	O
first	O
6	O
months	O
of	O
exposure,	O
leading	B-D007854
to	O
a	O
withdrawal	O
rate	O
for	O
an	O
application	O
site	O
event	O
of	O
14%	O

Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
diarrhea,	B-D003967
dyspepsia,	B-D004415
nausea,	B-D009325
flatulence,	B-D005414
abdominal	B-D015746
pain,	I-D015746
edema;	B-D004487
see	O
Table	O
1	O
)	O

The	O
combination	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
and	O
oral	O
diclofenac,	B-D004008
compared	O
to	O
oral	O
diclofenac	B-D004008
alone,	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
hemorrhage	B-D006470
(3%	O
vs	O

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
creatinine	B-D003404
(12%	O
vs	O

7%),	O
urea	B-D014508
(20%	O
vs	O

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
liver	B-D008099
transaminases	B-D000637
	O

Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution,	O
where	O
the	O
rate	O
in	O
the	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O
group	O
exceeded	O
placebo,	O
from	O
seven	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
	O

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
patients	B-D010361
treated	O
with	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Solution	O
in	O
placebo	O
and	O
oral	O
diclofenac-controlled	B-D004008
trials	O

Treatment	O
Group:	O
Diclofenac	B-D004008
SodiumTopical	B-D012964
SolutionN=911	O
Topical	O
PlaceboN=332	O
Adverse	O
ReactionPreferred	O
Term	O
according	O
to	O
COSTART	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis,	B-D003872
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
solution	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

Body	O
as	O
a	O
Whole:	O
abdominal	B-D015746
pain,	I-D015746
accidental	O
injury,	O
allergic	O
reaction,	O
asthenia,	B-D001247
back	B-D001416
pain,	I-D001416
body	O
odor,	O
chest	B-D002637
pain,	I-D002637
edema,	B-D004487
face	B-D005145
edema,	B-D004487
halitosis,	B-D006209
headache,	B-D006261
lack	O
of	O
drug	O
effect,	O
neck	B-D009333
rigidity,	O
pain	B-D010146
Cardiovascular:	O
palpitation,	O
cardiovascular	O
disorder	O
Digestive:	O
diarrhea,	B-D003967
dry	O
mouth,	B-D009055
dyspepsia,	B-D004415
gastroenteritis,	B-D005759
decreased	O
appetite,	B-D001066
mouth	B-D009055
ulceration,	B-D014456
nausea,	B-D009325
rectal	O
hemorrhage,	B-D006470
ulcerative	B-D014456
stomatitis	B-D013280
Metabolic	O
and	O
Nutritional:	O
creatinine	B-D003404
increased	O
Musculoskeletal:	O
leg	B-D007866
cramps,	O
myalgia	B-D063806
Nervous:	O
depression,	B-D003863
dizziness,	B-D004244
drowsiness,	O
lethargy,	B-D053609
paresthesia,	B-D010292
paresthesia	B-D010292
at	O
application	O
site	O
Respiratory:	O
asthma,	B-D001249
dyspnea,	B-D004417
laryngismus,	B-D007826
laryngitis,	B-D007827
pharyngitis	B-D010612
Skin	B-D012867
and	O
Appendages:	O
At	O
the	O
Application	O
Site:	O
contact	O
dermatitis,	B-D003877
contact	I-D003877
dermatitis	B-D003872
with	O
vesicles,	O
dry	O
skin,	B-D012867
pruritus,	B-D011537
rash;	O
Other	O
Skin	B-D012867
and	O
Appendages	O
Adverse	O
Reactions:	O
eczema,	B-D004485
rash,	O
pruritus,	B-D011537
skin	B-D012867
discoloration,	O
urticaria	B-D014581
Special	O
Senses:	O
abnormal	O
vision,	O
blurred	O
vision,	O
cataract,	B-D002386
ear	B-D004423
pain,	B-D010146
eye	B-D005123
disorder,	O
eye	B-D058447
pain,	I-D058447
taste	B-D013649
perversion	O
Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(See	O
WARNINGS.)	O
Diclofenac	B-D004008
sodium	B-D012964
extended-release	O
tablets,	B-D013607
USP	O
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(See	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
sodium	B-D012964
extended-release	O
tablets,	B-D013607
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O

Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
adverse	O
reactions	O
are	O
drowsiness	O
and	O
dizziness	B-D004244
	O

Less	O
frequent	O
adverse	O
reactions	O
are	O
lightheadedness	B-D008027
and	O
gastrointestinal	O
disturbances	O
including	O
nausea,	B-D009325
vomiting,	B-D014839
and	O
flatulence	B-D005414
	O

A	O
single	O
incidence	B-D015994
of	O
bone	B-D001853
marrow	I-D001853
suppression	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
butalbital,	B-C004470
aspirin,	B-D001241
and	O
caffeine	B-D002110
capsules	B-D002214
	O

Several	O
cases	O
of	O
dermatological	O
reactions	O
including	O
toxic	O
epidermal	O
necrolysis	O
and	O
erythema	B-D004892
multiforme	I-D004892
have	O
been	O
reported	O

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
capsulesincreases	B-D002214
the	O
risk	B-D012306
of	O
bleeding	O
(5.1)	O
Avoid	O
use	O
in	O
patients	B-D010361
with	O
severe	O
hepatic	O
or	O
renal	B-D051437
insufficiency	I-D051437
(5.2,	O
5.3)	O
Can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman,	O
especially	O
in	O
the	O
third	O
trimester	O
(5.4)	O
5.1	O
Risk	B-D012306
of	O
Bleeding	O
Aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
increases	O
the	O
risk	B-D012306
of	O
bleeding	O

Risk	B-D012307
factors	I-D012307
for	O
bleeding	O
include	O
the	O
use	O
of	O
other	O
drugs	O
that	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
(e.g.,	O
anticoagulants,	B-D000925
antiplatelet	O
agents,	O
heparin,	B-D006493
anagrelide,	B-C021139
fibrinolytic	B-D005337
therapy	O
and	O
chronic	O
use	O
of	O
NSAIDs)	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
	O

Intracranial	O
Hemorrhage	B-D006470
In	O
European	B-D005060
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2),	O
the	O
incidence	B-D015994
of	O
intracranial	O
hemorrhage	B-D006470
was	O
0.6%	O
in	O
the	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
group,	O
0.5%	O
in	O
the	O
extended-release	O
dipyridamole	B-D004176
(ER-DP)	O
group,	O
0.4%	O
in	O
the	O
aspirin	B-D001241
(ASA)	O
group	O
and	O
0.4%	O
in	O
the	O
placebo	O
groups	O

Gastrointestinal	O
(GI)	O
Side	O
Effects	O
GI	O
side	O
effects	O
include	O
stomach	B-D013270
pain,	B-D010146
heartburn,	B-D006356
nausea,	B-D009325
vomiting	B-D014839
and	O
gross	O
GI	O
bleeding	O

Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
dyspepsia,	B-D004415
are	O
common	O
and	O
can	O
occur	O
anytime	O
during	O
therapy,	O
physicians	B-D010820
should	O
remain	O
alert	O
for	O
signs	O
of	O
ulceration	B-D014456
and	O
bleeding,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
GI	O
symptoms	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
side	O
effects	O
and	O
what	O
steps	O
to	O
take	O
if	O
they	O
occur	O

In	O
ESPS2,	O
the	O
incidence	B-D015994
of	O
gastrointestinal	O
bleeding	O
was	O
4.1%	O
in	O
the	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
group,	O
2.2%	O
in	O
the	O
extended-release	O
dipyridamole	B-D004176
group,	O
3.2%	O
in	O
the	O
aspirin	B-D001241
group	O
and	O
2.1%	O
in	O
the	O
placebo	O
groups	O

Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Avoid	O
using	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
a	O
history	B-D006664
of	O
active	O
peptic	B-D010437
ulcer	I-D010437
disease,	B-D004194
which	O
can	O
cause	O
gastric	B-D005753
mucosal	I-D005753
irritation	O
and	O
bleeding	O

Alcohol	O
Warning	O
Because	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
capsules	B-D002214
contain	O
aspirin,	B-D001241
counsel	O
patients	B-D010361
who	O
consume	O
three	O
or	O
more	O
alcoholic	O
drinks	O
every	O
day	O
about	O
the	O
bleeding	O
risks	B-D012306
involved	O
with	O
chronic,	O
heavy	O
alcohol	O
use	O
while	O
taking	O
aspirin	B-D001241
	O

5.2	O
Renal	O
Failure	O
Avoid	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
severe	O
renal	O
failure	O
(glomerular	O
filtration	B-D005374
rate	O
less	O
than	O
10	O
mL/minute)	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.6)	O
and	O
Clinical	O
Pharmacology	B-D010600
(12.3)]	O
	O

5.3	O
Hepatic	B-D048550
Insufficiency	I-D048550
Elevations	O
of	O
hepatic	O
enzymes	B-D004798
and	O
hepatic	O
failure	O
have	O
been	O
reported	O
in	O
association	B-D001244
with	O
dipyridamole	B-D004176
administration	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.6)	O
and	O
Clinical	O
Pharmacology	B-D010600
(12.3)]	O
	O

5.4	O
Pregnancy	B-D011247
Because	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
capsules	B-D002214
contain	O
aspirin,	B-D001241
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
capsules	B-D002214
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O

Maternal	O
aspirin	B-D001241
use	O
during	O
later	O
stages	O
of	O
pregnancy	B-D011247
may	O
cause	O
low	O
birth	B-D001724
weight,	I-D001724
increased	O
incidence	B-D015994
for	O
intracranial	O
hemorrhage	B-D006470
in	O
premature	B-C070504
infants,	B-D007223
stillbirths	B-D050497
and	O
neonatal	B-D009356
death	B-D003643
	O

Because	O
of	O
the	O
above	O
and	O
because	O
of	O
the	O
known	O
effects	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
on	O
the	O
fetal	O
cardiovascular	B-D002319
system	I-D002319
(closure	O
of	O
the	O
ductus	B-D004373
arteriosus),	I-D004373
avoid	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
in	O
the	O
third	O
trimester	O
of	O
pregnancy	B-D011247
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)]	O
	O

Aspirin	B-D001241
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
rats	B-D051381
(spina	O
bifida,	O
exencephaly,	O
microphthalmia	O
and	O
coelosomia)	O
and	O
rabbits	B-D011817
(congested	O
fetuses,	B-D005333
agenesis	O
of	O
skull	B-D012886
and	O
upper	O
jaw,	B-D007568
generalized	O
edema	B-D004487
with	O
malformation	O
of	O
the	O
head	B-D006257
and	O
diaphanous	O
skin)	B-D012867
at	O
oral	O
doses	O
of	O
330	O
mg/kg/day	O
and	O
110	O
mg/kg/day,	O
respectively	B-D000078682
	O

These	O
doses,	O
which	O
also	O
resulted	O
in	O
a	O
high	O
resorption	O
rate	O
in	O
rats	B-D051381
(63%	O
of	O
implantations	O
versus	O
5%	O
in	O
controls),	O
are,	O
on	O
a	O
mg/m	O
2	O
basis,	O
about	O
66	O
and	O
44	O
times,	B-D013995
respectively,	B-D000078682
the	O
dose	O
of	O
aspirin	B-D001241
contained	O
in	O
the	O
maximum	O
recommended	O
daily	O
human	O
dose	O
of	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
	O

Reproduction	B-D012098
studies	O
with	O
dipyridamole	B-D004176
have	O
been	O
performed	O
in	O
mice,	B-D051379
rabbits	B-D011817
and	O
rats	B-D051381
at	O
oral	O
doses	O
of	O
up	O
to	O
125	O
mg/kg,	O
40	O
mg/kg	O
and	O
1,000	O
mg/kg,	O
respectively	B-D000078682
(about	O
1½,	O
2	O
and	O
25	O
times	B-D013995
the	O
maximum	O
recommended	O
daily	O
human	O
oral	O
dose,	O
respectively,	B-D000078682
on	O
a	O
mg/m	O
2	O
basis)	O
and	O
have	O
revealed	O
no	O
evidence	O
of	O
harm	O
to	O
the	O
fetus	B-D005333
due	O
to	O
dipyridamole	B-D004176
	O

When	O
330	O
mg	O
aspirin/kg/day	B-D001241
was	O
combined	O
with	O
75	O
mg	O
dipyridamole/kg/day	B-D004176
in	O
the	O
rat,	O
the	O
resorption	O
rate	O
approached	O
100%,	O
indicating	O
potentiation	O
of	O
aspirin-related	B-D001241
fetal	O
toxicity	O

There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
of	O
the	O
use	O
of	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
in	O
pregnant	B-D037841
women	I-D037841
	O

If	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
is	O
used	O
during	O
pregnancy,	B-D011247
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole,	B-D004176
inform	O
the	O
patient	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	B-D005333
	O

5.5	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324
Dipyridamole	B-D004176
has	O
a	O
vasodilatory	O
effect	O

Chest	B-D002637
pain	I-D002637
may	O
be	O
precipitated	O
or	O
aggravated	O
in	O
patients	B-D010361
with	O
underlying	O
coronary	B-D003324
artery	I-D003324
disease	I-D003324
who	O
are	O
receiving	O
dipyridamole	B-D004176
	O

For	O
stroke	B-D020521
or	O
TIA	O
patients	B-D010361
for	O
whom	O
aspirin	B-D001241
is	O
indicated	O
to	O
prevent	O
recurrent	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
or	O
angina	B-D000787
pectoris,	I-D000787
the	O
aspirin	B-D001241
in	O
this	O
product	O
may	O
not	O
provide	O
adequate	O
treatment	O
for	O
the	O
cardiac	B-D002299
indications	O

5.6	O
Hypotension	B-D007022
Dipyridamole	B-D004176
produces	O
peripheral	O
vasodilation,	B-D014664
which	O
can	O
exacerbate	O
pre-existing	O
hypotension	B-D007022
	O

5.7	O
General	O
Aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
capsules	B-D002214
are	O
not	O
interchangeable	O
with	O
the	O
individual	O
components	O
of	O
aspirin	B-D001241
and	O
dipyridamole	B-D004176
tablets	B-D013607
	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Hypersensitivity	B-D006967
[see	O
Contraindications	B-D000075202
(4.1)]	O
Allergy	O
[see	O
Contraindications	B-D000075202
(4.2)]	O
Risk	B-D012306
of	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(>10%	O
and	O
greater	O
than	O
placebo)	O
were	O
headache,	B-D006261
dyspepsia,	B-D004415
abdominal	B-D015746
pain,	I-D015746
nausea	B-D009325
and	O
diarrhea	B-D003967
(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
AvKARE	O
at	O
1-855-361-3993	O
or	O
www.avkare.com	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
efficacy	O
and	O
safety	B-D012449
of	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
was	O
established	O
in	O
the	O
European	B-D005060
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2)	O

ESPS2	O
was	O
a	O
double-blind,	O
placebo-controlled	O
study	O
that	O
evaluated	O
6,602	O
patients	B-D010361
over	O
the	O
age	O
of	O
18	O
years	O
who	O
had	O
a	O
previous	O
ischemic	O
stroke	B-D020521
or	O
transient	O
ischemic	O
attack	O
within	O
ninety	O
days	O
prior	O
to	O
entry	O

Patients	B-D010361
were	O
randomized	O
to	O
either	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole,	B-D004176
aspirin,	B-D001241
ER-DP,	O
or	O
placebo	O
[see	O
Clinical	O
Studies	O
(14)]	O
;	O
primary	O
endpoints	O
included	O
stroke	B-D020521
(fatal	O
or	O
nonfatal)	O
and	O
death	B-D003643
from	O
all	O
causes	O

This	O
24-month,	O
multicenter,	O
double-blind,	O
randomized	O
study	O
(ESPS2)	O
was	O
conducted	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	B-D012449
of	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
with	O
placebo,	O
extended-release	O
dipyridamole	B-D004176
alone	O
and	O
aspirin	B-D001241
alone	O

The	O
study	O
was	O
conducted	O
in	O
a	O
total	O
of	O
6,602	O
male	B-D008297
and	O
female	B-D005260
patients	B-D010361
who	O
had	O
experienced	O
a	O
previous	O
ischemic	O
stroke	B-D020521
or	O
transient	O
ischemia	B-D007511
of	O
the	O
brain	B-D001921
within	O
three	O
months	O
prior	O
to	O
randomization	O

Table	O
1	O
presents	O
the	O
incidence	B-D015994
of	O
adverse	O
events	O
that	O
occurred	O
in	O
1%	O
or	O
more	O
of	O
patients	B-D010361
treated	O
with	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
where	O
the	O
incidence	B-D015994
was	O
also	O
greater	O
than	O
in	O
those	O
patients	B-D010361
treated	O
with	O
placebo	O

There	O
is	O
no	O
clear	O
benefit	O
of	O
the	O
dipyridamole/aspirin	B-D004176
combination	O
over	O
aspirin	B-D001241
with	O
respect	B-D000078682
to	O
safety	B-D012449
	O

Table	O
1	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
in	O
ESPS2	O
a	O
Individual	O
Treatment	O
Group	O
Aspirin	B-D001241
and	O
Extended-release	O
Dipyridamole	B-D004176
ER-DP	O
Alone	O
ASA	O
Alone	O
Placebo	O
Body	O
System/Preferred	O
Term	O
1,650	O
1,654	O
1,649	O
1,649	O
Total	O
Number	O
of	O
Patients	B-D010361
Total	O
Number	O
(%)	O
of	O
Patients	B-D010361
With	O
at	O
Least	O
One	O
On-Treatment	O
Adverse	O
Event	O
1,319	O
(80%)	O
1,305	O
(79%)	O
1,323	O
(80%)	O
1,304	O
(79%)	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Disorders	O
Headache	B-D006261
647	O
(39%)	O
634	O
(38%)	O
558	O
(34%)	O
543	O
(33%)	O
Convulsions	O
28	O
(2%)	O
15	O
(1%)	O
28	O
(2%)	O
26	O
(2%)	O
Gastrointestinal	O
System	O
Disorders	O
Dyspepsia	B-D004415
303	O
(18%)	O
288	O
(17%)	O
299	O
(18%)	O
275	O
(17%)	O
Abdominal	B-D015746
Pain	I-D015746
289	O
(18%)	O
255	O
(15%)	O
262	O
(16%)	O
239	O
(14%)	O
Nausea	B-D009325
264	O
(16%)	O
254	O
(15%)	O
210	O
(13%)	O
232	O
(14%)	O
Diarrhea	B-D003967
210	O
(13%)	O
257	O
(16%)	O
112	O
(7%)	O
161	O
(10%)	O
Vomiting	B-D014839
138	O
(8%)	O
129	O
(8%)	O
101	O
(6%)	O
118	O
(7%)	O
Hemorrhage	B-D006470
Rectum	B-D012007
26	O
(2%)	O
22	O
(1%)	O
16	O
(1%)	O
13	O
(1%)	O
Melena	B-D008551
31	O
(2%)	O
10	O
(1%)	O
20	O
(1%)	O
13	O
(1%)	O
Hemorrhoids	B-D006484
16	O
(1%)	O
13	O
(1%)	O
10	O
(1%)	O
10	O
(1%)	O
GI	O
Hemorrhage	B-D006470
20	O
(1%)	O
5	O
(0%)	O
15	O
(1%)	O
7	O
(0%)	O
Body	O
as	O
a	O
Whole	O
-	O
General	O
Disorders	O
Pain	B-D010146
105	O
(6%)	O
88	O
(5%)	O
103	O
(6%)	O
99	O
(6%)	O
Fatigue	B-D005221
95	O
(6%)	O
93	O
(6%)	O
97	O
(6%)	O
90	O
(5%)	O
Back	B-D001416
Pain	I-D001416
76	O
(5%)	O
77	O
(5%)	O
74	O
(4%)	O
65	O
(4%)	O
Accidental	O
Injury	O
42	O
(3%)	O
24	O
(1%)	O
51	O
(3%)	O
37	O
(2%)	O
Malaise	O
27	O
(2%)	O
23	O
(1%)	O
26	O
(2%)	O
22	O
(1%)	O
Asthenia	B-D001247
29	O
(2%)	O
19	O
(1%)	O
17	O
(1%)	O
18	O
(1%)	O
Syncope	B-D013575
17	O
(1%)	O
13	O
(1%)	O
16	O
(1%)	O
8	O
(0%)	O
Psychiatric	O
Disorders	O
Amnesia	B-D000647
39	O
(2%)	O
40	O
(2%)	O
57	O
(3%)	O
34	O
(2%)	O
Confusion	B-D003221
18	O
(1%)	O
9	O
(1%)	O
22	O
(1%)	O
15	O
(1%)	O
Anorexia	B-D000855
19	O
(1%)	O
17	O
(1%)	O
10	O
(1%)	O
15	O
(1%)	O
Somnolence	O
20	O
(1%)	O
13	O
(1%)	O
18	O
(1%)	O
9	O
(1%)	O
Musculoskeletal	B-D009141
System	I-D009141
Disorders	O
Arthralgia	B-D018771
91	O
(6%)	O
75	O
(5%)	O
91	O
(6%)	O
76	O
(5%)	O
Arthritis	B-D001168
34	O
(2%)	O
25	O
(2%)	O
17	O
(1%)	O
19	O
(1%)	O
Arthrosis	B-D001154
18	O
(1%)	O
22	O
(1%)	O
13	O
(1%)	O
14	O
(1%)	O
Myalgia	B-D063806
20	O
(1%)	O
16	O
(1%)	O
11	O
(1%)	O
11	O
(1%)	O
Respiratory	B-D012137
System	I-D012137
Disorders	O
Coughing	B-D003371
25	O
(2%)	O
18	O
(1%)	O
32	O
(2%)	O
21	O
(1%)	O
Upper	O
Respiratory	O
Tract	O
Infection	O
16	O
(1%)	O
9	O
(1%)	O
16	O
(1%)	O
14	O
(1%)	O
Cardiovascular	O
Disorders,	O
General	O
Cardiac	B-D002299
Failure	O
26	O
(2%)	O
17	O
(1%)	O
30	O
(2%)	O
25	O
(2%)	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
Hemorrhage	B-D006470
NOS	O
52	O
(3%)	O
24	O
(1%)	O
46	O
(3%)	O
24	O
(1%)	O
Epistaxis	B-D004844
39	O
(2%)	O
16	O
(1%)	O
45	O
(3%)	O
25	O
(2%)	O
Purpura	B-D011693
23	O
(1%)	O
8	O
(0%)	O
9	O
(1%)	O
7	O
(0%)	O
Neoplasm	O
Neoplasm	O
NOS	O
28	O
(2%)	O
16	O
(1%)	O
23	O
(1%)	O
20	O
(1%)	O
Red	O
Blood	B-D001769
Cell	O
Disorders	O
Anemia	B-D000740
27	O
(2%)	O
16	O
(1%)	O
19	O
(1%)	O
9	O
(1%)	O
a	O
Reported	O
by	O
≥1%	O
of	O
patients	B-D010361
during	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
treatment	O
where	O
the	O
incidence	B-D015994
was	O
greater	O
than	O
in	O
those	O
treated	O
with	O
placebo	O

Note:	O
ER-DP	O
=	O
extended-release	O
dipyridamole	B-D004176
200	O
mg;	O
ASA	O
=	O
aspirin	B-D001241
25	O
mg	O

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O

NOS	O
=	O
not	O
otherwise	O
specified	O

Discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
ESPS2	O
was	O
25%	O
for	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole,	B-D004176
25%	O
for	O
extended-release	O
dipyridamole,	B-D004176
19%	O
for	O
aspirin	B-D001241
and	O
21%	O
for	O
placebo	O
(refer	O
to	O
Table	O
2)	O

Table	O
2	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
that	O
Led	O
to	O
the	O
Discontinuation	O
of	O
Treatment:	O
Adverse	O
Events	O
with	O
an	O
Incidence	B-D015994
of	O
≥1%	O
in	O
the	O
Aspirin	B-D001241
and	O
Extended-release	O
Dipyridamole	B-D004176
Group	O
Treatment	O
Groups	O
Aspirin	B-D001241
and	O
Extended-release	O
Dipyridamole	B-D004176
ER-DP	O
ASA	O
Placebo	O
Total	O
Number	O
of	O
Patients	B-D010361
1,650	O
1,654	O
1,649	O
1,649	O
Patients	B-D010361
with	O
at	O
least	O
one	O
Adverse	O
Event	O
that	O
led	O
to	O
treatment	O
discontinuation	O
417	O
(25%)	O
419	O
(25%)	O
318	O
(19%)	O
352	O
(21%)	O
Headache	B-D006261
165	O
(10%)	O
166	O
(10%)	O
57	O
(3%)	O
69	O
(4%)	O
Dizziness	B-D004244
85	O
(5%)	O
97	O
(6%)	O
69	O
(4%)	O
68	O
(4%)	O
Nausea	B-D009325
91	O
(6%)	O
95	O
(6%)	O
51	O
(3%)	O
53	O
(3%)	O
Abdominal	B-D015746
Pain	I-D015746
74	O
(4%)	O
64	O
(4%)	O
56	O
(3%)	O
52	O
(3%)	O
Dyspepsia	B-D004415
59	O
(4%)	O
61	O
(4%)	O
49	O
(3%)	O
46	O
(3%)	O
Vomiting	B-D014839
53	O
(3%)	O
52	O
(3%)	O
28	O
(2%)	O
24	O
(1%)	O
Diarrhea	B-D003967
35	O
(2%)	O
41	O
(2%)	O
9	O
(<1%)	O
16	O
(<1%)	O
Stroke	B-D020521
39	O
(2%)	O
48	O
(3%)	O
57	O
(3%)	O
73	O
(4%)	O
Transient	O
Ischemic	O
Attack	O
35	O
(2%)	O
40	O
(2%)	O
26	O
(2%)	O
48	O
(3%)	O
Angina	B-D000787
Pectoris	I-D000787
23	O
(1%)	O
20	O
(1%)	O
16	O
(<1%)	O
26	O
(2%)	O
Note:	O
ER-DP	O
=	O
extended-release	O
dipyridamole	B-D004176
200	O
mg;	O
ASA	O
=	O
aspirin	B-D001241
25	O
mg	O

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O

Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment	O

Other	O
Adverse	O
Events	O
Adverse	O
reactions	O
that	O
occurred	O
in	O
less	O
than	O
1%	O
of	O
patients	B-D010361
treated	O
with	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
in	O
the	O
ESPS2	O
study	O
and	O
that	O
were	O
medically	O
judged	O
to	O
be	O
possibly	O
related	O
to	O
either	O
dipyridamole	B-D004176
or	O
aspirin	B-D001241
are	O
listed	O
below	O

Body	O
as	O
a	O
Whole:	O
Allergic	O
reaction,	O
fever	B-D005334
Cardiovascular:	O
Hypotension	B-D007022
Central	B-D002490
Nervous	I-D002490
System:	I-D002490
Coma,	B-D003128
dizziness,	B-D004244
paresthesia,	B-D010292
cerebral	B-D002543
hemorrhage,	I-D002543
intracranial	O
hemorrhage,	B-D006470
subarachnoid	B-D013345
hemorrhage	I-D013345
Gastrointestinal:	O
Gastritis,	B-D005756
ulceration	B-D014456
and	O
perforation	O
Hearing	B-D006309
and	O
Vestibular	O
Disorders:	O
Tinnitus	B-D014012
and	O
deafness	B-D003638
	O

Patients	B-D010361
with	O
high	O
frequency	O
hearing	B-D034381
loss	I-D034381
may	O
have	O
difficulty	O
perceiving	O
tinnitus	B-D014012
	O

In	O
these	O
patients,	B-D010361
tinnitus	B-D014012
cannot	O
be	O
used	O
as	O
a	O
clinical	O
indicator	O
of	O
salicylism	O
Heart	B-D006339
Rate	I-D006339
and	O
Rhythm	O
Disorders:	O
Tachycardia,	B-D013610
palpitation,	O
arrhythmia,	O
supraventricular	O
tachycardia	B-D013610
Liver	B-D008099
and	O
Biliary	O
System	O
Disorders:	O
Cholelithiasis,	B-D002769
jaundice,	B-D007565
hepatic	O
function	O
abnormal	O
Metabolic	O
and	O
Nutritional	O
Disorders:	O
Hyperglycemia,	B-D006943
thirst	B-D013894
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders:	O
Hematoma,	B-D006406
gingival	B-D005881
bleeding	O
Psychiatric	O
Disorders:	O
Agitation	O
Reproductive:	O
Uterine	B-D014592
hemorrhage	I-D014592
Respiratory:	O
Hyperpnea,	O
asthma,	B-D001249
bronchospasm,	O
hemoptysis,	B-D006469
pulmonary	B-D011654
edema	I-D011654
Special	O
Senses	O
Other	O
Disorders:	O
Taste	B-D013649
loss	O
Skin	B-D012867
and	O
Appendages	O
Disorders:	O
Pruritus,	B-D011537
urticaria	B-D014581
Urogenital:	O
Renal	B-D051437
insufficiency	I-D051437
and	O
failure,	O
hematuria	B-D006417
Vascular	O
(Extracardiac)	O
Disorders:	O
Flushing	B-D005483
Laboratory	O
Changes	O
Over	O
the	O
course	O
of	O
the	O
24-month	O
study	O
(ESPS2),	O
patients	B-D010361
treated	O
with	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
showed	O
a	O
decline	O
(mean	O
change	O
from	O
baseline)	O
in	O
hemoglobin	O
of	O
0.25	O
g/dL,	O
hematocrit	B-D006400
of	O
0.75%	O
and	O
erythrocyte	B-D004906
count	I-D004906
of	O
0.13x10	O
6/mm	O
3	O

6.2	O
Post-Marketing	O
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
either	O
in	O
the	O
literature	B-D008091
or	O
are	O
from	O
post-marketing	O
spontaneous	O
reports	O
for	O
either	O
dipyridamole	B-D004176
or	O
aspirin	B-D001241
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
estimate	O
reliably	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

Decisions	O
to	O
include	O
these	O
reactions	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
reaction,	O
(2)	O
frequency	O
of	O
reporting,	O
or	O
(3)	O
strength	O
of	O
causal	O
connection	O
to	O
aspirin	B-D001241
and	O
extended-release	O
dipyridamole	B-D004176
	O

Body	O
as	O
a	O
Whole:	O
Hypothermia,	B-D007035
chest	B-D002637
pain	I-D002637
Cardiovascular:	O
Angina	B-D000787
pectoris	I-D000787
Central	B-D002490
Nervous	I-D002490
System:	I-D002490
Cerebral	B-C079279
edema	B-D004487
Fluid	O
and	O
Electrolyte:	O
Hyperkalemia,	B-D006947
metabolic	O
acidosis,	B-D000142
respiratory	I-D000142
alkalosis,	B-D000471
hypokalemia	B-D007008
Gastrointestinal:	O
Pancreatitis,	B-D010195
Reye	B-D012202
syndrome,	I-D012202
hematemesis	B-D006396
Hearing	B-D006309
and	O
Vestibular	O
Disorders:	O
Hearing	B-D034381
loss	I-D034381
Immune	B-D007107
System	I-D007107
Disorders:	O
Hypersensitivity,	B-D006967
acute	O
anaphylaxis,	B-D000707
laryngeal	B-D007819
edema	I-D007819
Liver	B-D008099
and	O
Biliary	O
System	O
Disorders:	O
Hepatitis,	B-D006505
hepatic	O
failure	O
Musculoskeletal:	O
Rhabdomyolysis	B-D012206
Metabolic	O
and	O
Nutritional	O
Disorders:	O
Hypoglycemia,	B-D007003
dehydration	B-D003681
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders:	O
Prolongation	O
of	O
the	O
prothrombin	B-D011517
time,	I-D011517
disseminated	B-D004211
intravascular	I-D004211
coagulation,	I-D004211
coagulopathy,	O
thrombocytopenia	B-D013921
Reproductive:	O
Prolonged	O
pregnancy	B-D011247
and	O
labor,	O
stillbirths,	B-D050497
lower	O
birth	B-D001724
weight	I-D001724
infants,	B-D007223
antepartum	O
and	O
postpartum	O
bleeding	O
Respiratory:	O
Tachypnea,	B-D059246
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages	O
Disorders:	O
Rash,	O
alopecia,	B-D000505
angioedema,	B-D000799
Stevens-Johnson	B-D013262
syndrome,	I-D013262
skin	B-D012867
hemorrhages	B-D006470
such	O
as	O
bruising,	O
ecchymosis	B-D004438
and	O
hematoma	B-D006406
Urogenital:	O
Interstitial	O
nephritis,	B-D009393
papillary	O
necrosis,	B-D009336
proteinuria	B-D011507
Vascular	O
(Extracardiac)	O
Disorders:	O
Allergic	O
vasculitis	B-D014657
Other	O
Adverse	O
Events:	O
anorexia,	B-D000855
aplastic	O
anemia,	B-D000740
migraine,	O
pancytopenia,	B-D010198
thrombocytosis	B-D013922
	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
contact	O
AvKARE,	O
Inc	O

at	O
1-855-361-3993;	O
email	O
drugsafety@avkare.com;	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

BOXED	O
WARNING	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(See	O
WARNINGS	O
and	O
PRECAUTIONS)	O

•	O
Ibuprofen	B-D007052
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDS	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
is	O
gastrointestinal	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
percentage	O
of	O
patients	B-D010361
reporting	O
one	O
or	O
more	O
gastrointestinal	O
complaints	O
ranged	O
from	O
4%	O
to	O
16%	O

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052
tablets	B-D013607
were	O
compared	O
to	O
aspirin	B-D001241
and	O
indomethacin	B-D007213
in	O
equally	O
effective	O
doses,	O
the	O
overall	B-D016424
incidence	B-D015994
of	O
gastrointestinal	O
complaints	O
was	O
about	O
half	O
that	O
seen	O
in	O
either	O
the	O
aspirin-	B-D001241
or	O
indomethacin-treated	B-D007213
patients	B-D010361
	O

Adverse	O
reactions	O
observed	O
during	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
at	O
an	O
incidence	B-D015994
greater	O
than	O
1%	O
are	O
listed	O
in	O
the	O
table	O

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
observations	B-D019370
in	O
approximately	O
3,000	O
patients	B-D010361
	O

More	O
than	O
500	O
of	O
these	O
patients	B-D010361
were	O
treated	O
for	O
periods	O
of	O
at	O
least	O
54	O
weeks	O

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
and	O
from	O
marketing	B-D040541
experience	O

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
where	O
the	O
probability	B-D011336
of	O
a	O
causal	O
relationship	O
exists:	O
for	O
the	O
reactions	O
in	O
Column	O
three,	O
a	O
causal	O
relationship	O
with	O
Ibuprofen	B-D007052
tablets	B-D013607
has	O
not	O
been	O
established	O

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
patients	B-D010361
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

The	O
increases	O
in	O
incidence	B-D015994
were	O
slight	O
and	O
still	O
within	O
the	O
ranges	O
reported	O
in	O
the	O
table	O

Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)Probable	O
Causal	O
Relationship*	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)Probable	O
Causal	O
Relationship**[/	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINALNausea*,	O
epigastric	O
pain*,	B-D010146
heartburn*,	B-D006356
diarrhea,	B-D003967
abdominal	O
distress,	O
nausea	B-D009325
and	O
vomiting,	B-D014839
indigestion,	O
constipation,	B-D003248
abdominal	O
cramps	O
or	O
Pain,	B-D010146
fullness	O
of	O
GI	O
tract	O
(bloating	O
and	O
flatulence	B-D005414
Gastric	O
or	O
duodenal	B-D004381
ulcer	I-D004381
with	O
bleeding	O
and/or	O
perforation,	O
gastrointestinal	B-D006471
hemorrhage,	I-D006471
melena,	B-D008551
gastritis,	B-D005756
hepatitis,	B-D006505
jaundice,	B-D007565
abnormal	O
liver	B-D008111
function	I-D008111
tests;	I-D008111
pancreatitis	B-D010195
CENTRAL	B-D002490
NERVOUS	I-D002490
SYSTEMDizziness*,	I-D002490
headache,	B-D006261
nervousness	O
Depression,	B-D003863
insomnia,	O
confusion,	B-D003221
emotional	O
liability,	O
somnolence,	O
aseptic	O
meningitis	B-D008581
with	O
fever	B-D005334
and	O
coma	B-D003128
(see	O
PRECAUTIONS)	O
Paresthesias,	B-D010292
hallucinations,	B-D006212
dream	O
abnormalities,	O
pseudotumor	B-D011559
cerebri	I-D011559
DERMATOLOGICRash*,	O
(including	O
maculopapular	O
type),	O
pruritus	B-D011537
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-	O
Johnson	O
syndrome,	B-D013577
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
SPECIAL	O
SENSESTinnitus	O
Vesiculobullous	O
eruptions,	O
urticaria,	B-D014581
erythema	B-D004892
multiforme,	I-D004892
Stevens-	O
Johnson	O
syndrome,	B-D013577
alopecia	B-D000505
Toxic	O
epidermal	O
necrolysis,	O
photoallergic	O
skin	B-D012867
reactions	O
HEMATOLOGIC	O
Neutropenia,agranulocytosis,	B-D009503
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia	B-D000740
(sometimes	O
Coombs	O
positive),	O
thrombocytopenia	B-D013921
with	O
or	O
without	O
purpura,	B-D011693
eosinophilia,	B-D004802
decreases	O
in	O
hemoglobin	B-D006441
and	I-D006441
hematocrit	B-D006400
(see	O
PRECAUTIONS)	O
Bleeding	O
episodes	O
(eg	O
epistaxis,	B-D004844
menorrhagia)	B-D008595
METABOLIC/ENDOCRINEDecreased	O
appetite	B-D001066
Gynecomastia,	B-D006177
hypoglycemic	O
reaction,	O
acidosis	B-D000138
CARDIOVASCULAREdema,	O
fluid	O
retention	O
(generally	O
responds	O
promptly	O
to	O
drug	O
discontinuation)	O
(see	O
PRECAUTIONS)	O
Congestive	O
heart	B-D006333
failure	I-D006333
in	O
patients	B-D010361
with	O
marginal	O
cardiac	B-D002299
function,	O
elevate	O
blood	B-D001794
pressure,	I-D001794
palpitations	O
Arrhythmias	O
(sinus	O
tachycardia,	B-D013616
sinus	I-D013616
bradycardia)	B-D001919
ALLERGIC	O
Syndrome	B-D013577
of	O
abdominal	B-D015746
pain,	I-D015746
fever,	B-D005334
chills,	B-D023341
nausea	B-D009325
and	O
vomiting;	B-D014839
anaphylaxis;	B-D000707
bronchospasm	O
(see	O
CONTRAINDICATIONS)	B-D000075202
Serum	B-D012713
sickness,	I-D012713
lupus	O
erythematosus	B-D004890
syndrome	B-D013577
	O

Henoch-Schonlein	O
vasculitis,	B-D014657
angioedema	B-D000799
RENAL	O
Acute	O
renal	O
failure	O
(see	O
PRECAUTIONS),	O
decreased	O
creatinine	B-D003404
clearance,	O
poliuria,	O
azotemia,	B-D053099
cystitis,	B-D003556
Hematuria	B-D006417
Renal	O
papillary	O
necrosis	B-D009336
MISCELLANEOUS	O
Dry	O
eyes	B-D005123
and	O
mouth,	B-D009055
gingival	B-D005881
ulcer,	B-D014456
rhinitis	B-D012220
*	O
Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
ibuprofen	B-D007052
tablets	B-D013607
	O

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
patients	B-D010361
are	O
unmarked.)	O
**	O
Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Systemic	O
exposure	O
to	O
phenylephrine	B-D010656
may	O
cause	O
elevations	O
in	O
blood	B-D001794
pressure	I-D001794
	O

(5.1)	O
5.1	O
Elevated	O
Blood	B-D001794
Pressure	I-D001794
Systemic	O
exposure	O
to	O
phenylephrine	B-D010656
can	O
cause	O
elevations	O
in	O
blood	B-D001794
pressure	I-D001794
	O

5.2	O
Cross-Sensitivity	O
or	O
Hypersensitivity	B-D006967
There	O
is	O
the	O
potential	O
for	O
cross-sensitivity	O
to	O
acetylsalicylic	O
acid,	O
phenylacetic	B-C025136
acid	I-C025136
derivatives,	O
and	O
other	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O

There	O
have	O
been	O
reports	O
of	O
bronchospasm	O
or	O
exacerbation	O
of	O
asthma	B-D001249
associated	O
with	O
the	O
use	O
of	O
ketorolac	B-D020910
in	O
patients	B-D010361
who	O
either	O
have	O
a	O
known	O
hypersensitivity	B-D006967
to	O
aspirin/NSAIDs	B-D001241
or	O
a	O
past	O
medical	O
history	B-D006664
of	O
asthma	B-D001249
	O

Therefore,	O
use	O
Omidria	O
with	O
caution	O
in	O
individuals	O
who	O
have	O
previously	O
exhibited	O
sensitivities	O
to	O
these	O
drugs	O

6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
reported	O
adverse	O
reactions	O
(≥2%)	O
are	O
eye	B-D005123
irritation,	O
posterior	B-D019519
capsule	B-D058442
opacification,	I-D058442
increased	O
intraocular	B-D007429
pressure,	I-D007429
and	O
anterior	B-D000867
chamber	I-D000867
inflammation	B-D007249
	O

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Omeros	O
Corporation	O
at	O
1-844-OMEROS1	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
	O

6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
the	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

Table	O
1	O
shows	O
frequently	O
reported	O
ocular	O
adverse	O
reactions	O
with	O
an	O
incidence	B-D015994
of	O
≥	O
2%	O
of	O
adult	B-D000328
patients	B-D010361
as	O
seen	O
in	O
the	O
combined	O
clinical	B-D016430
trial	I-D016430
results	O
from	O
three	O
randomized,	O
placebo-controlled	O
studies	O
[see	O
Clinical	O
Studies	O
(14)]	O

Table	O
1:	O
Ocular	O
Adverse	O
Reactions	O
Reported	O
by	O
≥	O
2%	O
of	O
Adult	B-D000328
Patients	B-D010361
MedDRA	O
Preferred	O
Term	O
Placebo(N=462)	O
Omidria(N=459)	O
n	O
(%)	O
n	O
(%)	O
Ocular	O
Events	O
Anterior	B-D000867
Chamber	I-D000867
Inflammation	B-D007249
102	O
(22%)	O
111	O
(24%)	O
Intraocular	B-D007429
Pressure	I-D007429
Increased	O
15	O
(3%)	O
20	O
(4%)	O
Posterior	B-D019519
Capsule	B-D058442
Opacification	I-D058442
16	O
(4%)	O
18	O
(4%)	O
Eye	B-D005123
Irritation	O
6	O
(1%)	O
9	O
(2%)	O
Foreign	O
Body	O
Sensation	B-D012677
in	O
Eyes	B-D005123
11	O
(2%)	O
8	O
(2%)	O
In	O
a	O
safety	B-D012449
study	O
that	O
enrolled	O
72	O
pediatric	O
patients	B-D010361
up	O
to	O
3	O
years	O
old,	O
no	O
overall	B-D016424
difference	O
in	O
safety	B-D012449
was	O
observed	O
between	O
pediatric	O
and	O
adult	B-D000328
patients	B-D010361
	O

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS	O
)	O

Diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets,	B-D013607
USP	O
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
EVENTS,	O
contact	O
Actavis	O
at	O
1-800-432-8534	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
http://www.fda.gov/	O
for	O
voluntary	O
reporting	O
of	O
adverse	O
reactions	O

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O
	O

Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
a	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
etodolac	B-D017308
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal),	O
vomiting	B-D014839
	O

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritis,	O
rashes,	O
tinnitus	B-D014012
	O

Adverse-reaction	O
information	O
for	O
etodolac	B-D017308
was	O
derived	O
from	O
2,629	O
arthritic	B-D001154
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
in	O
double-blind	O
and	O
open-label	O
clinical	B-D016430
trials	I-D016430
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies	O

In	O
clinical	B-D016430
trials,	I-D016430
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient	O

The	O
discontinuation	O
rate	O
in	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

New	O
patient	O
complaints	O
(with	O
an	O
incidence	B-D015994
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system	O

The	O
incidences	B-D015994
were	O
determined	O
from	O
clinical	B-D016430
trials	I-D016430
involving	O
465	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	B-D017308
b.i.d	O

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever	B-D005334
	O

Digestive	B-D004064
system	I-D004064
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	B-D015746
pain*,	I-D015746
diarrhea*,	B-D003967
flatulence*,	B-D005414
nausea*,	B-D009325
constipation,	B-D003248
gastritis,	B-D005756
melena,	B-D008551
vomiting	B-D014839
	O

Nervous	B-D009420
system	I-D009420
-	O
Asthenia/malaise*,	B-D001247
dizziness*,	B-D004244
depression,	B-D003863
nervousness	O

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus,	B-D011537
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus	B-D014012
	O

Urogenital	B-D014566
system	I-D014566
-	O
Dysuria,	B-D053159
urinary	O
frequency	O

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	B-D016430
trials,	I-D016430
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock)	B-D012769
	O

Cardiovascular	B-D002319
system	I-D002319
-	O
Hypertension,	B-D006973
congestive	O
heart	B-D006333
failure,	I-D006333
flushing,	B-D005483
palpitations,	O
syncope,	B-D013575
vasculitis	B-D014657
(including	O
necrotizing	O
and	O
allergic)	O

Digestive	B-D004064
system	I-D004064
-	O
Thirst,	B-D013894
dry	O
mouth,	B-D009055
ulcerative	B-D014456
stomatitis,	B-D013280
anorexia,	B-D000855
eructation,	B-D004884
elevated	O
liver	B-D008099
enzymes,	B-D004798
cholestatic	O
hepatitis,	B-D006505
hepatitis,	B-D006505
cholestatic	O
jaundice,	B-D007565
duodenitis,	B-D004382
jaundice,	B-D007565
hepatic	O
failure,	O
liver	B-D008099
necrosis,	B-D009336
peptic	B-D010437
ulcer	I-D010437
with	O
or	O
without	O
bleeding	O
and/or	O
perforation	O
,	O
intestinal	O
ulceration,	B-D014456
pancreatitis	B-D010195
	O

Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
Ecchymosis,	B-D004438
anemia,	B-D000740
thrombocytopenia,	B-D013921
bleeding	B-D001760
time	I-D001760
increased,	O
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000740
leukopenia,	B-D007970
neutropenia,	B-D009503
pancytopenia	B-D010198
	O

Metabolic	O
and	O
nutritional	O
-	O
Edema,	B-D004487
serum	B-D044967
creatinine	B-D003404
increase,	O
hyperglycemia	B-D006943
in	O
previously	O
controlled	O
diabetic	O
patients	B-D010361
	O

Nervous	B-D009420
system	I-D009420
-	O
Insomnia,	O
somnolence	O

Respiratory	B-D012137
system	I-D012137
-	O
Asthma,	B-D001249
pulmonary	O
infiltration	O
with	O
eosinophilia	B-D004802
	O

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema,	B-D000799
sweating,	B-D013546
urticaria,	B-D014581
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	B-D014657
with	O
purpura,	B-D011693
Stevens-Johnson	B-D013262
Syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis,	O
hyperpigmentation	B-D017495
,	O
erythema	B-D004892
multiforme	I-D004892
	O

Special	O
senses	O
-	O
Photophobia,	B-D020795
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
system	I-D014566
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	B-D051437
insufficiency,	I-D051437
renal	O
papillary	O
necrosis	B-D009336
	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	B-D017308
is	O
uncertain	O

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	B-D010820
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache	B-D006261
	O

Cardiovascular	B-D002319
system	I-D002319
-	O
Arrhythmias,	O
myocardial	B-D009203
infarction,	I-D009203
cerebrovascular	B-C079279
accident	O

Digestive	B-D004064
system	I-D004064
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis	B-D003092
	O

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
system	I-D009420
-	O
Paresthesia,	B-D010292
confusion	B-D003221
	O

Respiratory	B-D012137
system	I-D012137
-	O
Bronchitis,	B-D001991
dyspnea,	B-D004417
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis	B-D012852
	O

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia,	B-D000505
maculopapular	O
rash,	O
photosensitivity,	O
skin	B-D012867
peeling	O

Special	O
senses	O
-	O
Conjunctivitis,	B-D003231
deafness,	B-D003638
taste	B-D013649
perversion	O

Urogenital	B-D014566
system	I-D014566
-	O
Cystitis,	B-D003556
hematuria,	B-D006417
leukorrhea,	B-D007973
renal	O
calculus,	O
interstitial	O
nephritis,	B-D009393
uterine	O
bleeding	O
irregularities	O

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis,	B-D018805
death	B-D003643
Cardiovascular	B-D002319
system	I-D002319
-	O
Tachycardia	B-D013610
Digestive	B-D004064
system	I-D004064
-	O
Gastric	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis	B-D006396
Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
Lymphadenopathy	B-D000072281
Nervous	B-D009420
system	I-D009420
-	O
Anxiety,	B-D001007
dream	O
abnormalities,	O
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis,	B-D008581
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
system	I-D012137
-	O
Respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Urogenital	B-D014566
system	I-D014566
-	O
Oliguria/polyuria,	B-D009846
proteinuria	B-D011507
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(	O
5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(	O
4	O
,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(	O
5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(	O
4)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(	O
5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(	O
5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(	O
5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(	O
5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(	O
5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(	O
5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(	O
5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(	O
5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(	O
5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

Clinical	B-D016430
trials	I-D016430
of	O
several	O
cyclooxygenase-2	O
(COX-2)	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	B-D012306
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
for	O
the	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
and	O
celecoxib	B-D000068579
capsules	B-D002214
200	O
mg	O
twice	O
daily	O
treatment	O
arms	B-D001132
compared	O
to	O
placebo	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
risk	B-D012306
of	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
for	O
the	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
and	O
celecoxib	B-D000068579
capsules	B-D002214
200	O
mg	O
twice	O
daily	O
treatment	O
arms	B-D001132
compared	O
to	O
placebo	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(	O
14.7)]	O

A	O
randomized	B-D016449
controlled	I-D016449
trial	I-D016449
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs	O

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	B-D012306
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	B-D000068579
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	B-D009288
and	O
ibuprofen	B-D007052
	O

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	B-D009288
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	B-D007052
600	O
to	O
800	O
mg	O
three	O
times	B-D013995
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists’	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	B-D003643
(including	O
hemorrhagic	O
death),	B-D003643
non-fatal	O
myocardial	B-D009203
infarction,	I-D009203
and	O
non-fatal	O
stroke	B-D020521
A	O
randomized	B-D016449
controlled	I-D016449
trial	I-D016449
entitled	O
the	O
Prospective	O
Randomized	O
Evaluation	O
of	O
Celecoxib	B-D000068579
Integrated	O
Safety	B-D012449
vs	O

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
risk	B-D012306
of	O
a	O
COX-2	O
inhibitor,	O
celecoxib,	B-D000068579
compared	O
to	O
the	O
non-selective	O
NSAIDs	O
naproxen	B-D009288
and	O
ibuprofen	B-D007052
	O

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
naproxen	B-D009288
375	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
ibuprofen	B-D007052
600	O
to	O
800	O
mg	O
three	O
times	B-D013995
daily	O
for	O
the	O
composite	O
endpoint	O
of	O
the	O
Antiplatelet	O
Trialists’	O
Collaboration	O
(APTC),	O
which	O
consists	O
of	O
cardiovascular	O
death	B-D003643
(including	O
hemorrhagic	O
death),	B-D003643
non-fatal	O
myocardial	B-D009203
infarction,	I-D009203
and	O
non-fatal	O
stroke	B-D020521
[See	O
Clinical	O
Studies	O
(	O
14.6)]	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
]	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-	O
cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-	O
cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
celecoxib	B-D000068579
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
celecoxib	B-D000068579
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
antiplatelet	O
drugs	O
(such	O
as	O
aspirin),	B-D001241
anticoagulants;	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(	O
14.7)]	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
celecoxib	B-D000068579
capsules,	B-D002214
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
capsules	B-D002214
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash),	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
]	O

NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

See	O
(	O
,	O
)	O
for	O
additional	O
blood	B-D001794
pressure	I-D001794
data	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
	O

See	O
Clinical	O
Studies	O
(	O
14.6,	O
14.7)	O
for	O
additional	O
blood	B-D001794
pressure	I-D001794
data	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy.Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
celecoxib	B-D000068579
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7)]	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(	O
14.7)]	O
,	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE	O
inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-	O
hypoaldosteronism	B-D006994
state	O

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
celecoxib	B-D000068579
and	O
in	O
patients	B-D010361
with	O
aspirin	B-D001241
sensitive	O
asthma	B-D001249
	O

Celecoxib	B-D000068579
capsules	B-D002214
are	O
sulfonamides	B-D013449
and	O
both	O
NSAIDs	O
and	O
sulfonamides	B-D013449
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	B-D019369
or	O
less	O
severe	O
asthmatic	B-D001249
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)	O
]	O

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

When	O
celecoxib	B-D000068579
capsules	B-D002214
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	B-D012867
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib	B-D000068579
capsules,	B-D002214
including	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	B-D056150
generalized	I-D056150
exanthematous	I-D056150
pustulosis	I-D056150
(AGEP)	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Celecoxib	B-D000068579
capsules	B-D002214
are	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
celecoxib	B-D000068579
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	B-D000068579
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

NSAIDs,	O
including	O
celecoxib	B-D000068579
capsules,	B-D002214
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
drugs	O
(e.g.,	O
aspirin),	B-D001241
SSRIs	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[	O
see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	B-D000068579
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
,	O
5.3	O
,	O
5.6)	O
]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
capsules	B-D002214
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
with	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	B-D010361
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	B-D010361
and	O
their	O
caregivers	B-D017028
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo)	O
are:	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(	O
6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Of	O
the	O
celecoxib-treated	B-D000068579
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	B-D000068579
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
celecoxib	B-D000068579
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
celecoxib	B-D000068579
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	B-D000068579
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	B-D000068579
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
%	O
to	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
(100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General:	O
Hypersensitivity,	B-D006967
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
blood	B-D001806
urea	I-D001806
nitrogen	I-D001806
(BUN)	O
increased,	O
creatine	B-D003401
phosphokinase	O
(CPK)	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia,	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients:	B-D010361
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis	B-D013924
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
General:	O
Sepsis,	B-D018805
sudden	O
death	B-D003643
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	B-D008196
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia,	B-D001259
suicide	B-D013405
[see	O
Drug	B-D004347
Interactions	I-D004347
(	O
7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Clinical	O
Studies	O
(	O
14.7)]	O
Hematological	O
Events:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
celecoxib	B-D000068579
was	O
maintained	O
with	O
or	O
without	O
aspirin	B-D001241
use	O
[	O
see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	B-D000068579
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
twice	O
daily	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Celecoxib	B-D000068579
3	O
mg/kg	O
Celecoxib	B-D000068579
6	O
mg/kg	O
Naproxen	B-D009288
7.5	O
mg/kg	O
Preferred	O
Term	O
N=77	O
N=82	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*	O
Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	B-D000068579
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	B-D000068579
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(	O
14.7)]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	B-D000068579
pre-marketing	O
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
Placebo	O
N=	O
2285	O
N=	O
1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
celecoxib,	B-D000068579
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning,	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post	O
approval	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
General:	O
Anaphylactoid	O
reaction,	O
angioedema	B-D000799
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	B-D009336
hepatitis,	B-D006505
jaundice,	B-D007565
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	B-D008196
Agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
Renal:	O
Interstitial	O
nephritis	B-D009393
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS)	O

Diclofenac	B-D004008
potassium	B-D011188
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS,	B-D000075202
WARNINGS)	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
(see	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

In	O
718	O
patients	B-D010361
treated	O
for	O
shorter	O
periods,	O
i.e.,	O
2	O
weeks	O
or	O
less,	O
with	O
diclofenac	B-D004008
tablets,	B-D013607
adverse	O
reactions	O
were	O
reported	O
one-half	O
to	O
one-tenth	O
as	O
frequently	O
as	O
by	O
patients	B-D010361
treated	O
for	O
longer	O
periods	O

In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
diclofenac	B-D004008
potassium	B-D011188
tablets	B-D013607
(N	O
=	O
196)	O
versus	O
diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
(N	O
=	O
197)	O
versus	O
ibuprofen	B-D007052
(N	O
=	O
197),	O
adverse	O
reactions	O
were	O
similar	O
in	O
nature	B-D019368
and	O
frequency	O

In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
potassium	B-D011188
tablets	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
•	O
Celecoxibis	B-D000068579
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
(GI)	O
events	O

[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
the	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O

(5.1)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(5.3)	O
•	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(5.4,	O
7)	O
•	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(5.5)	O
•	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(5.6)	O
•	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
•	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(5.8)	O
•	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(5.9)	O
•	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(5.10,	O
8.1)	O
•	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
to	O
8.5)	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
to	O
7.2)	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
celecoxib,	B-D000068579
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10	O
to	O
14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O
	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
celecoxib	B-D000068579
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3	O
to	O
6	O
months,	O
and	O
in	O
about	O
2%	O
to	O
4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants;	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)]	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
•Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

•Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

•Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
celecoxib	B-D000068579
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal	O
[ULN])	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
NSAID-treated	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
	O

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure	O
have	O
been	O
reported	O

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
times	B-D013995
ULN)	O
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
including	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
celecoxib,	B-D000068579
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
celecoxib	B-D000068579
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
celecoxib	B-D000068579
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

The	O
rates	O
of	O
hypertension	B-D006973
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	B-D000068579
ibuprofen	B-D007052
and	O
diclofenac-treated	B-D004008
patients	B-D010361
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	B-D000078682
[see	O
Clinical	O
Studies	O
(14.6)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
celecoxib	B-D000068579
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
]	O
	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O
,	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors	O
or	O
the	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
celecoxib	B-D000068579
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
celecoxib	B-D000068579
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
celecoxib	B-D000068579
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoadosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
celecoxib	B-D000068579
and	O
in	O
patients	B-D010361
with	O
aspirin	B-D001241
sensitive	O
asthma	B-D001249
	O

Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
sulfonamides	B-D013449
may	O
cause	O
allergic	O
type	O
reactions	O
including	O
anaphylactic	O
symptoms	O
and	O
life-threatening	B-D019369
or	O
less	O
severe	O
asthmatic	B-D001249
episodes	O
in	O
certain	O
susceptible	O
people	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)]	O

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)]	O

When	O
celecoxib	B-D000068579
capsules	B-D002214
are	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
skin	B-D012867
reactions	O
have	O
occurred	O
following	O
treatment	O
with	O
celecoxib,	B-D000068579
including	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
drug	O
reaction	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS),	O
and	O
acute	B-D056150
generalized	I-D056150
exanthematous	I-D056150
pustulosis	I-D056150
(AGEP)	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
celecoxib,	B-D000068579
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)]	O

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
celecoxib	B-D000068579
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
celecoxib	B-D000068579
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	B-D000068579
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

NSAIDs,	O
including	O
celecoxib,	B-D000068579
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
celecoxib	B-D000068579
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
with	O
use	O
of	O
celecoxib	B-D000068579
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA,	O
monitor	O
patients	B-D010361
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
abnormal	O
clotting	O
or	O
bleeding,	O
and	O
inform	O
patients	B-D010361
and	O
their	O
caregivers	B-D017028
to	O
report	O
symptoms	O
as	O
soon	O
as	O
possible	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(greater	O
than	O
or	O
equal	O
to	O
2%	O
and	O
greater	O
than	O
or	O
equal	O
to	O
placebo)	O
are:	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Of	O
the	O
celecoxib	B-D000068579
-treated	O
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	B-D000068579
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
celecoxib	B-D000068579
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
greater	O
than	O
or	O
equal	O
to	O
2%	O
of	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
Greater	O
Than	O
or	O
Equal	O
to	O
2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
Placebo	O
NAP	O
DCF	O
IBU	O
N=4146	O
N=1864	O
N=1366	O
N=387	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	B-D000068579
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	B-D000068579
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
(100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General:	O
Hypersensitivity,	B-D006967
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
enzyme	O
increased	O
(including	O
SGOT	O
increased,	O
SGPT	O
increased)	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia,	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
cough,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
less	O
than	O
0.1%	O
of	O
patients:	B-D010361
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis	B-D013924
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
General:	O
Sepsis,	B-D018805
sudden	O
death	B-D003643
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis	B-D002769
Hemic	O
and	O
lymphatic:	B-D008196
Thrombocytopenia	B-D013921
Nervous:	O
Ataxia,	B-D001259
suicide	B-D013405
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)]	O
Hematological	O
Events:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(greater	O
than	O
2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
celecoxib	B-D000068579
was	O
maintained	O
with	O
or	O
without	O
aspirin	B-D001241
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	B-D000068579
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
twice	O
daily,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
twice	O
daily	O

The	O
most	O
commonly	O
occurring	O
(greater	O
than	O
or	O
equal	O
to	O
5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(greater	O
than	O
or	O
equal	O
to	O
5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
twice	O
daily	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
twice	O
daily	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
Greater	O
Than	O
or	O
Equal	O
to	O
5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
Celecoxib	B-D000068579
Celecoxib	B-D000068579
Naproxen	B-D009288
System	O
Organ	O
Class	O
3	O
mg/kg	O
6	O
mg/kg	O
7.5	O
mg/kg	O
Preferred	O
Term	O
N=77	O
N=82	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
*	O
Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies	O
:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	B-D000068579
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	B-D000068579
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.6)]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	B-D000068579
pre-marketing	O
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
Placebo	O
N	O
=	O
2285	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
Nephrolithiasis	B-D053040
2.1%	O
0.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
greater	O
than	O
or	O
equal	O
to	O
0.1%	O
and	O
less	O
than	O
1%	O
of	O
patients	B-D010361
taking	O
celecoxib,	B-D000068579
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post	O
approval	O
use	O
of	O
celecoxib	B-D000068579
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
Cardiovascular:	O
Vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
General:	O
Anaphylactoid	O
reaction,	O
angioedema	B-D000799
Liver	B-D008099
and	O
biliary:	O
Liver	B-D008099
necrosis,	B-D009336
hepatitis,	B-D006505
jaundice,	B-D007565
hepatic	O
failure	O
Hemic	O
and	O
lymphatic:	B-D008196
Agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
Renal:	O
Interstitial	O
nephritis	B-D009393
ADVERSE	O
REACTIONS	O
Commonly	O
Observed	O
The	O
most	O
commonly	O
reported	O
adverse	O
events	O
associated	O
with	O
the	O
use	O
of	O
butalbital,	B-C004470
aspirin,	B-D001241
caffeine	B-D002110
and	O
codeine	B-D003061
and	O
not	O
reported	O
at	O
an	O
equivalent	O
incidence	B-D015994
by	O
placebo-treated	O
patients	B-D010361
were	O
nausea	B-D009325
and/or	O
abdominal	B-D015746
pain,	I-D015746
drowsiness,	O
and	O
dizziness	B-D004244
	O

Associated	O
with	O
Treatment	O
Discontinuation	O
Of	O
the	O
382	O
patients	B-D010361
treated	O
with	O
Butalbital,	B-C004470
Aspirin,	B-D001241
Caffeine	B-D002110
and	O
Codeine	B-D003061
in	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
three	O
(0.8%)	O
discontinued	O
treatment	O
because	O
of	O
adverse	O
events	O

One	O
patient	O
each	O
discontinued	O
treatment	O
for	O
the	O
following	O
reasons:	O
gastrointestinal	O
upset;	O
lightheadedness	B-D008027
and	O
heavy	O
eyelids;	B-D005143
and	O
drowsiness	O
and	O
generalized	O
tingling	B-D014001
	O

Incidence	B-D015994
in	O
Controlled	B-D018848
Clinical	I-D018848
Trials	I-D018848
The	O
following	O
table	O
summarizes	O
the	O
incidence	B-D015994
rates	O
of	O
the	O
adverse	O
events	O
reported	O
by	O
at	O
least	O
1%	O
of	O
the	O
Butalbital,	B-C004470
Aspirin,	B-D001241
Caffeine	B-D002110
and	O
Codeine	B-D003061
treated	O
patients	B-D010361
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
comparing	O
the	O
combination	O
product	O
to	O
placebo,	O
and	O
provides	O
a	O
comparison	O
to	O
the	O
incidence	B-D015994
rates	O
reported	O
by	O
the	O
placebo-treated	O
patients	B-D010361
	O

The	O
prescriber	O
should	O
be	O
aware	O
that	O
these	O
figures	O
cannot	O
be	O
used	O
to	O
predict	O
the	O
incidence	B-D015994
of	O
side	O
effects	O
in	O
the	O
course	O
of	O
usual	O
medical	O
practice	O
where	O
patient	O
characteristics	B-D002605
and	O
other	O
factors	O
differ	O
from	O
those	O
that	O
prevailed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
	O

Similarly,	O
the	O
cited	O
frequencies	O
cannot	O
be	O
compared	O
with	O
figures	O
obtained	O
from	O
other	O
clinical	O
investigations	O
involving	O
different	O
treatments,	O
uses,	O
and	O
investigators	O

Adverse	O
Events	O
Reported	O
by	O
at	O
Least	O
1%	O
of	O
Butalbital,	B-C004470
Aspirin,	B-D001241
Caffeine	B-D002110
and	O
Codeine	B-D003061
Treated	O
Patients	B-D010361
During	O
Placebo	O
Controlled	B-D018848
Clinical	I-D018848
Trials	I-D018848
Incidence	B-D015994
Rate	O
of	O
Adverse	O
Events	O
Body	O
System/Adverse	O
Event	O
Butalbital,	B-C004470
Aspirin,	B-D001241
Caffeine	B-D002110
and	O
Codeine	B-D003061
(N=382)	O
Placebo	O
N=(377)	O
Central	O
Nervous	O
Drowsiness	O
2.4%	O
0.5%	O
Dizziness/lightheadedness	B-D004244
2.6%	O
0.5%	O
Intoxicated	O
Feeling	O
1.0%	O
0%	O
Gastrointestinal	O
Nausea/Abdominal	B-D009325
Pain	B-D010146
3.7%	O
0.8%	O
Other	O
Adverse	O
Events	O
Reported	O
During	O
Controlled	B-D018848
Clinical	I-D018848
Trials	I-D018848
The	O
listing	O
that	O
follows	O
represents	O
the	O
proportion	O
of	O
the	O
382	O
patients	B-D010361
exposed	O
to	O
butalbital,	B-C004470
aspirin,	B-D001241
caffeine	B-D002110
and	O
codeine	B-D003061
while	O
participating	O
in	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
who	O
reported,	O
on	O
at	O
least	O
one	O
occasion,	O
an	O
adverse	O
event	O
of	O
the	O
type	O
cited	O

All	O
reported	O
adverse	O
events,	O
except	O
those	O
already	O
presented	O
in	O
the	O
previous	O
table,	O
are	O
included	O

It	O
is	O
important	O
to	O
emphasize	O
that,	O
although	O
the	O
adverse	O
events	O
reported	O
did	O
occur	O
while	O
the	O
patient	O
was	O
receiving	O
the	O
combination	O
product,	O
the	O
adverse	O
events	O
were	O
not	O
necessarily	O
caused	O
by	O
butalbital,	B-C004470
aspirin,	B-D001241
caffeine	B-D002110
and	O
codeine	B-D003061
	O

Adverse	O
events	O
are	O
classified	O
by	O
body	O
system	O
and	O
frequency	O

“Frequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
which	O
occurred	O
in	O
at	O
least	O
1/100	O
(1%)	O
of	O
the	O
patients;	B-D010361
all	O
adverse	O
events	O
listed	O
in	O
the	O
previous	O
table	O
are	O
frequent	O

“Infrequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
that	O
occurred	O
in	O
less	O
than	O
1/100	O
patients	B-D010361
but	O
at	O
least	O
1/1000	O
patients	B-D010361
	O

All	O
adverse	O
events	O
tabulated	O
below	O
are	O
classified	O
as	O
infrequent	O

Central	O
Nervous:	O
headache,	B-D006261
shaky	O
feeling,	O
tingling,	B-D014001
agitation,	O
fainting,	O
fatigue,	B-D005221
heavy	O
eyelids,	B-D005143
high	O
energy,	O
hot	O
spells,	O
numbness,	O
and	O
sluggishness	O

Autonomic	O
Nervous:	O
dry	O
mouth	B-D009055
and	O
hyperhidrosis	B-D006945
	O

Gastrointestinal:	O
vomiting,	B-D014839
difficulty	O
swallowing,	O
and	O
heartburn	B-D006356
	O

Cardiovascular:	O
tachycardia	B-D013610
	O

Musculoskeletal:	O
leg	B-D007866
pain	B-D010146
and	O
muscle	B-D018763
fatigue	I-D018763
	O

Genitourinary:	O
diuresis	B-D004231
	O

Miscellaneous:	O
pruritus,	B-D011537
fever,	B-D005334
earache,	B-D004433
nasal	B-C015378
congestion,	O
and	O
tinnitus	B-D014012
	O

Voluntary	O
reports	O
of	O
adverse	O
drug	O
events,	O
temporally	B-C003959
associated	O
with	O
Butalbital,	B-C004470
Aspirin,	B-D001241
Caffeine	B-D002110
and	O
Codeine,	B-D003061
that	O
have	O
been	O
received	O
since	O
market	O
introduction	O
and	O
that	O
were	O
not	O
reported	O
in	O
clinical	B-D016430
trials	I-D016430
by	O
the	O
patients	B-D010361
treated	O
with	O
the	O
combination	O
product,	O
are	O
listed	O
below	O

Many	O
or	O
most	O
of	O
these	O
events	O
may	O
have	O
no	O
causal	O
relationship	O
with	O
the	O
drug	O
and	O
are	O
listed	O
according	O
to	O
body	O
system	O

Central	O
Nervous:	O
Abuse,	O
addiction,	O
anxiety,	B-D001007
depression,	B-D003863
disorientation,	O
hallucination,	O
hyperactivity,	O
insomnia,	O
libido	B-D007989
decrease,	O
nervousness,	O
neuropathy,	O
psychosis,	O
sedation,sexual	O
activity	O
increase,	O
slurred	O
speech,	B-D013060
twitching,	O
unconsciousness,	B-D014474
vertigo	B-D014717
	O

Autonomic	O
Nervous:	O
epitaxis,	O
flushing,	B-D005483
miosis,	B-D015877
salivation	B-D012472
	O

Gastrointestinal:	O
anorexia,	B-D000855
appetite	B-D001066
increased,	O
constipation,	B-D003248
diarrhea,	B-D003967
esophagitis,	B-D004941
gastroenteritis,	B-D005759
gastrointestinal	O
spasm,	B-D013035
hiccup,	B-D006606
mouth	B-D009055
burning,	O
pyloric	O
ulcer	B-D014456
	O

Cardiovascular:	O
chest	B-D002637
pain,	I-D002637
hypotensive	O
reaction,	O
palpitations,syncope	O

Skin:	B-D012867
erythema,	B-D004890
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
hives,	B-D006678
rash,	O
toxic	O
epidermal	O
necrolysis	O

Urinary:	O
kidney	B-D007668
impairment,	O
urinary	O
difficulty	O

Miscellaneous:	O
allergic	O
reaction,	O
anaphylactic	O
shock,	B-D012769
cholangiocarcinoma,	B-D018281
drug	O
interaction	O
with	O
erythromycin	B-D004917
(stomach	O
upset),	O
edema	B-D004487
	O

The	O
following	O
adverse	O
drug	O
events	O
may	O
be	O
borne	O
in	O
mind	O
as	O
potential	O
effects	O
of	O
the	O
components	O
of	O
this	O
product	O

Potential	O
effects	O
of	O
high	O
dosage	O
are	O
listed	O
in	O
the	O
OVERDOSAGE	O
section	O
of	O
this	O
insert	O

Aspirin:	B-D001241
occult	B-D009780
blood	I-D009780
loss,	O
hemolytic	O
anemia,	B-D000740
iron	B-D007501
deficiency	O
anemia,	B-D000740
gastric	O
distress,	O
heartburn,	B-D006356
nausea,	B-D009325
peptic	B-D010437
ulcer,	I-D010437
prolonged	O
bleeding	B-D001760
time,	I-D001760
acute	O
airway	B-D000402
obstruction,	I-D000402
renal	O
toxicity	O
when	O
taken	O
in	O
high	O
doses	O
for	O
prolonged	O
periods,	O
impaired	O
urate	O
excretion,	O
hepatitis	B-D006505
	O

Caffeine:	B-D002110
cardiac	B-D002299
stimulation,	O
irritability,	O
tremor,	B-D014202
dependence,	O
nephrotoxicity,	O
hyperglycemia	B-D006943
	O

Codeine:	B-D003061
nausea,	B-D009325
vomiting,	B-D014839
drowsiness,	O
lightheadedness,	B-D008027
constipation,	B-D003248
pruritus	B-D011537
	O

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
AGGRENOX	O
increases	O
the	O
risk	B-D012306
of	O
bleeding	O
(5.1)	O
Avoid	O
use	O
in	O
patients	B-D010361
with	O
severe	O
hepatic	O
or	O
renal	B-D051437
insufficiency	I-D051437
(5.2,	O
5.3)	O
Can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman,	O
especially	O
in	O
the	O
third	O
trimester	O
(5.4)	O
5.1	O
Risk	B-D012306
of	O
Bleeding	O
AGGRENOX	O
increases	O
the	O
risk	B-D012306
of	O
bleeding	O

Risk	B-D012307
factors	I-D012307
for	O
bleeding	O
include	O
the	O
use	O
of	O
other	O
drugs	O
that	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
(e.g.,	O
anticoagulants,	B-D000925
antiplatelet	O
agents,	O
heparin,	B-D006493
anagrelide,	B-C021139
fibrinolytic	B-D005337
therapy,	O
and	O
chronic	O
use	O
of	O
NSAIDs)	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)	O
]	O

Intracranial	O
Hemorrhage	B-D006470
In	O
European	B-D005060
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2),	O
the	O
incidence	B-D015994
of	O
intracranial	O
hemorrhage	B-D006470
was	O
0.6%	O
in	O
the	O
AGGRENOX	O
group,	O
0.5%	O
in	O
the	O
extended-release	O
dipyridamole	B-D004176
(ER-DP)	O
group,	O
0.4%	O
in	O
the	O
aspirin	B-D001241
(ASA)	O
group	O
and	O
0.4%	O
in	O
the	O
placebo	O
groups	O

Gastrointestinal	O
(GI)	O
Side	O
Effects	O
GI	O
side	O
effects	O
include	O
stomach	B-D013270
pain,	B-D010146
heartburn,	B-D006356
nausea,	B-D009325
vomiting,	B-D014839
and	O
gross	O
GI	O
bleeding	O

Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
dyspepsia,	B-D004415
are	O
common	O
and	O
can	O
occur	O
anytime	O
during	O
therapy,	O
physicians	B-D010820
should	O
remain	O
alert	O
for	O
signs	O
of	O
ulceration	B-D014456
and	O
bleeding,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
GI	O
symptoms	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
side	O
effects	O
and	O
what	O
steps	O
to	O
take	O
if	O
they	O
occur	O

In	O
ESPS2,	O
the	O
incidence	B-D015994
of	O
gastrointestinal	O
bleeding	O
was	O
4.1%	O
in	O
the	O
AGGRENOX	O
group,	O
2.2%	O
in	O
the	O
extended-release	O
dipyridamole	B-D004176
group,	O
3.2%	O
in	O
the	O
aspirin	B-D001241
group,	O
and	O
2.1%	O
in	O
the	O
placebo	O
groups	O

Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Avoid	O
using	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
a	O
history	B-D006664
of	O
active	O
peptic	B-D010437
ulcer	I-D010437
disease,	B-D004194
which	O
can	O
cause	O
gastric	B-D005753
mucosal	I-D005753
irritation	O
and	O
bleeding	O

Alcohol	O
Warning	O
Because	O
AGGRENOX	O
contains	O
aspirin,	B-D001241
counsel	O
patients	B-D010361
who	O
consume	O
three	O
or	O
more	O
alcoholic	O
drinks	O
every	O
day	O
about	O
the	O
bleeding	O
risks	B-D012306
involved	O
with	O
chronic,	O
heavy	O
alcohol	O
use	O
while	O
taking	O
aspirin	B-D001241
	O

5.2	O
Renal	O
Failure	O
Avoid	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
severe	O
renal	O
failure	O
(glomerular	O
filtration	B-D005374
rate	O
less	O
than	O
10	O
mL/minute)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.6)	O
and	O
Clinical	O
Pharmacology	B-D010600
(12.3)	O
]	O

5.3	O
Hepatic	B-D048550
Insufficiency	I-D048550
Elevations	O
of	O
hepatic	O
enzymes	B-D004798
and	O
hepatic	O
failure	O
have	O
been	O
reported	O
in	O
association	B-D001244
with	O
dipyridamole	B-D004176
administration	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.6)	O
and	O
Clinical	O
Pharmacology	B-D010600
(12.3)	O
]	O

5.4	O
Pregnancy	B-D011247
Because	O
AGGRENOX	O
contains	O
aspirin,	B-D001241
AGGRENOX	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O

Maternal	O
aspirin	B-D001241
use	O
during	O
later	O
stages	O
of	O
pregnancy	B-D011247
may	O
cause	O
low	O
birth	B-D001724
weight,	I-D001724
increased	O
incidence	B-D015994
for	O
intracranial	O
hemorrhage	B-D006470
in	O
premature	B-C070504
infants,	B-D007223
stillbirths	B-D050497
and	O
neonatal	B-D009356
death	B-D003643
	O

Because	O
of	O
the	O
above	O
and	O
because	O
of	O
the	O
known	O
effects	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
on	O
the	O
fetal	O
cardiovascular	B-D002319
system	I-D002319
(closure	O
of	O
the	O
ductus	B-D004373
arteriosus),	I-D004373
avoid	O
AGGRENOX	O
in	O
the	O
third	O
trimester	O
of	O
pregnancy	B-D011247
[	O
see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

Aspirin	B-D001241
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
rats	B-D051381
(spina	O
bifida,	O
exencephaly,	O
microphthalmia	O
and	O
coelosomia)	O
and	O
rabbits	B-D011817
(congested	O
fetuses,	B-D005333
agenesis	O
of	O
skull	B-D012886
and	O
upper	O
jaw,	B-D007568
generalized	O
edema	B-D004487
with	O
malformation	O
of	O
the	O
head,	B-D006257
and	O
diaphanous	O
skin)	B-D012867
at	O
oral	O
doses	O
of	O
330	O
mg/kg/day	O
and	O
110	O
mg/kg/day,	O
respectively	B-D000078682
	O

These	O
doses,	O
which	O
also	O
resulted	O
in	O
a	O
high	O
resorption	O
rate	O
in	O
rats	B-D051381
(63%	O
of	O
implantations	O
versus	O
5%	O
in	O
controls),	O
are,	O
on	O
a	O
mg/m2	O
basis,	O
about	O
66	O
and	O
44	O
times,	B-D013995
respectively,	B-D000078682
the	O
dose	O
of	O
aspirin	B-D001241
contained	O
in	O
the	O
maximum	O
recommended	O
daily	O
human	O
dose	O
of	O
AGGRENOX	O

Reproduction	B-D012098
studies	O
with	O
dipyridamole	B-D004176
have	O
been	O
performed	O
in	O
mice,	B-D051379
rabbits	B-D011817
and	O
rats	B-D051381
at	O
oral	O
doses	O
of	O
up	O
to	O
125	O
mg/kg,	O
40	O
mg/kg	O
and	O
1000	O
mg/kg,	O
respectively	B-D000078682
(about	O
1½,	O
2	O
and	O
25	O
times	B-D013995
the	O
maximum	O
recommended	O
daily	O
human	O
oral	O
dose,	O
respectively,	B-D000078682
on	O
a	O
mg/m2	O
basis)	O
and	O
have	O
revealed	O
no	O
evidence	O
of	O
harm	O
to	O
the	O
fetus	B-D005333
due	O
to	O
dipyridamole	B-D004176
	O

When	O
330	O
mg	O
aspirin/kg/day	B-D001241
was	O
combined	O
with	O
75	O
mg	O
dipyridamole/kg/day	B-D004176
in	O
the	O
rat,	O
the	O
resorption	O
rate	O
approached	O
100%,	O
indicating	O
potentiation	O
of	O
aspirin-related	B-D001241
fetal	O
toxicity	O

There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
of	O
the	O
use	O
of	O
AGGRENOX	O
in	O
pregnant	B-D037841
women	I-D037841
	O

If	O
AGGRENOX	O
is	O
used	O
during	O
pregnancy,	B-D011247
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
AGGRENOX,	O
inform	O
the	O
patient	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	B-D005333
	O

5.5	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324
Dipyridamole	B-D004176
has	O
a	O
vasodilatory	O
effect	O

Chest	B-D002637
pain	I-D002637
may	O
be	O
precipitated	O
or	O
aggravated	O
in	O
patients	B-D010361
with	O
underlying	O
coronary	B-D003324
artery	I-D003324
disease	I-D003324
who	O
are	O
receiving	O
dipyridamole	B-D004176
	O

For	O
stroke	B-D020521
or	O
TIA	O
patients	B-D010361
for	O
whom	O
aspirin	B-D001241
is	O
indicated	O
to	O
prevent	O
recurrent	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
or	O
angina	B-D000787
pectoris,	I-D000787
the	O
aspirin	B-D001241
in	O
this	O
product	O
may	O
not	O
provide	O
adequate	O
treatment	O
for	O
the	O
cardiac	B-D002299
indications	O

5.6	O
Hypotension	B-D007022
Dipyridamole	B-D004176
produces	O
peripheral	O
vasodilation,	B-D014664
which	O
can	O
exacerbate	O
pre-existing	O
hypotension	B-D007022
	O

5.7	O
General	O
AGGRENOX	O
capsules	B-D002214
are	O
not	O
interchangeable	O
with	O
the	O
individual	O
components	O
of	O
aspirin	B-D001241
and	O
dipyridamole	B-D004176
tablets	B-D013607
	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Hypersensitivity	B-D006967
[	O
see	O
Contraindications	B-D000075202
(4.1)	O
]	O
Allergy	O
[	O
see	O
Contraindications	B-D000075202
(4.2)	O
]	O
Risk	B-D012306
of	O
Bleeding	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(>10%	O
and	O
greater	O
than	O
placebo)	O
were	O
headache,	B-D006261
dyspepsia,	B-D004415
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
and	O
diarrhea	B-D003967
(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Boehringer	O
Ingelheim	O
Pharmaceuticals,	O
Inc	O

at	O
(800)	O
542-6257	O
or	O
(800)	O
459-9906	O
TTY	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
efficacy	O
and	O
safety	B-D012449
of	O
AGGRENOX	O
was	O
established	O
in	O
the	O
European	B-D005060
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2)	O

ESPS2	O
was	O
a	O
double-blind,	O
placebo-controlled	O
study	O
that	O
evaluated	O
6602	O
patients	B-D010361
over	O
the	O
age	O
of	O
18	O
years	O
who	O
had	O
a	O
previous	O
ischemic	O
stroke	B-D020521
or	O
transient	O
ischemic	O
attack	O
within	O
ninety	O
days	O
prior	O
to	O
entry	O

Patients	B-D010361
were	O
randomized	O
to	O
either	O
AGGRENOX,	O
aspirin,	B-D001241
ER-DP,	O
or	O
placebo	O
[	O
see	O
Clinical	O
Studies	O
(14)	O
];	O
primary	O
endpoints	O
included	O
stroke	B-D020521
(fatal	O
or	O
nonfatal)	O
and	O
death	B-D003643
from	O
all	O
causes	O

This	O
24-month,	O
multicenter,	O
double-blind,	O
randomized	O
study	O
(ESPS2)	O
was	O
conducted	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	B-D012449
of	O
AGGRENOX	O
with	O
placebo,	O
extended-release	O
dipyridamole	B-D004176
alone	O
and	O
aspirin	B-D001241
alone	O

The	O
study	O
was	O
conducted	O
in	O
a	O
total	O
of	O
6602	O
male	B-D008297
and	O
female	B-D005260
patients	B-D010361
who	O
had	O
experienced	O
a	O
previous	O
ischemic	O
stroke	B-D020521
or	O
transient	O
ischemia	B-D007511
of	O
the	O
brain	B-D001921
within	O
three	O
months	O
prior	O
to	O
randomization	O

Table	O
1	O
presents	O
the	O
incidence	B-D015994
of	O
adverse	O
events	O
that	O
occurred	O
in	O
1%	O
or	O
more	O
of	O
patients	B-D010361
treated	O
with	O
AGGRENOX	O
where	O
the	O
incidence	B-D015994
was	O
also	O
greater	O
than	O
in	O
those	O
patients	B-D010361
treated	O
with	O
placebo	O

There	O
is	O
no	O
clear	O
benefit	O
of	O
the	O
dipyridamole/aspirin	B-D004176
combination	O
over	O
aspirin	B-D001241
with	O
respect	B-D000078682
to	O
safety	B-D012449
	O

Table	O
1	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
in	O
ESPS2a	O
Individual	O
Treatment	O
Group	O
AGGRENOX	O
ER-DP	O
Alone	O
ASA	O
Alone	O
Placebo	O
Body	O
System/Preferred	O
Term	O
aReported	O
by	O
≥1%	O
of	O
patients	B-D010361
during	O
AGGRENOX	O
treatment	O
where	O
the	O
incidence	B-D015994
was	O
greater	O
than	O
in	O
those	O
treated	O
with	O
placebo	O

Note:	O
ER-DP	O
=	O
extended-release	O
dipyridamole	B-D004176
200	O
mg;	O
ASA	O
=	O
aspirin	B-D001241
25	O
mg	O

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O

NOS	O
=	O
not	O
otherwise	O
specified	O

1650	O
1654	O
1649	O
1649	O
Total	O
Number	O
of	O
Patients	B-D010361
Total	O
Number	O
(%)	O
of	O
Patients	B-D010361
With	O
atLeast	O
One	O
On-Treatment	O
AdverseEvent	O
1319	O
(80%)	O
1305	O
(79%)	O
1323	O
(80%)	O
1304	O
(79%)	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Disorders	O
Headache	B-D006261
647	O
(39%)	O
634	O
(38%)	O
558	O
(34%)	O
543	O
(33%)	O
Convulsions	O
28	O
(2%)	O
15	O
(1%)	O
28	O
(2%)	O
26	O
(2%)	O
Gastrointestinal	O
System	O
Disorders	O
Dyspepsia	B-D004415
303	O
(18%)	O
288	O
(17%)	O
299	O
(18%)	O
275	O
(17%)	O
Abdominal	B-D015746
Pain	I-D015746
289	O
(18%)	O
255	O
(15%)	O
262	O
(16%)	O
239	O
(14%)	O
Nausea	B-D009325
264	O
(16%)	O
254	O
(15%)	O
210	O
(13%)	O
232	O
(14%)	O
Diarrhea	B-D003967
210	O
(13%)	O
257	O
(16%)	O
112	O
(7%)	O
161	O
(10%)	O
Vomiting	B-D014839
138	O
(8%)	O
129	O
(8%)	O
101	O
(6%)	O
118	O
(7%)	O
Hemorrhage	B-D006470
Rectum	B-D012007
26	O
(2%)	O
22	O
(1%)	O
16	O
(1%)	O
13	O
(1%)	O
Melena	B-D008551
31	O
(2%)	O
10	O
(1%)	O
20	O
(1%)	O
13	O
(1%)	O
Hemorrhoids	B-D006484
16	O
(1%)	O
13	O
(1%)	O
10	O
(1%)	O
10	O
(1%)	O
GI	O
Hemorrhage	B-D006470
20	O
(1%)	O
5	O
(0%)	O
15	O
(1%)	O
7	O
(0%)	O
Body	O
as	O
a	O
Whole	O
-	O
General	O
Disorders	O
Pain	B-D010146
105	O
(6%)	O
88	O
(5%)	O
103	O
(6%)	O
99	O
(6%)	O
Fatigue	B-D005221
95	O
(6%)	O
93	O
(6%)	O
97	O
(6%)	O
90	O
(5%)	O
Back	B-D001416
Pain	I-D001416
76	O
(5%)	O
77	O
(5%)	O
74	O
(4%)	O
65	O
(4%)	O
Accidental	O
Injury	O
42	O
(3%)	O
24	O
(1%)	O
51	O
(3%)	O
37	O
(2%)	O
Malaise	O
27	O
(2%)	O
23	O
(1%)	O
26	O
(2%)	O
22	O
(1%)	O
Asthenia	B-D001247
29	O
(2%)	O
19	O
(1%)	O
17	O
(1%)	O
18	O
(1%)	O
Syncope	B-D013575
17	O
(1%)	O
13	O
(1%)	O
16	O
(1%)	O
8	O
(0%)	O
Psychiatric	O
Disorders	O
Amnesia	B-D000647
39	O
(2%)	O
40	O
(2%)	O
57	O
(3%)	O
34	O
(2%)	O
Confusion	B-D003221
18	O
(1%)	O
9	O
(1%)	O
22	O
(1%)	O
15	O
(1%)	O
Anorexia	B-D000855
19	O
(1%)	O
17	O
(1%)	O
10	O
(1%)	O
15	O
(1%)	O
Somnolence	O
20	O
(1%)	O
13	O
(1%)	O
18	O
(1%)	O
9	O
(1%)	O
Musculoskeletal	B-D009141
System	I-D009141
Disorders	O
Arthralgia	B-D018771
91	O
(6%)	O
75	O
(5%)	O
91	O
(6%)	O
76	O
(5%)	O
Arthritis	B-D001168
34	O
(2%)	O
25	O
(2%)	O
17	O
(1%)	O
19	O
(1%)	O
Arthrosis	B-D001154
18	O
(1%)	O
22	O
(1%)	O
13	O
(1%)	O
14	O
(1%)	O
Myalgia	B-D063806
20	O
(1%)	O
16	O
(1%)	O
11	O
(1%)	O
11	O
(1%)	O
Respiratory	B-D012137
System	I-D012137
Disorders	O
Coughing	B-D003371
25	O
(2%)	O
18	O
(1%)	O
32	O
(2%)	O
21	O
(1%)	O
Upper	O
Respiratory	O
Tract	O
Infection	O
16	O
(1%)	O
9	O
(1%)	O
16	O
(1%)	O
14	O
(1%)	O
Cardiovascular	O
Disorders,	O
General	O
Cardiac	B-D002299
Failure	O
26	O
(2%)	O
17	O
(1%)	O
30	O
(2%)	O
25	O
(2%)	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
Hemorrhage	B-D006470
NOS	O
52	O
(3%)	O
24	O
(1%)	O
46	O
(3%)	O
24	O
(1%)	O
Epistaxis	B-D004844
39	O
(2%)	O
16	O
(1%)	O
45	O
(3%)	O
25	O
(2%)	O
Purpura	B-D011693
23	O
(1%)	O
8	O
(0%)	O
9	O
(1%)	O
7	O
(0%)	O
Neoplasm	O
Neoplasm	O
NOS	O
28	O
(2%)	O
16	O
(1%)	O
23	O
(1%)	O
20	O
(1%)	O
Red	O
Blood	B-D001769
Cell	O
Disorders	O
Anemia	B-D000740
27	O
(2%)	O
16	O
(1%)	O
19	O
(1%)	O
9	O
(1%)	O
Discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
ESPS2	O
was	O
25%	O
for	O
AGGRENOX,	O
25%	O
for	O
extended-release	O
dipyridamole,	B-D004176
19%	O
for	O
aspirin,	B-D001241
and	O
21%	O
for	O
placebo	O
(refer	O
to	O
Table	O
2)	O
Table	O
2	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
that	O
Led	O
to	O
the	O
Discontinuation	O
of	O
Treatment:	O
Adverse	O
Events	O
with	O
an	O
Incidence	B-D015994
of	O
≥1%	O
in	O
the	O
AGGRENOX	O
Group	O
Treatment	O
Groups	O
AGGRENOX	O
ER-DP	O
ASA	O
Placebo	O
Note:	O
ER-DP	O
=	O
extended-release	O
dipyridamole	B-D004176
200	O
mg;	O
ASA	O
=	O
aspirin	B-D001241
25	O
mg	O

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O

Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Patients	B-D010361
with	O
at	O
least	O
one	O
Adverse	O
Eventthat	O
led	O
to	O
treatment	O
discontinuation	O
417	O
(25%)	O
419	O
(25%)	O
318	O
(19%)	O
352	O
(21%)	O
Headache	B-D006261
165	O
(10%)	O
166	O
(10%)	O
57	O
(3%)	O
69	O
(4%)	O
Dizziness	B-D004244
85	O
(5%)	O
97	O
(6%)	O
69	O
(4%)	O
68	O
(4%)	O
Nausea	B-D009325
91	O
(6%)	O
95	O
(6%)	O
51	O
(3%)	O
53	O
(3%)	O
Abdominal	B-D015746
Pain	I-D015746
74	O
(4%)	O
64	O
(4%)	O
56	O
(3%)	O
52	O
(3%)	O
Dyspepsia	B-D004415
59	O
(4%)	O
61	O
(4%)	O
49	O
(3%)	O
46	O
(3%)	O
Vomiting	B-D014839
53	O
(3%)	O
52	O
(3%)	O
28	O
(2%)	O
24	O
(1%)	O
Diarrhea	B-D003967
35	O
(2%)	O
41	O
(2%)	O
9	O
(<1%)	O
16	O
(<1%)	O
Stroke	B-D020521
39	O
(2%)	O
48	O
(3%)	O
57	O
(3%)	O
73	O
(4%)	O
Transient	O
Ischemic	O
Attack	O
35	O
(2%)	O
40	O
(2%)	O
26	O
(2%)	O
48	O
(3%)	O
Angina	B-D000787
Pectoris	I-D000787
23	O
(1%)	O
20	O
(1%)	O
16	O
(<1%)	O
26	O
(2%)	O
Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment	O

Other	O
Adverse	O
Events	O
Adverse	O
reactions	O
that	O
occurred	O
in	O
less	O
than	O
1%	O
of	O
patients	B-D010361
treated	O
with	O
AGGRENOX	O
in	O
the	O
ESPS2	O
study	O
and	O
that	O
were	O
medically	O
judged	O
to	O
be	O
possibly	O
related	O
to	O
either	O
dipyridamole	B-D004176
or	O
aspirin	B-D001241
are	O
listed	O
below	O

Body	O
as	O
a	O
Whole:	O
Allergic	O
reaction,	O
fever	B-D005334
Cardiovascular:	O
Hypotension	B-D007022
Central	B-D002490
Nervous	I-D002490
System:	I-D002490
Coma,	B-D003128
dizziness,	B-D004244
paresthesia,	B-D010292
cerebral	B-D002543
hemorrhage,	I-D002543
intracranial	O
hemorrhage,	B-D006470
subarachnoid	B-D013345
hemorrhage	I-D013345
Gastrointestinal:	O
Gastritis,	B-D005756
ulceration	B-D014456
and	O
perforation	O
Hearing	B-D006309
and	O
Vestibular	O
Disorders:	O
Tinnitus,	B-D014012
and	O
deafness	B-D003638
	O

Patients	B-D010361
with	O
high	O
frequency	O
hearing	B-D034381
loss	I-D034381
may	O
have	O
difficulty	O
perceiving	O
tinnitus	B-D014012
	O

In	O
these	O
patients,	B-D010361
tinnitus	B-D014012
cannot	O
be	O
used	O
as	O
a	O
clinical	O
indicator	O
of	O
salicylism	O
Heart	B-D006339
Rate	I-D006339
and	O
Rhythm	O
Disorders:	O
Tachycardia,	B-D013610
palpitation,	O
arrhythmia,	O
supraventricular	O
tachycardia	B-D013610
Liver	B-D008099
and	O
Biliary	O
System	O
Disorders:	O
Cholelithiasis,	B-D002769
jaundice,	B-D007565
hepatic	O
function	O
abnormal	O
Metabolic	O
and	O
Nutritional	O
Disorders:	O
Hyperglycemia,	B-D006943
thirst	B-D013894
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders:	O
Hematoma,	B-D006406
gingival	B-D005881
bleeding	O
Psychiatric	O
Disorders:	O
Agitation	O
Reproductive:	O
Uterine	B-D014592
hemorrhage	I-D014592
Respiratory:	O
Hyperpnea,	O
asthma,	B-D001249
bronchospasm,	O
hemoptysis,	B-D006469
pulmonary	B-D011654
edema	I-D011654
Special	O
Senses	O
Other	O
Disorders:	O
Taste	B-D013649
loss	O
Skin	B-D012867
and	O
Appendages	O
Disorders:	O
Pruritus,	B-D011537
urticaria	B-D014581
Urogenital:	O
Renal	B-D051437
insufficiency	I-D051437
and	O
failure,	O
hematuria	B-D006417
Vascular	O
(Extracardiac)	O
Disorders:	O
Flushing	B-D005483
Laboratory	O
Changes	O
Over	O
the	O
course	O
of	O
the	O
24-month	O
study	O
(ESPS2),	O
patients	B-D010361
treated	O
with	O
AGGRENOX	O
showed	O
a	O
decline	O
(mean	O
change	O
from	O
baseline)	O
in	O
hemoglobin	O
of	O
0.25	O
g/dL,	O
hematocrit	B-D006400
of	O
0.75%,	O
and	O
erythrocyte	B-D004906
count	I-D004906
of	O
0.13x106/mm3	O

6.2	O
Post-Marketing	O
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
either	O
in	O
the	O
literature	B-D008091
or	O
are	O
from	O
post-marketing	O
spontaneous	O
reports	O
for	O
either	O
dipyridamole	B-D004176
or	O
aspirin	B-D001241
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
estimate	O
reliably	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

Decisions	O
to	O
include	O
these	O
reactions	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
reaction,	O
(2)	O
frequency	O
of	O
reporting,	O
or	O
(3)	O
strength	O
of	O
causal	O
connection	O
to	O
AGGRENOX	O

Body	O
as	O
a	O
Whole:	O
Hypothermia,	B-D007035
chest	B-D002637
pain	I-D002637
Cardiovascular:	O
Angina	B-D000787
pectoris	I-D000787
Central	B-D002490
Nervous	I-D002490
System:	I-D002490
Cerebral	B-C079279
edema	B-D004487
Fluid	O
and	O
Electrolyte:	O
Hyperkalemia,	B-D006947
metabolic	O
acidosis,	B-D000142
respiratory	I-D000142
alkalosis,	B-D000471
hypokalemia	B-D007008
Gastrointestinal:	O
Pancreatitis,	B-D010195
Reye	B-D012202
syndrome,	I-D012202
hematemesis	B-D006396
Hearing	B-D006309
and	O
Vestibular	O
Disorders:	O
Hearing	B-D034381
loss	I-D034381
Immune	B-D007107
System	I-D007107
Disorders:	O
Hypersensitivity,	B-D006967
acute	O
anaphylaxis,	B-D000707
laryngeal	B-D007819
edema	I-D007819
Liver	B-D008099
and	O
Biliary	O
System	O
Disorders:	O
Hepatitis,	B-D006505
hepatic	O
failure	O
Musculoskeletal:	O
Rhabdomyolysis	B-D012206
Metabolic	O
and	O
Nutritional	O
Disorders:	O
Hypoglycemia,	B-D007003
dehydration	B-D003681
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders:	O
Prolongation	O
of	O
the	O
prothrombin	B-D011517
time,	I-D011517
disseminated	B-D004211
intravascular	I-D004211
coagulation,	I-D004211
coagulopathy,	O
thrombocytopenia	B-D013921
Reproductive:	O
Prolonged	O
pregnancy	B-D011247
and	O
labor,	O
stillbirths,	B-D050497
lower	O
birth	B-D001724
weight	I-D001724
infants,	B-D007223
antepartum	O
and	O
postpartum	O
bleeding	O
Respiratory:	O
Tachypnea,	B-D059246
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages	O
Disorders:	O
Rash,	O
alopecia,	B-D000505
angioedema,	B-D000799
Stevens-Johnson	B-D013262
syndrome,	I-D013262
skin	B-D012867
hemorrhages	B-D006470
such	O
as	O
bruising,	O
ecchymosis,	B-D004438
and	O
hematoma	B-D006406
Urogenital:	O
Interstitial	O
nephritis,	B-D009393
papillary	O
necrosis,	B-D009336
proteinuria	B-D011507
Vascular	O
(Extracardiac)	O
Disorders:	O
Allergic	O
vasculitis	B-D014657
Other	O
Adverse	O
Events:	O
anorexia,	B-D000855
aplastic	O
anemia,	B-D000740
migraine,	O
pancytopenia,	B-D010198
thrombocytosis	B-D013922
	O

PrevidolRx	O
Plus	O
Analgesic	O
PakGenPak	O
Solutions	B-D012996
LLCPrevidolRx	O
Plus	O
Analgesic	O
Pak	O
(Part	O
1	O
of	O
2)	O
DESCRIPTION:	O
DICLOFENAC	B-D004008
SODIUM	B-D012964
DELAYED-RELEASE	O
TABLETS	B-D013607
USP-75MGRx	O
only	O
Cardiovascular	O
Risk	B-D012306
NASAIDs	B-C015378
may	O
cause	O
an	O
increase	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
a	O
greater	O
risk	B-D012306
	O

(see	O
WARNINGS)	O
Diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
WARNINGS)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increase	O
risk	B-D012306
of	O
serious	O
gastrointestional	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
a	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(see	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
Diclofenac	B-D004008
Sodium	B-D012964
Delayed-release	O
Tablets,	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	B-D010361
are:	O
•	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting.•	B-D014839
Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
liver	B-D017093
failure,	I-D017093
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Unique	O
Pharmaceutical	O
Laboratories	B-D007753
toll-free	O
at	O
(800)	O
521-5340	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	B-D000068579
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O

(5.4)	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
celecoxib,	B-D000068579
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke	B-D020521
	O

Patients	B-D010361
with	O
known	O
CV	O
disease/risk	B-D004194
factors	O
may	O
be	O
at	O
greater	O
risk	B-D012306
(5.1,	O
14.6,	O
17.2)	O

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
risk	B-D012306
is	O
greater	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
GI	O
bleeding,	O
and	O
in	O
patients	B-D010361
at	O
high	O
risk	B-D012306
for	O
GI	O
events,	O
especially	O
the	O
elderly	O

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	B-D010361
(5.4,	O
8.5,	O
14.6,	O
17.3)	O

Elevated	O
liver	B-D008099
enzymes	B-D004798
and,	O
rarely,	O
severe	O
hepatic	O
reactions	O

Discontinue	O
use	O
of	O
celecoxib	B-D000068579
immediately	O
if	O
abnormal	O
liver	B-D008099
enzymes	B-D004798
persist	O
or	O
worsen	O
(5.5,	O
17.4)	O

New	O
onset	O
or	O
worsening	O
of	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	B-D000068579
(5.2,	O
7.4,	O
17.2)	O

Fluid	O
retention	O
and	O
edema	B-D004487
	O

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
(5.3,	O
17.6)	O

Renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use	O

Use	O
celecoxib	B-D000068579
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
and	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
or	O
angiotensin	B-D000804
II	I-D000804
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6)	O

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O
(5.7,	O
10,	O
17.7)	O

Serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy	O

Discontinue	O
celecoxib	B-D000068579
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	B-D012867
reactions	O
(5.8,	O
17.5)	O

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	B-D000068579
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib,	B-D000068579
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
celecoxib	B-D000068579
does	O
increase	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O

Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)	O
]	O

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	B-D000068579
can	O
lead	B-D007854
to	O
the	O
onset	O
of	O
new	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

NSAIDs,	O
including	O
celecoxib,	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	B-D000068579
and	O
throughout	O
the	O
course	O
of	O
therapy	O

The	O
rates	O
of	O
hypertension	B-D006973
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	B-D000068579
ibuprofen	B-D007052
and	O
diclofenac-treated	B-D004008
patients	B-D010361
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	B-D000078682
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
taking	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
[see	O
Adverse	O
Reactions	O
(6.1)	O
]	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulceration,	B-D014456
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	B-D000068579
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	B-D013995
during	O
the	O
course	O
of	O
therapy	O

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
with	O
neither	O
of	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population	B-D011153
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
celecoxib	B-D000068579
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

For	O
high-risk	O
patients,	B-D010361
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
active	O
GI	O
bleeding	O

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	B-D008099
enzymes	B-D004798
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
with	O
NSAIDs	O

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	B-D007565
and	O
fatal	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis	B-D009336
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	B-D017809
outcome)	I-D017809
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
[see	O
Adverse	O
Reactions	O
(6.1)	O
]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
celecoxib,	B-D000068579
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
celecoxib	B-D000068579
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	B-D008099
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	B-D008099
test	B-C004551
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib	B-D000068579
	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
celecoxib	B-D000068579
should	O
be	O
discontinued	O

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
angiotensin	B-D000804
II	I-D000804
receptor	O
antagonists,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
trials	I-D016430
with	O
celecoxib	B-D000068579
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

Therefore,	O
treatment	O
with	O
celecoxib	B-D000068579
is	O
not	O
recommended	O
in	O
these	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

If	O
celecoxib	B-D000068579
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	B-D010361
without	O
known	O
prior	O
exposure	O
to	O
celecoxib	B-D000068579
	O

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	B-D000799
have	O
been	O
reported	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
	O

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	B-D010361
without	O
prior	O
known	O
sulfa	O
allergy	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012877
manifestations	I-D012877
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	B-D011247
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	B-D000068579
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	B-D007854
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness	O

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
celecoxib	B-D000068579
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	B-D000068579
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	B-D000339
platelet	B-D010976
counts,	I-D010976
prothrombin	B-D011517
time	I-D011517
(PT),	O
or	O
partial	B-D010314
thromboplastin	I-D010314
time	I-D010314
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	B-D010974
aggregation	I-D010974
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
	O

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

The	O
use	O
of	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal	O

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	B-D001241
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
celecoxib	B-D000068579
should	O
not	O
be	O
administered	O
to	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

5.14	O
Laboratory	O
Tests	B-C004551
Because	O
serious	O
GI	O
tract	O
ulcerations	B-D014456
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	B-D010820
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
checked	O
periodically	B-D020492
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
or	O
renal	O
tests	B-C004551
persist	O
or	O
worsen,	O
celecoxib	B-D000068579
should	O
be	O
discontinued	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	B-D000068579
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	B-D010146
conditions	O

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	B-D000068579
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	B-D012306
of	O
adverse	O
reactions	O

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	B-D000068579
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	B-D000068579
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
celecoxib	B-D000068579
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	B-D000068579
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	B-D000068579
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia,	O
Psychiatric	O
:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders	O
:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary	O
:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	B-D010361
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis,	B-D013924
vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
Gastrointestinal	O
:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis,	B-D002769
hepatitis,	B-D006505
jaundice,	B-D007565
liver	B-D017093
failure	I-D017093
Hemic	O
and	O
lymphatic	B-D008196
:	O
Thrombocytopenia,	B-D013921
agranulocytosis,aplastic	B-D000380
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous	O
:	O
Ataxia,	B-D001259
suicide,	B-D013405
aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	B-D009393
Skin:	B-D012867
Erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	B-D006967
syndrome)	B-D013577
General	O
:	O
Sepsis,	B-D018805
sudden	O
death,	B-D003643
anaphylactoid	O
reaction,	O
angioedema	B-D000799
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
celecoxib	B-D000068579
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	B-D000068579
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

6.3	O
Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
BID,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
BID	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib3	B-D000068579
mg/kgN=77	O
Celecoxib6	B-D000068579
mg/kgN=82	O
Naproxen7.5	B-D009288
mg/kgN=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
InvestigationsAbnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	B-D000068579
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
celecoxib	B-D000068579
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	B-D000068579
pre-marketing	O
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib(400	B-D000068579
to	O
800	O
mg	O
daily)N	O
=	O
2285	O
PlaceboN=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
celecoxib,	B-D000068579
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders	O
:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

ZIPSOR	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

Gastrointestinal	O
Risk	B-D012306
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O

WARNING:	O
RISK	B-D012306
OF	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O
ZIPSOR	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
(5.2)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(5.4,7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
ZIPSOR	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
ZIPSOR	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
ZIPSOR	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
ZIPSOR	O
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
gestation	O
(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	B-D004008
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
ZIPSOR	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
ZIPSOR	O
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2%-4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
higher	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
ZIPSOR	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.3	O
Hepatotoxicity	O
In	O
clinical	B-D016430
trials	I-D016430
of	O
diclofenac-containing	B-D004008
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
were	O
observed	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O

In	O
a	O
large	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
with	O
oral	O
diclofenac	B-D004008
sodium	B-D012964
for	O
2–6	O
months,	O
patients	B-D010361
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3–8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
tests	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy	O

but	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

In	O
a	O
European	B-D005060
retrospective	O
population-based,	B-D011153
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	B-D004008
associated	O
drug-induced	O
liver	B-D008099
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	B-D004008
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	B-D016017
ratio	I-D016017
of	O
liver	B-D008099
injury	O

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	B-D016424
number	O
of	O
10	O
cases	O
of	O
liver	B-D008099
injury	O
associated	O
with	O
diclofenac,	B-D004008
the	O
adjusted	O
odds	B-D016017
ratio	I-D016017
increased	O
further	O
with	O
female	B-D005260
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
then	O
90	O
days	O

In	O
a	O
European	B-D005060
retrospective	O
population-based,	B-D011153
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	B-D004008
associated	O
drug-induced	O
liver	B-D008099
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	B-D004008
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	B-D016017
ratio	I-D016017
of	O
liver	B-D008099
injury	O

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	B-D016424
number	O
of	O
10	O
cases	O
of	O
liver	B-D008099
injury	O
associated	O
with	O
diclofenac,	B-D004008
the	O
adjusted	O
odds	B-D016017
ratio	I-D016017
increased	O
further	O
with	O
female	B-D005260
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
then	O
90	O
days	O

Physicians	B-D010820
should	O
measure	O
transaminases	B-D000637
at	O
baseline	O
and	O
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
ZIPSOR,	O
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
transaminases	B-D000637
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
patients	B-D010361
should	O
take	O
if	O
these	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
appear	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
ZIPSOR	O
should	O
be	O
discontinued	O
immediately	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
ZIPSOR	O
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver-related	B-D008099
event	O
in	O
patients	B-D010361
treated	O
with	O
ZIPSOR,	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Exercise	B-D015444
caution	O
when	O
prescribing	O
ZIPSOR	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
acetaminophen,	B-D000082
antibiotics,	O
antiepileptics)	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
ZIPSOR,	O
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
pre-	O
existing	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
diclofenac	B-D004008
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
ZIPSOR	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
ZIPSOR	O
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
ZIPSOR	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
ZIPSOR	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
preexisting	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
ZIPSOR	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
ZIPSOR	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
ZIPSOR	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
ZIPSOR	O
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
have	O
been	O
reported	O
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
diclofenac	B-D004008
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
ZIPSOR	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)]	O

When	O
ZIPSOR	O
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
ZIPSOR	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

ZIPSOR	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
ZIPSOR,	O
in	O
pregnant	B-D037841
women	I-D037841
starting	O
at	O
30	O
weeks	O
of	O
gestation	O
(third	O
trimester)	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
ZIPSOR	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
ZIPSOR,	O
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
warfarin,	B-D014859
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
ZIPSOR	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.3,	O
5.6)]	O

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
1%)	O
are	O
gastrointestinal	O
experiences	O
including	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
nausea,	B-D009325
vomiting,	B-D014839
dizziness,	B-D004244
headache,	B-D006261
somnolence,	O
pruritus,	B-D011537
and	O
increased	O
sweating	B-D013546
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Depomed,	B-C020884
Inc	O

at	O
1-866-458-6389	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
the	O
rates	O
in	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
safety	B-D012449
of	O
ZIPSOR	O
was	O
evaluated	O
in	O
965	O
subjects	O

In	O
patients	B-D010361
treated	O
with	O
ZIPSOR	O
25	O
mg	O
(N=345)	O
or	O
a	O
higher	O
dose,	O
three	O
or	O
four	O
times	B-D013995
a	O
day,	O
for	O
4	O
to	O
5	O
days,	O
the	O
most	O
common	O
adverse	O
reactions	O
(i.e.,	O
reported	O
in	O
≥	O
1%	O
of	O
ZIPSOR	O
treated	O
patients)	B-D010361
were	O
as	O
follows:	O
gastrointestinal	O
experiences	O
including	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
nausea,	B-D009325
vomiting,	B-D014839
dizziness,	B-D004244
headache,	B-D006261
somnolence,	O
pruritus,	B-D011537
and	O
increased	O
sweating	B-D013546
	O

(see	O
Table	O
1)	O
Table	O
1	O
Incidence	B-D015994
of	O
Treatment	O
Emergent	O
Adverse	O
Reactions	O
with	O
Incidence	B-D015994
≥	O
1%	O
of	O
ZIPSOR	O
Treated	O
Patients	B-D010361
in	O
Multiple-Dose	O
Studies	O
*There	O
was	O
greater	O
use	O
of	O
concomitant	O
opioid	O
rescue	O
medication	O
in	O
placebo	O
treated	O
patients	B-D010361
than	O
in	O
ZIPSOR	O
treated	O
patients	B-D010361
	O

MedDRA	O
System	O
Organ	O
Class	O
and	O
Preferred	O
Term	O
ZIPSOR*	O
25	O
mg	O
n=345	O
n	O
(%)	O
Placebo*	O
n=327	O
n	O
(%)	O
Any	O
Adverse	O
Events	O
144	O
(41.7)	O
181	O
(55.4)	O
Abdominal	B-D015746
Pain	I-D015746
24	O
(7.0)	O
11	O
(3.4)	O
Constipation	B-D003248
11	O
(3.2)	O
9	O
(2.8)	O
Diarrhea	B-D003967
8	O
(2.3)	O
9	O
(2.8)	O
Dyspepsia	B-D004415
4	O
(1.2)	O
8	O
(2.4)	O
Nausea	B-D009325
57	O
(16.5)	O
66	O
(20.2)	O
Vomiting	B-D014839
20	O
(5.8)	O
26	O
(8.0)	O
Dizziness	B-D004244
12	O
(3.5)	O
17	O
(5.2)	O
Headache	B-D006261
43	O
(12.5)	O
56	O
(17.1)	O
Somnolence	O
9	O
(2.6)	O
6	O
(1.8)	O
Pruritus	B-D011537
5	O
(1.4)	O
6	O
(1.8)	O
Sweating	B-D013546
Increase	O
4	O
(1.2)	O
2	O
(0.6)	O
In	O
patients	B-D010361
taking	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes,	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
in	O
patients	B-D010361
taking	O
other	O
NSAIDs	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions	O
in	O
patients	B-D010361
taking	O
other	O
NSAIDs,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
liver	B-D017093
failure,	I-D017093
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
WARNING;	O
LIMITATIONS	O
OF	O
USE,	O
GASTROINTESTINAL,	O
BLEEDING,	O
CARDIOVASCULAR,	O
and	O
RENAL	O
RISK	B-D012306
Limitations	O
of	O
Use	O
SPRIX	O
(ketorolac	O
tromethamine),	B-D014325
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID),	O
is	O
indicated	O
for	O
short-term	O
(up	O
to	O
5	O
days	O
in	O
adults)	B-D000328
management	O
of	O
moderate	O
to	O
moderately	O
severe	O
pain	B-D010146
that	O
requires	O
analgesia	B-D000698
at	O
the	O
opioid	O
level	O

Do	O
not	O
exceed	O
a	O
total	O
combined	O
duration	O
of	O
use	O
of	O
SPRIX	O
and	O
other	O
ketorolac	B-D020910
formulations	B-D020478
(IM/IV	O
or	O
oral)	O
of	O
5	O
days	O
[see	O
Dosage	O
and	O
Administration,	O
(2.1)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

SPRIX	O
is	O
not	O
indicated	O
for	O
use	O
in	O
pediatric	O
patients	B-D010361
and	O
it	O
is	O
not	O
indicated	O
for	O
minor	O
or	O
chronic	B-D059350
painful	I-D059350
conditions	O

Gastrointestinal	O
Risk	B-D012306
Ketorolac	B-D020911
tromethamine,	I-D020911
including	O
SPRIX,	O
can	O
cause	O
peptic	B-D010437
ulcers,	I-D010437
gastrointestinal	O
bleeding	O
and/or	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Therefore,	O
SPRIX	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
active	O
peptic	B-D010437
ulcer	I-D010437
disease,	B-D004194
in	O
patients	B-D010361
with	O
recent	O
gastrointestinal	O
bleeding	O
or	O
perforation,	O
and	O
in	O
patients	B-D010361
with	O
a	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

Bleeding	O
Risk	B-D012306
Ketorolac	B-D020911
tromethamine	I-D020911
inhibits	O
platelet	O
function	O
and	O
is,	O
therefore,	O
contraindicated	O
in	O
patients	B-D010361
with	O
suspected	O
or	O
confirmed	O
cerebrovascular	B-C079279
bleeding,	O
patients	B-D010361
with	O
hemorrhagic	O
diathesis,	O
incomplete	O
hemostasis	B-D006487
and	O
those	O
at	O
high	O
risk	B-D012306
of	O
bleeding	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.3)]	O

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O

SPRIX	O
Nasal	B-C015378
spray	O
is	O
contraindicated	O
for	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)]	O

Renal	O
Risk	B-D012306
SPRIX	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
impairment	O
and	O
in	O
patients	B-D010361
at	O
risk	B-D012306
for	O
renal	O
failure	O
due	O
to	O
volume	O
depletion	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.4)]	O

WARNING:	O
LIMITATIONS	O
OF	O
USE,	O
GASTROINTESTINAL,	O
BLEEDING,	O
CARDIOVASCULAR,	O
and	O
RENAL	O
RISK	B-D012306
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Limitations	O
of	O
Use	O
–	O
The	O
total	O
duration	O
of	O
use	O
of	O
SPRIX	O
and	O
other	O
ketorolac	B-D020910
formulations	B-D020478
should	O
not	O
exceed	O
5	O
days	O

(2.1)	O
Gastrointestinal	O
(GI)	O
Risk	B-D012306
–	O
Ketorolac	B-D020910
can	O
cause	O
peptic	B-D010437
ulcers,	I-D010437
GI	O
bleeding,	O
and/or	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

SPRIX	O
is	O
CONTRAINDICATED	O
in	O
patients	B-D010361
with	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
or	O
history	B-D006664
of	O
GI	O
bleeding	O

(4)	O
Bleeding	O
Risk	B-D012306
–	O
SPRIX	O
inhibits	O
platelet	O
function	O
and	O
is	O
CONTRAINDICATED	O
in	O
patients	B-D010361
with	O
suspected	O
or	O
confirmed	O
cerebrovascular	B-C079279
bleeding,	O
hemorrhagic	O
diathesis,	O
incomplete	O
hemostasis,	B-D006487
or	O
high	O
risk	B-D012306
of	O
bleeding	O

(4)	O
Cardiovascular	O
(CV)	O
Risk	B-D012306
–	O
NSAIDs	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.6)	O
SPRIX	O
is	O
CONTRAINDICATED	O
for	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4)	O
Renal	O
risk	B-D012306
–	O
SPRIX	O
is	O
CONTRAINDICATED	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
impairment	O
and	O
in	O
patients	B-D010361
at	O
risk	B-D012306
for	O
renal	O
failure	O
due	O
to	O
volume	O
depletion	O

(4)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
SPRIX	O
should	O
not	O
be	O
used	O
concomitantly	O
with	O
IM/IV	O
or	O
oral	O
ketorolac,	B-D020910
aspirin,	B-D001241
or	O
other	O
NSAIDs	O

(5.1)	O
Ketorolac	B-D020910
can	O
cause	O
serious	O
GI	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O

SPRIX	O
should	O
be	O
prescribed	O
with	O
caution	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
GI	O
bleeding	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O

(4,	O
5.2)	O
NSAIDs	O
affect	B-D000339
platelet	B-D010974
aggregation	I-D010974
and	O
may	O
cause	O
bleeding	O
complications	O

SPRIX	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
who	O
have	O
coagulation	O
disorders	O
or	O
are	O
on	O
therapy	O
that	O
affects	B-D000339
hemostasis	B-D006487
	O

Do	O
not	O
use	O
SPRIX	O
in	O
patients	B-D010361
for	O
whom	O
hemostasis	B-D006487
is	O
critical	O

(4,	O
5.3)	O
Ketorolac	B-D020910
can	O
cause	O
renal	O
injury	O

SPRIX	O
should	O
not	O
be	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
or	O
patients	B-D010361
at	O
risk	B-D012306
for	O
renal	O
failure	O
due	O
to	O
volume	O
depletion,	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
taking	O
diuretics	B-D004232
or	O
ACE	O
inhibitors	O

(4,	O
5.4,	O
12.4)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	B-D010361
with	O
or	O
without	O
a	O
history	B-D006664
of	O
allergic	O
reactions	O
to	O
aspirin	B-D001241
or	O
NSAIDs	O

SPRIX	O
should	O
be	O
discontinued	O
immediately	O
in	O
patients	B-D010361
with	O
allergic	O
reactions	O

(4,	O
5.5,	O
5.7,	O
5.11)	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke	B-D020521
can	O
occur	O
with	O
NSAID	O
treatment	O

(5.6)	O
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
patients	B-D010361
taking	O
NSAIDs	O

SPRIX	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
cardiac	B-D002299
decompensation	O
or	O
similar	O
conditions	O

(5.4,	O
5.6)	O
NSAIDs	O
can	O
cause	O
serious	O
dermatologic	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
and	O
toxic	O
epidermal	O
necrolysis,	O
which	O
can	O
be	O
fatal	O

SPRIX	O
should	O
be	O
discontinued	O
immediately	O
in	O
patients	B-D010361
with	O
skin	B-D012867
reactions	O

(4,	O
5.7)	O
During	O
pregnancy,	B-D011247
use	O
of	O
SPRIX	O
beyond	O
30	O
weeks	O
gestation	O
can	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus,	I-D004373
resulting	O
in	O
fetal	O
harm	O

(5.8)	O
5.1	O
Limitations	O
of	O
Use	O
The	O
total	O
duration	O
of	O
use	O
of	O
SPRIX	O
alone	O
or	O
sequentially	O
with	O
other	O
forms	B-D020478
of	O
ketorolac	B-D020910
is	O
not	O
to	O
exceed	O
5	O
days	O

SPRIX	O
must	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
forms	B-D020478
of	O
ketorolac	B-D020910
or	O
other	O
NSAIDs	O
[see	O
Dosage	O
and	O
Administration	O
(2.1)]	O

5.2	O
Gastrointestinal	O
(GI)	O
Effects	O
-	O
Risk	B-D012306
of	O
Ulceration,	B-D014456
Bleeding,	O
and	O
Perforation	O
SPRIX	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previously	O
documented	O
peptic	B-D010437
ulcers	I-D010437
and/or	O
GI	O
bleeding	O
[see	O
Contraindications	B-D000075202
(4)]	O

Ketorolac	B-D020911
tromethamine	I-D020911
can	O
cause	O
serious	O
GI	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
ketorolac	B-D020910
	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Minor	O
upper	O
GI	O
problems,	O
such	O
as	O
dyspepsia,	B-D004415
are	O
common	O
and	O
may	O
also	O
occur	O
at	O
any	O
time	B-D013995
during	O
NSAID	O
therapy	O

The	O
incidence	B-D015994
and	O
severity	O
of	O
GI	O
complications	O
increases	O
with	O
increasing	O
dose	O
of,	O
and	O
duration	O
of	O
treatment	O
with,	O
ketorolac	B-D020910
	O

Even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

In	O
addition	O
to	O
past	O
history	B-D006664
of	O
ulcer	B-D014456
disease,	B-D004194
other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
for	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients,	B-D010361
and	O
therefore,	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population	B-D011153
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
possible	O
duration	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy,	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

This	O
should	O
include	O
discontinuation	O
of	O
SPRIX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

For	O
high	O
risk	B-D012306
patients,	B-D010361
consider	O
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O

Use	O
great	O
care	O
when	O
giving	O
SPRIX	O
to	O
patients	B-D010361
with	O
a	O
history	B-D006664
of	O
inflammatory	O
bowel	O
disease	B-D004194
(ulcerative	O
colitis,	B-D003092
Crohn's	O
disease)	B-D004194
as	O
their	O
condition	O
may	O
be	O
exacerbated	O

5.3	O
Hematological	O
Effects	O
Because	O
prostaglandins	B-D011453
play	O
an	O
important	O
role	B-D012380
in	O
hemostasis	B-D006487
and	O
NSAIDs	O
affect	B-D000339
platelet	B-D010974
aggregation	I-D010974
as	O
well,	O
use	O
caution	O
with	O
use	O
of	O
ketorolac	B-D020911
tromethamine	I-D020911
in	O
patients	B-D010361
who	O
have	O
coagulation	O
disorders,	O
and	O
monitor	O
these	O
patients	B-D010361
carefully	O

The	O
effects	O
of	O
NSAIDs	O
other	O
than	O
aspirin	B-D001241
on	O
platelet	O
function	O
are	O
reversible	O

Patients	B-D010361
on	O
therapeutic	O
doses	O
of	O
anticoagulants	B-D000925
(e.g.,	O
heparin	B-D006493
or	O
dicumarol	B-D001728
derivatives)	O
have	O
an	O
increased	O
risk	B-D012306
of	O
bleeding	O
complications	O
if	O
given	O
ketorolac	B-D020911
tromethamine	I-D020911
concurrently;	O
therefore,	O
administer	O
such	O
concomitant	O
therapy	O
only	O
with	O
extreme	O
caution	O

The	O
concurrent	O
use	O
of	O
ketorolac	B-D020911
tromethamine	I-D020911
and	O
therapy	O
that	O
affects	B-D000339
hemostasis,	B-D006487
including	O
prophylactic	O
low	O
dose	O
heparin	B-D006493
(2500	O
to	O
5000	O
units	O
q12h),	O
warfarin	B-D014859
and	O
dextrans,	B-D003911
has	O
not	O
been	O
studied	O
extensively,	O
but	O
may	O
also	O
be	O
associated	O
with	O
an	O
increased	O
risk	B-D012306
of	O
bleeding	O

Until	O
data	O
from	O
such	O
studies	O
are	O
available,	O
carefully	O
weigh	O
the	O
benefits	O
against	O
the	O
risks	B-D012306
and	O
use	O
such	O
concomitant	O
therapy	O
in	O
these	O
patients	B-D010361
only	O
with	O
extreme	O
caution	O

Monitor	O
patients	B-D010361
receiving	O
therapy	O
that	O
affects	B-D000339
hemostasis	B-D006487
closely	O

In	O
clinical	B-D016430
trials,	I-D016430
serious	O
adverse	O
events	O
related	O
to	O
bleeding	O
were	O
more	O
common	O
in	O
patients	B-D010361
treated	O
with	O
SPRIX	O
than	O
placebo	O

In	O
clinical	B-D016430
trials	I-D016430
and	O
in	O
postmarketing	O
experience	O
with	O
ketorolac	B-D020910
IV	O
and	O
IM	O
dosing,	O
postoperative	O
hematomas	B-D006406
and	O
other	O
signs	O
of	O
wound	O
bleeding	O
have	O
been	O
reported	O
in	O
association	B-D001244
with	O
peri-operative	O
use	O

Therefore,	O
use	O
SPRIX	O
with	O
caution	O
in	O
the	O
postoperative	O
setting	O
when	O
hemostasis	B-D006487
is	O
critical	O

Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	B-D010361
receiving	O
NSAIDs	O

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	B-D001769
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoiesis	B-D004920
	O

Do	O
not	O
use	O
SPRIX	O
in	O
patients	B-D010361
for	O
whom	O
hemostasis	B-D006487
is	O
critical	O
[see	O
Contraindications	B-D000075202
(4),	O
Drug	B-D004347
Interactions	I-D004347
(7.1,	O
7.2,	O
7.10)]	O

5.4	O
Renal	O
Effects	O
Ketorolac	B-D020910
and	O
its	O
metabolites	O
are	O
eliminated	O
primarily	O
by	O
the	O
kidneys	B-D007668
	O

Patients	B-D010361
with	O
reduced	O
creatinine	B-D003404
clearance	O
will	O
have	O
diminished	O
clearance	O
of	O
the	O
drug	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.4)]	O

SPRIX	O
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
impairment	O
[see	O
Contraindications	B-D000075202
(4)]	O

In	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion,	B-D010477
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Decreased	O
intravascular	O
volume	O
such	O
as	O
when	O
oral	O
intake	O
is	O
poor	O
increases	O
the	O
risks	B-D012306
of	O
renal	O
toxicity	O
with	O
NSAIDs	O

Therefore,	O
patients	B-D010361
treated	O
with	O
SPRIX	O
should	O
be	O
adequately	O
hydrated	B-D006829
	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Use	O
SPRIX	O
with	O
caution	O
in	O
patients	B-D010361
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
or	O
ACE	O
inhibitors,	O
and	O
the	O
elderly	O

Assess	O
the	O
risks	B-D012306
and	O
benefits	O
prior	O
to	O
giving	O
SPRIX	O
to	O
these	O
patients,	B-D010361
and	O
follow	O
these	O
patients	B-D010361
closely	O
during	O
SPRIX	O
therapy	O

Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O
such	O
as	O
interstitial	O
nephritis	B-D009393
and	O
nephrotic	B-D009404
syndrome	I-D009404
	O

5.5	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	B-D010361
with	O
or	O
without	O
a	O
history	B-D006664
of	O
allergic	O
reactions	O
to	O
aspirin	B-D001241
or	O
NSAIDs	O
and	O
in	O
patients	B-D010361
without	O
known	O
prior	O
exposure	O
to	O
ketorolac	B-D020910
	O

SPRIX	O
should	O
be	O
discontinued	O
immediately	O
in	O
patients	B-D010361
with	O
allergic	O
reactions	O

SPRIX	O
should	O
not	O
be	O
given	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.11)]	O

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.6	O
Cardiovascular	O
Effects	O
Cardiovascular	O
(CV)	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
an	O
NSAID,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID	O
increases	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O

Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.2),	O
Drug	B-D004347
Interactions	I-D004347
(7.2,	O
7.3,	O
7.7)]	O

Hypertension	B-D006973
NSAIDs	O
can	O
lead	B-D007854
to	O
onset	O
of	O
new	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.3)]	O

Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention,	O
edema,	B-D004487
retention	O
of	O
NaCl,	O
oliguria,	B-D009846
and	O
elevations	O
of	O
serum	B-D044967
urea	B-D014508
nitrogen	B-D009584
and	O
creatinine	B-D003404
have	O
been	O
reported	O
in	O
clinical	B-D016430
trials	I-D016430
with	O
ketorolac	B-D020910
	O

Therefore,	O
only	O
use	O
SPRIX	O
very	O
cautiously	O
in	O
patients	B-D010361
with	O
cardiac	B-D002299
decompensation	O
or	O
similar	O
conditions	O

5.7	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
ketorolac,	B-D020910
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012877
manifestations,	I-D012877
and	O
discontinue	O
use	O
of	O
the	O
drug	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
[see	O
Contraindications	B-D000075202
(4)]	O

5.8	O
Pregnancy	B-D011247
Starting	O
at	O
30	O
weeks	O
gestation,	O
SPRIX	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
due	O
to	O
an	O
increased	O
risk	B-D012306
of	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
	O

If	O
SPRIX	O
is	O
used	O
at	O
or	O
after	O
30	O
weeks	O
gestation,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
a	O
fetus	B-D005333
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)]	O

5.9	O
Hepatic	O
Effects	O
Use	O
SPRIX	O
with	O
caution	O
in	O
patients	B-D010361
with	O
impaired	O
hepatic	O
function	O
or	O
a	O
history	B-D006664
of	O
liver	B-D008099
disease	B-D004194
	O

Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver	B-D008099
tests	B-C004551
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
taking	O
NSAIDs,	O
including	O
ketorolac	B-D020910
	O

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
three	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
with	O
NSAIDs	O

In	O
addition,	O
rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice,	B-D007565
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis,	B-D009336
and	O
hepatic	O
failure,	O
some	O
of	O
them	O
with	O
fatal	B-D017809
outcomes,	I-D017809
have	O
been	O
reported	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4,	O
5.6),Clinical	O
Pharmacology	B-D010600
(12.4)]	O

Evaluate	O
patients	B-D010361
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	B-D008099
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	B-D008099
test	B-C004551
has	O
occurred,	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
SPRIX	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
SPRIX	O

5.10	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
SPRIX	O
in	O
reducing	O
inflammation	B-D007249
and	O
fever	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.11	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

The	O
use	O
of	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
has	O
been	O
associated	O
with	O
severe	O
bronchospasm	O
which	O
can	O
be	O
fatal	O

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
do	O
not	O
administer	O
SPRIX	O
to	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity,	O
and	O
use	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.5)]	O

5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
SPRIX	O
with	O
the	O
eyes	B-D005123
	O

If	O
eye	B-D005123
contact	O
occurs,	O
wash	O
out	O
the	O
eye	B-D005123
with	O
water	B-D014867
or	O
saline,	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Gastrointestinal	O
effects	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hemorrhage	B-D006470
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Renal	O
effects	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Anaphylactoid	O
reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Cardiovascular	O
thrombotic	O
events	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Congestive	O
heart	B-D006333
failure	I-D006333
and	O
edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Serious	O
skin	B-D012867
reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Hepatic	O
effects	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
were	O
related	O
to	O
local	O
symptoms,	O
i.e.,	O
nasal	B-C015378
discomfort	O
or	O
irritation	O

These	O
reactions	O
were	O
generally	O
mild	O
and	O
transient	O
in	O
nature	B-D019368
	O

The	O
most	O
common	O
drug-related	O
adverse	O
events	O
leading	B-D007854
to	O
premature	B-C070504
discontinuation	O
were	O
nasal	B-C015378
discomfort	O
or	O
nasal	B-C015378
pain	B-D010146
(rhinalgia)	O

The	O
most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
2%)	O
in	O
patients	B-D010361
treated	O
with	O
SPRIX	O
and	O
occurring	O
at	O
a	O
rate	O
at	O
least	O
twice	O
that	O
of	O
placebo	O
are	O
nasal	B-C015378
discomfort,	O
rhinalgia,	O
increased	O
lacrimation,	O
throat	O
irritation,	O
oliguria,	B-D009846
rash,	O
bradycardia,	B-D001919
decreased	O
urine	B-D014556
output,	O
increased	O
ALT	O
and/or	O
AST,	O
hypertension,	B-D006973
and	O
rhinitis	B-D012220
	O

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
American	O
Regent,	O
Inc	O

at	O
1-800-734-9236	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Experience	O
from	O
SPRIX	O
Clinical	O
Studies	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
SPRIX	O
in	O
patients	B-D010361
enrolled	O
in	O
placebo-controlled	O
efficacy	O
studies	O
of	O
acute	B-D059787
pain	I-D059787
following	O
major	O
surgery	O

The	O
studies	O
enrolled	O
828	O
patients	B-D010361
(183	O
men,	B-D008571
645	O
women)	B-D014930
ranging	O
from	O
18	O
years	O
to	O
over	O
75	O
years	O
of	O
age	O

The	O
patients	B-D010361
in	O
the	O
postoperative	O
pain	B-D010146
studies	O
had	O
undergone	O
major	O
abdominal,	O
orthopedic,	O
gynecologic,	O
or	O
other	O
surgery;	O
455	O
patients	B-D010361
received	O
SPRIX	O
(31.5	O
mg)	O
three	O
or	O
four	O
times	B-D013995
a	O
day	O
for	O
up	O
to	O
5	O
days,	O
and	O
245	O
patients	B-D010361
received	O
placebo	O

Most	O
patients	B-D010361
were	O
receiving	O
concomitant	O
opioids,	O
primarily	O
PCA	O
morphine	B-D009020
	O

Table	O
1	O

Post-operative	O
Patients	B-D010361
with	O
Adverse	O
Reactions	O
Observed	O
at	O
a	O
rate	O
of	O
2%	O
or	O
more	O
and	O
at	O
least	O
twice	O
the	O
incidence	B-D015994
of	O
the	O
placebo	O
group	O

SPRIX	O
(N=455)	O
Placebo	O
(N=	O
245)	O
Nasal	B-C015378
discomfort	O
15%	O
2%	O
Rhinalgia	O
13%	O
<1%	O
Lacrimation	O
increased	O
5%	O
0%	O
Throat	O
irritation	O
4%	O
<1%	O
Oliguria	B-D009846
3%	O
1%	O
Rash	O
3%	O
<1%	O
Bradycardia	B-D001919
2%	O
<1%	O
Urine	B-D014556
output	O
decreased	O
2%	O
<1%	O
ALT	O
and/or	O
AST	O
increased	O
2%	O
1%	O
Hypertension	B-D006973
2%	O
1%	O
Rhinitis	B-D012220
2%	O
<1%	O
In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
in	O
major	O
surgery,	O
primarily	O
knee	B-D007717
and	O
hip	B-D006615
replacements	O
and	O
abdominal	O
hysterectomies,	O
seven	O
patients	B-D010361
(N=455,	O
1.5%)	O
treated	O
with	O
SPRIX	O
experienced	O
serious	O
adverse	O
events	O
of	O
bleeding	O
(4	O
patients)	B-D010361
or	O
hematoma	B-D006406
(3	O
patients)	B-D010361
at	O
the	O
operative	O
site	O
versus	O
one	O
patient	O
(N=245,	O
0.4%)	O
treated	O
with	O
placebo	O
(hematoma)	O

Six	O
of	O
the	O
seven	O
patients	B-D010361
treated	O
with	O
SPRIX	O
underwent	O
a	O
surgical	O
procedure	O
and/or	O
blood	B-D001803
transfusion	I-D001803
and	O
the	O
placebo	O
patient	O
subsequently	O
required	O
a	O
blood	B-D001803
transfusion	I-D001803
	O

6.2	O
Adverse	O
Reactions	O
Reported	O
in	O
Clinical	B-D016430
Trials	I-D016430
with	O
Other	O
Dosage	B-D004304
Forms	I-D004304
of	O
Ketorolac	B-D020910
or	O
Other	O
NSAIDs	O
Adverse	O
reaction	O
rates	O
increase	O
with	O
higher	O
doses	O
of	O
ketorolac	B-D020910
	O

It	O
is	O
necessary	O
to	O
remain	O
alert	O
for	O
the	O
severe	O
complications	O
of	O
treatment	O
with	O
ketorolac,	B-D020910
such	O
as	O
GI	O
ulceration,	B-D014456
bleeding,	O
and	O
perforation,	O
postoperative	O
bleeding,	O
acute	O
renal	O
failure,	O
anaphylactic	O
and	O
anaphylactoid	O
reactions,	O
and	O
liver	B-D017093
failure	I-D017093
	O

These	O
complications	O
can	O
be	O
serious	O
in	O
certain	O
patients	B-D010361
for	O
whom	O
ketorolac	B-D020910
is	O
indicated,	O
especially	O
when	O
the	O
drug	O
is	O
used	O
inappropriately	O

In	O
patients	B-D010361
taking	O
ketorolac	B-D020910
or	O
other	O
NSAIDs	O
in	O
clinical	B-D016430
trials,	I-D016430
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
(GI)	O
experiences	O
including:	O
*Incidence	O
greater	O
than	O
10%	O
abdominal	B-D015746
pain	I-D015746
constipation/diarrhea	B-D003248
dyspepsia	B-D004415
flatulence	B-D005414
GI	O
fullness	O
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
gross	O
bleeding/perforation	O
heartburn	B-D006356
nausea*	B-D009325
stomatitis	B-D013280
vomiting	B-D014839
Other	O
experiences:	O
abnormal	O
renal	O
function	O
anemia	B-D000740
dizziness	B-D004244
drowsiness	O
edema	B-D004487
elevated	O
liver	B-D008099
enzymes	B-D004798
headache*	B-D006261
hypertension	B-D006973
increased	O
bleeding	B-D001760
time	I-D001760
injection	O
site	O
pain	B-D010146
pruritus	B-D011537
purpura	B-D011693
rash	O
tinnitus	B-D014012
sweating	B-D013546
Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
(<1%	O
in	O
patients	B-D010361
taking	O
ketorolac	B-D020910
or	O
other	O
NSAIDs	O
in	O
clinical	B-D016430
trials)	I-D016430
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
palpitation,	O
pallor,	B-D010167
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
anorexia,	B-D000855
dry	O
mouth,	B-D009055
eructation,	B-D004884
esophagitis,	B-D004941
excessive	O
thirst,	B-D013894
gastritis,	B-D005756
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
increased	O
appetite,	B-D001066
jaundice,	B-D007565
melena,	B-D008551
rectal	O
bleeding	O
Hemic	O
and	O
Lymphatic:	B-D008196
ecchymosis,	B-D004438
eosinophilia,	B-D004802
epistaxis,	B-D004844
leukopenia,	B-D007970
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
change	O
Nervous	B-D009420
System:	I-D009420
abnormal	O
dreams,	B-D004325
abnormal	O
thinking,	B-D013850
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
euphoria,	B-D005059
extrapyramidal	O
symptoms,	O
hallucinations,	B-D006212
hyperkinesis,	B-D006948
inability	O
to	O
concentrate,	O
insomnia,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
stupor,	B-D053608
tremors,	B-D014202
vertigo,	B-D014717
malaise	O
Respiratory:	O
asthma,	B-D001249
dyspnea,	B-D004417
pulmonary	B-D011654
edema,	I-D011654
rhinitis	B-D012220
Special	O
Senses:	O
abnormal	O
taste,	B-D013649
abnormal	O
vision,	O
blurred	O
vision,	O
hearing	B-D034381
loss	I-D034381
Urogenital:	O
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
increased	O
urinary	O
frequency,	O
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure,	O
urinary	B-D016055
retention	I-D016055
6.3	O
Adverse	O
Reactions	O
from	O
Postmarketing	O
Experience	O
with	O
Other	O
Dosage	B-D004304
Forms	I-D004304
of	O
Ketorolac	B-D020910
or	O
Other	O
NSAIDs	O
Other	O
observed	O
reactions	O
(reported	O
from	O
postmarketing	O
experience	O
in	O
patients	B-D010361
taking	O
ketorolac	B-D020910
or	O
other	O
NSAIDs)	O
are:	O
Body	O
as	O
a	O
Whole:	O
angioedema,	B-D000799
death,	B-D003643
hypersensitivity	B-D006967
reactions	O
such	O
as	O
anaphylaxis,	B-D000707
anaphylactoid	O
reaction,	O
laryngeal	B-D007819
edema,	I-D007819
tongue	B-D014059
edema,	B-D004487
myalgia	B-D063806
Cardiovascular:	O
arrhythmia,	O
bradycardia,	B-D001919
chest	B-D002637
pain,	I-D002637
flushing,	B-D005483
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
vasculitis	B-D014657
Dermatologic:	O
exfoliative	O
dermatitis,	B-D003872
erythema	B-D004892
multiforme,	I-D004892
Lyell's	B-D008191
syndrome,	B-D013577
bullous	O
reactions	O
including	O
Stevens-Johnson	B-D013262
syndrome	I-D013262
and	O
toxic	O
epidermal	O
necrolysis	O
Gastrointestinal:	O
acute	O
pancreatitis,	B-D010195
liver	B-D017093
failure,	I-D017093
ulcerative	B-D014456
stomatitis,	B-D013280
exacerbation	O
of	O
inflammatory	O
bowel	O
disease	B-D004194
(ulcerative	O
colitis,	B-D003092
Crohn's	O
disease)	B-D004194
Hemic	O
and	O
Lymphatic:	B-D008196
agranulocytosis,	B-D000380
aplastic	O
anemia,	B-D000743
hemolytic	I-D000743
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia,	B-D010198
postoperative	O
wound	O
hemorrhage	B-D006470
(rarely	O
requiring	O
blood	B-D001803
transfusion)	I-D001803
Metabolic	O
and	O
Nutritional:	O
hyperglycemia,	B-D006943
hyperkalemia,	B-D006947
hyponatremia	B-D007010
Nervous	B-D009420
System:	I-D009420
aseptic	O
meningitis,	B-D008581
convulsions,	O
coma,	B-D003128
psychosis	O
Respiratory:	O
bronchospasm,	O
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Special	O
Senses:	O
conjunctivitis	B-D003231
Urogenital:	O
flank	B-D021501
pain	I-D021501
with	O
or	O
without	O
hematuria	B-D006417
and/or	O
azotemia,	B-D053099
hemolytic	O
uremic	O
syndrome	B-D013577
CARDIOVASCULAR	O
RISK	B-D012306
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
]	O

Diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
and	O
Warnings	O
]	O

GASTROINTESTINAL	O
RISK	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

[see	O
Warnings	O
]	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets,	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System	I-D002319
:	O
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System	I-D004064
:	O
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional	O
:	O
weight	O
changes	O
Nervous	B-D009420
System	I-D009420
:	O
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System	I-D014566
:	O
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System	I-D002319
:	O
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional	O
:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System	I-D012137
:	O
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages	O
:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses	O
:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O

Etodolac	B-D017308
extended-release	O
tablets	B-D013607
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS)	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(See	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
patients	B-D010361
were	O
exposed	O
to	O
etodolac	B-D017308
extended-release	O
tablets	B-D013607
in	O
controlled	O
clinical	O
studies	O
of	O
at	O
least	O
4	O
weeks	O
in	O
length	O
and	O
using	O
daily	O
doses	O
in	O
the	O
range	O
of	O
400	O
to	O
1200	O
mg	O

In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
incidence	B-D015994
of	O
events	O
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	B-D017308
extended-release	O
tablets	B-D013607
	O

As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
time	B-D013995
with	O
extended	O
therapy	O

In	O
patients	B-D010361
taking	O
NSAIDs,	O
including	O
etodolac	B-D017308
extended-release	O
tablets,	B-D013607
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain	I-D015746
constipation	B-D003248
diarrhea	B-D003967
dyspepsia	B-D004415
flatulence	B-D005414
GI	O
ulcers	B-D014456
(gastric/duodenal)*	O
gross	O
bleeding/perforation*	O
nausea	B-D009325
vomiting	B-D014839
other	O
events	O
including:	O
abnormal	O
renal	O
function*	O
anemia*	B-D000740
asthenia	B-D001247
dizziness	B-D004244
edema*	B-D004487
elevated	O
liver	B-D008099
enzymes*	B-D004798
headaches	B-D006261
hypertension	B-D006973
increased	O
bleeding	B-D001760
time*	I-D001760
infection	O
pharyngitis	B-D010612
pruritus	B-D011537
rashes	O
rhinitis	B-D012220
tinnitus*	B-D014012
*	O
Adverse	O
events	O
that	O
were	O
observed	O
in	O
<	O
1%	O
of	O
patients	B-D010361
in	O
the	O
first	O
30	O
days	O
of	O
treatment	O
with	O
etodolac	B-D017308
extended-release	O
tablets	B-D013607
in	O
clinical	B-D016430
trials	I-D016430
	O

Additional	O
NSAID	O
Adverse	O
Experiences	O
Reported	O
Occasionally	O
with	O
NSAIDs	O
or	O
Etodolac	B-D017308
Extended-Release	O
Tablets	B-D013607
Include	O
Body	O
as	O
a	O
whole	O
-	O
allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock),	B-D012769
chills,	B-D023341
fever,	B-D005334
sepsis	B-D018805
Cardiovascular	B-D002319
system	I-D002319
-	O
congestive	O
heart	B-D006333
failure,	I-D006333
flushing,	B-D005483
palpitations,	O
tachycardia,	B-D013610
syncope,	B-D013575
vasculitis	B-D014657
(including	O
necrotizing	O
and	O
allergic)	O
Digestive	B-D004064
system	I-D004064
-	O
anorexia,	B-D000855
cholestatic	O
hepatitis,	B-D006505
cholestatic	O
jaundice,	B-D007565
dry	O
mouth,	B-D009055
duodenitis,	B-D004382
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastric/peptic	O
ulcers,	B-D014456
glossitis,	B-D005928
hepatic	O
failure,	O
hepatitis,	B-D006505
hematemesis,	B-D006396
intestinal	O
ulceration,	B-D014456
jaundice,	B-D007565
liver	B-D008099
necrosis,	B-D009336
melena,	B-D008551
pancreatitis,	B-D010195
rectal	O
bleeding,	O
stomatitis	B-D013280
Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
agranulocytosis,	B-D000380
ecchymosis,	B-D004438
eosinophilia,	B-D004802
hemolytic	O
anemia,	B-D000740
leukopenia,	B-D007970
neutropenia,	B-D009503
pancytopenia,	B-D010198
purpura,	B-D011693
thrombocytopenia	B-D013921
Metabolic	O
and	O
nutritional	O
-	O
hyperglycemia	B-D006943
in	O
previously	O
controlled	O
diabetic	O
patients	B-D010361
Nervous	B-D009420
system	I-D009420
-	O
anxiety,	B-D001007
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
insomnia,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
system	I-D012137
-	O
asthma,	B-D001249
dyspnea,	B-D004417
pulmonary	O
infiltration	O
with	O
eosinophilia	B-D004802
Skin	B-D012867
and	O
appendages	O
-	O
angioedema,	B-D000799
cutaneous	O
vasculitis	B-D014657
with	O
purpura,	B-D011693
erythema	B-D004892
multiforme,	I-D004892
hyperpigmentation,	B-D017495
sweating,	B-D013546
urticaria,	B-D014581
vesiculobullous	O
rash	O
Special	O
senses	O
-	O
blurred	O
vision,	O
photophobia,	B-D020795
transient	O
visual	O
disturbances	O
Urogenital	B-D014566
system	I-D014566
-	O
dysuria,	B-D053159
elevated	O
BUN,	O
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure,	O
renal	B-D051437
insufficiency,	I-D051437
renal	O
papillary	O
necrosis,	B-D009336
serum	B-D044967
creatinine	B-D003404
increase,	O
urinary	O
frequency	O
Other	O
NSAID	O
Adverse	O
Reactions,	O
Which	O
Occur	O
Rarely	O
Are	O
Body	O
as	O
a	O
whole	O
-	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
system	I-D002319
-	O
arrhythmia,	O
cerebrovascular	B-C079279
accident,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction	I-D009203
Digestive	B-D004064
system	I-D004064
-	O
colitis,	B-D003092
esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
thirst,	B-D013894
ulcerative	B-D014456
stomatitis	B-D013280
Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
aplastic	O
anemia,	B-D000740
lymphadenopathy	B-D000072281
Metabolic	O
and	O
nutritional	O
-	O
change	O
in	O
weight	O
Nervous	B-D009420
system	I-D009420
-	O
coma,	B-D003128
convulsions,	O
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	O
-	O
bronchitis,	B-D001991
pneumonia,	B-D011014
respiratory	O
depression,	B-D003863
sinusitis	B-D012852
Skin	B-D012867
and	O
appendages	O
-	O
alopecia,	B-D000505
exfoliative	O
dermatitis,	B-D003872
maculopapular	O
rash,	O
photosensitivity,	O
skin	B-D012867
peeling,	O
Stevens-Johnson	B-D013262
syndrome,	I-D013262
toxic	O
epidermal	O
necrosis	B-D009336
Special	O
senses	O
-	O
conjunctivitis,	B-D003231
deafness,	B-D003638
hearing	B-D006309
impairment,	O
taste	B-D013649
perversion	O
Urogenital	B-D014566
system	I-D014566
-	O
cystitis,	B-D003556
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
leukorrhea,	B-D007973
renal	O
calculus,	O
uterine	O
bleeding	O
irregularities	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
]	O

Diclofenac	B-D004008
sodium	B-D012964
delayed-release	O
tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
and	O
Warnings	O
]	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
Diclofenac	B-D004008
Sodium	B-D012964
Delayed-Release	O
Tablets,	B-D013607
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1%-10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal)	O
and	O
vomiting	B-D014839
	O

Abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritus,	B-D011537
rashes	O
and	O
tinnitus	B-D014012
	O

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
fever,	B-D005334
infection,	O
sepsis	B-D018805
Cardiovascular	B-D002319
System:	I-D002319
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
tachycardia,	B-D013610
syncope	B-D013575
Digestive	B-D004064
System:	I-D004064
dry	O
mouth,	B-D009055
esophagitis,	B-D004941
gastric/peptic	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis,	B-D006396
hepatitis,	B-D006505
jaundice	B-D007565
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
ecchymosis,	B-D004438
eosinophilia,	B-D004802
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
rectal	O
bleeding,	O
stomatitis,	B-D013280
thrombocytopenia	B-D013921
Metabolic	O
and	O
Nutritional:	O
weight	O
changes	O
Nervous	B-D009420
System:	I-D009420
anxiety,	B-D001007
asthenia,	B-D001247
confusion,	B-D003221
depression,	B-D003863
dream	O
abnormalities,	O
drowsiness,	O
insomnia,	O
malaise,	O
nervousness,	O
paresthesia,	B-D010292
somnolence,	O
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
System:	I-D012137
asthma,	B-D001249
dyspnea	B-D004417
Skin	B-D012867
and	O
Appendages:	O
alopecia,	B-D000505
photosensitivity,	O
sweating	B-D013546
increased	O
Special	O
Senses:	O
blurred	O
vision	O
Urogenital	B-D014566
System:	I-D014566
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
oliguria/polyuria,	B-D009846
proteinuria,	B-D011507
renal	O
failure	O
Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
appetite	B-D001066
changes,	O
death	B-D003643
Cardiovascular	B-D002319
System:	I-D002319
arrhythmia,	O
hypotension,	B-D007022
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
vasculitis	B-D014657
Digestive	B-D004064
System:	I-D004064
colitis,	B-D003092
eructation,	B-D004884
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
liver	B-D017093
failure,	I-D017093
liver	B-D008099
necrosis,	B-D009336
pancreatitis	B-D010195
Hemic	O
and	O
Lymphatic	B-D008208
System:	I-D008208
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
lymphadenopathy,	B-D000072281
pancytopenia	B-D010198
Metabolic	O
and	O
Nutritional:	O
hyperglycemia	B-D006943
Nervous	B-D009420
System:	I-D009420
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis	B-D008581
Respiratory	B-D012137
System:	I-D012137
respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Skin	B-D012867
and	O
Appendages:	O
angioedema,	B-D000799
toxic	O
epidermal	O
necrolysis,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
urticaria	B-D014581
Special	O
Senses:	O
conjunctivitis,	B-D003231
hearing	B-D006309
impairment	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Rising	O
Pharmaceuticals,	O
Inc	O

at	O
1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

WARNING:	O
RISK	B-D012306
OF	O
UTERINE	B-D014597
RUPTURE,	I-D014597
ABORTION,	O
PREMATURE	B-D047928
BIRTH,	I-D047928
BIRTH	O
DEFECTS;	O
AND	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
ARTHROTEC®	B-C078133
CONTAINS	O
DICLOFENAC	B-D004008
SODIUM	B-D012964
AND	O
MISOPROSTOL	B-D016595
	O

ADMINISTRATION	O
OF	O
MISOPROSTOL	B-D016595
TO	O
WOMEN	B-D014930
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	B-D047928
BIRTH,	I-D047928
BIRTH	O
DEFECTS,	O
OR	O
UTERINE	B-D014597
RUPTURE	I-D014597
	O

UTERINE	B-D014597
RUPTURE	I-D014597
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	B-D016595
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	B-D037841
WOMEN	I-D037841
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O

THE	O
RISK	B-D012306
OF	O
UTERINE	B-D014597
RUPTURE	I-D014597
INCREASES	O
WITH	O
ADVANCING	O
GESTATIONAL	B-D005865
AGES	I-D005865
AND	O
WITH	O
PRIOR	O
UTERINE	O
SURGERY,	O
INCLUDING	O
CESAREAN	O
DELIVERY	O

ARTHROTEC	B-C078133
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	B-D037841
WOMEN	I-D037841
[see	O
Contraindications	B-D000075202
(4)	O
,	O
Warnings	O
and	O
Precautions	O
(5.10),	O
and	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)]	O

PATIENTS	B-D010361
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS	O

ARTHROTEC	B-C078133
should	O
not	O
be	O
used	O
in	O
women	B-D014930
of	O
childbearing	B-D002648
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	B-D012306
of	O
developing	O
gastric	O
or	O
duodenal	B-D004381
ulceration	I-D004381
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	B-D004381
ulcers	I-D004381
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID	O

In	O
such	O
patients,	B-D010361
ARTHROTEC	B-C078133
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
has	O
had	O
a	O
negative	O
serum	B-D044967
pregnancy	B-D011247
test	B-C004551
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy	O

is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	B-D016595
the	O
risk	B-D012306
of	O
possible	O
contraception	B-D003267
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	B-D014930
of	O
childbearing	B-D002648
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake	O

will	O
begin	O
ARTHROTEC	B-C078133
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	B-D008571
period	O
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.3)]	O

WARNING:	O
RISK	B-D012306
OF	O
UTERINE	B-D014597
RUPTURE,	I-D014597
ABORTION,	O
PREMATURE	B-D047928
BIRTH,	I-D047928
BIRTH	O
DEFECTS;	O
AND	O
SERIOUS	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
EVENTS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

ARTHROTEC	B-C078133
®	O
CONTAINS	O
DICLOFENAC	B-D004008
SODIUM	B-D012964
AND	O
MISOPROSTOL	B-D016595
	O

ADMINISTRATION	O
OF	O
MISOPROSTOL	B-D016595
TO	O
WOMEN	B-D014930
WHO	O
ARE	O
PREGNANT	O
CAN	O
CAUSE	O
ABORTION,	O
PREMATURE	B-D047928
BIRTH,	I-D047928
BIRTH	O
DEFECTS,	O
OR	O
UTERINE	B-D014597
RUPTURE	I-D014597
	O

UTERINE	B-D014597
RUPTURE	I-D014597
HAS	O
BEEN	O
REPORTED	O
WHEN	O
MISOPROSTOL	B-D016595
WAS	O
ADMINISTERED	O
IN	O
PREGNANT	B-D037841
WOMEN	I-D037841
TO	O
INDUCE	O
LABOR	O
OR	O
TO	O
INDUCE	O
ABORTION	O

THE	O
RISK	B-D012306
OF	O
UTERINE	B-D014597
RUPTURE	I-D014597
INCREASES	O
WITH	O
ADVANCING	O
GESTATIONAL	B-D005865
AGES	I-D005865
AND	O
WITH	O
PRIOR	O
UTERINE	O
SURGERY,	O
INCLUDING	O
CESAREAN	O
DELIVERY	O

ARTHROTEC	B-C078133
SHOULD	O
NOT	O
BE	O
TAKEN	O
BY	O
PREGNANT	B-D037841
WOMEN	I-D037841
(4,	O
5.10,	O
8.1)	O

PATIENTS	B-D010361
MUST	O
BE	O
ADVISED	O
OF	O
THE	O
ABORTIFACIENT	O
PROPERTY	O
AND	O
WARNED	O
NOT	O
TO	O
GIVE	O
THE	O
DRUG	O
TO	O
OTHERS	O

ARTHROTEC	B-C078133
should	O
not	O
be	O
used	O
in	O
women	B-D014930
of	O
childbearing	B-D002648
potential	O
unless	O
the	O
patient	O
requires	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O
therapy	O
and	O
is	O
at	O
high	O
risk	B-D012306
of	O
developing	O
gastric	O
or	O
duodenal	B-D004381
ulceration	I-D004381
or	O
for	O
developing	O
complications	O
from	O
gastric	O
or	O
duodenal	B-D004381
ulcers	I-D004381
associated	O
with	O
the	O
use	O
of	O
the	O
NSAID	O

In	O
such	O
patients,	B-D010361
ARTHROTEC	B-C078133
may	O
be	O
prescribed	O
if	O
the	O
patient:	O
has	O
had	O
a	O
negative	O
serum	B-D044967
pregnancy	B-D011247
test	B-C004551
within	O
2	O
weeks	O
prior	O
to	O
beginning	O
therapy	O
(8.3)	O

is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
misoprostol,	B-D016595
the	O
risk	B-D012306
of	O
possible	O
contraception	B-D003267
failure,	O
and	O
the	O
danger	O
to	O
other	O
women	B-D014930
of	O
childbearing	B-D002648
potential	O
should	O
the	O
drug	O
be	O
taken	O
by	O
mistake	O

will	O
begin	O
ARTHROTEC	B-C078133
only	O
on	O
the	O
second	O
or	O
third	O
day	O
of	O
the	O
next	O
normal	O
menstrual	B-D008571
period	O

Cardiovascular	O
Thrombotic	O
Events	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(5.1)	O

ARTHROTEC	B-C078133
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(4,	O
5.1)	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
(5.2)	O

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

ARTHROTEC	B-C078133
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)	O
,	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O

Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
and	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
patients	B-D010361
of	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O

Discontinue	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O
or	O
if	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
liver	B-D008099
disease	B-D004194
develop	O
(5.3)	O
Hypertension:	B-D006973
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema:	B-D004487
Avoid	O
use	O
of	O
ARTHROTEC	B-C078133
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
	O

Avoid	O
use	O
of	O
ARTHROTEC	B-C078133
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O
(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
ARTHROTEC	B-C078133
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

Monitor	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
aspirin	B-D001241
sensitivity)	O
(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
ARTHROTEC	B-C078133
at	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
(5.9)	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus:	I-D004373
Avoid	O
use	O
in	O
pregnancy	B-D011247
	O

Diclofenac	B-D004008
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
in	O
patients	B-D010361
with	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
(MI)	O
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
risk	B-D012306
for	O
CV	O
thrombotic	O
events	O
is	O
similar	O
for	O
all	O
NSAIDs	O

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

However,	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
had	O
a	O
higher	O
absolute	O
incidence	B-D015994
of	O
excess	O
serious	O
CV	O
thrombotic	O
events,	O
due	O
to	O
their	O
increased	O
baseline	O
rate	O

Some	O
observational	B-D019370
studies	O
found	O
that	O
this	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
began	O
as	O
early	B-D004423
as	O
the	O
first	O
weeks	O
of	O
treatment	O

The	O
increase	O
in	O
CV	O
thrombotic	O
risk	B-D012306
has	O
been	O
observed	O
most	O
consistently	O
at	O
higher	O
doses	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
NSAID-treated	O
patients,	B-D010361
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
throughout	O
the	O
entire	O
treatment	O
course,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
an	O
NSAID,	O
such	O
as	O
diclofenac,	B-D004008
increases	O
the	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
(GI)	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
	O

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observational	B-D019370
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
in	O
the	O
post-MI	O
period	O
were	O
at	O
increased	O
risk	B-D012306
of	O
reinfarction,	O
CV-related	O
death,	B-D003643
and	O
all-cause	O
mortality	B-D009026
beginning	O
in	O
the	O
first	O
week	O
of	O
treatment	O

In	O
this	O
same	O
cohort,	O
the	O
incidence	B-D015994
of	O
death	B-D003643
in	O
the	O
first	O
year	O
post-MI	O
was	O
20	O
per	O
100	O
person	O
years	O
in	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
12	O
per	O
100	O
person	O
years	O
in	O
non-NSAID	O
exposed	O
patients	B-D010361
	O

Although	O
the	O
absolute	O
rate	O
of	O
death	B-D003643
declined	O
somewhat	O
after	O
the	O
first	O
year	O
post-MI,	O
the	O
increased	O
relative	O
risk	B-D012306
of	O
death	B-D003643
in	O
NSAID	O
users	O
persisted	O
over	O
at	O
least	O
the	O
next	O
four	O
years	O
of	O
follow-up	O

Avoid	O
the	O
use	O
of	O
ARTHROTEC	B-C078133
in	O
patients	B-D010361
with	O
a	O
recent	O
MI	O
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
recurrent	O
CV	O
thrombotic	O
events	O

If	O
ARTHROTEC	B-C078133
is	O
used	O
in	O
patients	B-D010361
with	O
a	O
recent	O
MI,	O
monitor	O
patients	B-D010361
for	O
signs	O
of	O
cardiac	B-D002299
ischemia	B-D007511
	O

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
esophagus,	B-D004947
stomach,	B-D013270
small	O
intestine,	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occurred	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3–6	O
months,	O
and	O
in	O
about	O
2%–4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulceration,	B-D014456
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
GI	O
bleeding	O
who	O
used	O
NSAIDs	O
had	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
without	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
longer	O
duration	O
of	O
NSAID	O
therapy;	O
concomitant	O
use	O
of	O
oral	O
corticosteroids,	O
aspirin,	B-D001241
anticoagulants,	B-D000925
or	O
selective	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs);	O
smoking;	B-D012907
use	O
of	O
alcohol;	O
older	O
age;	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
	O

Additionally,	O
patients	B-D010361
with	O
advanced	O
liver	B-D008099
disease	B-D004194
and/or	O
coagulopathy	O
are	O
at	O
increased	O
risk	B-D012306
for	O
GI	O
bleeding	O

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risks	B-D012306
in	O
NSAID-treated	O
patients:	B-D010361
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
time	B-D013995
	O

Avoid	O
use	O
in	O
patients	B-D010361
at	O
high	O
risk	B-D012306
unless	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
increased	O
risk	B-D012306
of	O
bleeding	O

For	O
such	O
patients,	B-D010361
as	O
well	O
as	O
those	O
with	O
active	O
GI	O
bleeding,	O
consider	O
alternate	O
therapies	O
other	O
than	O
NSAIDs	O

Remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
NSAID	O
therapy	O

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
ARTHROTEC	B-C078133
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
aspirin	B-D001241
for	O
cardiac	B-D002299
prophylaxis,	O
monitor	O
patients	B-D010361
more	O
closely	O
for	O
evidence	O
of	O
GI	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.3	O
Hepatotoxicity	O
In	O
clinical	B-D016430
trials	I-D016430
with	O
ARTHROTEC,	B-C078133
meaningful	O
elevation	O
of	O
ALT	O
(SGPT,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN	O
[ULN	O
=	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range])	O
occurred	O
in	O
1.6%	O
of	O
2,184	O
patients	B-D010361
treated	O
with	O
ARTHROTEC	B-C078133
and	O
in	O
1.4%	O
of	O
1,691	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
	O

These	O
increases	O
were	O
generally	O
transient,	O
and	O
enzyme	O
levels	O
returned	O
to	O
within	O
the	O
normal	O
range	O
upon	O
discontinuation	O
of	O
therapy	O
with	O
ARTHROTEC	B-C078133
	O

The	O
misoprostol	B-D016595
component	O
of	O
ARTHROTEC	B-C078133
does	O
not	O
appear	O
to	O
exacerbate	O
the	O
hepatic	O
effects	O
caused	O
by	O
the	O
diclofenac	B-D004008
sodium	B-D012964
component	O

In	O
clinical	B-D016430
trials	I-D016430
of	O
diclofenac-containing	B-D004008
products,	O
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(SGOT)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
with	O
oral	O
diclofenac	B-D004008
sodium	B-D012964
for	O
2–6	O
months,	O
patients	B-D010361
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(i.e.,	O
greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3–8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(greater	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
tests	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

In	O
a	O
European	B-D005060
retrospective	O
population-based,	B-D011153
case-controlled	O
study,	O
10	O
cases	O
of	O
diclofenac	B-D004008
associated	O
drug-induced	O
liver	B-D008099
injury	O
with	O
current	O
use	O
compared	O
with	O
non-use	O
of	O
diclofenac	B-D004008
were	O
associated	O
with	O
a	O
statistically	O
significant	O
4-fold	O
adjusted	O
odds	B-D016017
ratio	I-D016017
of	O
liver	B-D008099
injury	O

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
overall	B-D016424
number	O
of	O
10	O
cases	O
of	O
liver	B-D008099
injury	O
associated	O
with	O
diclofenac,	B-D004008
the	O
adjusted	O
odds	B-D016017
ratio	I-D016017
increased	O
further	O
with	O
female	B-D005260
gender,	O
doses	O
of	O
150	O
mg	O
or	O
more,	O
and	O
duration	O
of	O
use	O
for	O
more	O
than	O
90	O
days	O

Physicians	B-D010820
should	O
measure	O
transaminases	B-D000637
at	O
baseline	O
and	O
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
transaminases	B-D000637
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
ARTHROTEC	B-C078133
should	O
be	O
discontinued	O
immediately	O

Inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
"flu-like"	O
symptoms)	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
discontinue	O
ARTHROTEC	B-C078133
immediately,	O
and	O
perform	O
a	O
clinical	O
evaluation	O
of	O
the	O
patient	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver	B-D008099
related	O
event	O
in	O
patients	B-D010361
treated	O
with	O
ARTHROTEC,	B-C078133
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible	O

Exercise	B-D015444
caution	O
when	O
prescribing	O
ARTHROTEC	B-C078133
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
antibiotics,	O
anti-epileptics)	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
ARTHROTEC,	B-C078133
can	O
lead	B-D007854
to	O
new	O
onset	O
of	O
hypertension	B-D006973
or	O
worsening	O
of	O
pre-existing	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
diuretics,	B-D004232
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Monitor	O
blood	B-D001794
pressure	I-D001794
(BP)	O
during	O
the	O
initiation	O
of	O
NSAID	O
treatment	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
meta-analysis	B-D017418
of	O
randomized	B-D016449
controlled	I-D016449
trials	I-D016449
demonstrated	O
an	O
approximately	O
two-fold	O
increase	O
in	O
hospitalizations	B-D006760
for	O
heart	B-D006333
failure	I-D006333
in	O
COX-2	O
selective-treated	O
patients	B-D010361
and	O
nonselective	O
NSAID-treated	O
patients	B-D010361
compared	O
to	O
placebo-treated	O
patients	B-D010361
	O

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
patients	B-D010361
with	O
heart	B-D006333
failure,	I-D006333
NSAID	O
use	O
increased	O
the	O
risk	B-D012306
of	O
MI,	O
hospitalization	B-D006760
for	O
heart	B-D006333
failure,	I-D006333
and	O
death	B-D003643
	O

Additionally,	O
fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Use	O
of	O
diclofenac	B-D004008
may	O
blunt	O
the	O
CV	O
effects	O
of	O
several	O
therapeutic	O
agents	O
used	O
to	O
treat	O
these	O
medical	O
conditions	O
(e.g.,	O
diuretics,	B-D004232
ACE	O
inhibitors,	O
or	O
angiotensin	O
receptor	O
blockers	O
[ARBs])	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

Avoid	O
the	O
use	O
of	O
ARTHROTEC	B-C078133
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure	I-D006333
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

If	O
ARTHROTEC	B-C078133
is	O
used	O
in	O
patients	B-D010361
with	O
severe	O
heart	B-D006333
failure,	I-D006333
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
dehydration,	B-D003681
hypovolemia,	B-D020896
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE	O
inhibitors	O
or	O
ARBs,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
ARTHROTEC	B-C078133
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

The	O
renal	O
effects	O
of	O
ARTHROTEC	B-C078133
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
patients	B-D010361
with	O
pre-existing	O
renal	O
disease	B-D004194
	O

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
patients	B-D010361
prior	O
to	O
initiating	O
ARTHROTEC	B-C078133
	O

Monitor	O
renal	O
function	O
in	O
patients	B-D010361
with	O
renal	O
or	O
hepatic	O
impairment,	O
heart	B-D006333
failure,	I-D006333
dehydration,	B-D003681
or	O
hypovolemia	B-D020896
during	O
use	O
of	O
ARTHROTEC	B-C078133
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O
	O

Avoid	O
the	O
use	O
of	O
ARTHROTEC	B-C078133
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
unless	O
the	O
benefits	O
are	O
expected	O
to	O
outweigh	O
the	O
risk	B-D012306
of	O
worsening	O
renal	O
function	O

If	O
ARTHROTEC	B-C078133
is	O
used	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease,	B-D004194
monitor	O
patients	B-D010361
for	O
signs	O
of	O
worsening	O
renal	O
function	O

Hyperkalemia	B-D006947
Increases	O
in	O
serum	B-D044967
potassium	B-D011188
concentration,	O
including	O
hyperkalemia,	B-D006947
with	O
use	O
of	O
NSAIDs,	O
even	O
in	O
some	O
patients	B-D010361
without	O
renal	O
impairment	O

In	O
patients	B-D010361
with	O
normal	O
renal	O
function,	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
a	O
hyporeninemic-hypoaldosteronism	O
state	O

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac/misoprostol	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
patients	B-D010361
with	O
and	O
without	O
known	O
hypersensitivity	B-D006967
to	O
diclofenac/misoprostol	B-D004008
and	O
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.8)]	O

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
which	O
may	O
include	O
chronic	O
rhinosinusitis	O
complicated	O
by	O
nasal	B-C015378
polyps;	B-D011127
severe,	O
potentially	O
fatal	O
bronchospasm;	O
and/or	O
intolerance	O
to	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O

Because	O
cross-reactivity	O
between	O
aspirin	B-D001241
and	O
other	O
NSAIDs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
ARTHROTEC	B-C078133
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
[see	O
Contraindications	B-D000075202
(4)]	O

When	O
ARTHROTEC	B-C078133
is	O
used	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
(without	O
known	O
aspirin	B-D001241
sensitivity),	O
monitor	O
patients	B-D010361
for	O
changes	O
in	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
asthma	B-D001249
	O

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
reactions	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
patients	B-D010361
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012867
reactions,	O
and	O
to	O
discontinue	O
the	O
use	O
of	O
ARTHROTEC	B-C078133
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

ARTHROTEC	B-C078133
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
previous	O
serious	O
skin	B-D012867
reactions	O
to	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4)]	O

5.10	O
Premature	B-C070504
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
fetal	O
ductus	B-D004373
arteriosus	I-D004373
	O

ARTHROTEC	B-C078133
is	O
contraindicated	O
in	O
pregnant	B-D037841
women	I-D037841
	O

Advise	O
pregnant	B-D037841
women	I-D037841
of	O
the	O
potential	O
risk	B-D012306
to	O
a	O
fetus	B-D005333
	O

Verify	O
the	O
pregnancy	B-D011247
status	O
of	O
females	B-D005260
of	O
reproductive	O
potential	O
prior	O
to	O
initiation	O
of	O
ARTHOTEC	B-C444205
	O

Advise	O
females	B-D005260
of	O
reproductive	O
potential	O
to	O
use	O
effective	O
contraception	B-D003267
during	O
treatment	O
with	O
ARTHROTEC	B-C078133
[see	O
Contraindications	B-D000075202
(4)	O
and	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1,	O
8.3)]	O

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
patients	B-D010361
	O

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
blood	B-D001769
loss,	O
fluid	O
retention,	O
or	O
an	O
incompletely	O
described	O
effect	O
on	O
erythropoiesis	B-D004920
	O

If	O
a	O
patient	O
treated	O
with	O
ARTHROTEC	B-C078133
has	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia,	B-D000740
monitor	O
hemoglobin	O
or	O
hematocrit	B-D006400
	O

NSAIDs,	O
including	O
ARTHROTEC,	B-C078133
may	O
increase	O
the	O
risk	B-D012306
of	O
bleeding	O
events	O

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
warfarin	B-D014859
and	O
other	O
anticoagulants,	B-D000925
antiplatelet	O
agents	O
(e.g.,	O
aspirin),	B-D001241
and	O
serotonin	B-D012701
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
serotonin	B-D012701
norepinephrine	B-D009638
reuptake	O
inhibitors	O
(SNRIs)	O
may	O
increase	O
this	O
risk	B-D012306
	O

Monitor	O
these	O
patients	B-D010361
for	O
signs	O
of	O
bleeding	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)]	O

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
ARTHROTEC	B-C078133
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
diagnostic	O
signs	O
in	O
detecting	O
infections	B-D007239
	O

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
patients	B-D010361
on	O
long-term	O
NSAID	O
treatment	O
with	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
periodically	B-D020492
[see	O
Warnings	O
and	O
Precautions	O
(5.2,	O
5.6)]	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulceration	B-D014456
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
2%	O
from	O
clinical	B-D016430
trials)	I-D016430
are:	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
nausea,	B-D009325
flatulence,	B-D005414
gastritis,	B-D005756
vomiting,	B-D014839
constipation,	B-D003248
headache,	B-D006261
dizziness,	B-D004244
alanine	B-D000409
aminotransferase	O
increased,	O
hematocrit	B-D006400
decreased	O
(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

Adverse	O
reaction	O
information	O
for	O
ARTHROTEC	B-C078133
is	O
derived	O
from	O
Phase	O
III	O
multinational	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
in	O
over	O
2,000	O
patients	B-D010361
receiving	O
ARTHROTEC	B-C078133
50	O
or	O
ARTHROTEC	B-C078133
75,	O
as	O
well	O
as	O
from	O
blinded,	O
controlled	O
trials	O
of	O
diclofenac	B-D004008
delayed-release	O
tablets	B-D013607
and	O
misoprostol	B-D016595
tablets	B-D013607
	O

Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
incidence	B-D015994
of	O
adverse	O
events	O
for	O
patients	B-D010361
receiving	O
ARTHROTEC	B-C078133
	O

These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
patients	B-D010361
on	O
ARTHROTEC	B-C078133
and	O
5%	O
of	O
patients	B-D010361
on	O
diclofenac	B-D004008
	O

For	O
GI	O
ulcer	B-D014456
rates,	O
[see	O
Clinical	O
Studies	O
(14)]	O
	O

GI	O
disorder	O
ARTHROTEC	B-C078133
Diclofenac	B-D004008
Abdominal	B-D015746
pain	I-D015746
21%	O
15%	O
Diarrhea	B-D003967
19%	O
11%	O
Dyspepsia	B-D004415
14%	O
11%	O
Nausea	B-D009325
11%	O
6%	O
Flatulence	B-D005414
9%	O
4%	O
ARTHROTEC	B-C078133
can	O
cause	O
more	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
and	O
other	O
GI	O
symptoms	O
than	O
diclofenac	B-D004008
alone	O

Diarrhea	B-D003967
and	O
abdominal	B-D015746
pain	I-D015746
developed	O
early	B-D004423
in	O
the	O
course	O
of	O
therapy,	O
and	O
were	O
usually	O
self-limited	O
(resolved	O
after	O
2	O
to	O
7	O
days)	O

Rare	O
instances	O
of	O
profound	O
diarrhea	B-D003967
leading	B-D007854
to	O
severe	O
dehydration	B-D003681
have	O
been	O
reported	O
in	O
patients	B-D010361
receiving	O
misoprostol	B-D016595
	O

Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
disease,	B-D004194
or	O
those	O
in	O
whom	O
dehydration,	B-D003681
were	O
it	O
to	O
occur,	O
would	O
be	O
dangerous,	O
should	O
be	O
monitored	O
carefully	O
if	O
ARTHROTEC	B-C078133
is	O
prescribed	O

The	O
incidence	B-D015994
of	O
diarrhea	B-D003967
can	O
be	O
minimized	O
by	O
administering	O
ARTHROTEC	B-C078133
with	O
food	B-D005502
and	O
by	O
avoiding	O
coadministration	O
with	O
magnesium-containing	B-D008274
antacids	B-D000863
	O

Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
misoprostol	B-D016595
use	O
have	O
also	O
been	O
reported	O
for	O
women	B-D014930
receiving	O
ARTHROTEC	B-C078133
(see	O
below)	O

Postmenopausal	O
vaginal	B-D014621
bleeding	O
may	O
be	O
related	O
to	O
administration	O
of	O
ARTHROTEC	B-C078133
	O

If	O
it	O
occurs,	O
diagnostic	O
workup	B-D014937
should	O
be	O
undertaken	O
to	O
rule	O
out	O
gynecological	O
pathology	B-D010336
[see	O
Boxed	O
Warnings,	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5)]	O

Elderly	O
Overall,	B-D016424
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
safety	B-D012449
profile	B-C546490
of	O
ARTHROTEC	B-C078133
in	O
over	O
500	O
patients	B-D010361
65	O
years	O
of	O
age	O
or	O
older	O
compared	O
with	O
younger	O
patients	B-D010361
	O

Other	O
adverse	O
experiences	O
reported	O
occasionally	O
with	O
ARTHROTEC,	B-C078133
diclofenac	B-D004008
or	O
other	O
NSAIDs,	O
or	O
misoprostol	B-D016595
are:	O
Body	O
as	O
a	O
whole:	O
asthenia,	B-D001247
fatigue,	B-D005221
malaise	O

Central	O
and	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
dizziness,	B-D004244
drowsiness,	O
headache,	B-D006261
insomnia,	O
paresthesia,	B-D010292
vertigo	B-D014717
	O

Digestive:	O
anorexia,	B-D000855
appetite	B-D001066
changes,	O
constipation,	B-D003248
dry	O
mouth,	B-D009055
dysphagia,	O
esophageal	O
ulceration,	B-D014456
oesophagitis,	O
eructation,	B-D004884
gastritis,	B-D005756
gastroesophageal	B-D005764
reflux,	I-D005764
GI	O
neoplasm	O
benign,	O
peptic	B-D010437
ulcer,	I-D010437
tenesmus,	O
vomiting	B-D014839
	O

Female	B-D005260
reproductive	O
disorders:	O
breast	B-D001940
pain,	B-D010146
dysmenorrhea,	B-D004412
menstrual	B-D008571
disorder,	O
menorrhagia,	B-D008595
vaginal	B-D014621
hemorrhage	B-D006470
	O

Hemic	O
and	O
lymphatic	B-D008208
system:	I-D008208
epistaxis,	B-D004844
leukopenia,	B-D007970
melena,	B-D008551
purpura,	B-D011693
decreased	O
hematocrit	B-D006400
	O

Metabolic	O
and	O
nutritional:	O
alanine	B-D000409
aminotransferase	O
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
aspartate	O
aminotransferase	O
increased,	O
dehydration,	B-D003681
hyponatremia	B-D007010
	O

Musculoskeletal	B-D009141
system:	I-D009141
arthralgia,	B-D018771
myalgia	B-D063806
	O

Psychiatric:	O
anxiety,	B-D001007
concentration	O
impaired,	O
depression,	B-D003863
irritability	O

Respiratory	B-D012137
system:	I-D012137
asthma,	B-D001249
coughing,	B-D003371
hyperventilation	B-D006985
	O

Skin	B-D012867
and	O
appendages:	O
alopecia,eczema,	B-D000505
pemphigoid	O
reaction,	O
photosensitivity,	O
sweating	B-D013546
increased,	O
pruritus	B-D011537
	O

Special	O
senses:	O
taste	B-D013649
perversion,	O
tinnitus	B-D014012
	O

Renal	O
and	O
urinary	O
disorders:	O
dysuria,	B-D053159
nocturia,	B-D053158
polyuria,	B-D011141
proteinuria,	B-D011507
urinary	B-D014551
tract	I-D014551
infection	O

Vision:	O
diplopia	B-D004172
	O

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	B-D007060
during	O
post	O
approval	O
of	O
ARTHROTEC,	B-C078133
diclofenac	B-D004008
or	O
misoprostol	B-D016595
	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	B-D011153
of	O
uncertain	O
size,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliable	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O

Body	O
as	O
a	O
whole:	O
death,	B-D003643
fever,	B-D005334
infection,	O
sepsis,	B-D018805
chills,	B-D023341
edema	B-D004487
	O

Cardiovascular	B-D002319
system:	I-D002319
arrhythmia,	O
atrial	B-D001281
fibrillation,	I-D001281
congestive	O
heart	B-D006333
failure,	I-D006333
hypertension,	B-D006973
hypotension,	B-D007022
increased	O
CPK,	O
increased	O
LDH,	O
myocardial	B-D009203
infarction,	I-D009203
palpitations,	O
phlebitis,	B-D010689
premature	B-C070504
ventricular	O
contractions,	O
syncope,	B-D013575
tachycardia,	B-D013610
vasculitis	B-D014657
	O

Central	O
and	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
coma,	B-D003128
convulsions,	O
hyperesthesia,	B-D006941
hypertonia,	O
hypoesthesia,	O
meningitis,	B-D008581
migraine,	O
neuralgia,	B-D009437
somnolence,	O
stroke,	B-D020521
tremor	B-D014202
	O

Congenital,	O
familial	O
and	O
genetic	O
disorders:	O
birth	O
defects	O

Digestive:	O
enteritis,	B-D004751
GI	O
bleeding,	O
glossitis,	B-D005928
heartburn,	B-D006356
hematemesis,	B-D006396
hemorrhoids,	B-D006484
intestinal	B-D007416
perforation,	I-D007416
stomatitis	B-D013280
and	O
ulcerative	B-D014456
stomatitis	B-D013280
	O

Female	B-D005260
reproductive	O
disorders:	O
intermenstrual	O
bleeding,	O
leukorrhea,	B-D007973
vaginitis,	B-D014627
uterine	O
cramping,	O
uterine	B-D014592
hemorrhage	I-D014592
	O

Hemic	O
and	O
lymphatic	B-D008208
system:	I-D008208
agranulocytosis,	B-D000380
anemia,	B-D000741
aplastic	I-D000741
anemia,	B-D000740
coagulation	O
time	B-D013995
increased,	O
ecchymosis,	B-D004438
eosinophilia,	B-D004802
hemolytic	O
anemia,	B-D000740
leukocytosis,	B-D007964
lymphadenopathy,	B-D000072281
pancytopenia,	B-D010198
pulmonary	B-D011655
embolism,	I-D011655
rectal	O
bleeding,	O
thrombocythemia,	O
thrombocytopenia	B-D013921
	O

Hypersensitivity:	B-D006967
angioedema,	B-D000799
laryngeal/pharyngeal	O
edema,	B-D004487
urticaria	B-D014581
	O

Liver	B-D008099
and	O
biliary	O
system:	O
abnormal	O
hepatic	O
function,	O
bilirubinemia,	B-D001663
liver	B-D017093
failure,	I-D017093
pancreatitis,	B-D010195
hepatitis,	B-D006505
jaundice	B-D007565
	O

Male	B-D008297
reproductive	O
disorders:	O
impotence,	O
perineal	O
pain	B-D010146
	O

Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
glycosuria,	B-D006029
gout,	B-D006073
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hyperuricemia,	B-D033461
hypoglycemia,	B-D007003
periorbital	O
edema,	B-D004487
porphyria,	O
weight	O
changes,	O
fluid	O
retention	O

Pregnancy,	B-D011247
puerperium	O
and	O
perinatal	O
conditions:	O
abnormal	O
uterine	B-D014590
contractions,	I-D014590
uterine	B-D014597
rupture/perforation,	I-D014597
retained	O
placenta,	B-D010920
amniotic	B-D000653
fluid	I-D000653
embolism,	B-D004617
incomplete	O
abortion,	O
premature	B-D047928
birth,	I-D047928
fetal	B-D005313
death	I-D005313
	O

Psychiatric:	O
confusion,	B-D003221
disorientation,	O
dream	O
abnormalities,	O
hallucinations,	B-D006212
nervousness,	O
paranoia,	O
psychotic	O
reaction	O

Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
female	B-D005260
fertility	B-D005298
decreased	O

Respiratory	B-D012137
system:	I-D012137
dyspnea,	B-D004417
pneumonia,	B-D011014
respiratory	O
depression	B-D003863
	O

Skin	B-D012867
and	O
appendages:	O
acne,	O
bruising,	O
erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
pruritus	B-D011538
ani,	I-D011538
rash,	O
skin	B-D012883
ulceration,	I-D012883
Stevens-Johnson	B-D013262
syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis,	O
cutaneous	O
reactions	O
(bullous	O
eruption)	O

Special	O
senses:	O
hearing	B-D006309
impairment,	O
taste	B-D013649
loss	O

Renal	O
and	O
urinary	O
disorders:	O
cystitis,	B-D003556
hematuria,	B-D006417
interstitial	O
nephritis,	B-D009393
micturition	O
frequency,	O
nephrotic	B-D009404
syndrome,	I-D009404
oliguria,	B-D009846
papillary	O
necrosis,	B-D009336
renal	O
failure,	O
glomerulonephritis	B-D005921
membranous,	O
glomerulonephritis	B-D005921
minimal	O
lesion,	O
glomerulohephritis	O

Vision:	O
amblyopia,	B-D000550
blurred	O
vision,	O
conjunctivitis,	B-D003231
glaucoma,	B-D005901
iritis,	B-D007500
lacrimation	O
abnormal,	O
night	B-D009755
blindness,	I-D009755
vision	O
abnormal	O

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	B-D012306
Cardiovascular	O
Risk	B-D012306
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
	O

•	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)]	O
	O

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
	O

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	B-D012306
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O

Cardiovascular	O
Risk	B-D012306
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

(5.1)	O
•	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

Gastrointestinal	O
Risk	B-D012306
(4,	O
5.1)	O
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs),	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel,	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke	B-D020521
can	O
occur	O
with	O
NSAID	O
treatment	O

The	O
lowest	O
possible	O
dose	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
be	O
used	O
in	O
patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
	O

(5.1)	O
•NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
inflammation,	B-D007249
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
be	O
prescribed	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

(5.2)	O
•Elevation	O
of	O
one	O
or	O
more	O
liver	B-D008099
tests	B-C004551
may	O
occur	O
during	O
therapy	O
with	O
diclofenac	B-D004008
	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
be	O
discontinued	O
immediately	O
if	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen	O

(5.3)	O
•Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction,	O
including	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
and	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE-inhibitors	O

(5.6)	O
•Hypertension	O
can	O
occur	O
with	O
NSAID	O
treatment	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O

(5.4)	O
•Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
taking	O
NSAIDs	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

(5.5)	O
•Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O
or	O
in	O
patients	B-D010361
without	O
prior	O
exposure	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
and	O
should	O
be	O
discontinued	O
immediately	O
if	O
an	O
anaphylactoid	O
reaction	O
occurs	O

(5.7)	O
•NSAIDs	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
be	O
discontinued	O
if	O
rash	O
or	O
other	O
signs	O
of	O
local	O
skin	B-D012867
reaction	O
occur	O

(5.8)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAIDs	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
NSAIDs	O
such	O
as	O
diclofenac,	B-D004008
does	O
increase	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
.Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)]	O
	O

5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulceration,	B-D014456
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2-4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	B-D013995
during	O
the	O
course	O
of	O
therapy	O

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk.NSAIDs	B-D012306
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
with	O
neither	O
of	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAIDs	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population.To	B-D011153
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
possible	O
duration	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
diclofenac	B-D004008
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

For	O
high-risk	O
patients,	B-D010361
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered	O

5.3	O
Hepatic	O
Effects	O
Elevations	O
of	O
one	O
or	O
more	O
liver	B-D008099
tests	B-C004551
may	O
occur	O
during	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
	O

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy	O

Borderline	O
elevations	O
(i.e	O

less	O
than	O
3	O
times	B-D013995
the	O
ULN	O
[ULN	O
=	O
the	O
upper	O
limit	O
of	O
normal	O
range])	O
or	O
greater	O
elevations	O
of	O
transaminases	B-D000637
occurred	O
in	O
about	O
15%	O
of	O
diclofenac-treated	B-D004008
patients	B-D010361
	O

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	B-D008099
injury.In	O
clinical	B-D016430
trials,	I-D016430
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(GOT)	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
for	O
2-6	O
months,	O
patients	B-D010361
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(i.e.,	O
more	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3-8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(>8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis.Almost	B-D001168
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
tests	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations.In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation.Physicians	I-D016031
should	O
measure	O
transaminases	B-D000637
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
transaminases	B-D000637
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac.If	B-D004008
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
diclofenac	B-D004008
sodium	B-D012964
should	O
be	O
discontinued	O
immediately	O

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
physicians	B-D010820
should	O
inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
“flu-like”	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
patients	B-D010361
should	O
take	O
if	O
these	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
appear.To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver	B-D008099
related	O
event	O
in	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium,	B-D012964
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible	O

Caution	O
should	O
be	O
exercised	B-D015444
in	O
prescribing	O
diclofenac	B-D004008
sodium	B-D012964
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
antibiotics,	O
anti-epileptics)	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel,	O
can	O
lead	B-D007854
to	O
the	O
onset	O
of	O
new	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
cardiovascular	O
events	O

Patients	B-D010361
taking	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE-inhibitors,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

Therefore,	O
treatment	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
is	O
not	O
recommended	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

If	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	B-D010361
without	O
prior	O
exposure	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
not	O
be	O
given	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)].	O

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel,	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
Syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012877
manifestations,	I-D012877
and	O
the	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
signs	O
of	O
hypersensitivity	B-D006967
	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
not	O
be	O
applied	O
to	O
open	O
skin	B-D012867
wounds,	O
infections,	B-D007239
inflammations,	B-D007249
or	O
exfoliative	O
dermatitis,	B-D003872
as	O
it	O
may	O
affect	B-D000339
absorption	B-D000042
and	O
tolerability	O
of	O
the	O
drug	O

Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
not	O
be	O
allowed	O
to	O
come	O
into	O
contact	O
with	O
the	O
eyes	B-D005123
or	O
with	O
mucous	B-D009092
membranes.The	I-D009092
effect	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
under	O
occlusive	B-D009779
dressings	I-D009779
has	O
not	O
been	O
evaluated,	O
and	O
should	O
be	O
avoided	O

5.9	O
Pregnancy	B-D011247
As	O
with	O
other	O
NSAIDs,	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
be	O
avoided	O
in	O
late	O
pregnancy,	B-D011247
because	O
it	O
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
	O

5.10	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	B-D007854
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness	O

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
diclofenac	B-D004008
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	B-D010146
conditions	O

5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	B-D010361
receiving	O
NSAIDs	O

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
blood	B-D001769
loss,	O
or	O
an	O
incompletely	O
described	O
effect	O
upon	O
erythropoeisis	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel,	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss.NSAIDs	O
inhibit	O
platelet	B-D010974
aggregation	I-D010974
and	O
have	O
been	O
shown	O
to	O
prolong	O
bleeding	B-D001760
time	I-D001760
in	O
some	O
patients	B-D010361
	O

Unlike	O
aspirin,	B-D001241
their	O
effect	O
on	O
platelet	O
function	O
is	O
quantitatively	O
less,	O
of	O
shorter	O
duration,	O
and	O
reversible	O

Patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
who	O
may	O
be	O
adversely	O
affected	B-D000339
by	O
alteration	O
in	O
platelet	O
function,	O
such	O
as	O
those	O
with	O
coagulation	O
disorders	O
or	O
patients	B-D010361
receiving	O
anticoagulants	B-D000925
should	O
be	O
carefully	O
monitored	O

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

The	O
use	O
of	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal	O

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	B-D001241
and	O
other	O
non-steroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
not	O
be	O
administered	O
to	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
artificial	B-D001154
sunlight	B-D013472
on	O
treated	O
areas	O
because	O
studies	O
in	O
animals	B-D000818
indicated	O
topical	O
diclofenac	B-D004008
treatment	O
resulted	O
in	O
an	O
earlier	B-D004423
onset	O
of	O
ultraviolet	O
light	B-D008027
induced	O
skin	B-D012867
tumors	O

The	O
potential	O
effects	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
on	O
skin	B-D012867
response	O
to	O
ultraviolet	O
damage	O
in	O
humans	B-D006801
are	O
not	O
known	O

5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
with	O
eyes	B-D005123
and	O
mucosa,	O
although	O
not	O
studied,	O
should	O
be	O
avoided	O

Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
eye	B-D005123
contact	O
occurs,	O
they	O
should	O
immediately	O
wash	O
out	O
the	O
eye	B-D005123
with	O
water	B-D014867
or	O
saline	O
and	O
consult	O
a	O
physician	O
if	O
irritation	O
persists	O
for	O
more	O
than	O
an	O
hour	O

5.16	O
Laboratory	O
Tests	B-C004551
Because	O
serious	O
GI	O
tract	O
ulcerations	B-D014456
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	B-D010820
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
checked	O
periodically	B-D020492
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
or	O
renal	O
tests	B-C004551
persist	O
or	O
worsen,	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
should	O
be	O
discontinued	O

6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
and	O
greater	O
than	O
placebo)	O
are	O
application	O
site	O
reactions,	O
including	O
dermatitis	B-D003872
	O

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sandoz	B-D000080463
Inc	O

at	O
1-800-398-5876	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
	O

6.1	O
Clinical	B-D016430
Trials	I-D016430
Experience	O
Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice.During	O
clinical	O
development,	O
913	O
patients	B-D010361
were	O
exposed	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
in	O
randomized,	O
double-blind,	O
multicenter,	O
vehicle-controlled,	O
parallel-group	O
studies	O
in	O
osteoarthritis	B-D010003
of	O
the	O
superficial	O
joints	B-D007596
of	O
the	O
extremities	B-D005121
	O

Of	O
these,	O
513	O
patients	B-D010361
received	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
for	O
osteoarthritis	B-D010003
of	O
the	O
knee	B-D007717
and	O
400	O
were	O
treated	O
for	O
osteoarthritis	B-D010003
of	O
the	O
hand	B-D006225
	O

Additionally,	O
583	O
patients	B-D010361
were	O
exposed	O
to	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
in	O
an	O
uncontrolled,	O
open-label,	O
long-term	O
safety	B-D012449
trial	O
in	O
osteoarthritis	B-D010003
of	O
the	O
knee	B-D007717
	O

Of	O
these,	O
355	O
patients	B-D010361
were	O
treated	O
for	O
osteoarthritis	B-D010003
of	O
1	O
knee	B-D007717
and	O
228	O
were	O
treated	O
for	O
osteoarthritis	B-D010003
of	O
both	O
knees	B-D007717
	O

Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
safety	B-D012449
trial	O

Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel:	O
Non-serious	O
adverse	O
reactions	O
that	O
were	O
reported	O
during	O
the	O
short-term	O
placebo-controlled	O
studies	O
comparing	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
and	O
placebo	O
(vehicle	O
gel)	O
over	O
study	O
periods	O
of	O
8	O
to	O
12	O
weeks	O
(16	O
g	O
per	O
day),	O
were	O
application	O
site	O
reactions	O

These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>1%	O
of	O
treated	O
patients	B-D010361
with	O
a	O
greater	O
frequency	O
in	O
the	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
group	O
(7%)	O
than	O
the	O
placebo	O
group	O
(2%)	O

Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported	O

Application	O
site	O
dermatitis	B-D003872
was	O
the	O
most	O
frequent	O
type	O
of	O
application	O
site	O
reaction	O
and	O
was	O
reported	O
by	O
4%	O
of	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel,	O
compared	O
to	O
1%	O
of	O
placebo	O
patients	B-D010361
	O

Table	O
1:	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
Patients)	B-D010361
–	O
Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction†	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
N=913	O
Placebo	O
(vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
dermatitis	B-D003872
32	O
(4)	O
6	O
(<1)	O
Application	O
site	O
pruritus	B-D011537
7	O
(<1)	O
1	O
(<1)	O
Application	O
site	O
erythema	B-D004890
6	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
paresthesia	B-D010292
5	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
dryness	O
4	O
(<1)	O
3	O
(<1)	O
Application	O
site	O
vesicles	O
3	O
(<1)	O
0	O
Application	O
site	O
irritation	O
2	O
(<1)	O
0	O
Application	O
site	O
papules	O
1	O
(<1)	O
0	O
†	O
Preferred	O
Term	O
according	O
to	O
MedDRA	O
9.1	O

In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel,	O
and	O
3%	O
for	O
patients	B-D010361
in	O
the	O
placebo	O
group	O

Application	O
site	O
reactions,	O
including	O
application	O
site	O
dermatitis,	B-D003872
were	O
the	O
most	O
frequent	O
reason	O
for	O
treatment	O
discontinuation	O

Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
safety	B-D012449
study,	O
distribution	O
of	O
adverse	O
reactions	O
was	O
similar	O
to	O
that	O
in	O
the	O
placebo-controlled	O
studies	O

In	O
this	O
study,	O
where	O
patients	B-D010361
were	O
treated	O
for	O
up	O
to	O
1	O
year	O
with	O
diclofenac	B-D004008
sodium	B-D012964
topical	O
gel	O
up	O
to	O
32	O
g	O
per	O
day,	O
application	O
site	O
dermatitis	B-D003872
was	O
observed	O
in	O
11%	O
of	O
patients	B-D010361
	O

Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
patients	B-D010361
	O

The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
dermatitis,	B-D003872
which	O
was	O
experienced	O
by	O
6%	O
of	O
patients	B-D010361
	O

TAMPER-EVIDENT	O
BOTTLE	O
DO	O
NOT	O
USE	O
IF	O
INNER	O
FOIL	O
SEAL	O
IMPRINTED	O
WITH	O
“SEALED	O
for	O
YOUR	O
PROTECTION”IS	O
BROKEN	O
OR	O
MISSING	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
Cardiovascular	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
capsules	B-D002214
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
celecoxib,	B-D000068579
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
capsules	B-D002214
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
celecoxib,	B-D000068579
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke	B-D020521
	O

Patients	B-D010361
with	O
known	O
CV	O
disease/risk	B-D004194
factors	O
may	O
be	O
at	O
greater	O
risk	B-D012306
(5.1,	O
14.6,	O
17.2)	O

•	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
risk	B-D012306
is	O
greater	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
GI	O
bleeding,	O
and	O
in	O
patients	B-D010361
at	O
high	O
risk	B-D012306
for	O
GI	O
events,	O
especially	O
the	O
elderly	O

Celecoxib	B-D000068579
capsules	B-D002214
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	B-D010361
(5.4,	O
8.5,	O
14.6,	O
17.3)	O

•	O
Elevated	O
liver	B-D008099
enzymes	B-D004798
and,	O
rarely,	O
severe	O
hepatic	O
reactions	O

Discontinue	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
immediately	O
if	O
abnormal	O
liver	B-D008099
enzymes	B-D004798
persist	O
or	O
worsen	O
(5.5,	O
17.4)	O

•	O
New	O
onset	O
or	O
worsening	O
of	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
(5.2,	O
7.4,	O
17.2)	O

•	O
Fluid	O
retention	O
and	O
edema	B-D004487
	O

Celecoxib	B-D000068579
capsules	B-D002214
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
(5.3,	O
17.6)	O

•	O
Renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use	O

Use	O
celecoxib	B-D000068579
capsules	B-D002214
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
and	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
or	O
angiotensin	B-D000804
II	I-D000804
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6)	O

•	O
Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
celecoxib	B-D000068579
capsules	B-D002214
in	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O
(5.7,	O
10,	O
17.7)	O

•	O
Serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy	O

Discontinue	O
celecoxib	B-D000068579
capsules	B-D002214
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	B-D012867
reactions	O
(5.8,	O
17.5)	O

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	B-D000068579
capsules	B-D002214
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(14.6)]	O

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib,	B-D000068579
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
celecoxib	B-D000068579
does	O
increase	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O

Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)]	O

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	B-D000068579
can	O
lead	B-D007854
to	O
the	O
onset	O
of	O
new	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

NSAIDs,	O
including	O
celecoxib,	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	B-D000068579
and	O
throughout	O
the	O
course	O
of	O
therapy	O

The	O
rates	O
of	O
hypertension	B-D006973
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	B-D000068579
ibuprofen	B-D007052
and	O
diclofenac-treated	B-D004008
patients	B-D010361
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	B-D000078682
[see	O
Clinical	O
Studies	O
(14.6)]	O

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
taking	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
[see	O
Adverse	O
Reactions	O
(6.1)]	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
capsules	B-D002214
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Celecoxib	B-D000068579
capsules	B-D002214
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulceration,	B-D014456
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	B-D000068579
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)]	O

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	B-D013995
during	O
the	O
course	O
of	O
therapy	O

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
with	O
neither	O
of	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population	B-D011153
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
celecoxib	B-D000068579
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

For	O
high-risk	O
patients,	B-D010361
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered	O

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	B-D008099
enzymes	B-D004798
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
with	O
NSAIDs	O

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	B-D007565
and	O
fatal	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis	B-D009336
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	B-D017809
outcome)	I-D017809
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
[see	O
Adverse	O
Reactions	O
(6.1)]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
celecoxib,	B-D000068579
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
celecoxib	B-D000068579
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	B-D008099
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	B-D008099
test	B-C004551
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib	B-D000068579
capsules	B-D002214
	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
celecoxib	B-D000068579
capsules	B-D002214
should	O
be	O
discontinued	O

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
angiotensin	B-D000804
II	I-D000804
receptor	O
antagonists,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
trials	I-D016430
with	O
celecoxib	B-D000068579
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

Therefore,	O
treatment	O
with	O
celecoxib	B-D000068579
is	O
not	O
recommended	O
in	O
these	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

If	O
celecoxib	B-D000068579
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	B-D010361
without	O
known	O
prior	O
exposure	O
to	O
celecoxib	B-D000068579
	O

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	B-D000799
have	O
been	O
reported	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
	O

Celecoxib	B-D000068579
capsules	B-D002214
should	O
not	O
be	O
given	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)]	O

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	B-D010361
without	O
prior	O
known	O
sulfa	O
allergy	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012877
manifestations	I-D012877
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	B-D011247
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	B-D000068579
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)]	O

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	B-D007854
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness	O

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
capsules	B-D002214
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
celecoxib	B-D000068579
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	B-D000068579
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	B-D000339
platelet	B-D010976
counts,	I-D010976
prothrombin	B-D011517
time	I-D011517
(PT),	O
or	O
partial	B-D010314
thromboplastin	I-D010314
time	I-D010314
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	B-D010974
aggregation	I-D010974
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)]	O

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
capsules	B-D002214
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
	O

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

The	O
use	O
of	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal	O

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	B-D001241
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
celecoxib	B-D000068579
capsules	B-D002214
should	O
not	O
be	O
administered	O
to	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

5.14	O
Laboratory	O
Tests	B-C004551
Because	O
serious	O
GI	O
tract	O
ulcerations	B-D014456
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	B-D010820
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
checked	O
periodically	B-D020492
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
or	O
renal	O
tests	B-C004551
persist	O
or	O
worsen,	O
celecoxib	B-D000068579
capsules	B-D002214
should	O
be	O
discontinued	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	B-D000068579
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	B-D010146
conditions	O

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	B-D000068579
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	B-D012306
of	O
adverse	O
reactions	O

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	B-D000068579
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	B-D000068579
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
celecoxib	B-D000068579
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Watson	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
Placebo	O
NAP	O
DCF	O
IBU	O
N=4146	O
N=1864	O
N=1366	O
N=387	O
N=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	B-D000068579
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	B-D000068579
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
-	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
(100	O
-	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia,	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	B-D010361
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis,	B-D013924
vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis,	B-D002769
hepatitis,	B-D006505
jaundice,	B-D007565
liver	B-D017093
failure	I-D017093
Hemic	O
and	O
lymphatic:	B-D008196
Thrombocytopenia,	B-D013921
agranulocytosis,aplastic	B-D000380
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Ataxia,	B-D001259
suicide,	B-D013405
aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	B-D009393
Skin:	B-D012867
Erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis	O
General:	O
Sepsis,	B-D018805
sudden	O
death,	B-D003643
anaphylactoid	O
reaction,	O
angioedema	B-D000799
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)]	O
Hematological	O
Events:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
celecoxib	B-D000068579
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	B-D000068579
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

6.3	O
Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
BID,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
BID	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
>5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
Celecoxib	B-D000068579
Celecoxib	B-D000068579
Naproxen	B-D009288
System	O
Organ	O
Class	O
3	O
mg/kg	O
6	O
mg/kg	O
7.5	O
mg/kg	O
*	O
Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
Preferred	O
Term	O
N=77	O
N=82	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations*	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	B-D000068579
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
celecoxib	B-D000068579
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.6)]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	B-D000068579
pre-marketing	O
controlled	O
arthritis	B-D001168
trials,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
Placebo	O
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
Celecoxib	B-D000068579
capsules,	B-D002214
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
celecoxib,	B-D000068579
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O

(5.4)	O
Cardiovascular	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
celecoxib,	B-D000068579
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(5.4)	O
5.WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke	B-D020521
	O

Patients	B-D010361
with	O
known	O
CV	O
disease/risk	B-D004194
factors	O
may	O
be	O
at	O
greater	O
risk	B-D012306
(5.1,	O
14.6,	O
17.2)	O

•Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
risk	B-D012306
is	O
greater	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
GI	O
bleeding,	O
and	O
in	O
patients	B-D010361
at	O
high	O
risk	B-D012306
for	O
GI	O
events,	O
especially	O
the	O
elderly	O

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	B-D010361
(5.4,	O
8.5,	O
14.6,	O
17.3)	O

•Elevated	O
liver	B-D008099
enzymes	B-D004798
and,	O
rarely,	O
severe	O
hepatic	O
reactions	O

Discontinue	O
use	O
of	O
celecoxib	B-D000068579
immediately	O
if	O
abnormal	O
liver	B-D008099
enzymes	B-D004798
persist	O
or	O
worsen	O
(5.5,	O
17.4)	O

•New	O
onset	O
or	O
worsening	O
of	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
celecoxib	B-D000068579
(5.2,	O
7.4,	O
17.2)	O

•Fluid	O
retention	O
and	O
edema	B-D004487
	O

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
(5.3,	O
17.6)	O

•Renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use	O

Use	O
celecoxib	B-D000068579
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
and	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
or	O
angiotensin	B-D000804
II	I-D000804
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6)	O

•Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O
(5.7,	O
10,	O
17.7)	O

•Serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy	O

Discontinue	O
celecoxib	B-D000068579
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	B-D012867
reactions	O
(5.8,	O
17.5)	O

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
celecoxib	B-D000068579
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib,	B-D000068579
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
celecoxib	B-D000068579
does	O
increase	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O

Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)	O
]	O

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
celecoxib	B-D000068579
can	O
lead	B-D007854
to	O
the	O
onset	O
of	O
new	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

NSAIDs,	O
including	O
celecoxib,	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
celecoxib	B-D000068579
and	O
throughout	O
the	O
course	O
of	O
therapy	O

The	O
rates	O
of	O
hypertension	B-D006973
from	O
the	O
CLASS	O
trial	O
in	O
the	O
celecoxib,	B-D000068579
ibuprofen	B-D007052
and	O
diclofenac-treated	B-D004008
patients	B-D010361
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	B-D000078682
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
taking	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
[see	O
Adverse	O
Reactions	O
(6.1)	O
]	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulceration,	B-D014456
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
celecoxib,	B-D000068579
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	B-D013995
during	O
the	O
course	O
of	O
therapy	O

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
with	O
neither	O
of	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population	B-D011153
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
celecoxib	B-D000068579
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

For	O
high-risk	O
patients,	B-D010361
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
patients	B-D010361
with	O
active	O
GI	O
bleeding	O

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	B-D008099
enzymes	B-D004798
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
with	O
NSAIDs	O

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	B-D007565
and	O
fatal	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis	B-D009336
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	B-D017809
outcome)	I-D017809
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
celecoxib	B-D000068579
[see	O
Adverse	O
Reactions	O
(6.1)	O
]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
celecoxib,	B-D000068579
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
celecoxib	B-D000068579
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
celecoxib	B-D000068579
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	B-D008099
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	B-D008099
test	B-C004551
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
celecoxib	B-D000068579
	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
celecoxib	B-D000068579
should	O
be	O
discontinued	O

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
angiotensin	B-D000804
II	I-D000804
receptor	O
antagonists,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
trials	I-D016430
with	O
celecoxib	B-D000068579
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
celecoxib	B-D000068579
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

Therefore,	O
treatment	O
with	O
celecoxib	B-D000068579
is	O
not	O
recommended	O
in	O
these	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

If	O
celecoxib	B-D000068579
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	B-D010361
without	O
known	O
prior	O
exposure	O
to	O
celecoxib	B-D000068579
	O

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	B-D000799
have	O
been	O
reported	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
	O

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	B-D010361
without	O
prior	O
known	O
sulfa	O
allergy	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012877
manifestations	I-D012877
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

5.9Pregnancy	O
In	O
late	O
pregnancy,	B-D011247
starting	O
at	O
30	O
weeks	O
gestation,	O
celecoxib	B-D000068579
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	B-D007854
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness	O

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
celecoxib	B-D000068579
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
celecoxib	B-D000068579
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

Celecoxib	B-D000068579
does	O
not	O
generally	O
affect	B-D000339
platelet	B-D010976
counts,	I-D010976
prothrombin	B-D011517
time	I-D011517
(PT),	O
or	O
partial	B-D010314
thromboplastin	I-D010314
time	I-D010314
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	B-D010974
aggregation	I-D010974
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
	O

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

The	O
use	O
of	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal	O

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	B-D001241
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
celecoxib	B-D000068579
should	O
not	O
be	O
administered	O
to	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

5.14	O
Laboratory	O
Tests	B-C004551
Because	O
serious	O
GI	O
tract	O
ulcerations	B-D014456
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	B-D010820
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
checked	O
periodically	B-D020492
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
or	O
renal	O
tests	B-C004551
persist	O
or	O
worsen,	O
celecoxib	B-D000068579
should	O
be	O
discontinued	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
celecoxib	B-D000068579
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	B-D010146
conditions	O

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
celecoxib	B-D000068579
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	B-D012306
of	O
adverse	O
reactions	O

6.ADVERSE	O
REACTIONS	O
Of	O
the	O
celecoxib-treated	B-D000068579
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
celecoxib	B-D000068579
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
celecoxib	B-D000068579
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
celecoxib	B-D000068579
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
celecoxib	B-D000068579
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
celecoxib	B-D000068579
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting):	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia,	O
Psychiatric:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic:	O
Anemia	B-D000740
Respiratory:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	B-D010361
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis,	B-D013924
vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
Gastrointestinal:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
Liver	B-D008099
and	O
biliary:	O
Cholelithiasis,	B-D002769
hepatitis,	B-D006505
jaundice,	B-D007565
liver	B-D017093
failure	I-D017093
Hemic	O
and	O
lymphatic:	B-D008196
Thrombocytopenia,	B-D013921
agranulocytosis,aplastic	B-D000380
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous:	O
Ataxia,	B-D001259
suicide,	B-D013405
aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	B-D009393
Skin:	B-D012867
Erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	B-D006967
syndrome)	B-D013577
General:	O
Sepsis,	B-D018805
sudden	O
death,	B-D003643
anaphylactoid	O
reaction,	O
angioedema	B-D000799
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
celecoxib	B-D000068579
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
celecoxib	B-D000068579
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
celecoxib,	B-D000068579
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

6.3	O
Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
BID,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
BID	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N=77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N=82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
Investigations	O
Abnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
celecoxib	B-D000068579
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
celecoxib	B-D000068579
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
celecoxib	B-D000068579
pre-marketing	O
controlled	O
arthritis	B-D001168
trials	O
,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
celecoxib	B-D000068579
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
Celecoxib	B-D000068579
(400	O
to	O
800	O
mg	O
daily)	O
N	O
=	O
2285	O
Placebo	O
N=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
celecoxib,	B-D000068579
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies,	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders:	O
Ovarian	O
cyst	O
Investigations:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISKS	B-D012306
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O

(5.4)	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke	B-D020521
	O

Patients	B-D010361
with	O
known	O
CV	O
disease/risk	B-D004194
factors	O
may	O
be	O
at	O
greater	O
risk	B-D012306
(5.1,	O
14.6,	O
17.2)	O

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
risk	B-D012306
is	O
greater	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
GI	O
bleeding,	O
and	O
in	O
patients	B-D010361
at	O
high	O
risk	B-D012306
for	O
GI	O
events,	O
especially	O
the	O
elderly	O

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	B-D010361
(5.4,	O
8.5,	O
14.6,	O
17.3)	O

Elevated	O
liver	B-D008099
enzymes	B-D004798
and,	O
rarely,	O
severe	O
hepatic	O
reactions	O

Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
liver	B-D008099
enzymes	B-D004798
persist	O
or	O
worsen	O
(5.5,	O
17.4)	O

New	O
onset	O
or	O
worsening	O
of	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
treatment	O
with	O
CELEBREX	O
(5.2,	O
7.4,	O
17.2)	O

Fluid	O
retention	O
and	O
edema	B-D004487
	O

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
(5.3,	O
17.6)	O

Renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O
with	O
long	O
term	O
use	O

Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
and	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
or	O
angiotensin	B-D000804
II	I-D000804
antagonists	O
(5.6,	O
7.4,	O
8.7,	O
17.6)	O

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
CELEBREX	O
in	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O
(5.7,	O
10,	O
17.7)	O

Serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O
and	O
can	O
occur	O
without	O
warning	O
even	O
without	O
known	O
prior	O
sulfa	O
allergy	O

Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
skin	B-D012867
reactions	O
(5.8,	O
17.5)	O

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
adverse	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib)	B-D000068579
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
death,	B-D003643
MI,	O
or	O
stroke	B-D020521
was	O
3.4	O
(95%	O
CI	O
1.4	O
–	O
8.5)	O
for	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
and	O
2.8	O
(95%	O
CI	O
1.1	O
–	O
7.2)	O
with	O
CELEBREX	O
200	O
mg	O
twice	O
daily	O
compared	O
to	O
placebo	O

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
respectively,	B-D000078682
compared	O
to	O
0.9%	O
(6/679	O
subjects)	O
with	O
placebo	O
treatment	O

The	O
increases	O
in	O
both	O
celecoxib	B-D000068579
dose	O
groups	O
versus	O
placebo-treated	O
patients	B-D010361
were	O
mainly	O
due	O
to	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
CELEBREX,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAID	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
CELEBREX	O
does	O
increase	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O

Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
different	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10–14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)	O
]	O

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
lead	B-D007854
to	O
the	O
onset	O
of	O
new	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
CV	O
events	O

Patients	B-D010361
taking	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
CELEBREX	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

The	O
rates	O
of	O
hypertension	B-D006973
from	O
the	O
CLASS	O
trial	O
in	O
the	O
CELEBREX,	O
ibuprofen	B-D007052
and	O
diclofenac-treated	B-D004008
patients	B-D010361
were	O
2.4%,	O
4.2%	O
and	O
2.5%,	O
respectively	B-D000078682
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
taking	O
NSAIDs,	O
including	O
CELEBREX	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
]	O

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
edema	B-D004487
in	O
patients	B-D010361
on	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
(4-fold	O
and	O
2-fold	O
the	O
recommended	O
OA	O
and	O
RA	O
doses,	O
respectively),	B-D000078682
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
and	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
were	O
4.5%,	O
6.9%	O
and	O
4.7%,	O
respectively	B-D000078682
	O

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulceration,	B-D014456
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Complicated	O
and	O
symptomatic	O
ulcer	B-D014456
rates	O
were	O
0.78%	O
at	O
nine	O
months	O
for	O
all	O
patients	B-D010361
in	O
the	O
CLASS	O
trial,	O
and	O
2.19%	O
for	O
the	O
subgroup	O
on	O
low-dose	O
ASA	O

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
incidence	B-D015994
of	O
1.40%	O
at	O
nine	O
months,	O
3.06%	O
when	O
also	O
taking	O
ASA	O
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	B-D013995
during	O
the	O
course	O
of	O
therapy	O

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
with	O
neither	O
of	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAID	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population	B-D011153
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
individual	O
patient	O
treatment	O
goals	B-D006040
	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
CELEBREX	O
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

For	O
high-risk	O
patients,	B-D010361
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered	O

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
liver-associated	B-D008099
enzymes	B-D004798
may	O
occur	O
in	O
up	O
to	O
15%	O
of	O
patients	B-D010361
taking	O
NSAIDs,	O
and	O
notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
3	O
or	O
more	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
have	O
been	O
reported	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
in	O
clinical	B-D016430
trials	I-D016430
with	O
NSAIDs	O

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
jaundice	B-D007565
and	O
fatal	O
fulminant	O
hepatitis,	B-D006505
liver	B-D008099
necrosis	B-D009336
and	O
hepatic	O
failure	O
(some	O
with	O
fatal	B-D017809
outcome)	I-D017809
have	O
been	O
reported	O
with	O
NSAIDs,	O
including	O
CELEBREX	O
[see	O
Adverse	O
Reactions	O
(6.1)	O
]	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
of	O
CELEBREX,	O
the	O
incidence	B-D015994
of	O
borderline	O
elevations	O
(greater	O
than	O
or	O
equal	O
to	O
1.2	O
times	B-D013995
and	O
less	O
than	O
3	O
times	B-D013995
the	O
upper	O
limit	O
of	O
normal)	O
of	O
liver	B-D008099
associated	O
enzymes	B-D004798
was	O
6%	O
for	O
CELEBREX	O
and	O
5%	O
for	O
placebo,	O
and	O
approximately	O
0.2%	O
of	O
patients	B-D010361
taking	O
CELEBREX	O
and	O
0.3%	O
of	O
patients	B-D010361
taking	O
placebo	O
had	O
notable	O
elevations	O
of	O
ALT	O
and	O
AST	O

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
liver	B-D008099
dysfunction,	O
or	O
in	O
whom	O
an	O
abnormal	O
liver	B-D008099
test	B-C004551
has	O
occurred,	O
should	O
be	O
monitored	O
carefully	O
for	O
evidence	O
of	O
the	O
development	O
of	O
a	O
more	O
severe	O
hepatic	O
reaction	O
while	O
on	O
therapy	O
with	O
CELEBREX	O

If	O
clinical	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
etc.),	O
CELEBREX	O
should	O
be	O
discontinued	O

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics,	B-D004232
ACE-inhibitors,	O
angiotensin	B-D000804
II	I-D000804
receptor	O
antagonists,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
trials	I-D016430
with	O
CELEBREX	O
have	O
shown	O
renal	O
effects	O
similar	O
to	O
those	O
observed	O
with	O
comparator	O
NSAIDs	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
patients	B-D010361
with	O
advanced	O
renal	O
disease	B-D004194
	O

If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
patients	B-D010361
without	O
known	O
prior	O
exposure	O
to	O
CELEBREX	O

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
angioedema	B-D000799
have	O
been	O
reported	O
in	O
patients	B-D010361
receiving	O
CELEBREX	O

CELEBREX	O
should	O
not	O
be	O
given	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
skin	B-D012867
adverse	O
events	O
such	O
as	O
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome	I-D013262
(SJS),	O
and	O
toxic	O
epidermal	O
necrolysis	O
(TEN),	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
patients	B-D010361
without	O
prior	O
known	O
sulfa	O
allergy	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
serious	O
skin	B-D012877
manifestations	I-D012877
and	O
use	O
of	O
the	O
drug	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
appearance	O
of	O
skin	B-D012867
rash	O
or	O
any	O
other	O
sign	O
of	O
hypersensitivity	B-D006967
	O

5.9	O
Pregnancy	B-D011247
In	O
late	O
pregnancy,	B-D011247
starting	O
at	O
30	O
weeks	O
gestation,	O
CELEBREX	O
should	O
be	O
avoided	O
because	O
it	O
may	O
cause	O
premature	B-C070504
closure	O
of	O
the	O
ductus	B-D004373
arteriosus	I-D004373
[see	O
Use	O
in	O
Specific	O
Populations	B-D011153
(8.1)	O
]	O

5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
lead	B-D007854
to	O
exacerbation	O
of	O
corticosteroid-responsive	O
illness	O

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
patients	B-D010361
receiving	O
CELEBREX	O

In	O
controlled	B-D018848
clinical	I-D018848
trials	I-D018848
the	O
incidence	B-D015994
of	O
anemia	B-D000740
was	O
0.6%	O
with	O
CELEBREX	O
and	O
0.4%	O
with	O
placebo	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
hematocrit	B-D006400
checked	O
if	O
they	O
exhibit	O
any	O
signs	O
or	O
symptoms	O
of	O
anemia	B-D000740
or	O
blood	B-D001769
loss	O

CELEBREX	O
does	O
not	O
generally	O
affect	B-D000339
platelet	B-D010976
counts,	I-D010976
prothrombin	B-D011517
time	I-D011517
(PT),	O
or	O
partial	B-D010314
thromboplastin	I-D010314
time	I-D010314
(PTT),	O
and	O
does	O
not	O
inhibit	O
platelet	B-D010974
aggregation	I-D010974
at	O
indicated	O
dosages	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
patients	B-D010361
with	O
systemic	O
onset	O
JRA	O
due	O
to	O
the	O
risk	B-D012306
of	O
disseminated	B-D004211
intravascular	I-D004211
coagulation	I-D004211
	O

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
asthma	B-D001249
may	O
have	O
aspirin-sensitive	B-D001241
asthma	B-D001249
	O

The	O
use	O
of	O
aspirin	B-D001241
in	O
patients	B-D010361
with	O
aspirin-sensitive	B-D001241
asthma	B-D001249
has	O
been	O
associated	O
with	O
severe	O
bronchospasm,	O
which	O
can	O
be	O
fatal	O

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
aspirin	B-D001241
and	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
has	O
been	O
reported	O
in	O
such	O
aspirin-sensitive	B-D001241
patients,	B-D010361
CELEBREX	O
should	O
not	O
be	O
administered	O
to	O
patients	B-D010361
with	O
this	O
form	B-D020478
of	O
aspirin	B-D001241
sensitivity	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
preexisting	O
asthma	B-D001249
	O

5.14	O
Laboratory	O
Tests	B-C004551
Because	O
serious	O
GI	O
tract	O
ulcerations	B-D014456
and	O
bleeding	O
can	O
occur	O
without	O
warning	O
symptoms,	O
physicians	B-D010820
should	O
monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
GI	O
bleeding	O

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
chemistry	B-D002621
profile	B-C546490
checked	O
periodically	B-D020492
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
or	O
renal	O
tests	B-C004551
persist	O
or	O
worsen,	O
CELEBREX	O
should	O
be	O
discontinued	O

In	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
elevated	O
BUN	O
occurred	O
more	O
frequently	O
in	O
patients	B-D010361
receiving	O
CELEBREX	O
compared	O
with	O
patients	B-D010361
on	O
placebo	O

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
patients	B-D010361
who	O
received	O
comparator	O
NSAIDs	O
in	O
these	O
studies	O

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
inflammation,	B-D007249
and	O
possibly	O
fever,	B-D005334
may	O
diminish	O
the	O
utility	O
of	O
these	O
diagnostic	O
signs	O
in	O
detecting	O
infectious	O
complications	O
of	O
presumed	O
noninfectious,	O
painful	B-D010146
conditions	O

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
risk	B-D012306
of	O
adverse	O
reactions	O

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
patients	B-D010361
in	O
the	O
pre-marketing	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
approximately	O
4,250	O
were	O
patients	B-D010361
with	O
OA,	O
approximately	O
2,100	O
were	O
patients	B-D010361
with	O
RA,	O
and	O
approximately	O
1,050	O
were	O
patients	B-D010361
with	O
post-surgical	O
pain	B-D010146
	O

More	O
than	O
8,500	O
patients	B-D010361
received	O
a	O
total	O
daily	O
dose	O
of	O
CELEBREX	O
of	O
200	O
mg	O
(100	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily)	O
or	O
more,	O
including	O
more	O
than	O
400	O
treated	O
at	O
800	O
mg	O
(400	O
mg	O
twice	O
daily)	O

Approximately	O
3,900	O
patients	B-D010361
received	O
CELEBREX	O
at	O
these	O
doses	O
for	O
6	O
months	O
or	O
more;	O
approximately	O
2,300	O
of	O
these	O
have	O
received	O
it	O
for	O
1	O
year	O
or	O
more	O
and	O
124	O
of	O
these	O
have	O
received	O
it	O
for	O
2	O
years	O
or	O
more	O

Because	O
clinical	B-D016430
trials	I-D016430
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	B-D016430
trials	I-D016430
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

The	O
adverse	O
reaction	O
information	O
from	O
clinical	B-D016430
trials	I-D016430
does,	O
however,	O
provide	O
a	O
basis	O
for	O
identifying	B-D007060
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O

Most	O
common	O
adverse	O
reactions	O
in	O
arthritis	B-D001168
trials	O
(>2%	O
and	O
>placebo):	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
peripheral	O
edema,	B-D004487
accidental	O
injury,	O
dizziness,	B-D004244
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis,	B-D012852
upper	O
respiratory	O
tract	O
infection,	O
rash	O
(6.1)	O

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
causality,	B-D015984
occurring	O
in	O
≥2%	O
of	O
patients	B-D010361
receiving	O
CELEBREX	O
from	O
12	O
controlled	O
studies	O
conducted	O
in	O
patients	B-D010361
with	O
OA	O
or	O
RA	O
that	O
included	O
a	O
placebo	O
and/or	O
a	O
positive	O
control	O
group	O

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
patients	B-D010361
in	O
the	O
trials	O
may	O
not	O
have	O
been	O
exposed	O
for	O
the	O
same	O
duration	O
of	O
time,	B-D013995
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
system	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
clinical	B-D016430
trials,	I-D016430
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
events	O
was	O
7.1%	O
for	O
patients	B-D010361
receiving	O
CELEBREX	O
and	O
6.1%	O
for	O
patients	B-D010361
receiving	O
placebo	O

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
dyspepsia	B-D004415
and	O
abdominal	B-D015746
pain	I-D015746
(cited	O
as	O
reasons	O
for	O
discontinuation	O
in	O
0.8%	O
and	O
0.7%	O
of	O
CELEBREX	O
patients,	B-D010361
respectively)	B-D000078682
	O

Among	O
patients	B-D010361
receiving	O
placebo,	O
0.6%	O
discontinued	O
due	O
to	O
dyspepsia	B-D004415
and	O
0.6%	O
withdrew	O
due	O
to	O
abdominal	B-D015746
pain	I-D015746
	O

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
patients	B-D010361
treated	O
with	O
CELEBREX	O
(100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily):	O
Gastrointestinal	O
:	O
Constipation,	B-D003248
diverticulitis,	B-D004238
dysphagia,	O
eructation,	B-D004884
esophagitis,	B-D004941
gastritis,	B-D005756
gastroenteritis,	B-D005759
gastroesophageal	B-D005764
reflux,	I-D005764
hemorrhoids,	B-D006484
hiatal	O
hernia,	B-D006547
melena,	B-D008551
dry	O
mouth,	B-D009055
stomatitis,	B-D013280
tenesmus,	O
vomiting	B-D014839
Cardiovascular:	O
Aggravated	O
hypertension,	B-D006973
angina	B-D000787
pectoris,	I-D000787
coronary	O
artery	B-D001154
disorder,	O
myocardial	B-D009203
infarction	I-D009203
General	O
:	O
Allergy	O
aggravated,	O
allergic	O
reaction,	O
chest	B-D002637
pain,	I-D002637
cyst	O
NOS,	O
edema	B-D004487
generalized,	O
face	B-D005145
edema,	B-D004487
fatigue,	B-D005221
fever,	B-D005334
hot	O
flushes,	O
influenza-like	O
symptoms,	O
pain,	B-D010146
peripheral	O
pain	B-D010146
Central,	O
peripheral	B-D017933
nervous	I-D017933
system:	I-D017933
Leg	B-D007866
cramps,	O
hypertonia,	O
hypoesthesia,	O
migraine,	O
paresthesia,	B-D010292
vertigo	B-D014717
Hearing	B-D006309
and	O
vestibular	O
:	O
Deafness,	B-D003638
tinnitus	B-D014012
Heart	B-D006339
rate	I-D006339
and	O
rhythm	O
:	O
Palpitation,	O
tachycardia	B-D013610
Liver	B-D008099
and	O
biliary	O
:	O
Hepatic	O
function	O
abnormal,	O
SGOT	O
increased,	O
SGPT	O
increased	O
Metabolic	O
and	O
nutritional	O
:	O
BUN	O
increased,	O
CPK	O
increased,	O
hypercholesterolemia,	B-D006937
hyperglycemia,	B-D006943
hypokalemia,	B-D007008
NPN	O
increased,	O
creatinine	B-D003404
increased,	O
alkaline	B-D000469
phosphatase	I-D000469
increased,	O
weight	O
increased	O
Musculoskeletal	O
:	O
Arthralgia,	B-D018771
arthrosis,	B-D001154
myalgia,	B-D063806
synovitis,	B-D013585
tendinitis	O
Platelets	O
(bleeding	O
or	O
clotting)	O
:	O
Ecchymosis,	B-D004438
epistaxis,	B-D004844
thrombocythemia	O
Psychiatric	O
:	O
Anorexia,	B-D000855
anxiety,	B-D001007
appetite	B-D001066
increased,	O
depression,	B-D003863
nervousness,	O
somnolence	O
Hemic	O
:	O
Anemia	B-D000740
Respiratory	O
:	O
Bronchitis,	B-D001991
bronchospasm,	O
bronchospasm	O
aggravated,	O
coughing,	B-D003371
dyspnea,	B-D004417
laryngitis,	B-D007827
pneumonia	B-D011014
Skin	B-D012867
and	O
appendages	O
:	O
Alopecia,	B-D000505
dermatitis,	B-D003872
photosensitivity	O
reaction,	O
pruritus,	B-D011537
rash	O
erythematous,	B-D004890
rash	O
maculopapular,	O
skin	B-D012867
disorder,	O
skin	B-D012867
dry,	O
sweating	B-D013546
increased,	O
urticaria	B-D014581
Application	O
site	O
disorders	O
:	O
Cellulitis,	B-D002481
dermatitis	B-D003872
contact	O
Urinary	O
:	O
Albuminuria,	B-D000419
cystitis,	B-D003556
dysuria,	B-D053159
hematuria,	B-D006417
micturition	O
frequency,	O
renal	O
calculus	O
The	O
following	O
serious	O
adverse	O
events	O
(causality	O
not	O
evaluated)	O
occurred	O
in	O
<0.1%	O
of	O
patients	B-D010361
(cases	O
reported	O
only	O
in	O
post-marketing	O
experience	O
are	O
indicated	O
in	O
italics):	O
Cardiovascular	O
:	O
Syncope,	B-D013575
congestive	O
heart	B-D006333
failure,	I-D006333
ventricular	B-D014693
fibrillation,	I-D014693
pulmonary	B-D011655
embolism,	I-D011655
cerebrovascular	B-C079279
accident,	O
peripheral	O
gangrene,	B-D005734
thrombophlebitis,	B-D013924
vasculitis,	B-D014657
deep	O
venous	B-D020246
thrombosis	I-D020246
Gastrointestinal	O
:	O
Intestinal	B-D007415
obstruction,	I-D007415
intestinal	B-D007416
perforation,	I-D007416
gastrointestinal	O
bleeding,	O
colitis	B-D003092
with	O
bleeding,	O
esophageal	B-D004939
perforation,	I-D004939
pancreatitis,	B-D010195
ileus	B-D045823
Liver	B-D008099
and	O
biliary	O
:	O
Cholelithiasis,	B-D002769
hepatitis,	B-D006505
jaundice,	B-D007565
liver	B-D017093
failure	I-D017093
Hemic	O
and	O
lymphatic	B-D008196
:	O
Thrombocytopenia,	B-D013921
agranulocytosis,aplastic	B-D000380
anemia,	B-D000740
pancytopenia,	B-D010198
leucopenia	O
Metabolic:	O
Hypoglycemia,	B-D007003
hyponatremia	B-D007010
Nervous	O
:	O
Ataxia,	B-D001259
suicide,	B-D013405
aseptic	O
meningitis,	B-D008581
ageusia,	B-D000370
anosmia,	O
fatal	O
intracranial	O
hemorrhage	B-D006470
[see	O
Drug	B-D004347
Interactions	I-D004347
(7.1)]	O
Renal	O
:	O
Acute	O
renal	O
failure,	O
interstitial	O
nephritis	B-D009393
Skin:	B-D012867
Erythema	B-D004892
multiforme,	I-D004892
exfoliative	O
dermatitis,	B-D003872
Stevens-Johnson	B-D013262
syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis	O
drug	O
rash	O
with	O
eosinophilia	B-D004802
and	O
systemic	O
symptoms	O
(DRESS,	O
or	O
hypersensitivity	B-D006967
syndrome)	B-D013577
General	O
:	O
Sepsis,	B-D018805
sudden	O
death,	B-D003643
anaphylactoid	O
reaction,	O
angioedema	B-D000799
6.2	O
The	O
Celecoxib	B-D000068579
Long-Term	O
Arthritis	B-D001168
Safety	B-D012449
Study	O
[see	O
Special	O
Studies	O
(14.6)	O
]	O
Hematological	O
Events	O
:	O
The	O
incidence	B-D015994
of	O
clinically	O
significant	O
decreases	O
in	O
hemoglobin	O
(>2	O
g/dL)	O
was	O
lower	O
in	O
patients	B-D010361
on	O
CELEBREX	O
400	O
mg	O
twice	O
daily	O
(0.5%)	O
compared	O
to	O
patients	B-D010361
on	O
either	O
diclofenac	B-D004008
75	O
mg	O
twice	O
daily	O
(1.3%)	O
or	O
ibuprofen	B-D007052
800	O
mg	O
three	O
times	B-D013995
daily	O
1.9%	O

The	O
lower	O
incidence	B-D015994
of	O
events	O
with	O
CELEBREX	O
was	O
maintained	O
with	O
or	O
without	O
ASA	O
use	O
[see	O
Clinical	O
Pharmacology	B-D010600
(12.2)	O
]	O

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
diclofenac	B-D004008
and	O
ibuprofen	B-D007052
were	O
24%,	O
29%,	O
and	O
26%,	O
respectively	B-D000078682
	O

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
hospitalization	B-D006760
or	O
felt	O
to	O
be	O
life-threatening	B-D019369
or	O
otherwise	O
medically	O
significant),	O
regardless	O
of	O
causality,	B-D015984
were	O
not	O
different	O
across	O
treatment	O
groups	O
(8%,	O
7%,	O
and	O
8%,	O
respectively)	B-D000078682
	O

6.3	O
Juvenile	O
Rheumatoid	B-D012250
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
patients	B-D010361
2	O
years	O
to	O
17	O
years	O
of	O
age	O
were	O
treated	O
with	O
celecoxib	B-D000068579
or	O
naproxen;	B-D009288
77	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
3	O
mg/kg	O
BID,	O
82	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID,	O
and	O
83	O
patients	B-D010361
were	O
treated	O
with	O
naproxen	B-D009288
7.5	O
mg/kg	O
BID	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
celecoxib	B-D000068579
treated	O
patients	B-D010361
were	O
headache,	B-D006261
fever	B-D005334
(pyrexia),	O
upper	O
abdominal	B-D015746
pain,	I-D015746
cough,	B-D003371
nasopharyngitis,	B-C015378
abdominal	B-D015746
pain,	I-D015746
nausea,	B-D009325
arthralgia,	B-D018771
diarrhea	B-D003967
and	O
vomiting	B-D014839
	O

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
naproxen-treated	B-D009288
patients	B-D010361
were	O
headache,	B-D006261
nausea,	B-D009325
vomiting,	B-D014839
fever,	B-D005334
upper	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
cough,	B-D003371
abdominal	B-D015746
pain,	I-D015746
and	O
dizziness	B-D004244
(Table	O
2)	O

Compared	O
with	O
naproxen,	B-D009288
celecoxib	B-D000068579
at	O
doses	O
of	O
3	O
and	O
6	O
mg/kg	O
BID	O
had	O
no	O
observable	O
deleterious	O
effect	O
on	O
growth	B-D048788
and	I-D048788
development	I-D048788
during	O
the	O
course	O
of	O
the	O
12-week	O
double-blind	O
study	O

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
uveitis	B-D014605
or	O
systemic	O
features	O
of	O
JRA	O
among	O
treatment	O
groups	O

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
patients	B-D010361
were	O
treated	O
with	O
celecoxib	B-D000068579
6	O
mg/kg	O
BID	O

The	O
incidence	B-D015994
of	O
adverse	O
events	O
was	O
similar	O
to	O
that	O
observed	O
during	O
the	O
double-blind	O
study;	O
no	O
unexpected	O
adverse	O
events	O
of	O
clinical	O
importance	O
emerged	O

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
patients	B-D010361
with	O
events)	O
All	O
Doses	O
Twice	O
Daily	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
Celecoxib3	B-D000068579
mg/kgN=77	O
Celecoxib6	B-D000068579
mg/kgN=82	O
Naproxen7.5	B-D009288
mg/kgN=83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
pain	I-D015746
NOS	O
4	O
7	O
7	O
Abdominal	B-D015746
pain	I-D015746
upper	O
8	O
6	O
10	O
Vomiting	B-D014839
NOS	O
3	O
6	O
11	O
Diarrhea	B-D003967
NOS	O
5	O
4	O
8	O
Nausea	B-D009325
7	O
4	O
11	O
General	O
13	O
11	O
18	O
Pyrexia	O
8	O
9	O
11	O
Infections	B-D007239
25	O
20	O
27	O
Nasopharyngitis	B-C015378
5	O
6	O
5	O
Injury	O
and	O
Poisoning	B-D011041
4	O
6	O
5	O
InvestigationsAbnormal	O
laboratory	O
tests,	B-C004551
which	O
include:	O
Prolonged	O
activated	O
partial	B-D010314
thromboplastin	I-D010314
time,	I-D010314
Bacteriuria	B-D001437
NOS	O
present,	O
Blood	B-D001769
creatine	B-D003401
phosphokinase	O
increased,	O
Blood	B-D000071997
culture	I-D000071997
positive,	O
Blood	B-D001786
glucose	I-D001786
increased,	O
Blood	B-D001794
pressure	I-D001794
increased,	O
Blood	B-D001769
uric	B-D014527
acid	I-D014527
increased,	O
Hematocrit	B-D006400
decreased,	O
Hematuria	B-D006417
present,	O
Hemoglobin	B-C032001
decreased,	I-C032001
Liver	B-D008111
function	I-D008111
tests	I-D008111
NOS	O
abnormal,	O
Proteinuria	B-D011507
present,	O
Transaminase	O
NOS	O
increased,	O
Urine	B-D014556
analysis	O
abnormal	O
NOS	O
3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
vertigo)	B-D014717
1	O
1	O
7	O
Respiratory	O
8	O
15	O
15	O
Cough	B-D003371
7	O
7	O
8	O
Skin	B-D012867
&	O
Subcutaneous	O
10	O
7	O
18	O
6.4	O
Other	O
Pre-Approval	O
Studies	O
Adverse	O
Events	O
from	O
Ankylosing	O
Spondylitis	B-D013166
Studies:	O
A	O
total	O
of	O
378	O
patients	B-D010361
were	O
treated	O
with	O
CELEBREX	O
in	O
placebo-	O
and	O
active-controlled	O
AS	O
studies	O

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
patients	B-D010361
were	O
treated	O
with	O
CELEBREX	O
in	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O

All	O
patients	B-D010361
in	O
post-oral	O
surgery	O
pain	B-D010146
studies	O
received	O
a	O
single	O
dose	O
of	O
study	O
medication	O

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
dysmenorrhea	B-D004412
and	O
post-orthopedic	O
surgery	O
pain	B-D010146
studies	O

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
analgesia	B-D000698
and	O
dysmenorrhea	B-D004412
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
arthritis	B-D001168
studies	O

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
osteitis	B-D010000
(dry	O
socket)	O
in	O
the	O
post-oral	O
surgery	O
pain	B-D010146
studies	O

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenomatous	B-D000236
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
patients	B-D010361
than	O
in	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
(treatment	O
durations	O
up	O
to	O
12	O
weeks;	O
see	O
Adverse	O
events	O
from	O
CELEBREX	O
pre-marketing	O
controlled	O
arthritis	B-D001168
trials	O
,	O
above)	O

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
patients	B-D010361
treated	O
with	O
CELEBREX	O
were	O
greater	O
as	O
compared	O
to	O
the	O
arthritis	B-D001168
pre-marketing	O
trials	O
were	O
as	O
follows:	O
CELEBREX(400	O
to	O
800	O
mg	O
daily)N	O
=	O
2285	O
PlaceboN=1303	O
Diarrhea	B-D003967
10.5%	O
7.0%	O
Gastroesophageal	B-D005764
reflux	I-D005764
disease	B-D004194
4.7%	O
3.1%	O
Nausea	B-D009325
6.8%	O
5.3%	O
Vomiting	B-D014839
3.2%	O
2.1%	O
Dyspnea	B-D004417
2.8%	O
1.6%	O
Hypertension	B-D006973
12.5%	O
9.8%	O
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
≥0.1%	O
and	O
<1%	O
of	O
patients	B-D010361
taking	O
CELEBREX,	O
at	O
an	O
incidence	B-D015994
greater	O
than	O
placebo	O
in	O
the	O
long-term	O
polyp	O
prevention	O
studies	O
and	O
were	O
either	O
not	O
reported	O
during	O
the	O
controlled	O
arthritis	B-D001168
pre-marketing	O
trials	O
or	O
occurred	O
with	O
greater	O
frequency	O
in	O
the	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Nervous	B-D009420
system	I-D009420
disorders:	O
Cerebral	B-D002544
infarction	I-D002544
Eye	B-D005123
disorders	O
:	O
Vitreous	O
floaters,	O
conjunctival	B-D003228
hemorrhage	B-D006470
Ear	B-D004423
and	O
labyrinth	O
:	O
Labyrinthitis	B-D007762
Cardiac	B-D002299
disorders	O
:	O
Angina	O
unstable,	O
aortic	B-D001021
valve	I-D001021
incompetence,	O
coronary	O
artery	B-D001154
atherosclerosis,	B-D050197
sinus	O
bradycardia,	B-D001919
ventricular	O
hypertrophy	B-D006984
Vascular	O
disorders	O
:	O
Deep	O
vein	O
thrombosis	B-D013927
Reproductive	O
system	O
and	O
breast	B-D001940
disorders	O
:	O
Ovarian	O
cyst	O
Investigations	O
:	O
Blood	B-D001769
potassium	B-D011188
increased,	O
blood	B-D001769
sodium	B-D012964
increased,	O
blood	B-D001769
testosterone	B-D013739
decreased	O
Injury,	O
poisoning	B-D011041
and	O
procedural	O
complications:	O
Epicondylitis,	O
tendon	O
rupture	B-D012421
Cardiovascular	O
Thrombotic	O
Events	O
1.Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
including	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
occur	O
early	B-D004423
in	O
treatment	O
and	O
may	O
increase	O
with	O
duration	O
of	O
use	O
(see	O
WARNINGS	O
and	O
PRECAUTIONS)	O

2.Etodolac	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
(see	O
CONTRAINDICATIONS	B-D000075202
and	O
WARNINGS	O
)	O

Gastrointestinal	O
Risk	B-D012306
1.NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
a	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
(GI)	O
events	O
(see	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
patients	B-D010361
taking	O
etodolac	B-D017308
or	O
other	O
NSAIDs,	O
the	O
most	O
frequently	O
reported	O
adverse	O
experiences	O
occurring	O
in	O
approximately	O
1	O
to	O
10%	O
of	O
patients	B-D010361
are:	O
Gastrointestinal	O
experiences	O
including:	O
abdominal	B-D015746
pain,	I-D015746
constipation,	B-D003248
diarrhea,	B-D003967
dyspepsia,	B-D004415
flatulence,	B-D005414
gross	O
bleeding/perforation,	O
heartburn,	B-D006356
nausea,	B-D009325
GI	O
ulcers	B-D014456
(gastric/duodenal),	O
vomiting	B-D014839
	O

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
anemia,	B-D000740
dizziness,	B-D004244
edema,	B-D004487
elevated	O
liver	B-D008099
enzymes,	B-D004798
headaches,	B-D006261
increased	O
bleeding	B-D001760
time,	I-D001760
pruritis,	O
rashes,	O
tinnitus	B-D014012
	O

Adverse-reaction	O
information	O
for	O
etodolac	B-D017308
was	O
derived	O
from	O
2,629	O
arthritic	B-D001154
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
in	O
double-blind	O
and	O
open-label	O
clinical	B-D016430
trials	I-D016430
of	O
4	O
to	O
320	O
weeks	O
in	O
duration	O
and	O
worldwide	O
postmarketing	O
surveillance	O
studies	O

In	O
clinical	B-D016430
trials,	I-D016430
most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient	O

The	O
discontinuation	O
rate	O
in	O
controlled	B-D018848
clinical	I-D018848
trials,	I-D018848
because	O
of	O
adverse	O
events,	O
was	O
up	O
to	O
10%	O
for	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

New	O
patient	O
complaints	O
(with	O
an	O
incidence	B-D015994
greater	O
than	O
or	O
equal	O
to	O
1%)	O
are	O
listed	O
below	O
by	O
body	O
system	O

The	O
incidences	B-D015994
were	O
determined	O
from	O
clinical	B-D016430
trials	I-D016430
involving	O
465	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
treated	O
with	O
300	O
to	O
500	O
mg	O
of	O
etodolac	B-D017308
b.i.d	O

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
fever	B-D005334
	O

Digestive	B-D004064
system	I-D004064
-	O
Dyspepsia	B-D004415
(10%),	O
abdominal	B-D015746
pain*,	I-D015746
diarrhea*,	B-D003967
flatulence*,	B-D005414
nausea*,	B-D009325
constipation,	B-D003248
gastritis,	B-D005756
melena,	B-D008551
vomiting	B-D014839
	O

Nervous	B-D009420
system	I-D009420
-	O
Asthenia/malaise*,	B-D001247
dizziness*,	B-D004244
depression,	B-D003863
nervousness	O

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus,	B-D011537
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
tinnitus	B-D014012
	O

Urogenital	B-D014566
system	I-D014566
-	O
Dysuria,	B-D053159
urinary	O
frequency	O

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
patients	B-D010361
treated	O
with	O
etodolac	B-D017308
	O

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
clinical	B-D016430
trials,	I-D016430
are	O
considered	O
rarer	O
and	O
are	O
italicized.)	O
Body	O
as	O
a	O
whole	O
-	O
Allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
shock)	B-D012769
	O

Cardiovascular	B-D002319
system	I-D002319
-	O
Hypertension,	B-D006973
congestive	O
heart	B-D006333
failure,	I-D006333
flushing,	B-D005483
palpitations,	O
syncope,	B-D013575
vasculitis	B-D014657
(including	O
necrotizing	O
and	O
allergic)	O

Digestive	B-D004064
system	I-D004064
-	O
Thirst,	B-D013894
dry	O
mouth,	B-D009055
ulcerative	B-D014456
stomatitis,	B-D013280
anorexia,	B-D000855
eructation,	B-D004884
elevated	O
liver	B-D008099
enzymes,	B-D004798
cholestatic	O
hepatitis,	B-D006505
hepatitis,	B-D006505
cholestatic	O
jaundice,	B-D007565
duodenitis,	B-D004382
jaundice,	B-D007565
hepatic	O
failure,	O
liver	B-D008099
necrosis,	B-D009336
peptic	B-D010437
ulcer	I-D010437
with	O
or	O
without	O
bleeding	O
and/or	O
perforation,	O
intestinal	O
ulceration,	B-D014456
pancreatitis	B-D010195
	O

Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
Ecchymosis,	B-D004438
anemia,	B-D000740
thrombocytopenia,	B-D013921
bleeding	B-D001760
time	I-D001760
increased,	O
agranulocytosis,	B-D000380
hemolytic	O
anemia,	B-D000740
leukopenia,	B-D007970
neutropenia,	B-D009503
pancytopenia	B-D010198
	O

Metabolic	O
and	O
nutritional	O
-	O
Edema,	B-D004487
serum	B-D044967
creatinine	B-D003404
increase,	O
hyperglycemia	B-D006943
in	O
previously	O
controlled	O
diabetic	O
patients	B-D010361
	O

Nervous	B-D009420
system	I-D009420
-	O
Insomnia,	O
somnolence	O

Respiratory	B-D012137
system	I-D012137
-	O
Asthma,	B-D001249
pulmonary	O
infiltration	O
with	O
eosinophilia	B-D004802
	O

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema,	B-D000799
sweating,	B-D013546
urticaria,	B-D014581
vesiculobullous	O
rash,	O
cutaneous	O
vasculitis	B-D014657
with	O
purpura,	B-D011693
Stevens-Johnson	B-D013262
Syndrome,	I-D013262
toxic	O
epidermal	O
necrolysis,	O
hyperpigmentation,	B-D017495
erythema	B-D004892
multiforme	I-D004892
	O

Special	O
senses	O
-	O
Photophobia,	B-D020795
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
system	I-D014566
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
renal	B-D051437
insufficiency,	I-D051437
renal	O
papillary	O
necrosis	B-D009336
	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
etodolac	B-D017308
is	O
uncertain	O

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
physicians.)	B-D010820
Body	O
as	O
a	O
whole	O
-	O
Infection,	O
headache	B-D006261
	O

Cardiovascular	B-D002319
system	I-D002319
-	O
Arrhythmias,	O
myocardial	B-D009203
infarction,	I-D009203
cerebrovascular	B-C079279
accident	O

Digestive	B-D004064
system	I-D004064
-	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
colitis	B-D003092
	O

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
system	I-D009420
-	O
Paresthesia,	B-D010292
confusion	B-D003221
	O

Respiratory	B-D012137
system	I-D012137
-	O
Bronchitis,	B-D001991
dyspnea,	B-D004417
pharyngitis,	B-D010612
rhinitis,	B-D012220
sinusitis	B-D012852
	O

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia,	B-D000505
maculopapular	O
rash,	O
photosensitivity,	O
skin	B-D012867
peeling	O

Special	O
senses	O
-	O
Conjunctivitis,	B-D003231
deafness,	B-D003638
taste	B-D013649
perversion	O

Urogenital	B-D014566
system	I-D014566
-	O
Cystitis,	B-D003556
hematuria,	B-D006417
leukorrhea,	B-D007973
renal	O
calculus,	O
interstitial	O
nephritis,	B-D009393
uterine	O
bleeding	O
irregularities	O

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis,	B-D018805
death	B-D003643
Cardiovascular	B-D002319
system	I-D002319
-	O
Tachycardia	B-D013610
Digestive	B-D004064
system	I-D004064
-	O
Gastric	O
ulcers,	B-D014456
gastritis,	B-D005756
gastrointestinal	O
bleeding,	O
glossitis,	B-D005928
hematemesis	B-D006396
Hemic	O
and	O
lymphatic	B-D008208
system	I-D008208
-	O
Lymphadenopathy	B-D000072281
Nervous	B-D009420
system	I-D009420
-	O
Anxiety,	B-D001007
dream	O
abnormalities,	O
convulsions,	O
coma,	B-D003128
hallucinations,	B-D006212
meningitis,	B-D008581
tremors,	B-D014202
vertigo	B-D014717
Respiratory	B-D012137
system	I-D012137
-	O
Respiratory	O
depression,	B-D003863
pneumonia	B-D011014
Urogenital	B-D014566
system	I-D014566
-	O
Oliguria/polyuria,	B-D009846
proteinuria	B-D011507
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
RISK	B-D012306
Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

This	O
risk	B-D012306
may	O
increase	O
with	O
duration	O
of	O
use	O

Patients	B-D010361
with	O
cardiovascular	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
cardiovascular	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
	O

Voltaren®	O
Gel	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
pain	B-D010146
in	O
the	O
setting	O
of	O
coronary	B-D001026
artery	I-D001026
bypass	I-D001026
graft	O
(CABG)	O
surgery	O
[see	O
Contraindications	B-D000075202
(4)]	O
	O

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
gastrointestinal	O
adverse	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach	B-D013270
or	O
intestines,	B-D007422
which	O
can	O
be	O
fatal	O

These	O
events	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
use	O
and	O
without	O
warning	O
symptoms	O

Elderly	O
patients	B-D010361
are	O
at	O
greater	O
risk	B-D012306
for	O
serious	O
gastrointestinal	O
events	O
[see	O
Warnings	O
and	O
Precautions(5.2)]	O

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Elevations	O
of	O
one	O
or	O
more	O
liver	B-D008099
tests	B-C004551
may	O
occur	O
during	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
	O

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy	O

Borderline	O
elevations	O
(i.e	O

less	O
than	O
3	O
times	B-D013995
the	O
ULN	O
[ULN	O
=	O
the	O
upper	O
limit	O
of	O
normal	O
range])	O
or	O
greater	O
elevations	O
of	O
transaminases	B-D000637
occurred	O
in	O
about	O
15%	O
of	O
diclofenac-treated	B-D004008
patients	B-D010361
	O

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	B-D008099
injury	O

In	O
clinical	B-D016430
trials,	I-D016430
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(GOT)	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
for	O
2-6	O
months,	O
patients	B-D010361
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/orAST	O
occurred	O
in	O
about	O
4%	O
of	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(i.e.,	O
more	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3-8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(>8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
tests	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

Physicians	B-D010820
should	O
measure	O
transaminases	B-D000637
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
transaminases	B-D000637
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
diclofenac	B-D004008
sodium	B-D012964
should	O
be	O
discontinued	O
immediately	O

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
physicians	B-D010820
should	O
inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
“flu-like”	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
patients	B-D010361
should	O
take	O
if	O
these	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
appear	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver	B-D008099
related	O
event	O
in	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium,	B-D012964
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible	O

Caution	O
should	O
be	O
exercised	B-D015444
in	O
prescribing	O
diclofenac	B-D004008
sodium	B-D012964
with	O
concomitant	O
drugs	O
that	O
are	O
know	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
antibiotics,	O
anti-epileptics)	O

(5.3)	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose	O
dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O

Patients	B-D010361
at	O
greatest	O
risk	B-D012306
of	O
this	O
reaction	O
are	O
those	O
with	O
impaired	O
renal	O
function,	O
heart	B-D006333
failure,	I-D006333
liver	B-D008099
dysfunction,	O
those	O
taking	O
diuretics	B-D004232
and	O
ACE-inhibitors,	O
and	O
the	O
elderly	O

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

(5.6)	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
patients	B-D010361
without	O
prior	O
exposure	O
to	O
Voltaren®	O
Gel	O

Voltaren®	O
Gel	O
should	O
not	O
be	O
given	O
to	O
patients	B-D010361
with	O
the	O
aspirin	B-D001241
triad	O

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
asthmatic	B-D001249
patients	B-D010361
who	O
experience	O
rhinitis	B-D012220
with	O
or	O
without	O
nasal	B-C015378
polyps,	B-D011127
or	O
who	O
exhibit	O
severe,	O
potentially	O
fatal	O
bronchospasm	O
after	O
taking	O
aspirin	B-D001241
or	O
other	O
NSAIDs	O
[see	O
Contraindications	B-D000075202
(4),	O
Warnings	O
and	O
Precautions	O
(5.7)]	O

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

(5.7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
trials	I-D016430
of	O
several	O
COX-2	O
selective	O
and	O
nonselective	O
NSAIDs	O
of	O
up	O
to	O
three	O
years	O
duration	O
have	O
shown	O
an	O
increased	O
risk	B-D012306
of	O
serious	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
myocardial	B-D009203
infarction,	I-D009203
and	O
stroke,	B-D020521
which	O
can	O
be	O
fatal	O

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
risk	B-D012306
	O

Patients	B-D010361
with	O
known	O
CV	O
disease	B-D004194
or	O
risk	B-D012307
factors	I-D012307
for	O
CV	O
disease	B-D004194
may	O
be	O
at	O
greater	O
risk	B-D012306
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
CV	O
event	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
the	O
development	O
of	O
such	O
events,	O
even	O
in	O
the	O
absence	O
of	O
previous	O
CV	O
symptoms	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
aspirin	B-D001241
mitigates	O
the	O
increased	O
risk	B-D012306
of	O
serious	O
CV	O
thrombotic	O
events	O
associated	O
with	O
NSAIDs	O
use	O

The	O
concurrent	O
use	O
of	O
aspirin	B-D001241
and	O
NSAIDs	O
such	O
as	O
diclofenac,	B-D004008
does	O
increase	O
the	O
risk	B-D012306
of	O
serious	O
GI	O
events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O

Two	O
large,	O
controlled,	O
clinical	B-D016430
trials	I-D016430
of	O
a	O
COX-2	O
selective	O
NSAID	O
for	O
the	O
treatment	O
of	O
pain	B-D010146
in	O
the	O
first	O
10-14	O
days	O
following	O
CABG	O
surgery	O
found	O
an	O
increased	O
incidence	B-D015994
of	O
myocardial	B-D009203
infarction	I-D009203
and	O
stroke	B-D020521
[see	O
Contraindications	B-D000075202
(4)]	O

5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulceration,	B-D014456
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
diclofenac,	B-D004008
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
events	O
including	O
bleeding,	O
ulceration,	B-D014456
and	O
perforation	O
of	O
the	O
stomach,	B-D013270
small	O
intestine	O
or	O
large	O
intestine,	O
which	O
can	O
be	O
fatal	O

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
time,	B-D013995
with	O
or	O
without	O
warning	O
symptoms,	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O

Only	O
one	O
in	O
five	O
patients	B-D010361
who	O
develop	O
a	O
serious	O
upper	O
GI	O
adverse	O
event	O
on	O
NSAID	O
therapy	O
is	O
symptomatic	O

Upper	O
GI	O
ulcers,	B-D014456
gross	O
bleeding,	O
or	O
perforation	O
caused	O
by	O
NSAIDs	O
occur	O
in	O
approximately	O
1%	O
of	O
patients	B-D010361
treated	O
for	O
3-6	O
months,	O
and	O
in	O
about	O
2-4%	O
of	O
patients	B-D010361
treated	O
for	O
one	O
year	O

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
time	B-D013995
during	O
the	O
course	O
of	O
therapy	O

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
risk	B-D012306
	O

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
ulcer	B-D014456
disease	B-D004194
or	O
gastrointestinal	O
bleeding	O

Patients	B-D010361
with	O
a	O
prior	O
history	B-D006664
of	O
peptic	B-D010437
ulcer	I-D010437
disease	B-D004194
and/or	O
gastrointestinal	O
bleeding	O
who	O
use	O
NSAIDs	O
have	O
a	O
greater	O
than	O
10-fold	O
increased	O
risk	B-D012306
for	O
developing	O
a	O
GI	O
bleed	O
compared	O
to	O
patients	B-D010361
with	O
neither	O
of	O
these	O
risk	B-D012307
factors	I-D012307
	O

Other	O
factors	O
that	O
increase	O
the	O
risk	B-D012306
of	O
GI	O
bleeding	O
in	O
patients	B-D010361
treated	O
with	O
NSAIDs	O
include	O
concomitant	O
use	O
of	O
oral	O
corticosteroids	O
or	O
anticoagulants,	B-D000925
longer	O
duration	O
of	O
NSAIDs	O
therapy,	O
smoking,	B-D012907
use	O
of	O
alcohol,	O
older	O
age,	O
and	O
poor	O
general	O
health	B-D006304
status	I-D006304
	O

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
patients	B-D010361
and	O
therefore	O
special	O
care	O
should	O
be	O
taken	O
in	O
treating	O
this	O
population	B-D011153
	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
GI	O
event,	O
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
possible	O
duration	O

Physicians	B-D010820
and	O
patients	B-D010361
should	O
remain	O
alert	O
for	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
GI	O
ulceration	B-D014456
and	O
bleeding	O
during	O
diclofenac	B-D004008
therapy	O
and	O
promptly	O
initiate	O
additional	O
evaluation	O
and	O
treatment	O
if	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected	O

For	O
high-risk	O
patients,	B-D010361
alternate	O
therapies	O
that	O
do	O
not	O
involve	O
NSAIDs	O
should	O
be	O
considered	O

5.3	O
Hepatic	O
Effects	O
Elevations	O
of	O
one	O
or	O
more	O
liver	B-D008099
tests	B-C004551
may	O
occur	O
during	O
therapy	O
with	O
diclofenac	B-D004008
sodium	B-D012964
	O

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy	O

Borderline	O
elevations	O
(i.e	O

less	O
than	O
3	O
times	B-D013995
the	O
ULN	O
[ULN	O
=	O
the	O
upper	O
limit	O
of	O
normal	O
range])	O
or	O
greater	O
elevations	O
of	O
transaminases	B-D000637
occurred	O
in	O
about	O
15%	O
of	O
diclofenac-treated	B-D004008
patients	B-D010361
	O

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
liver	B-D008099
injury	O

In	O
clinical	B-D016430
trials,	I-D016430
meaningful	O
elevations	O
(i.e.,	O
more	O
than	O
3	O
times	B-D013995
the	O
ULN)	O
of	O
AST	O
(GOT)	O
(ALT	O
was	O
not	O
measured	O
in	O
all	O
studies)	O
occurred	O
in	O
about	O
2%	O
of	O
approximately	O
5,700	O
patients	B-D010361
at	O
some	O
time	B-D013995
during	O
diclofenac	B-D004008
treatment	O

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
patients	B-D010361
treated	O
for	O
2-6	O
months,	O
patients	B-D010361
were	O
monitored	O
first	O
at	O
8	O
weeks	O
and	O
1,200	O
patients	B-D010361
were	O
monitored	O
again	O
at	O
24	O
weeks	O

Meaningful	O
elevations	O
of	O
ALT	O
and/orAST	O
occurred	O
in	O
about	O
4%	O
of	O
patients	B-D010361
and	O
included	O
marked	O
elevations	O
(i.e.,	O
more	O
than	O
8	O
times	B-D013995
the	O
ULN)	O
in	O
about	O
1%	O
of	O
the	O
3,700	O
patients	B-D010361
	O

In	O
that	O
open-label	O
study,	O
a	O
higher	O
incidence	B-D015994
of	O
borderline	O
(less	O
than	O
3	O
times	B-D013995
the	O
ULN),	O
moderate	O
(3-8	O
times	B-D013995
the	O
ULN),	O
and	O
marked	O
(>8	O
times	B-D013995
the	O
ULN)	O
elevations	O
of	O
ALT	O
or	O
AST	O
was	O
observed	O
in	O
patients	B-D010361
receiving	O
diclofenac	B-D004008
when	O
compared	O
to	O
other	O
NSAIDs	O

Elevations	O
in	O
transaminases	B-D000637
were	O
seen	O
more	O
frequently	O
in	O
patients	B-D010361
with	O
osteoarthritis	B-D010003
than	O
in	O
those	O
with	O
rheumatoid	B-D012250
arthritis	B-D001168
	O

Almost	O
all	O
meaningful	O
elevations	O
in	O
transaminases	B-D000637
were	O
detected	O
before	O
patients	B-D010361
became	O
symptomatic	O

Abnormal	O
tests	B-C004551
occurred	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
with	O
diclofenac	B-D004008
in	O
42	O
of	O
the	O
51	O
patients	B-D010361
in	O
all	O
trials	O
who	O
developed	O
marked	O
transaminase	O
elevations	O

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
liver	B-D008099
necrosis,	B-D009336
jaundice,	B-D007565
fulminant	O
hepatitis	B-D006505
with	O
and	O
without	O
jaundice,	B-D007565
and	O
liver	B-D017093
failure	I-D017093
	O

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
liver	B-D016031
transplantation	I-D016031
	O

Physicians	B-D010820
should	O
measure	O
transaminases	B-D000637
periodically	B-D020492
in	O
patients	B-D010361
receiving	O
long-term	O
therapy	O
with	O
diclofenac,	B-D004008
because	O
severe	O
hepatotoxicity	O
may	O
develop	O
without	O
a	O
prodrome	O
of	O
distinguishing	O
symptoms	O

The	O
optimum	O
times	B-D013995
for	O
making	O
the	O
first	O
and	O
subsequent	O
transaminase	O
measurements	O
are	O
not	O
known	O

Based	O
on	O
clinical	B-D016430
trial	I-D016430
data	O
and	O
postmarketing	O
experiences,	O
transaminases	B-D000637
should	O
be	O
monitored	O
within	O
4	O
to	O
8	O
weeks	O
after	O
initiating	O
treatment	O
with	O
diclofenac	B-D004008
	O

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
time	B-D013995
during	O
treatment	O
with	O
diclofenac	B-D004008
	O

If	O
abnormal	O
liver	B-D008099
tests	B-C004551
persist	O
or	O
worsen,	O
if	O
clinical	O
signs	O
and/or	O
symptoms	O
consistent	O
with	O
liver	B-D008099
disease	B-D004194
develop,	O
or	O
if	O
systemic	O
manifestations	O
occur	O
(e.g.,	O
eosinophilia,	B-D004802
rash,	O
abdominal	B-D015746
pain,	I-D015746
diarrhea,	B-D003967
dark	O
urine,	B-D014556
etc.),	O
diclofenac	B-D004008
sodium	B-D012964
should	O
be	O
discontinued	O
immediately	O

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
physicians	B-D010820
should	O
inform	O
patients	B-D010361
of	O
the	O
warning	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
of	O
hepatotoxicity	O
(e.g.,	O
nausea,	B-D009325
fatigue,	B-D005221
lethargy,	B-D053609
diarrhea,	B-D003967
pruritus,	B-D011537
jaundice,	B-D007565
right	O
upper	O
quadrant	O
tenderness,	O
and	O
“flu-like”	O
symptoms),	O
and	O
the	O
appropriate	O
action	O
patients	B-D010361
should	O
take	O
if	O
these	O
signs	B-D012816
and	I-D012816
symptoms	I-D012816
appear	O

To	O
minimize	O
the	O
potential	O
risk	B-D012306
for	O
an	O
adverse	O
liver	B-D008099
related	O
event	O
in	O
patients	B-D010361
treated	O
with	O
diclofenac	B-D004008
sodium,	B-D012964
the	O
lowest	O
effective	O
dose	O
should	O
be	O
used	O
for	O
the	O
shortest	O
duration	O
possible	O

Caution	O
should	O
be	O
exercised	B-D015444
in	O
prescribing	O
diclofenac	B-D004008
sodium	B-D012964
with	O
concomitant	O
drugs	O
that	O
are	O
know	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
antibiotics,	O
anti-epileptics)	O

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Voltaren®	O
Gel,	O
can	O
lead	B-D007854
to	O
the	O
onset	O
of	O
new	O
hypertension	B-D006973
or	O
worsening	O
of	O
preexisting	O
hypertension,	B-D006973
either	O
of	O
which	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	B-D015994
of	O
cardiovascular	O
events	O

Patients	B-D010361
taking	O
thiazides	B-D049971
or	O
loop	O
diuretics	B-D004232
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

NSAIDs,	O
including	O
Voltaren®	O
Gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
hypertension	B-D006973
	O

Blood	B-D001794
pressure	I-D001794
should	O
be	O
monitored	O
closely	O
during	O
the	O
initiation	O
of	O
therapy	O
with	O
Voltaren®	O
Gel	O
and	O
throughout	O
the	O
course	O
of	O
therapy	O

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
edema	B-D004487
have	O
been	O
observed	O
in	O
some	O
patients	B-D010361
treated	O
with	O
NSAIDs,	O
including	O
Voltaren®	O
Gel	O

Voltaren®	O
Gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	B-D010361
with	O
fluid	O
retention	O
or	O
heart	B-D006333
failure	I-D006333
	O

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
necrosis	B-D009336
and	O
other	O
renal	O
injury	O

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
patients	B-D010361
in	O
whom	O
renal	O
prostaglandins	B-D011463
have	I-D011463
a	O
compensatory	O
role	B-D012380
in	O
the	O
maintenance	B-D008283
of	O
renal	O
perfusion	B-D010477
	O

In	O
these	O
patients,	B-D010361
administration	O
of	O
an	O
NSAID	O
may	O
cause	O
a	O
dose-dependent	O
reduction	O
in	O
prostaglandin	O
formation	B-D020478
and,	O
secondarily,	O
in	O
renal	O
blood	B-D001769
flow,	O
which	O
may	O
precipitate	O
overt	O
renal	O
decompensation	O
